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These reactions were usually not severe and did not greatly
impede patients’ compliance with their regimen.
We conclude that adjuvant therapy with levamisole and
fluorouracil should be standard treatment for Stage C
colon carcinoma. Since most patients in our study were
treated by community oncologists, this approach should
be readily adaptable to conventional medical practice.
[N Engl J Med 1990; 322:352-8.)'
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DOSAGE & ADMINISTRATION
Toradol IM — Recommended dose 30mg, followed by 10-30mg Q4-6h prn.
During initial postoperative period, more frequent dosing (Q2h) or supple
mental narcotic analgesics may be used. Maximium daily dose: 120mg.
Toradol Tablets — lOmg Q4-6h prn. Maximum daily dose: 40mg.
Conversion of IM to p.o. — Total combined dose not to exceed 120mg on
day of conversion.
Toradol is not a controlled drug.

s

Drug Interactions: Toradol (ketorolac tromethamine) is highly bound to human plasma protein (mean 99.2%) and bind
ing is independent of concentration.

30m g IM INJECTIO NS & 1Omg TA BLETS

(keto rolactro m etham ine)

NARCOTIC EFFICACY WITHOUT NARCOTIC DRAWBACKS
TORADOL (ketorolac tromethamine) 10 mg tablets
TORADOL IM (ketorolac tromethamine) 15 m g/m l and 30 mg/mL intramuscular injections
THERAPEUTIC CLASSIFICATION
Analgesic Agent
ACTION
Toradol (ketorolac tromethamine) is a non-steroidal anti-inflammatory drug that exhibits analgesic activity, Its mode of
action is to inhibit the cyclo-oxygenase enzyme system, thereby inhibiting the synthesis of prostaglandins, and is consid
ered to be a peripherally acting analgesic, A t analgesic doses it has minimal anti-inflammatory and antipyretic activity.
Ketorolac tromethamine is rapidly and completely absorbed when administered by both the oral and intramuscular routes,
and pharmacokinetics are linear following single and multiple dosing.
Steady state plasma levels are attained after one day of Q.I.D. dosing. Based only on pharmacokinetic principles, a faster
attainm ent of the steady state plasma level might be achieved with a loading dose of about twice the maintenance
dose. This occurs when the dosing interval is approximately equal to the drug's half-life.
Following oral administration, peak plasma concentrations of 0.52 to 1.31 mcg/m l occurred 35 minutes after a single 10 mg
dose. The terminal plasma elimination half-life ranged between 4.1 and 6.1 hours in healthy adults, while in elderly sub
jects (m ean age: 72 years) it ranged between 3.0 and 6,1 hours. A high fat diet decreased the rate but not the extent
of absorption of oral ketorolac tromethamine, while antacid had no effect.
Following intramuscular administration, peak plasma concentrations of 2.2 to 3.0 m cg/m l occurred an average of 50
minutes after a single 30 mg dose. The terminal plasma half-life ranged betw een 3.8 and 6.3 hours in young adults and
betw een 4.4 and 8.6 hours in elderly subjects (mean age: 72).
The primary route of excretion of ketorolac tromethamine and its metabolites (conjugates and the p-hydroxy metabo
lite) is in the urine (91.4%) and the remainder is excreted in the feces.
More than 99% of the ketorolac in plasma is protein bound over a wide concentration range.
INDICATIONS
Orally administered Toradol (ketorolac tromethamine) is indicated for the short-term management of mild to moderately
severe pain, including post-surgical pain (such as general, orthopedic and dental surgery), acute musculoskeletal
traum a pain and post-partum uterine cramping pain.
Intramuscular injection of Toradol is indicated for the short-term management of m oderate to severe pain, including pain
following major abdominal, orthopedic and gynecological operative procedures.
CONTRAINDICATIONS
Toradol (ketorolac tromethamine) should not be used where there is a known or suspected hypersensitivity to the drug.
Because of the possibility of cross-sensitivity, ketorolac tromethamine should not be used in patients in whom acetylsalicylic acid (ASA) or other non-steroidal anti-inflammatory agents induce acute asthmatic attacks, urticaria, rhinitis a other
allergic manifestations. Fatal anaphylactoid reactions may occur in such individuals.
Toradol (ketorolac tromethamine) also should not be used in patients with peptic ulcer or active inflammatory disease
o f the gastrointestinal system.
WARNINGS
Long-term administration of ketorolac tromethamine oral formulation has shown th a t this drug shares the risks that other
non-steroidal anti-inflammatory drugs pose to patients when taken chronically. Peptic ulceration, perforation and gas
trointestinal bleeding, sometimes severe and occasionally fatal have been reported during therapy with non-steroidal
anti-inflammatory drugs and may occur with ketorolac tromethamine, both in the presence or absence of previous symp
toms. Elderly and debilitated individuals are most susceptible to these complications, the incidence of which increases
with dose and duration of treatment. Close medical supervision is recom m ended in patients prone to gastrointestinal
tract irritation, particularly those with a histoiy of peptic ulcer, diverticulosis a other inflammatory disease of the gastrointestinal
tract. In these cases the physician must weigh the benefits of treatm ent against the possible hazards.
Patients taking any non-steroidal anti-inflammatory drug including ketorolac tromethamine should be instructed to con
tact a physician immediately if they experience symptoms or signs suggestive of peptic ulceration or gastrointestinal bleeding.
These reactions can occur at any time during the treatment. If peptic ulceration is suspected or confirmed, or if gastrointestinal
bleeding occurs, ketorolac tromethamine should be discontinued and appropriate treatment instituted and the patient
closely monitored.
Ketorolac tromethamine is not recommended for routine use with other non-steroidal anti-inflammatory drugs because
of the potential for additive side effects.
Use in pregnancy, lactation and labour: The administration of ketorolac tromethamine is not recommended during preg
nancy or lactation.
Ketorolac tromethamine is not recom mended for use as an obstetrical preoperative medication or for obstetrical anal
gesia because of the known effects of non-steroidal anti-inflammatory drugs on uterine contraction and fetal circulation.
Use in children: Safety and efficacy in children have not been established. Therefore, Toradol is not recommended for
use in children under age 16.
Use in the elderly: Because ketorolac is cleared somewhat more slowly by the elderly (See PHARMACOKINETICS) who
are also more sensitive to the renal effects of non-steroidal anti-inflammatory drugs, extra caution and the lowest effec
tive dose should be used.
PRECAUTIONS
Renal effects: As with other drugs that inhibit prostaglandin biosynthesis, elevations of blood urea nitrogen (BUN) and cre
atinine have been reported in clinical trials with ketorolac tromethamine. Since ketorolac tromethamine and its metabolites
are excreted primarily by the kidney, patients with significant impairment of renal function (serum creatinine values greater
than 5 m g /d l) should not receive ketorolac tromethamine unless the expected benefits outweigh the risks. In patients
with moderately impaired renal function serum creatinine values ranging from 1.9 to 5,0 m g/d l, the rate of ketorolac
clearance was reduced to approximately half of normal. The total daily dose of ketorolac tromethamine should be reduced
by half in such patients. The disposition of ketorolac in dialysis patients has not been studied.
Patients who are volume depleted because of blood loss or severe dehydration m ay be dependent on renal prostaglandin
production to maintain renal perfusion and therefore glomerular filtration rate. In such situations the use of drugs which
inhibit prostaglandin synthesis might be expected to further decrease renal blood flow. Caution is advised if ketorolac
tromethamine is used in such circumstances. Close monitoring of urine output, serum urea and serum creatinine is rec
om m ended until the patient is normovolemic.
Hepatic effects: Meaningful elevations (greater than 3 times normal) of serum transaminases (glutamate pyruvate (SGPT
or ALT) and glutamic oxalacetic (SGOT or AST)) occurred in controlled clinical trials in less than 1% of patients. If clinical
signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc,),
ketorolac tromethamine should be discontinued, Patients with im paired hepatic function from cirrhosis do not have any
clinically important changes in ketorolac tromethamine clearance. Studies in patients with active hepatitis or cholesta
sis have not been performed.
Fluid and electrolyte balance: Fluid retention and edem a have been observed in patients treated with Toradol. Therefore,
as with many other non-steroidal anti-inflammatory drugs, the possibility of precipitating congestive heart failure in
elderly patients or those with compromised cardiac function should be borne in mind. Toradol should be used with cau
tion in patients with cardiac decompensation, hypertension or other conditions predisposing to fluid retention.
Hematologic effects: Ketorolac tromethamine inhibits platelet function and may prolong bleeding time. It does not affect
platelet count, prothrombin time (PT) or partial thromboplastin time (PIT). Patients who have coagulation disorders or
are receiving drug therapy that interferes with hemostasis should be carefully observed when ketorolac tromethamine
is administered. Unlike the prolonged effects from aspirin, the inhibition of platelet function by ketorolac tromethamine
is normalized within 24 to 48 hours after the drug is discontinued,
Blood dyscrasias associated with the use of non-steroidal anti-inflam m atory drugs are rare, bu t could occur with
severe consequences.
Infection: In comm on with other anti-inflammatory drugs, ketorolac tromethamine may mask the usual signs of infection.

Prothrombin time should be carefully monitored in all patients receiving oral anticoagulant therapy concomitantly with
ketorolac tromethamine.
Ketorolac tromethamine does not alter digoxin protein binding.
In vitro studies indicated that a t therapeutic concentrations of salicylates (300 mcg/mL), the binding of ketorolac
tromethamine was reduced from approximately 99,2% to 97,5%. Therapeutic concentrations of digoxin, warfarin,
acetaminophen, phenytoin, tolbutamide and piroxicam did not alter ketorolac tromethamine protein binding. Since ketoro
lac tromethamine is a highly potent drug and present in low concentrations in plasma, it would not be expected to displace
other protein-bound drugs significantly.
There is no evidence in anim al or human studies that ketorolac tromethamine induces or inhibits the hepatic enzymes
capable of metabolizing itself or other drugs. Hence, it would not be expected to alter the pharmacokinetics of other
drugs due to enzyme induction or inhibition mechanisms.
Ketorolac tromethamine mildly reduces the diuretic response to furosemide in normovolemic subjects. Inhibition of renal lithium
clearance leading to an increase in plasma lithium concentration and potential lithium toxicity has been reported with some
non-steroidal anti-inflammatory drugs. The effect of ketorolac tromethamine on lithium plasma levels has not been studied.
Concomitant administration of methotrexate and some non-steroidal anti-inflammatory drugs have been reported to
reduce the clearance of methotrexate, enhancing the toxicity of methotrexate. The effect of ketorolac tromethamine
on methotrexate clearance has not been studied.
There is limited experience on concurrent administration with morphine. Available information shows no evidence of adverse
interactions. The extent of a possible narcotic-sparing effect of ketorolac tromethamine is currently under investigation.
ADVERSE EFFECTS
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Toradol tablets: The incidence of adverse reactions in approximately 600 patients and subjects receiving short-term oral
therapy (less than 2 weeks) with Toradol (ketorolac tromethamine) are listed below. The most common adverse effects
include: Gastrointestinal: dyspepsia (2%), gastrointestinal pain (2%), nausea (2%). Central nervous system: headache (2%),
dizziness (2%).
The following adverse events are rare but have been reported (less than 1%): Gastrointestinal: flatulence, gastritis.
Respiratory: dyspnea. Dermatologic: urticaria, rash, pruritus, Metabolism/nutritional: edema. Body as a whole: asthenia.
Hemic and lymphatic: purpura. Musculoskeletal: myalgia.
Toradol IM: The adverse reactions listed below were reported to be probably related to Toradol IM in clinical trials in which
patients received up to 20 doses of 30 mg of intramuscularly administered Toradol over a period of up to five days.
Incidence between 3 and 9%: Gastrointestinal: nausea, dyspepsia, gastrointestinal pain. Central nervous system: drowsiness.
Incidence between 1 and 3%: Gastrointestinal: diarrhea. Central nervous system: dizziness, headache, sweating. Body as
a whole: edema. Injection site pain was reported by 2% of patients in multi-dose studies (vs. 5% for morphine control group).
Incidence 1% or less: Gastrointestinal: constipation, flatulence, gastrointestinal fullness, liver function abnormalities,
melena, peptic ulcer, rectal bleeding, stomatitis, vomiting, Body as a whole: asthenia, myalgia. Cardiovascular: vasodi
latation, pallor. Hemic and lymphatic: purpura. Nervous system: dry mouth, nervousness, paresthesia, abnormal thinking,
depression, euphoria, excessive thirst, inability to concentrate, insomnia, stimulation, vertigo. Respiratory: dyspnea,
asthma. Urogenital: increased urinary frequency, oliguria. Dermatologic: pruritus, urticaria. Special senses: abnormal taste,
abnormal vision.
OVERDOSAGE
The absence of experience with acute overdosage precludes characterization of sequelae and assessment of antido
tal efficacy a t this time. In a gastroscopic study of healthy subjects, daily doses of 360 mg given over an 8-hour interval
for each of five consecutive days (3 times the highest recommended dose) caused abdominal pain and peptic ulcers
which recovered after discontinuation of dosing.
DOSAGE AND ADMINISTRATION
Adults: Dosage should be adjusted according to the severity of the pain and the response of the patient.
Oral: The usual oral dose of Toradol (ketorolac tromethamine) is 10 mg every 4 to 6 hours for pain as required, Doses exceed
ing 40 mg per day are not recommended,
Toradol is recom mended for short-term use only i.e. for a maximum of a few weeks.
Parenteral: The recom mended usual initial dose is 30 mg. Subsequent dosing may be 10 mg to 30 mg every 4-6 hours as
needed to control pain. A lower initial dose may be suitable for patients under 50 kg in body weight, over age 65 years
and/or with less severe pain a t baseline. In the initial post-operative period, more frequent dosing (e.g., every 2 hours)
may be employed, but the total daily dose should not exceed 120 mg. Dose above 120 mg could cause drug toxicity
(see Warnings & Precautions). If supplemental analgesia is required, a concomitant low dose of opiate can be used.
The administration of continuous multiple daily doses of Toradol IM should not exceed 5 days for Injection dosing. There
has been limited experience with dosing for more than 5 days since the vast majority of patients have transferred to oral
medication or no longer required analgesic therapy after this time.
Directions for use: Insert the plunger into the syringe barrel and thread it onto the screw. WITHOUT REMOVING THE NEEDLE GUARD,
apply quick, firm pressure to the plunger to break the inner seal (you will feel it let go). Pull back on the plunger slightly to relieve
pressure. Remove 1he needle guard by twisting as you pull. Use the unit as you would a normal syringe. Dispose of properly.
CONVERSION FROM PARENTERAL TO ORAL THERAPY
Toradol tablets may be used either as monotherapy or as follow-on therapy to parenteral ketorolac. In the latter case,
the total combined daily dose of ketorolac should not exceed 120 mg on the day the change of formulation is made,
this includes a maximum of 4 of the 10 mg tablets.
Toradol (ketorolac tromethamine) is a Schedule F drug.
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COMPOSITION
Toradol Tablets: Each Toradol tablet contains ketorolac tromethamine, the active ingredient, with microcrystalline cel
lulose, lactose and magnesium stearate. The coating suspension contains hydroxy-propyl-methylcellulose, titanium
dioxide and polyethylene glycol.
Toradol IM: Toradol IM is available for intramuscular administration as: 15mg in 1 m l (1.5%), or 30 mg in 1 mL (3%) of ketoro
lac tromethamine in sterile solution. The 15 mg/mL solution contains 10% (w/v) alcohol, USP, and 6.68 mg sodium chloride
in sterile water. The 30 mg/mL solution contains 10% (w/v) alcohol, USP and 4.35 mg sodium chloride in sterile water. The
pH is adjusted with sodium hydroxide or hydrochloric acid. The sterile solutions are clear and slightly yellow in colour.
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STABILITY AND STORAGE RECOMMENDATIONS
Toradol Tablets: Store at room temperature. The blister package tablets should be protected from light.
Toradol IM: Store at room temperature with protection from light.
AVAILABILITY OF DOSAGE FORMS
*
Toradol (ketorolac tromethamine) is available as 10 mg white round film coated tablets with one side printed in red with
TORADOL inside a bold T and the other side with Syntex. Toradol (ketorolac tromethamine) 10 mg tablets are available
in bottles of 100 tablets.
Toradol IM is available in 1 mL syringes containing 15 or 30 mg/mL of ketorolac tromethamine.
Product Monograph available on request.
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Compartment Syndrome
James Symes, MD, MSc, FRCSC
Division o f Cardiovascular and Thoracic Surgery, Royal Victoria Hospital, Montreal, Que.
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ompartment syndrome has been
broadly defined as “a condition
in which increased pressure within
a limited space compromises the
circulation and function of the tis
sues within that space.”1 By defini
tion, therefore, there are two pre
requisites for the production of a
compartment syndrome: a limiting
envelope containing neuromuscular
tissue and a cause of increased
pressure within that envelope. Com
partment syndrome may arise in a
wide variety of circumstances, the
most common being swelling, frac
tures, soft-tissue trauma, excessive
muscular work and closure of fas
cial defects.
Regardless of the underlying eti
ology, the final common pathway is
interstitial edema and venous hyper
tension, which compromises the mi
crocirculation, producing ischemia
of the intracompartmental tissues.
The elevated local pressure reduces
the arteriolar-venuiar gradient and
thus capillary blood flow at the
tissue level. Further, any reduction
in arteriolar pressure, such as with
shock or elevation of the extremity,
will further compromise tissue per
fusion in this setting. Experimental
studies have documented in humans
abnormalities of neuromuscular
function occurring after as little as
15 minutes when intracompartmen
tal pressure is raised above 30 mm
Hg. Histologic evidence of muscle
necrosis can be seen with sustained

pressure of 30 to 60 mm Hg for 8
hours. Compartment pressures of
50 mm Hg will result in transient
complete obstruction of nerve con
duction, and irreversible nerve dam
age has been documented after 12
hours at a pressure of 40 mm Hg
even if fasciotomy is performed
then. Thus, both experimental and
clinical data suggest that intracom
partmental pressures of 50 to 60
mm Hg consistently produce neuro
muscular dysfunction. The relative
reversibility of this dysfunction then
becomes a function of the duration
of the insult.
This clinical diagnosis of com
partment syndrome is based on the
presence or absence of the follow
ing: pain out of proportion to that
anticipated from the clinical situa
tion; hypoesthesia in the distribu
tion of the nerves running through
that compartment; weakness of the
muscles in the compartment; pain
on passive stretch; and tenseness
over the compartment envelope.
Unfortunately, all of these symp
toms and signs may or may not be
present in each patient or may
appear late after permanent damage
has already been done. Importantly,
pallor and diminished pulsations at
the foot in the involved limb fre
quently do not accompany compart
ment syndrome. Capillary filling
and the dorsalis pedis pulse may be
normal even in the presence of
severe anterior compartment isch

emia. Clearly, the diagnosis will
only be made if this condition is
considered when the clinical setting
which may produce it is present.
The most direct diagnostic tech
nique available is measurement of
intracompartmental pressure using
a saline infusion and a Wick cathe
ter (normal compartment pressure
is approximately 5 mm Hg). Once
the diagnosis is made or suspected,
the treatment of choice is immedi
ate fasciotomy. Numerous studies,
including our own,2 have document
ed early fasciotomy (ideally before
reperfusion) as the most effective
means to prevent permanent dam
age and possible limb loss. Other
modalities, such as mannitol infu
sion, heparin or the use of oxygenfree-radical scavengers may be ben
eficial in some settings but are less
reliable. When fasciotomy is delayed
for even a few hours, the chances of
completely avoiding permanent
muscle necrosis or neurologic dys
function are greatly reduced.
In this issue (pages 359 to 362)
Macintosh and Blanchard describe
five patients in whom compartment
syndrome developed after general
surgical procedures performed in
the lithotomy position. In these
patients, whose legs were wrapped
in Ace bandages and elevated in
stirrups, compartment syndrome
presumably developed owing to
combined intracompartmental hy
pertension, resulting from external
CJS, VOL. 34, NO. 4, AUGUST 1991
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pressure, and decreased arterial per
fusion due to elevation. In all five
cases the operations lasted 6 hours
or longer. Importantly, complete re
covery of neuromuscular function
was only achieved in two cases in
which immediate diagnosis was fol
lowed by fasciotomy within 1 hour
of the original surgery. By contrast,
permanent dysfunction (motor and
sensory) resulted, despite fascioto
my, when this procedure was de-

layed 24 hours. As this unique
report emphasizes, all surgeons
who perform operations requiring
the lithotomy position should take
appropriate precautions to avoid
undue external pressure on the
lower limbs and should be meticu
lously vigilant for signs of compart
ment syndrome in the immediate
postoperative period. Suspicion of
this diagnosis should lead to confir
mation of the increased compart

ment pressure (if possible) and im
mediate return to the operating
room for fasciotomy.

first class graduated MD (Alberta) in
1925. As Tory said then, “this is the
only medical school between Winnipeg
and Peking and the only university in
Canada with a hospital entirely under
its control and direction.”
This book is written with insight into
the many outside influences that deter
mine the development of a medical
school and its teaching faculty. The two
great wars, the depression, the depen
dence on a single saleable product
(wheat) by the province, the growing
pains of expansion, conversion of a
medical school, which is concerned with
producing physicians, to a health sci
ences centre, which greatly enlarges
those involved in health care delivery,
are all skilfully woven into the intrigu
ing story. The early founders perceived
isolation, which stimulated the staff to
excel. A very interesting section on
medical education traces the unique
contributions of medicine in Canada to
the world scene. There is an excellent
summary of the many changes that
have taken place in all areas of teaching
in the University of Alberta’s Faculty of
Medicine over its first 75 years: under
graduate, graduate and continuing med
ical education.
This finely written book will be of
great interest to those concerned with
medical education and, particularly, to
graduates in medicine from University
of Alberta. They will be able to recall,
as have I, our outstanding and, at

times, very colourful teachers, our first
patients, Med Nite and the commence
ment of lifelong friendships. What start
ed as a 2-year preclinical school in
1913, in a university that was only 5
years old, located in a frontier com
munity, completely dependent on stu
dent fees and government funding, with
a faculty of six professors and a firstyear class of 27 students, has now
become 118 students per year of a full
professional program with a faculty of
over 1000. In addition, there are now
400 interns and residents participating
in postgraduate education in more than
30 specialties. It is a faculty recognized
for its excellence around the world. The
most dramatic changes for me, a gradu
ate of 1949, are the magnificent physi
cal facilities and the enormous research
activity. The Alberta Heritage Founda
tion has contributed significantly. As
former Dean D.F. Cameron said, “We
were hoping for $30 million; we got
$300 million.”
This is a story of incredible growth,
based on some very good ideas by the
original founder with some beautifully
told vignettes along the way.
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CRITIQUES DE LIVRES
FRONTIERS OF MEDICINE — A
HISTORY OF MEDICAL EDUCA
TION AND RESEARCH AT THE
UNIVERSITY OF ALBERTA. Elise A.
Corbet. 250 pp. Illust. University of
Alberta Press, Edmonton, Alta.
$34.95. ISBN 0-88864-231-8
This is a fascinating account of the
founding and development of the Facul
ty of Medicine at the University of
Alberta. The original plans of the Uni
versity made ample provision for a
medical school, its laboratories, hospital
and clinics. This could only have been
done by a man of great vision, Henry
Marshall Tory, the first president of the
University. He strongly recommended
that a university was not only a source
of the traditional humanities, classics
and philosophy but should also provide
that frontier community with graduates
in the professions — law, medicine,
engineering, agriculture, architecture
and accounting. The Faculty of Medi
cine officially opened in 1912 against
considerable opposition, articulated by
one critic who said, “We do not need
any college here at all; if we did, it
would turn out horse doctors.”
Enormous progress was made in the
1920s. The medical building was
opened in 1921. The medical school
achieved a class A rating. An important
endowment was received from the
Rockefeller Foundation and the pro
gram became a full degree course. The
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Dormant Metastases
Israel Penn, MD
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very surgeon has occasionally
seen a patient with breast can
cer, malignant melanoma or hyper
nephroma who appeared to have
been cured 15 to 20 years after
treatment, but then suffered a re
currence that rapidly progressed to
death. In this issue (pages 321 to
325), Stewart, Hollinshead and
Raman describe similar experiences
with patients who had pulmonary
non-small-cell cancers. Two funda
mental questions arise: What
force(s) kept the residual cancer
cells dormant and clinically invisible
for such long periods? and, equally
important, What force(s) caused
long-dormant cancer cells to be
come active, multiply and spread
widely?
One can only speculate as to the
factors that initially kept the tu
mour cells in check and later failed
to restrain them on their deadly
course. In animal models, a great
variety of mechanisms produce a
state of dormancy. Likewise, in
man, this is probably a very com
plex process.1’2 Immune processes
play an important role.1’2 Malignant
cells may escape immune destruc
tion by means of reduced antigen
expression, antigen shedding, anti
gen modulation, masking of antigen
by a coat of a-2-macroglobulin or
changes in lipid composition of the
cell membrane, reducing suscepti
bility to complement-dependent ly
sis. In addition, cells producing
small amounts of oncogenic viruses
may reduce the generation or recall
of a strong immune response and
thus protect themselves from de

struction. Similarly, if tumour cells
are blocked in certain phases of the
cell cycle, when they are resistant
to destruction, they may persist in
the presence of an immune re
sponse.
Cells that initially escape destruc
tion may have their growth re
strained by one of two mechanisms:
inhibition of tumour cell division or
unrestrained cell division accompa
nied by an equal amount of cell
destruction, resulting in zero tu
mour growth. Macrophages and
various lymphokines, such as inter
feron, are important in these mech
anisms. Nonimmunologic processes,
which may restrain neoplastic
growth, include hormone-depend
ence of certain tumours and inade
quate vascularization.1 Metastases
may escape from long periods of
growth restraint as a result of host
immunodepression, alteration of the
host’s hormonal status, develop
ment of an adequate blood supply,
or changes in the tumour cells
themselves, such as increased ex
pression of cell-surface antigens,
alterations in cell membrane compo
sition or changes in their cycling
behaviour.1
Stewart, Hollinshead and Raman
emphasize the role of immunosup
pression, by use of drugs, such as
steroids, or by an illness or psycho
logical stress, so impairing patient
immunity that it removes the re
straints on residual tumour cells,
permitting their uncontrolled prolif
eration. Experience with organ
transplant recipients who have been
treated for cancers before or at the

time of transplantion provides con
flicting results. Most of 434 renal
transplant recipients treated for
cancers of the kidney, breast, colon,
thyroid, skin and other organs usu
ally before or, occasionally, at the
time of transplantation were appar
ently cured and had no recurrences
in follow-ups ranging from 1 week
to 238 months.3 The recurrence
rate was 26% overall, with most of
the recurrences occurring within 2
years after transplantation. In 597
patients who underwent liver trans
plantation for primary or metastatic
hepatic malignant disease, the re
currence rate was 42% overall, with
81% of tumour-related deaths oc
curring within 2 years of transplan
tation.4 Unlike most renal trans
plant recipients, who were treated
for their neoplasms weeks, months
or years before transplantation,
many hepatic transplant recipients
had their tumour, which was often
large, removed at the time of trans
plantation and, strictly speaking,
did not have dormant, but rather
had undiagnosed, microscopic me
tastases. The fact that most recur
rences occurred within 2 years after
renal or hepatic transplantation
may suggest that immunosuppres
sive therapy stimulated growth and
dissemination of residual cancer
cells. In some patients with small
Klatskin’s tumours, the growth and
spread of recurrences were spectac
ular, far out of keeping with their
known natural history.
The behaviour of some large hep
atomas was exemplified by a patient
whose allograft was almost comCJS, VOL. 34, NO. 4, AUGUST 1991
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pletely replaced by recurrent tu
mour and who had multiple “can
non-ball” pulmonary metastases at
the time of his death, 143 days
after transplantation,5 demonstrat
ing a growth rate probably exceed
ing that of a normal fetus. Howev
er, in the majority of patients, it is
impossible to determine whether
the growth rate of recurrent tu
mour was affected by immunosup
pressive therapy or whether it mere
ly reflected the natural histories of
the various malignant tumours. If
immunosuppression is important in
triggering growth of dormant can
cer cells, it is surprising that a
substantial number of recurrences

occurred more than 2 years after
transplantation and that a small
group of patients in both series had
recurrences 5 years or more after
transplantation.34 One would have
expected all recurrences to have
occurred early after transplantation
when immunosuppressive therapy
was most intense, rather than years
later when daily maintenance doses
were much lower. These findings
suggest that, in at least some trans
plant patients,. immunosuppressive
therapy may not affect the growth
of residual cancer cells.
It is hoped that animal experi
ments will provide therapeutic
means to either prolong the dor

mant state or destroy all dormant
cancer cells.1
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SURGICAL ONCOLOGY. Edited by
C.S. McArdle. 332 pp. Ulust. Butterworths, London. 1990. $165 (US).
ISBN 0-407-01700-3
Surgical oncology is a new specialty
encompassing all oncologists who have
been trained primarily as surgeons. In
this textbook cancerous organs that are
managed by general surgery, urology
and orthopedic surgery are covered.
All the chapters are well organized
with clear headings for each of the
sections and subsections and the format
of presentation of the data is very clear
and concise, indicating good editing. It
was therefore a great pleasure to read
through the chapters which were unen
cumbered by flowery prose and indefi
nite data.
The contents of each chapter, with
few exceptions, were really up to date
and represent present-day knowledge of
each organ’s specific cancers and the
most modern therapeutic regimens
available for such cancers. Some men
tion of the contributions by surgeons
and others in the area of biotherapy of
melanoma would have made this chap
ter more complete.
The chapter dealing with lymphomas
is excellent reading for surgeons who
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wish to update their knowledge of this
interesting cancer. However, the section
on gastrointestinal lymphoma, which is
of great interest to surgeons, is very
brief, and more detail about the surgical
management of this cancer would have
been appropriate. The chapter on the
principles of cancer chemotherapy is a
very good review of what is available
and how new drugs are developed. The
conclusion that future cancer chemo
therapy will not be cytotoxic chemo
therapy but biologic response modifiers
is also very apropriate.
The last chapter deals with recent
advances in cancer research and gives a
thoughtful prediction of the future
areas of cancer research and how they
might affect clinical management.
In summary, this is a timely textbook
and would be most useful for surgeons
who are interested in updating their
knowledge of the cancers they deal with
in their everyday practice, as well as for
those who may be considering surgical
oncology as a future specialty.
Henry R. Shibata, MD, MSc, FRCSC, FACS
S10.22
Royal Victoria Hospital
687 Pine Ave. W
Montreal, PQ
H3A 1A1

NEONATAL SURGERY. 3rd edition.
Edited by James Lister and Irene M.
Irving. 733 pp. Illust. Butterworth &
Co. (Publishers) Ltd., London. 1990.
$185 (US). ISBN 0-407-01490-X
This third edition of Neonatal Surgery
is a “must use” text for all physicians
involved in the day-to-day care of neon
ates.
Like previous editions, the experi
ence of the Alder Hey Children’s Hospi
tal is the basis of the text; however, the
authors lucidly explain current theories
of etiology and management, including
the most recently reported experience
of surgeons in North America, Europe
and Japan.
The book is divided into eight parts.
Part 1 deals with general principles of
neonatal management. This is the first
surgical text I have encountered that
contains a chapter on ethics (all physi
cians may benefit from this well-written
essay).
The usual anomalies are described
in the sections on the head and neck,
the rib cage, diaphragm and lungs, the
abdominal wall, and the alimentary and
biliary systems. Not only are the chapcontinued on page 362

QUILL ON SCALPEL

Flow Cytometry — Implications for the
Surgeon
W. Temple, MD, FACS, FRCSC
Director o f surgery, Tom Baker Cancer Centre, Calgary, Alta. Member, Editorial Board,
Canadian Journal o f Surgery

n their paper in this issue on
DNA flow cytometry of largebowel biopsies (pages 343 to 348)
Frei and colleagues conclude that
the management of colonic polyps
may be influenced by the determina
tion of ploidy; however, their data
suggest that we will still continue
to rely on the usual endoscopic or
radiologic and pathological findings
for the management of any particu
lar polyp. The presence of aneuploidy in a histologically benign
polyp does not identify a “wolf in
sheep’s clothing,” that is, a histo
logically benign lesion that will act
in a malignant fashion. As these
authors acknowledge, colonic can
cers are diploid in about 40% of
patients, and benign polyps, partic
ularly those larger than 2 cm, are
aneuploid in about 20%. This deter
mination does not give significant
precision to influence surgical
judgement.
However, their finding of aneuploidy in benign polyps, supported
by similar observations in the litera
ture,1 is fascinating. In-depth chro
mosome studies of benign colonic
polyps as they progress to an infil
trating cancer have shown that a
number of mutations occur. These
include frequent expression of the
ras-gene with an accumulation of
molecular alterations of chromo
somes 5, 17 and 18 as they prog
ress from tubular or low-grade dysplastic adenomas to a villous or
high-grade adenoma to a carcino
ma.2 Clinical correlation of ploidy
changes in benign neoplastic tissue
or in those at high risk for neoplas
tic change has been reported in a

I

number of studies. In one study,3
follow-up of 27 patients with ploidy
measurements of histologic dysplastic changes of the uterine cervix
were described. In the 10 cases that
progressed to a carcinoma in situ, 9
had aneuploid DNA patterns com
pared with 0 of 17 cases in which
the dysplasia regressed.
Another, equally important, im
plication of aneuploidy of benign
tissue relates to its potential value
as a high-risk marker for synchro
nous invasive lesions.4’5 This was
demonstrated by a report of 52
patients who had total colectomy
for ulcerative colitis.5 In the eight
who had aneuploid changes in nor
mal mucosa, three were found to
have synchronous tumours in the
colectomy specimen, two of which
were unsuspected. This association
has also been reported in patients
with breast cancers in whom a
change in ploidy of normal-appear
ing glandular tissue may be detect
ed a number of years before a
clinical infiltrating cancer develops.6
This finding was reconfirmed in my
own study on this subject (unpub
lished) in 16 patients who had pre
vious benign breast biopsies many
years before an infiltrating breast
cancer developed. A significant dif
ference in ploidy was found between
the metachronous benign breast bi
opsy and the normal tissue in the
breast removed at the time of the
mastectomy. This suggests that in a
number of patients the development
of aneuploidy in normal tissue may
be a high-risk marker for those who
will ultimately have breast or colon
ic cancer.

Therefore, the challenge present
ed in these data is to determine
whether aneuploidy in benign tis
sue, as identified by Frei and col
leagues in their study of colorectal
polyps, will independently predict
the risk of a synchronous or a
metachronous colonic cancer. This
finding of aneuploidy in histologi
cally benign tissue may also provide
a useful measure to determine the
value of interventions designed to
decrease cancer risk, especially for
colonic and breast cancer in which
interesting strategies of diet or
pharmacologic manipulation are
being proposed.
The authors are to be congratu
lated for beginning to study some
of these relationships.
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Prescribing information
Classification
Antiandrogen

Action
Androcur (cyproterone acetate) is
a steroid which clinically demonstrates
two distinct properties:
a) Antiandrogenic: Cyproterone acetate
blocks the binding of dihydrotestosterone
- the active metabolite of testosterone to the specific receptors in the prostatic
carcinoma cell.
b) Progestogenic/antigonadotrophic:
Cyproterone acetate exerts a negative
feed-back on the hypothalamo-pituitary
axis, by inhibiting the secretion of
LH leading to diminished production of
testicular testosterone.
The absorption of Androcur following oral
administration is complete. Peak plasma
levels are reached 3-4 hours after
administration. Plasma levels tall rapidly
during the first 24 hours as a result of
tissue distribution and excretion, and
plasma half-life was 38 ± 5 hours.
Most of the cyproterone acetate is excreted
unchanged in the feces (60 %) or urine
(33%) within 72 hours. Cyproterone
acetate is eliminated with the urine mainly
in the form of unconjugated metabolites
and with the bile (feces) in the form of
glucuronidized metabolites.
The principal metabolite identified was
15/3-hydroxy-cyproterone acetate.
Androcur Depot: Following intramuscular
Androcur Depot administration, mean
maximum blood levels were attained
3.4 days after injection. The mean elimina
tion half-life was found to be 4 days.

Indications
Androcur (cyproterone acetate) is
indicated for the palliative treatment of
patients with advanced prostatic
carcinoma.

Contraindications
Known hypersensitivity to the drug. Active
liver disease and hepatic dysfunction.
Renal insufficiency.

Warnings
Liver Function: Cyproterone acetate has
been found at low doses of 2-10 mg/kg to
cause liver abnormalities in dogs and rats
in the form of proliferative liver changes
including increased liver weight, liver
cell hypertrophy with an increase in the
smooth endoplasmic reticulum and a
rise in the serum glutamic pyruvic
transaminase (SGPT). At high doses of
50-100 mg/kg, nodular hepatic hyper
plasia and hepatomas have also been
observed. Although cyproterone acetate
has shown good liver tolerance in man,
liver function tests including SGOT, SGPT
and LDH should be performed at least
semi-annually during Androcur therapy.
Inhibition of Spermatogenesis: The sperm
count and the volume of ejaculate are
reduced at oral doses of 50-300 mg per
day Infertility is usual, and there may be
azoospermia after 8 weeks of therapy,
which is associated with atrophy of semi
niferous tubules. Follow-up examinations
on discontinuation of therapy have shown
these changes to be reversible. Sperma
togenesis usually reverts to its previous
level about 3 -5 months after stopping
Androcur, or in some patients, after up to
20 months. Production of abnormal
spermatozoa during Androcur therapy
has been observed: their relationship to
abnormal fertilization or malformed
embryos is not known.

Gynecomastia: Benign nodules (hyper
plasia) of the breast have been reported:
these generally subside 1-3 months after
discontinuation of therapy and/or after
a reduction of dosage. The reduction of
dosage should be weighed against the
risk of inadequate tumor control.
Depression: Androcur therapy has
occasionally been associated with an
increased incidence of depressive mood
changes, especially during the first
6 -8 weeks of therapy. Similar mood
changes have also been seen following
surgical castration and are considered to
be due to androgen deprivation. Patients
with tendencies to depressive reaction
should be carefully observed.

Precautions
Thromboembolism: Clinical investigations
have shown that when cyproterone
acetate is used alone, it has a minor effect
on blood clotting factors. However, when
cyproterone acetate was combined with
ethinyl estradiol, changes were found in
increased coagulation capability. There is
an inherent risk for those patients with
a history of thrombophlebitis or thrombo
embolism for recurrence of the disease.
Cyproterone acetate should be disconti
nued at the first sign of thrombophlebitis
or thromboembolism. The patient should
be carefully re-evaluated if manifestations
of thrombotic disorders should occur, e. g.
thrombophlebitis, cerebrovascular compli
cations, renal thrombosis or pulmonary
embolism.
Adrenocortical Function: Suppression
of adrenocortical function tests have
occurred in patients receiving high doses
(lOOmg/m2) of Androcur. Reduced
response to endogenous ACTH was noted
by the metyrapone test: furthermore,
reduced ACTH and cortisol blood levels
determined by the Mattingly method were
also found. It is therefore recommended
that adrenocortical function tests should
be monitored periodically by serum
cortisol assay.
Diabetes: Androcur may impair carbohyd
rate metabolism. Parameters of carbohyd
rate metabolism, fasting blood glucose
and glucose tolerance tests, should be
examined carefully in all patients and
particularly in all diabetics before and
regularly during therapy with Androcur
Hematology: Hypochromic anemia has
been observed rarely during therapy
with Androcur. Regular hematological
assessment is recommended.
Nitrogen Balance: A negative nitrogen
balance is usual at the start of therapy,
but does generally correct itself within
3 months of continued therapy
Metabolic Effects: Fluid retention, hyper
calcemia and changes in plasma lipid
profile may occur. Accordingly, Androcur
should be used with caution in patients
with cardiac disease.
Skin: Androcur therapy may cause
a reduction of sebum production leading
to dryness of the skin, and transient
patchy loss of body hair.
Concomitant Alcohol: Alcohol may reduce
the antiandrogenic effect of Androcur in
hypersexuality The relevance of this in
prostatic carcinoma is not known.
However, it would be prudent to inform the
patients that the use of alcohol during
Androcur therapy is not advisable.
Physical Performance: Patients should
be informed that fatigue and lassitude
are common in the first few weeks of
therapy, but usually become much less
pronounced from the third month
onwards. Marked lassitude and asthenia
necessitate special care when driving or
operating machinery.

Adverse effects

The most frequently recorded adverse
effects with Androcur (cyproterone ace
tate) are those related to the hormonal
effects of the drug. These reactions
usually disappear upon discontinuation of
therapy or reduction of dose.
Hormonal: inhibition of spermatogenesis:
abnormal spermatozoa; impotence;
breast tenderness; breast enlargement;
gynecomastia; benign nodular hyper
plasia; galactorrhea.
Central Nervous System: fatigue; lassi
tude; weakness; depression; headache.
Gastrointestinal: diarrhea; nausea;
vomiting; constipation; indigestion.
Cardiovascular: edema; shortness of
breath on effort; thrombophlebitis.
Laboratory Function Tests: Abnormal
values have been found in the following
tests: Liver Function Test: SGPT and SGOT
increase. Adrenocortical Function test:
decreased response to ACTH and lowered
cortisol. Hematology: hypochromic
anemia. Negative nitrogen balance initially
and hypercalcemia.
Adverse reactions are rarely of sufficient
severity to require dosage reduction or
discontinuation of treatment. If reactions
are severe, it may be beneficial to reduce
the dosage.

Symptoms and Treatment
of Overdosage
There have been no reports of fatal
overdosage in man with Androcur
(cyproterone acetate). There are no
specific antidotes, and treatment should
be symptomatic. If oral overdosage is
discovered within two to three hours,
gastric lavage can safely be used if
indicated.
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Dosage and Administration
Oral Tablets: The usual daily initial
and maintenance dose of Androcur is
4 -6 tablets (200-300 mg) divided into
2 -3 doses and taken after meals.
After orchiectomy a lower daily dose
of 2 -4 tablets (100-200 mg) is
recommended.
Injectable: The usual initial and mainte
nance dose of Androcur Depot is one
weekly intramuscular injection of 3 mL
(300mg). For orchiectomized patients, the
recommended dose is one intramuscular
injection of 3 mL (300 mg) every two
weeks. Androcur or Androcur Depot
(cyproterone acetate) therapy should not
be discontinued when remission or
improvement occurs.
Because of their pharmacokinetic
properties, Androcur (oral) and Androcur
Depot (i. m.) can be interchanged in the
course of long-term treatment. The dosage
may be reduced if side effects are intoler
able but should be kept within the oral
range of 2 -6 tablets tablets daily
(100-300 mg) or intramuscular injections
of 300 mg at weekly intervals, or every
two weeks.
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Availability
Androcur (cyproterone acetate) 50 mg
tablets - bottles of 60. Each white, round,
flatsided scored tablet with bevelled
edges, imprinted one side "BV" in a
regular hexagon, other side scored,
contains 50 mg of cyproterone acetate.
Androcur Depot (cyproterone acetate)
3 mL (300 mg) ampoules.
Each 3 ml ampoule contains cyproterone
acetate 100mg/ml in a castor oil
solution.

Product monograph
available upon request.
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Laparoscopic Nissen’s Fundal
Plication Is Feasible
To the editors. Since its introduc
tion, laparoscopic surgery has been
gaining wide and rapid acceptance
all over the world. The initial re
sults obtained with laparoscopic
cholecystectomy and appendectomy
have been excellent and have
pushed many investigators to use
this technique with vagotomy, in
guinal hernia repair, lymphadenectomy and minimal access intestinal
surgery.
In late 1990, we started to use
the technique for cholecystectomy.
Our early results were excellent
with no complications and with a
noticeable improvement in the
speed of patient recovery. These
results led us to expand the use of
the laparoscope to appendectomy,
vagotomy and even Nissen’s fundal
plication.
On Apr. 29, 1991, we carried out
a Nissen’s fundal plication using
solely the laparoscopic technique.
The patient was a 43-year-old
woman with severe reflux esophagi
tis in whom medical treatment had
failed. A 24-hour pH study gave
abnormal results. Using a total of
five punctures we carried out a total
fundal wrap around the distal part
of the esophagus for a distance of 2
cm around a no. 60 French bougie,
exactly as we do with the conven
tional open technique. The patient’s
postoperative recovery was remark
able: she was discharged on the
morning of May 1 and returned to
her regular work on May 3. She
was asymptomatic.

To our knowledge there has been
no other report of Nissen’s fundal
plication done laparoscopically. We
believe that this technique is feasi
ble and a viable alternative to the
open technique. We believe also
that it offers many advantages over
the conventional operation. Never
theless, more of these procedures
should be done. These new laparo
scopic techniques need to be evalu
ated further for long-term effective
ness before drawing final conclu
sions. We are presently using this
technique for all patients who are
referred for surgical repair of reflux
esophagitis. We are also using the
laparoscope for all our highly selec
tive vagotomies. Patients who have
reflux associated with ulcers are
having the benefit of a concomitant
laparoscopic vagotomy and Nissen’s
fundal plication. Every effort will be
made to carry out preoperative and
postoperative 24-hour pH studies to
obtain objective evidence of the
effectiveness of this new laparo
scopic procedure.
T. Geagea, MD, FRCSC, FACS
Department of Surgery
Glace Bay General Hospital
300 South St.
Glace Bay, NS
B1A 1W5

The appropriate screening proce
dures for living donors of bone
allograft has been a controversial
and difficult issue. 1 believe that the
approach of La Prairie and Gross to
bone allografts is medically sound.
However, I would take issue with
their statement that the protocol
they describe meets or exceeds all
existing standards.
Health and Welfare Canada in
October 19891 recommended that
“where cryo preservation or other
preservation of organs or tissues is
undertaken, only preserved tissues
that have been quarantined for at
least six months should be utilized.
In this instance, living donors
should undergo voluntary serologic
testing at the time of donation and
six months following the dona
tion.”
Obviously Health and Welfare
Canada guidelines are not fulfilled
by the protocol of La Prairie and
Gross in that testing is not repeated
and the 6-month quarantine period
is not met.
James P. McAuley, MD, FRCSC
Ottawa General Hospital
Ottawa, ON
K1H 8L6

Reference
Protocol for Banking Bone
From Surgical Donors

1. Health and Welfare Canada: Guidelines
for prevention of HIV infection in organ
and tissue transplantation. Can Dis Wkly
Rep 1989; 15 (suppl 4): 1-17

To the editors. I read with interest
the article by La Prairie and Gross
in the February 1991 issue of the
journal (pages 41 to 48).

To the editors. Our paper (Can J
Surg 1991; 34: 41-48) demon
strates that the risk of transmission
of the human immunodeficiency
CJS, VOL. 34, NO. 4, AUGUST 1991
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virus (HIV) is less than 30 in 100
million with a single test for HIV-1
antibody after a 90-day quarantine.
To perform two tests, one at the
time of procurement and another
after 90 days, will not decrease that
risk and will only tax the resources
of the virology laboratory.
To increase the quarantine period
to 6 months, as is the case for
banked reproductive tissues, is un
warranted when a documented pro
tocol for screening of medical and
social history accompanies HIV-1
antibody testing after 90 days from
the time of surgical procurement. It
will not significantly change the
risk of HIV transmission.
Health and Welfare Canada sug
gested guidelines for cryopreserved
organs and tissues which included a
6-month quarantine before testing
for HIV.1 As mentioned in our dis
cussion, we corresponded with
Health and Welfare Canada (Clay
ton AJ, Schlech W: Personal com
munication, 1990), arguing, suc
cessfully, that this was an excessive
quarantine period for non
rejuvenating tissue, when the donor
did not return for repeat donation.
There is also a limit to the shelf life
of bone stored at —70°C; this is
not the case with reproductive tis
sues stored in liquid nitrogen.
We further stated in the adden
dum to our paper that to increase
the quarantine period to 180 days
may make the banking of surgicaldiscard tissue less feasible. A
90-day quarantine could be worked
into the patient's follow-up visit. At
6 months, a patient may no longer
be in contact with the surgeon or
referring physician. More orthope
dic practices may opt for cadaverbanked tissue. This tissue would
not have any options for quarantine
and, therefore, may be at higher
risk for HIV transmission.
Protocols in human tissue bank
ing will continue to change and
evolve. These protocols already rec
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ognize that there is a difference
between the banking and use of
blood products, solid organ trans
plants and reproductive tissues.
Standards for all these are set to
make transplantation as safe and
successful as possible within feasi
ble limits. The standards for surgi
cal-discard tissue must also reflect
these principles.
In summary, there is no benefit
to the potential recipient by increas
ing the quarantine period to 6
months, but there is a significant
disadvantage to the tissue or bone
bank in terms of logistics.
A. La Prairie BSc, CTBS
Bone bank technologist
M. Gross MD, FRCS, FRCSC
Bone bank medical director
Victoria General Hospital
Halifax, NS
B3H 2Y9

Reference
1. Health and Welfare Canada: Guidelines
for prevention of HIV infection in organ
and tissue transplantation. Can Dis Wkly
Rep 1989; 15 (suppl 4): 1-17

Nonoperative Management
for Blunt Splenic Trauma•
To the editors. In response to Tem
ple’s editorial (Can J Surg 1991;
34: 7-8), “Nonoperative manage
ment for adults with blunt splenic
trauma,” I agree that conservative
management of splenic trauma is
potentially hazardous if strict crit
eria are not adhered to. However. I
take exception to Temple’s claim
that these principles were applied
inappropriately in his centre, and
that, as a result, patients suffered
substantial morbidity. I trained at
his centre and, with Dr. W. Kidd,
initiated a review of how blunt
splenic trauma was managed there.1
Of the 70 cases of blunt splenic
trauma seen, 31% were initially ma

naged nonoperatively with a 77%
success rate, with no serious mor
bidity and with no deaths.
In the light of such well-docu
mented clinical work from his insti
tution, I question why Temple
chose to name his centre as an
example of one where blunt splenic
trauma is managed inappropriately.
Temple seems to favour operative
management for blunt splenic trau
ma as he quotes the success of
splenorrhaphy. I believe this rate
merely demonstrates that in those
cases reported, the spleen was not
seriously damaged. A substantial
number of those patients were like
ly subjected to an unnecessary lapa
rotomy when, with careful selec
tion, conservative management
would have sufficed.
I do not wish to detract from
Temple’s excellent review of splenic
trauma. I merely want to point out
to him that his institution has
played a major role in demonstrat
ing that blunt splenic trauma can be
managed conservatively in selected
cases.
Robert E.H. Khoo, MD, FRCSC, FACS
305 - 1167 Kensington Cres. NW
Calgary, AB
T2N 1X7

Reference
1. K idd WT, Lui RCK, K hoo R et al: The
management of blunt splenic trauma. J
Trauma 1986; 27: 977-979

To the editors. I appreciate Dr.
Khoo’s loyalty to our program and
agree that their study1 was a useful
contribution to the literature. How
ever, our experience since that re
trospective study of the conserva
tive management of blunt splenic
trauma was published would have
to include three incidents of major
morbidity. Two patients with a pre
sumptive diagnosis of a splenic in
jury were treated conservatively in
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error with a consequent delay in
treatment; they had transected vis
cera — pancreas in one and duode
num in the other. One patient, with
continued splenic hemorrhage, was
managed in the intensive care unit
for a number of days. These errors
would have been avoided by adher
ence to the guidelines that I dis
cussed,2 which must be coupled
with the realization that our current
radiologic studies are not good
enough to rule in or out other
visceral injuries. Therefore, when
dealing with adults with blunt sple
nic trauma, clinical judgement must
take precedence over indirect evalu
ations currently available to us.
When there is the slightest sugges
tion that conservative management
is failing, exploration should be
done with the expectation that splenorraphy will be carried out. I also
predict that our judgement will be
dramatically improved by our rapid
ly increasing abilities using laparo
scopic evaluation and surgery.
Dr. Khoo’s letter also points out
some very important misunder
standings about the value of retro
spective literature. First, if a retro
spective study identifies a negative
experience or an unexpected one, it
will tend to not be published, thus
leading to one-sided reporting in
the literature. Second, a retrospec
tive study frequently misses impor
tant events, because patient data is
captured through a relatively crude
system of coding. For instance, our
two patients who had transected

viscera would not have been coded
at all for a splenic injury. Prospec
tive studies and ongoing morbidity
evaluation, as we have continued to
do, more accurately assess the
problem. Third, at best, retrospec
tive data can only generate hypoth
eses, which must then be tested in
prospective trials. This has been
clearly demonstrated by the contro
versy over what is the appropriate
surgery in breast cancer and by its
resolution as a result of randomized
studies.34
I would encourage Dr. Khoo to
continue to study this issue pro
spectively and report to this journal
in the future.
Walley J. Temple, MD, FACS, FRCSC
Director of surgery,
Tom Baker Cancer Centre,
1331 - 29th St. NW
Calgary, AB
T2N 4N2
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An Unusual Case of Tear
of Spleen
To the editors. A 28-year-old
woman was seen in the emergency
department of the Temiskaming
Hospital in New Liskeard, Ont.,
complaining of abdominal pain. She
was 20 weeks’ pregnant and said
that she had been vomiting fre
quently for the last 3 to 4 hours. At
the time of admission the vomiting
had stopped, but she complained of
abdominal pain.
Over the next 3 hours her pain
increased. Signs of a hemoperitoneum developed. Her blood pres
sure fell and pulse rate increased.
Her hemoglobin level, which was
119 g /L initially, fell to 90 g /L ;
her leukocyte count was elevated at
23.0 X 109/L .
At laparotomy, a hemoperitoneum was found and 1700 mL of
blood was removed from the perito
neal cavity. There was bleeding
from the inferior pole of the spleen,
and one of the short gastric vessels
was bleeding profusely. Peritoneal
toilet was carried out and the bleed
ing vessels were tied off. Splenecto
my was not performed. She made a
smooth recovery.
It appears that the vessels in the
lower pole of her spleen were torn
as a result of severe and continuous
vomiting.
H.F. Jeffrey, MD
Bag F
Haileybury, ON
P0J 1K0
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Prescribing Information
ACTION
ERGAMISOL (levamisole hydrochloride) is capable of
restoring impaired immune responses preferentially of
the cell mediated type in compromised hosts. Therapeutic
doses of levamisole restore to normal the functions of
monocytes (phagocytes) and T lymphocytes but do not
directly influence B cells.
Levamisole is rapidly absorbed from the gastrointestinal
tract follow ing a single oral ingestion of 150 mg. In
patients with neoplastic disease, a mean peak blood level
of 0.86 m cg/m L is attained within 2 hours of intake.
The half-life of elimination of levamisole alone is between
3-4 hours. The metabolites are eliminated more slowly
w ith a te rm inal half-life of approximately 16 hours.
Levamisole is extensively metabolized by the liver in man
and excreted mainly by the kidneys (70% over 3 days).
Approximately 5% is excreted in the feces. Less than 5%
of the unchanged dose is excreted in the urine and less
than 0.2% in the feces.
INDICATIONS
ERGAMISOL (levamisole hydrochloride) is indicated as
adjuvant therapy in poor prognosis malignant melanoma
following complete surgical excision and exclusion of
metastatic disease. In such patients, levamisole has been
shown to produce an improvement in relapse free survival
and overall survival when compared to observation alone,
particularly in patients aged 55 years or older.
ERGAMISOL is also indicated as adjuvant therapy, in com
bination with 5-fluorouracil, in patients with completely
resected D ukes’ stage C colon cancer. Evidence of
metastatic disease must be excluded before initiating
therapy. In patients with Dukes' stage C carcinoma of the
colon, a regimen of levamisole plus 5-fluorouracil has
been shown to produce significant reductions in both
cancer recurrence and overall death rate.
CONTRAINDICATIONS
Levamisole is contraindicated in patients with a known
hypersensitivity to the drug.
WARNINGS
ERGAMISOL (levamisole hydrochloride) has been asso
ciated with reversible leukopenia and agranulocytosis,
therefore it is essential that appropriate hematological
m o n ito rin g be done ro u tin e ly during therapy w ith
ERGAMISOL.
Patients should be instructed to report immediately any
sudden change in their state of health which may be man
ifested by influenza-like symptoms (fever, lassitude, sore
throat, shivering or sweating) so that appropriate hema
tological testing can be done.
Leukopenia (total WBC below 3000/mm3) is not neces
sarily a sign of impending agranulocytosis; recovery is
possible w ithout withdrawal of the drug. However, with
a reduced neutrophil count (less than 20% of the total
white blood cell count) levamisole should be discontinued
permanently. (Agranulocytosis is attributed to antibody
form ation and absorption of immune complexes. This
process initiates complement activation and cell lysis; lev
amisole itself does not directly damage granulopoiesis.)
The HLA genotype B27 predisposes to the development
of agranulocytosis, particularly in females with concomi
tant rheumatoid arthritis. The onset is frequently sudden
and may be asymptomatic. Following discontinuation of
levamisole, neutrophil counts normalize within a week to
10 days. There is no evidence that steroids or WBC trans
fusions are of significant therapeutic value; prophylaxis
of infection during the acute phase of agranulocytosis
should be an important consideration.

PRECAUTIONS
Drug Interactions; The therapeutic effect of levamisole
may be antagonized by concomitant administration of cor
ticosteroids.
Additional caution is necessary when levamisole is used
in combination w ith other drugs potentially affecting
hemopoiesis.
Levamisole has been reported to produce “ANTABUSF""like side effects when given concomitantly with alcohol.
ADVERSE REACTIONS
Approximately half of all patients treated with ERGAMISOL
(levamisole hydrochloride) experience adverse effects of
the medication. Due to the interm ittent nature of the
dosage schedule, drug discontinuation may not be nec
essary for successful resolution.
The adverse reactions observed when levamisole is used
in combination with 5-fluorouracil are consistent with
those anticipated if 5-fluorouracil is given alone in a com
parable dose and schedule.
The incidence of adverse reactions for levamisole alone
in malignant melanoma patients and for levamisole plus
5-fluorouracil in colonic cancer patients is presented in
Table I.
An encephalopathy-like syndrome has been reported.
TABLE I: INCIDENCE OF ADVERSE REACTIONS
IN PATIENTS TREATED WITH LEVAMISOLE FOR
MALIGNANT MELANOMA OR COLONIC CANCER.
INCIDENCE (%)
LEVAMISOLE LEVAMISOLE+5-FU
COLONIC
MELA
INDUC MAINTE
NOMA
TION
NANCE

ADVERSE REACTIONS
GASTROINTESTINAL
24
nausea
vomiting
6
diarrhea
taste change
10
anorexia
1
MUCOCUTANEOUS
stomatitis
1
4
dermatitis
severe
alopecia
conjunctivitis
hyperpigmentation
HEMATOLOGICAL
leukopenia
10
2000 to 4000/mm3
less than 2000/mnf
thrombocytopenia
50000 to 130000 /mm’
less than 50000 /mm!
1.4
agranulocytosis
MUSCULOSKELETAL
arthralgia/myalgia
8
NEUROLOGIC
visual change
smell change
headache
dizziness/vertigo
ataxia
anxiety/i rritabi Iity
depression
insomnia
somnolence
impaired thinking
OTHER
fatigue/weakness
8
fever
impaired liver function

37
8
25
2

56
17
47
7

27
8
1
4
1

28
22
1
22
7
2

38
7

38
2

4
2

18
4

2

4

1

2
2
5
4
3
2
2
1
1
2

5

11

1

2

1
1
1
2
1

SYMPTOMS AND TREATMENT OF OVERDOSAGE
There is no experience of overdosage with ERGAMISOL
(levamisole hydrochloride). At high doses ERGAMISOL
exhibits positive inotropic and chronotropic properties on
heart muscle as well as convulsant properties. General
supportive measures are recommended.
DOSAGE AND ADMINISTRATION
In patients with malignant melanoma
ERGAMISOL (levamisole hydrochloride) should be admin
istered at a dose of 2.5 mg/kg given as a single daily dose,
preferably at night, on 2 consecutive days every week.
Higher doses are not recommended as they are associated
with increased toxicity and have not been shown to
provide any additional therapeutic benefit.
In patients with Dukes' stage C carcinoma of the colon
Levamisole plus 5-fluorouracil should be administered
only by or under the supervision of qualified physicians,
experienced in cancer chemotherapy, and well versed in
the use of potent antimetabolites.
Therapy with ERGAMISOL may be initiated as soon after
resection as patients are able to tolerate oral medication,
but no sooner than one week and no later than five weeks
after surgery.
ERGAMISOL should be administered orally at a dose of
50 mg t.i.d., for three consecutive days, every two weeks.
This therapy should be continued for at least one year.
Administration of 5-fluorouracil should be timed to begin
concomitantly with the second three day course of lev
amisole. The initial dosage of 5-fluorouracil should be 450
mg/nf/day, given intravenously, for five consecutive days.
Four weeks following the initial five day course of 5-fluorouracil, patients should begin maintenance therapy on
a once weekly basis with an intravenous injection of 5fluorouracil at a dose of 450 mg/m!. Treatment should
continue for as long as levamisole is administered.
If the patient experiences stomatitis, diarrhea or leukope
nia, the weekly 5-fluorouracil administrations should be
deferred until these side effects have subsided. If these
side effects are moderate to severe in intensity, 5-fluorouracil should be resumed with a 20% reduction in
the dose.
Dosage Forms:
Availability: ERGAMISOL tablets 50 mg are available in
blister packages of 36 tablets.
Storage:
ERGAMISOL tablets 50 mg should be stored
at room temperature and protected from
moisture and light.
Product monograph available on request.
1. Moertel CG et al. Levamisole and fluorouracil for adju
vant therapy of resected colon carcinoma. New Engl
J Med. 1990;322:352-8.
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Comparison of Mild and Deep
Hypothermia: Do They Provide Similar
Protection in All Neonatal Hearts?
C. Wittnich, DVM, MSc; W. Vincenti, MD; T.A. Salerno, MD
Despite various techniques of hypothermia it is still difficult to provide optimal
myocardial preservation in neonatal cardiac surgery. The early effects of moderate
and deep hypothermia were examined in neonatal pig hearts by studying metabolism
over time and the tolerance of the hearts to global ischemia. The latter was
measured by the time to onset of ischemic contracture, an indicator of irreversible
ischemic damage. After control right ventricular biopsies were done, 56, 3-day-old
neonatal hearts were excised and placed in one of four temperature-regulated baths
(37°C, 25°C, 19°C, 12°C). A compliant left ventricular balloon measured onset time
to ischemic contracture (TIC) (2 mm Hg increase in pressure). Biopsies were also
done at 15 and 30 minutes of ischemia.
Progressive hypothermia significantly (p < 0.001) prolonged TIC but resulted in
an increased standard error of the mean (SEM). Lactate accumulation was the least
in deep hypothermia (12°C, 19°C) (p < 0.05) and intermediate with moderate
hypothermia (25°C), and all were less (p < 0.01) than that at normothermia. The
decline of adenosine triphosphate was slowed more by hypothermia than
normothermia. These observations can be used to improve current methods of
myocardial preservation in neonatal hearts.

Malgre diverses techniques d’hypothermie, il demeure difficile d’assurer une
conservation optimale du myocarde en chirurgie cardiaque neonatale. Les effets
immediats d’une hypothermie moderee ou profonde ont ete mesures sur des coeurs
de pores nouveau-nes sur lesquels on a etudie le metabolisme par rapport au temps
et la tolerance a une ischemie totale. Cette derniere mesure a porte sur le temps
ecoule jusqu’a l’apparition des contractures ischemiques, un indicateur d’un
dommage ischemique irreversible. Apres prise de biopsies ventriculaires temoins, 56
coeurs de nouveau-nes de 3 jours ont ete excises et places dans un ou l’autre de
quatre bains a temperature controlee (37°C, 25°C, 19°C, 12°C). Un ballonnet de
compliance ventriculaire gauche a servi a mesurer le temps d’apparition des
contractures ischemiques (TCI) (augmentation de la pression de 2 mm Hg). Des
biopsies ont aussi ete prelevees apres 15 et 30 minutes d’ischemie.
Une hypothermie progressive a significativement (p < 0.001) prolonge le TCI,
mais au depens d’une augmentation de l’ecart-type de la moyenne (ETM).
L’accumulation de lactate etait moindre sous hypothermie profonde (12°C, 19°C) (p
< 0.05), intermediate sous hypothermie moyenne (25°C) et, dans tous les cas,
moindre que sous normothermie (p < 0.01). La chute de 1’adenosine triphosphate
fut ralentie par l’hypothermie, comparativement a la normothermie. Ces observa
tions pourraient etre utiliser pour ameliorer les methodes actuelles de conservation
du myocarde du nouveau-ne.

has been the single
Hypothermia
most important component of
myocardial protection for more than
30 years.1 Various techniques have
evolved for use in pediatric cardiac
surgery, including moderate (25°C)
and deep (19°C, 12°C) hypo
thermia, with or without cardio
pulmonary bypass (CPB), or circula
tory arrest, or both.2-5 However, the
effects of hypothermia on cardiac
metabolism in ischemia remains
poorly documented in neonates.
The purpose of this study was to
examine, in neonatal pig hearts, the
effects of varying degrees of clinical
hypothermia (25°C, 19°C, 12°C).
The early metabolic responses of
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these hearts during global ischemia
were documented as a function of
time. In addition, the ability of the
myocardium to tolerate ischemia
under these conditions was mea
sured using the time-to-ischemiccontracture model, a useful and
well documented method of assess
ing tolerance or resistance to isch
emic damage.6-8
Materials and Methods

Fifty-six 3-day-old piglets were
anesthetized with sodium pentobar
bital (30 mg/kg), intubated and
mechanically ventilated. After a
midline sternotomy, full-thickness
biopsies of the right ventricle were
taken by freeze-clamping segments
of the myocardium supplied by dis
tal coronary vessels. The hearts
were then excised, and this time
was noted as the onset of ischemia.
The hearts were placed in a subs
trate-free Krebs-Henseleit (SFKH)
bath at the following temperatures:
37°C (9 hearts); 25°C (9); 19°C
(20); and 12°C(18).
Myocardial temperature was
monitored by means of a Shiley
probe (Shiley Inc., Irvine, Calif.) in
the left ventricle. A compliant bal
loon was inserted into the left ven
tricle through the left atrium and
sutured to the apex of the heart.
The balloon was inflated to a pres
sure of 10 mm Hg through pres
sure tubing connected to a Bell &
Howell transducer (Bell & Howell
Instruments, Pasadena, Calif.) and a
Honeywell AR6 recorder (Honeywell
Information Systems, Pleasantville,
NY), allowing pressure in the bal
loon to be recorded continuously.
Additional sequential right ventricu
lar biopsy samples were taken at 15
and 30 minutes of ischemia. These
samples were obtained by freeze
clamping more proximal samples of
the myocardium and were stored at
—90 °C. Onset time to ischemic
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contracture (TIC) was recorded as
the time when pressure increased
by more than 2 mm Hg (TIC0) and
peak TIC when the pressure
reached a plateau (TICP). The time
difference between onset and peak
ischemic contracture (ATIC) was
also noted. The biopsy samples
were assayed for tissue lactate and
adenosine triphosphate (ATP).9
Concentrations were expressed per
gram of wet weight, and myocardial
wet to dry weight percentages were
determined for those biopsies. Data
were expressed as the mean ±
standard error of the mean (SEM)
and analysed by analysis of variance
and the Bonferroni test for compari
sons between temperature groups.
All animals were -treated humanely
in accordance with the guidelines of
The Canadian Council on Animal
Care.
Results

Both TIC0 and TICP were signifi
cantly (p < 0.001) prolonged with
progressive hypothermia, as was
the ATIC in each group at different
temperatures (Table I). It should be
noted also that with progressive
cooling the SEM became more pro
nounced.

nificantly more lactate (p < 0.001).
The moderate (25 °C) hypothermic
group was intermediate between the
other two with significantly more
lactate accumulation than the deep
hypothermic group (p < 0.01) but
significantly less than the normo
thermic group (p < 0.05). There
were no significant differences at
any time interval between 19°C and
12°C hypothermia in tissue lactate
accumulation.
Adenosine Triphosphate Levels
(Fig. 2)
Control adenosine triphosphate
levels were similar in all groups. At
15 minutes of ischemia ATP levels
were the lowest in the normotherm
ic group. Only minimal decline was
noted in the deep hypothermic
groups (19°C, 12°C), and an in
crease that was not significant was
noted in the moderate hypothermic
group (25°C). At 30 minutes of
ischemia ATP levels were signifi
cantly better preserved in all hypo
thermic hearts (p < 0.05) than in

Myocardial Lactate Levels (Fig. 1)
Control myocardial lactate levels
were similar in all groups. In the
first 15 minutes of ischemia, there
was no significant lactate accumula
tion with deep hypothermia (19°C,
12°C), there was a threefold accu
mulation of lactate with moderate
hypothermia (25°C) and a signifi
cant (p < 0.01), fourfold accumula
tion of lactate with normothermia.
By 30 minutes of ischemia, deep
hypothermia still demonstrated only
marginally elevated tissue lactate
concentrations, and normothermic
hearts continued to accumulate sig

Control

15

30

Ischemia, min

FIG. 1. Myocardial tissue lactate
(nmol/g) accumulation at 15 minutes
and 30 minutes of ischemia compared
with preischemia control values. Nor
mothermic hearts (broken line) are
compared with moderate hypothermia
(25°C, dotted line) and deep hypo
thermia (19°C, thick solid line, and
12°C, thin solid line).* = p < 0.01
from 37 °C; V = p < 0.05 between
25°C and 37°C or deep hypothermia
(19°C, 12°C).

HYPOTHERMIA FOR MYOCARDIAL PROTECTION

normothermic hearts. There was a
difference between 15 and 30 min
utes in the degree of ATP decline
between the hypothermic groups,
the greatest decline being at 25°C
and the least at 12°C. This could
account for the differences in TIC
seen between these groups.
Water Content
Across all groups, control myo
cardial water content was 72.7% ±
2.0%, and there was no significant
increase in water content over the
first 30 minutes of ischemia.

Discussion
A wide range of hypothermic
temperatures is used in clinical neo
natal heart surgery. Variations in
myocardial temperature, owing to
collateral circulation rewarming the
heart, may be particularly important
in congenital cardiac repair.10 Myo
cardial temperature ranges from 6°
to 25°C were reported in a group of

FIG. 2. Myocardial tissue adenosine
triphosphate (ATP) fiim ol/g) changes
at 15 and 30 minutes of ischemia
compared to preischemia control val
ues. Normothermic hearts (broken
line) are compared with moderate hy
pothermia (25°C, dotted line) and deep
hypothermia (19°C, thick solid line,
and 12°C, thin solid line). At 30
minutes hypothermia groups show sig
nificantly (p < 0.05) less decrease in
ATP than normothermia.

patients who underwent cold potas
sium cardioplegia and topical myo
cardial cooling with moderate hypo
thermia and aortic cross-clamping.3
The death rate was decreased in
patients who underwent cold cardi
oplegia, topical cooling and deep
(5° to 15°C) systemic hypo
thermia.3
The effect of this wide range of
hypothermia on myocardial metabo
lism in newborn hearts has not been
documented before. In neonates
most reports emphasize the effects
of either moderate or deep hypo
thermia on cerebral function and
the sensitivity of the central ner
vous system to this intervention.5 In
their paper on the effects of deep
hypothermia used during newborn
open-heart surgery, Shida and asso
ciates11 examined total body meta
bolic responses. They reported that
carbohydrate metabolism was pre
dominantly anaerobic (glycolysis),
with hyperglycemia and lactacidemia occurring during hypo
thermia.11 However, myocardial me
tabolism was not specifically ad
dressed. Other reports comparing
either deep hypothermic circulatory
arrest with limited cardiopulmonary
bypass versus conventional cardio
pulmonary bypass techniques dem
onstrated that infants in the first
few months of life, subjected to
conventional techniques, had a high
death rate.2 The combined tech
nique of deep hypothermic circula
tory arrest and limited cardiopulmo
nary bypass was thus particularly
useful in this age group.2 Operating
time during circulatory arrest is
reported to be limited by cerebral
damage rather than by any deleteri
ous effects on the myocardium.2
Adult data, examining the time
course of metabolic changes during
profound hypothermic cardioplegia
at 10 and 60 minutes, demonstrated
that these hearts had less intramyocardial lactate accumulation but a
greater decrease in ATP and cre

atine phosphate than did hearts
subjected to moderate hypothermia
(15°C). Kaijser and associates12
suggested that at lower tempera
tures energy generation processes
are thwarted more than energy con
sumption. The low temperature of
7.6°C reported in this adult study is
not commonly used or reported in
neonates. Our data demonstrated a
temperature-related decrease in lac
tate accumulation with no signifi
cant difference between hypo
thermia of 12°C and 19°C and an
intermediate effect with hypo
thermia of 25°C. The maximal ac
cumulation at normothermia was as
expected. The rapid decrease in
ATP we observed at 37°C was
blunted by hypothermia. However,
there was still a 25% decrease by 30
minutes with no statistical differ
ences between 12°C and 19°C. In
the 25°C group there was an initial
insignificant increase in ATP which
by 30 minutes had decreased to the
level of the other hypothermic
groups. This initial increase in ATP
may be a result of the balance of
supply and demand alluded to in the
paper by Castaneda and associates.2
Despite the protective effect of hy
pothermia, as evidenced by signifi
cantly less decrease in ATP levels
and less accumulation of lactate,
the ATP decrease eventually result
ed in ischemic contracture (Table I).
Only the rate of ATP decline is
progressively less with varying de
grees of hypothermia. The early
trend of metabolic profiles demon
strated in the first 15 minutes of
ischemia could be influenced by the
time required for the heart to reach
the appropriate temperature. All
hearts in this study reached their
temperatures within 1 to 2 minutes
of placement in the bath. Therefore
this factor cannot account for the
differences observed.
The clinical paper of Hammon
and colleagues13 examined cardiac
metabolism in children aged 1.16 ±
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this was significantly better than in
the normothermic group which
demonstrated a 60% decrease. Mod
erate hypothermia allowed ATP to
be maintained initially. This was not
sustained, and levels had dropped
rapidly by 30 minutes. The TIC was
prolonged with progressive hypo
thermia. However, with deep hypo
thermia this protection was not uni
formly afforded to all hearts. Al
though deep hypothermia did ap
pear to provide better protection, no
additional benefit within 30 minutes
of ischemia could be seen by going
to 12°C. These differences in neo
natal heart responses to various
clinically used levels of hypothermia
must be considered as we develop
strategies for improving myocardial
protective techniques in newborn
heart surgery.

0.3 years who underwent a variety
of cardiac operations with cold po
tassium cardioplegia. Of the 20 pa
tients studied, a large proportion
demonstrated at least a 40% de
crease in ATP concentration during
the ischemic period. This was also
reported in children with tetralogy
of Fallot who underwent cardiac
repair.14 Normal pig hearts in our
study also demonstrated ATP de
creases that were not prevented by
deep hypothermia.
With increasingly colder tempera
tures there was greater variability in
the TIC, which was most pro
nounced at 12°C. This could imply
that at deep hypothermia some
hearts are not as well protected as
one would anticipate.

Conclusions
The technical assistance of Mr. M.P.
Belanger and secretarial assistance of
Ms. V. Simpson are gratefully acknowl
edged. The materials donated by Ethicon and Wallis Carter Ltd. are also
appreciated.

We have documented, in new
born hearts, the early metabolic
responses to varying degrees of
clinically relevant hypothermia.
Lactate still accumulates during hy
pothermia, although significantly
less with deep than with moderate
hypothermia. No additional benefit
was seen at 12°C compared to
19°C. The ATP concentration had
decreased 25% by 30 minutes of
ischemia in hypothermic groups;
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ischem ic
contracture

TIC0
TICP
a TIC
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n

Tem perature
25°C

37 °C

37.0 ± 3.9
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12°C
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870.3 ± 40.9
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Tum our Dormancy: Initiation,
Maintenance and Termination in Animals
and Humans
T.H.M. Stewart, MB, ChB, FRCPC;* A.C. Hollinshead, PhD;t S. Raman, PhD$
The authors review the natural occurrence of tumour dormancy in man and animal
models, which show the importance of cellular defence mechanisms in inducing and
maintaining the state of tumour dormancy. Six cases of non-small-cell lung cancer
are described. The patients exhibited moderate to very strong delayed
hypersensitivity reactions to soluble lung-cancer antigen after specific
immunotherapy. Three patients had nonregional metastases at 11, 12 and 14 years.
Two had regional recurrence after 9 years, and in one patient a small hilar-node
metastasis was found at autopsy after 7.6 years. In each case an immunodepressive
event or drug treatment preceded resurgent growth. The effect of renal
transplantation in patients with a history of surgery for cancer supports the
conclusion that cellular defence mechanisms are crucial for the maintenance of
tumour dormancy in man.

Les auteurs passent en revue la survenue naturelle d’une inactivity tumorale chez
l’homme et dans les modeles experimentaux chez l’animal. Ce phenomene montre
l’importance des mecanismes de defense cellulaires pour provoquer et maintenir un
etat d’inactivite tumorale. Six cas d’epitheliomas du poumon autres qu’a petites
cellules sont decrits. Les patients ont revele des reactions d’hypersensibilite retardee
de moderees a tres fortes a des antigenes solubles du cancer du poumon apres une
immunotherapie specifique. Trois patients ont presente des metastases eloignees
apres 11, 12 et 14 ans. Deux on eu une recidive regionale apres 9 ans et, chez un
patient, une petite metastase au ganglion hilaire fut decouverte a l’autopsie apres
7,6 annees. Dans chaque cas, une immunodepression provoquee par un evenement
ou un traitement medicamenteux a precede la reapparition de la tumeur. L’effet
d’une greffe renale chez les patients qui ont des antecedents de chirurgie pour
cancer, soutient la conclusion que les mecanismes de defense cellulaire sont
primordiaux pour le maintien de l’inactivite tumorale chez l’homme.
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Those unknown forces which can keep
cancer cells dormant in the vicinity of
the exsected primary tumour or in the
lymph nodes or distal anatomical re
gions for a mammoth number of years
before their resurgence point to a great
auxiliary defensive power resident in the
host in some cases.
Sir Gordon Cordon-Taylor, KBE, CB. FRCS1

he phenomenon o f tumour dor
mancy in man has long been
recognized by pathologists,2'3 sur
geons14 and radiotherapists.5 On
reading these older papers by distin
guished authors one is struck by
the close agreement between them
on the possible mechanisms sug
gested for the initiation, mainte
nance and eventual termination o f
the dormant state (Table I). These
opinions were formed after a life
time o f observation. Table II lists a
group o f human tumours in which
dormancy has been observed; nota
ble by its absence is lung cancer.
Animal models have been de
signed to understand how tumour
dormancy may be established, main
tained and terminated.6-9 The sali
ent points that have emerged from
this work are as follows: Rats or
mice can be immunized to resist
growth o f inoculated malignant
cells: in the models described by
Alexander7 approximately 10% o f
immunized animals died quickly o f
distant metastases following inocu
lation, yet the rest remained tu
mour-free for 18 months, more

T
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than half their normal life span; at
least half of the immunized animals
carry dormant metastases that be
come manifest only after treatments
that are immunosuppressive, such
as whole-body irradiation, thoracicduct drainage or cyclosporine thera
py; in the model of Wheelock and
colleagues69 an intraperitoneal tu
mour dormant state is maintained
by immunologic mechanisms involv
ing lymphocytes, macrophages and
the production of physiologic quan
tities of cytokines; renewed tumour
growth is seen after the administra
tion of prostaglandin E2 or by anti
body inactivation of 7-interferon
and tumour necrosis factor, two
cytokines that can down-regulate
tumour growth in vitro.8

Clinical Data
Lung Cancer

In 1977 we published10 a survival
study on a group of 55 patients
with stage I or stage II (American

Table I. Conclusion of Distinguished
Pathologists, Radiologists and Surgeons on
Mechanisms of Tumour Dormancy
Induction
Metastases at time of
surgical excision are
prevented from growing
by a potent force causing
mitotic arrest
Maintenance This host resistance,
long-maintained cancer
immunity, is susceptible
to breakdown
Termination Advancing age, distress of
surgery, herpes zoster,
endogenous depression
Table II. Tumours in Which Dormancy Has
Been Observed (After Gordon-Taylor1)
Carcinoma of
Carcinoma of tongue,
cheek, lip
breast
Carcinoma of
Carcinoma of
hypopharynx and
stomach
esophagus
Carcinoma of
Carcinoma of body of
colon
pancreas
Carcinoma of
Carcinoma of kidney
rectum
Wilms’ tumour Osteoblastic sarcoma
Intraocular melanoma
Melanoma
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Joint Committee for Cancer Staging
and End Results Reporting) carcino
ma of the lung who were in a
randomized clinical trial of specific
active immunotherapy. In particular
we reported on the strengths of
delayed hypersensitivity reactions
(DHRs) seen on late testing of vari
ous subsets of patients with soluble
cancer antigen derived from autolo
gous or allogeneic sources (Fig. 1).
The strongest reactions, mean
greatest diameter at 48 hours, were
seen in the 13 patients who had
received immunochemotherapy, fol
lowed by the 16 patients who had
received immunotherapy, and both
groups had stronger reactions than
the 26 nonimmunized patients. We
suggested then that these strong
reactions reflected a heightened cel
lular defence against microscopic
foci of residual disease. In 1979
those with the strongest DHRs to
tumour antigen showed better sur
vival than those who had immuno
therapy,11 and in 1980 both groups
of patients showed better survival
than nonimmunized patients.12 Im

munochemotherapy consisted of
high-dose methotrexate as a modu
lator of vaccination with soluble
allogeneic antigens homogenized in
Freund’s complete adjuvant. Eight
of these 13 patients have survived
more than 10 years; 3 had nonregional metastases, with no new pri
mary tumour, discovered 11, 12
and 14 years after the primary
surgery. The cases histories of
these patients have been described
in detail8 (Table III).

Case 1. The first had a 9-cm
poorly differentiated adenocarcino
ma removed by a left pneumonecto
my in October 1976. He received
immunochemotherapy and re
mained tumour-free until a cerebral
metastasis (an adenocarcinoma) was
discovered in July 1987. A liver
computed tomography scan showed
no evidence of tumour at the time
of staging of the metastatic tumour.
Five months after cerebral irradia
tion and systemic administration of
steroids a liver metastasis was
found, which grew until his death
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FIG. 1. Intensity of induration at 48 hours on late testing for delayed hypersensitiv
ity to soluble cancer antigen. Mean greatest diameter was 4.8 mm, 11 mm and 33.4
mm respectively for nonimmunized, immunized and immunochemotherapy groups.
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13 years after the primary surgery.
An intensive search failed to reveal
a new primary tumour.
Case 2. The second patient had a
left pneumonectomy in March 1974
for an adenoid cystic carcinoma, 4
cm in diameter, arising from a sec
ondary bronchus in the upper lobe
of the left lung. He received immunochemotherapy. Six years after
the surgery he had an acute myo
cardial infarction. After 12 years he
presented with painful liver metastases. At autopsy 12 weeks later his
right lung was tumour-free.
Case 3. The third patient under
went right upper lobectomy in Au
gust 1973 for two primary adeno
carcinomas, one poorly differentiat
ed and one well differentiated. A
parietal pleural resection was need
ed because of adhesions. At 7 and
12 years after the lobectomy she
experienced severe endogenous de
pression requiring psychiatric hos
pitalization. On the 14th anniversa

ry of the primary surgery a right
scalene-node metastasis of adeno
carcinoma was removed, just adja
cent to the remote parietal pleural
resection.
In each of these patients resur
gence of the malignant disease fol
lowed an immunosuppressive drug
or event: in the first case liver
metastasis followed steroid therapy;
in the second liver metastasis fol
lowed a heart attack, immunosup
pressive up to 22 months;1314 and
in the third case tumour growth
followed severe endogenous depres
sion, a condition recognized to be
immunosuppressive and often to
herald reactivation of long dormant
cancer.8
The rarity of metastases occur
ring more than 10 years after pri
mary surgery is demonstrated in
Table IV,15-20 covering a patient
observation period of 31 years. The
eight patients from Ottawa who

T a b le III. D ata o n T h re e P a tie n ts F ro m O tta w a G eneral H o s p ita l S e rie s W ith La te N o n re g io n a l
M e ta s ta s e s and N o N e w P rim a ry T u m o u r
P atien t
S ex

A ge, yr

P rim a ry tum our

C ourse

M

58

P o o rly d iffe re n tia te d
a d e n o c a rc in o m a , T 2N 0

M

44

A d e n o id c y s tic c a rc in o m a , T 2 N 0

F

57

A d e n o c a rc in o m a , T 2 N 0

B ra in m e ta s ta s is 11 y r - ce re b ra l
irra d ia tio n and s te ro id s
L iv e r m e ta s ta s is 11 y r 5 m o
M y o c a rd ia l in fa rc tio n 6 y r
L iv e r m e ta s ta s is 12 y r
E n d o g e n o u s d e p re s s io n 7 and
12 y r
S c a le n e -n o d e m e ta s ta s is 14 y r

M ax
DH R , m m
20 x7

31 x 31
55X35

DHR = d e la ye d h y p e rs e n s itiv ity re a ctio n .

T a b le IV . F re q u e n c y o f Late N o n re g io n a l M e ta s ta s e s F ro m S ix P u b lis h e d S e rie s C o m p a re d W ith
T h a t o f th e O tta w a E x p e rie n c e

S ource

N o. p a tie n ts
s u rvivin g
> 10 yr

No. p a tie n ts w ith m e ta s ta s e s
seen a fte r 1 0 yr
No.

%

B e lc h e r & A n d e rs o n , 1 9 6 5 15
A b b e y S m ith , 1 9 7 0 ’ 6
A b b e y S m ith , 1 9 8 1 17
P a u lso n & R e is ch , 1 9 7 6 '8
T e m e c k , F le h in g e r & M a rtin i, 1 9 8 4 19
K irs h and a s s o c ia te s , 19 7 6 20

143
49
151
50
118
53

2
2
4
2
0
1

14
4 1
2 .6
40
0
1.9

T o ta l

564

11

2 .0

8

3

3 7 .5

O tta w a s e rie s

survived more than 10 years are
included in this table; three of them
had nonregional metastases discov
ered over a 19-month period, an
incidence that is 18-fold greater
than that reported for the six pub
lished series shown in Table IV. The
six published series are consistent
with the estimated overall occur
rence of 2% from the combined
series (x2 = 5.02, df = 5, p =
0.41). Comparison of the occur
rence rate of metastases after more
than 10 years between the Ottawa
experience (37.5%) and the experi
ence of the six series overall (2%)
yields a highly statistically signifi
cant result (p = 0.0006, based on
Poisson probability). Even if the
comparison is made with the high
est incidence reported (4.1%),16 the
results remain significant (p =
0.005). The observed outcome is
consistent with a relative-risk esti
mate of 18.75 (95% CL, range from
11.25 to 26.25) of nonregional me
tastases, based on our sample of
eight patients surviving 10 years or
more. The sample size of eight has
a statistical power of 75% to detect
a relative risk of 15 or more, at a
type I error level of 5%. Hence our
sample size, although small, is large
enough to detect such a high rela
tive risk of the occurrence of nonre
gional metastases.
A more recent report21 on the
incidence of recurrence of adenocar
cinoma or large-cell anaplastic car
cinoma in a large series has shown
no local or nonregional recurrence
after 7 years, with a follow-up of 12
years for some patients. All patients
had T1N0 disease at the time of
initial surgery. Two patients in Ot
tawa have been seen with late accel
erated local recurrence after treat
ment with steroids.
Case 4. The first of these was a
59-year-old woman who underwent
right lower lobectomy for squa
mous-cell carcinoma (T1N0) in AuCJS, VOL. 34, NO. 4, AUGUST 1991
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gust 1976. She also received immunochemotherapy in the initial tri
al. At 5 months she had a strong
DHR to 100 ng of soluble squa
mous-cell antigen (32 X 27 mm
induration) but 6 months later this
declined to the prevaccination level
(10 X 9 mm induration), despite
strengthening reactions to recall an
tigens. This prompted the opinion
that she had local, occult recur
rence. She was followed up closely
and over 7 years chronic interstitial
pneumonitis developed in each
lung. In October 1984 she was seen
with a 3-month history of fever, a
12.3-kg weight loss and marked
changes on the chest x-ray film
(Fig. 2a). Following a bronchial
biopsy, a right middle lobectomy
was done. Histologically there was
widespread fibrosis, lymphocytic in
filtration with lymphoid follicles and
multifocal areas of severe bronchial
dysplasia and carcinoma in situ. She
received a 6-month course of pred
nisone, 40 m g/d. In February 1986
a chest x-ray film showed ill-defined
lesions in the upper lobe of the left
lung (Fig. 2b). She died 2 months
later. At autopsy much of the left
upper lobe was airless because of
tumour infiltration, and there was a
subpleural lesion in the left lower
lobe. Mediastinal nodes were free of
tumour.
Two points may be made from

this case report: the patient had
accelerated tumour growth after
steroid therapy; and the chest x-ray
films possibly reflected a host re
sponse to multifocal microscopic
foci of disease, much as is seen in
pulmonary tuberculosis.
Case 5. The second of these
patients was a 43-year-old woman
who underwent right upper lobecto
my for an adenocarcinoma (T1N0)
in February 1980. One year after
immunotherapy she had a strong
DHR to tumour antigen (54 X 40
mm induration). She remained well
until November 1988 when she
complained of a 5.9-kg weight gain
and a 1-year history of asthma. A
chest x-ray film showed no evidence
of recurrence or metastases. After
diagnostic challenge in the respira
tory laboratory topical cortisone by
aerosol and prednisone 10 mg oral
ly, twice daily, were prescribed for 1
week, and the therapy was repeated
in January 1989. By July stridor
prompted the finding of ipsilateral
and mediastinal metastases, con
firmed by biopsy. No new primary
tumour was found. She died 10
years after the primary surgery.
Autopsy revealed extensive adeno
carcinoma in the remaining right
lung and in the left lung.
Case 6. Another patient, a
67-year-old man, had a right pneu

FIG. 2. Case 4. (a) Chest film in October 1984 shows diffuse interstitial
abnormality. Heart size is normal, (b) Film obtained in February 1986 shows
ill-defined patchy shadowing in left upper lobe. Heart size is increased.
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monectomy in April 1981 for a
large-cell anaplastic carcinoma
(T2N0), measuring 8 X 6 cm. At 1
year he had a DHR of 23 X 20 mm
induration to 100 pg of anaplastic
antigen after immunotherapy. Dur
ing the following years his course
was complicated by a mild left-sided
stroke in 1982, a myocardial infarc
tion in December 1984 and again in
1987 accompanied by pneumonia.
He died of acute bronchopneumonia
on Dec. 26, 1988. At autopsy an
incidental finding was an 11-mm
metastasis in a contralateral hilar
lymph node with anaplastic carcino
ma, very similar in morphology to
the original primary tumour. Mitot
ic figures were frequent in the pri
mary and in this small metastasis. A
scrupulous search failed to reveal a
new primary tumour. Had this pa
tient survived, the metastasis
should have become clinically ap
parent well after 8 years from the
time of primary resection.
Curative Surgery for Cancer,
Followed by Renal Transplantation
At the Ottawa General Hospital
we encountered a case in which
there was a resurgence of malig
nant disease after curative surgery
that was followed by immunosup
pressive therapy and renal trans
plantation.
Case 7. A 49-year-old woman
with polycystic kidney disease had a
right mastectomy in 1981 for a
ductal breast carcinoma with in
volvement of three of four axillary
nodes. She received tamoxifen for 2
years. In July 1987, when she was
clinically free of tumour she re
ceived a cadaveric renal transplant.
In March 1988 ipsilateral supraand infraclavicular metastases ap
peared. She had received cyclospo
rine, steroids and the immunosup
pressive monoclonal antibody
OKT3, also Imuran for immunosup-

TUMOUR DORMANCY

pression. She died in November
1989. Autopsy failed to show a new
breast primary tumour. It is of
interest that a consultant oncologist
expressed his foreboding in January
1987, wondering what the proposed
immunosuppression would do to
the breast cancer, and in April 1987
he warned the patient that her
tumour might recur after the renal
transplant.

suggests that resurgent tumour
growth after transplantation is due
to release of immunologic restraint.

Conclusions
In humans and animals cellular
immune mechanisms play a crucial
role in initiation and maintenance of
the tumour-dormant state. Im
munosuppressive events or drugs
lead to renewed growth. We sug
gest that specific active immuno
therapy induces tumour dormancy
in some lung-cancer metastases,
particularly adenocarcinoma, and
that the prognosis in such patients
can be improved.

This dramatic case prompted cor
respondence with Dr. J.R. Jeffery,
director of the transplant program
at the Health Sciences Centre in
Winnipeg. He described a similar
case.
Case 8. This woman had under
gone a left mastectomy for adeno
carcinoma in 1971. In May 1977
she received a cadaveric kidney
transplant. Imuran and prednisone
were given for immunosuppression.
Forty-two months later bilateral,
malignant pleural effusions devel
oped, containing well-differentiated
adenocarcinomatous cells. She died
in August 1981, but an autopsy did
not reveal any other source for
these metastases.
These two Canadian cases have
been added to the seven cases of
late tumour recurrence following
renal transplantation reported by
Penn,22 and summarized in Table V.
Penn describes late recurrences as
those developing more than 5 years
after treatment of the original ma
lignant tumour. The very close re
semblance of these cases to that of
termination of the tumour-dormant
state with cyclosporine in animals
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Cardiac Transplantation: Treatment
for Cardiogenic Shock
S.J. Jackson, MD; A.R.C. Dobell, MD, FRCSC, FACS; N. Poirier, MD, FRCSC;
A.J. Guerraty, MD, FRCSC; J.F. Symes, MD, MSc, FRCSC
Eighty-six patients received orthotopic cardiac transplants at the Royal Victoria
Hospital in Montreal between 1985 and 1989. Of these, 16 were mortally ill, being
sustained in hospital by the intravenous administration of inotropic agents (15
patients [94%]) or intra-aortic balloon counterpulsation (6 [38%]). There was one
early death (at 7 days), for a death rate of 6.3% (versus 8.6% for the 70 “elective”
transplants). Two others died of delayed infection: one of viral hepatitis at 6 weeks,
and one of pneumonia due to Pneumocystis 4 months after transplantation. The
other 13 patients are alive and well 12 to 66 months postoperatively. Nine have
returned to their preoperative work, three have decreased activity levels but are
functioning well, and one is retired.
Entre 1985 et 1989, 86 patients ont reu une greffe cardiaque orthotopique a
l’Hopital Royal Victoria de Montreal. Parmi ceux-ci, 16 etaient a Particle de la mort,
etant maintenu en vie, a l’hopital, a l’aide d’agents inotropes administres par voie
intraveineuse (15 patients [94 %]) ou d’un ballonnet intra-aortique a contre-pulsation (6 [38 %]). Un deces precoce a ete enregistre (apres 7 jours), pour un taux de
mortality de 6.3 %(comparativement a 8.6 % pour les 70 cas «differes»). Deux autres
sont morts d’infections tardives : un d’hepatite virale apres 6 semaines et un de
pneumonie a Pneumocystis, 4 mois apres la greffe. Les 13 autres patients sont
vivants et en sante, de 12 a 66 mois apres Toperation. Neuf sont retournes a leur
travail, trois ont reduit leurs activites et un est a la retraite.

ardiac transplantation is now
recognized as an acceptable
treatment for end-stage cardiac fail
ure.1 This is, in part, due to im
proved immunosuppressive regi
mens that include cyclosporine.2'3
As the results of transplantation
improve, the criteria for transplant
eligibility are broadening. Recently,
it has been shown that the results
after transplantation are excellent
even in mortally ill patients who
need intensive support to maintain

C

an adequate cardiac output.4-5 At
this centre 86 patients underwent
heart transplantation between 1985
and the end of 1989. Of these, 16
were identified as being in cardio
genic shock preoperatively, being
sustained in the intensive care unit
by the intravenous administration
of inotropic agents or by intra
aortic balloon counterpulsation, or
both. In this paper we review our
experience with these “emergency”
transplants to assess the outcome

and compare these results with
those obtained in more elective set
tings. We also include two case
reports that are representative of
the type of patients described as
mortally ill.

Patients and Methods
Data on the 16 mortally ill trans
plant recipients are presented in
Table I. The mean age was 47 years
(range from 19 to 58 years) at the
time of transplantation. Eleven of
the 16 patients were considered for
transplantation because they had
end-stage coronary atherosclerosis;
5 were suffering from cardiomyopa
thy (3 rheumatic and 2 idiopathic).
The number of inotropic agents
used ranged from one to three
(average two) per patient. Eight
patients were also receiving at least
one antiarrhythmic agent intrave
nously. Of the 11 patients so inves
tigated, all had a left ventricular
ejection fraction under 20%.
Over the same time period, eight
other mortally ill patients were con
sidered candidates for transplanta
tion, but died while awaiting a
suitable donor.

Results
From the Cardiovascular Research Unit, Royal Victoria Hospital, Montreal, Que.
Presented at the 10th annual meeting o f the Canadian Society o f Cardiovascular and Thoracic
Surgeons, held in conjunction with the 59 th annual meeting o f the Royal College o f Physicians
and Surgeons o f Canada, Toronto, Ont., Sept. 15, 1990
Accepted fo r publication Nov. 7, 1990
R eprint requests to: Dr. J.F. Symes, Cardiovascular Research Unit, Royal Victoria Hospital, 687
Pine Ave. W, Montreal, PQ H3A 1A1
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Three of the 16 patients who
received cardiac transplants died.
One patient had no neurologic func
tion postoperatively and died after 7
days. One other patient was well
until 5 weeks after transplantation
when a fulminant viral hepatitis

CARDIAC TRANSPLANTATION

developed, resulting in death 41
days postoperatively. The third pa
tient died 4 months postoperatively
of Pneumocystis carinii pneumonia.
The long-term success rate is thus
81%. The remaining 13 patients
were alive and well at the time of
this study. The mean follow-up was
40 months (range from 12 to 66
months). Nine of these 13 patients
resumed full-time work, 3 have de
creased activity levels but are func
tioning well, and one patient has
retired.
Of the 70 patients who received a
cardiac transplant on a more elec
tive basis, 59 are still alive, for a
long-term success rate of 84.3%.
There were seven (10%) deaths
within 30 days of surgery and four
(5.7%) delayed deaths (Table II).

Case Reports
Case 1
A 53-year-old physician under
went cardiac transplantation in
1985. He had been well until ap
proximately 8 weeks before trans
plantation when he began complain
ing of dyspnea on moderate exer
tion, fatigue and retrosternal chest
pain on at least one occasion. Four

weeks later, while travelling to Eu
rope for vacation, he sustained an
acute anteroseptal myocardial in
farction while in flight. He was
hospitalized for 2 weeks in an in
tensive care unit. After 6 days ven
tricular tachyarrhythmias devel
oped, necessitating defibrillation on
over 70 occasions. He was flown
back to a hospital in Montreal and
needed defibrillation several times
during the flight. Two days after
arrival, and while on maximal ino
tropic support, an intra-aortic bal
loon was inserted. He was intubated
and ventilated but continued to
have episodes of ventricular ta
chyarrhythmias despite antiarrhythmic medications, and so, was as
sessed for cardiac transplantation.
He was alert and oriented with a
blood pressure of 9 0 /7 0 mm Hg.
Laboratory results included the fol
lowing: leukocyte count 18.0 X
109/L , serum creatinine 106
(umol/L, normal liver function test
results, Pao2 90 mm Hg, PaC02 38
mm Hg (fractional intake of oxygen
[Fio2] 80%, positive end-expiratory
pressure [PEEP] 5 mm Hg). A chest
x-ray film showed a left lower-lobe
pneumonia. Cultures of sputum and
blood both grew Klebsiella sp. This
infection was treated with appropri
ate antibiotics. Five days after as

T a b le 1. Data on 16 M ortally III Patients
S u p p o rt/c o m p lic a tio n

Inotropic agents
Antiarrhythmic agents
Intra-aortic balloon counterpulsation
Mechanical ventilation
Pneumonia
Renal failure*
Hepatic fa ilu ref

N um ber

P e rc e n t

15
8
6
9
9
4
4

94
50
38
56
56
25
25

'Serum creatinine > 120 ^ m o l/L .
tS erum bilirubin > 35 M m ol/L.

T a b le II. Death Rates
D e a th ra te , % of p a tie n ts
Type of p rocedure

Emergency
Elective

O p e ra tiv e

Lon g -term

6.3
10.0

19.0
5.7

sessment for transplantation, the
patient was transferred to our insti
tution, as a compatible donor was
available. Cardiac arrest occurred
en route to the operating room and
cardiac massage was necessary. The
transplantation procedure was car
ried out and his postoperative sta
tus remained precarious. Hemodial
ysis was needed. Within 24 hours
the patient was weaned from intra
venous inotropic support as well as
from intra-aortic balloon counter
pulsation. Weaning from the respi
rator was delayed because of a flail
chest secondary to the preoperative
cardiac massage. He remained in
anuric renal failure, requiring daily
hemodialysis for 2 weeks. He re
ceived parenteral hyperalimentation
for 3 weeks. After being comatose
for 2 days, his mental status rapidly
improved. He was discharged from
hospital 5 weeks postoperatively.
The patient was well 5 years and
6 months after transplantation. He
had had no episodes of clinical
rejection and was working full time.

Case 2
A 57-year-old former construc
tion worker had a 1-year history of
class II angina with dyspnea that
was never treated. Four weeks be
fore transplantation, he presented
to a Montreal hospital with an an
teroseptal and lateral myocardial in
farction. The echocardiogram re
vealed a large anteroapical left ven
tricular aneurysm. The patient re
mained stable until 3 weeks after
admission when he had a cardiac
arrest requiring 45 minutes of ex
ternal massage. He was resuscitated
but remained in cardiogenic shock
despite intra-aortic balloon counter
pulsation and maximal doses of
inotropic agents. He was thus as
sessed for transplantation.
His blood pressure was 7 5 /4 0
mm Hg and his body temperature
CJS, VOL. 34, NO. 4, AU G U ST 1991
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was 39.2°C. Auscultation revealed
rales at both lung bases as well as a
large pericardial rub heard anterior
ly. Laboratory findings included a
platelet count of 68.0 X 109/L .
The serum urea and creatinine lev
els and liver function test results
were normal. The Fi02 was 100%,
Pa02 75 mm Hg and PaC02 45 mm
Hg. The left ventricular ejection
fraction was measured at 10%.
The patient was transferred to
our institution where he remained
in a precarious state for 6 days until
a donor heart was obtained. Preoperatively, treatment was instituted
for a pneumonia due to Pseudomo
nas infection (confirmed by culture
of sputum and blood). He was
placed on cardiopulmonary bypass
in order to dissect out the massively
dilated heart and the aneurysm rup
tured during the dissection. Postoperatively, the patient remained ven
tilator-dependent for 4 days. Serum
creatinine levels rose to 310
Mmol/L and total serum bilirubin
levels rose to 76 /unol/L. The
platelet level dropped to 4.0 X
109/ L 3 weeks postoperatively, re
quiring replacement of cyclosporine
with azathioprine. He received par
enteral hyperalimentation for 6
weeks. The patient remained quite
somnolent for 3 weeks, presumably
due to his preoperative shock state.
He was discharged from hospital 13
weeks after surgery, neurologically
intact.
The patient was well 4 years and
11 months after transplantation.
He had no episodes of clinical rejec
tion and was totally independent.

Discussion
Cardiac transplantation is an ac
cepted therapeutic option in the
treatment of end-stage cardiac dis
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ease.1 The routine evaluation of a
potential recipient includes assess
ment of both the physical and psy
chological status of the patient.
Acceptable candidates have irrevers
ible terminal cardiac disease but
should be otherwise in good health
and motivated toward maintaining
good postoperative health practices.
This detailed assessment is neces
sary to maximize the success rates
of the transplantation program,
which is essential, owing to the
short supply of donor organs. For
this reason it has generally been
accepted that patients who are mor
tally ill, should not be candidates
for transplantation. Recent reports
have shown that this need not be
the case. Reports from both the
National Heart Institute in London
and the University of Pittsburgh
have shown acceptable results when
even mortally ill patients received
cardiac transplants.2-3 The results in
our small series lead us to the same
conclusion. Our operative death
rate with the mortally ill patients
was 6.3% and the long-term death
rate was also acceptable at 19%
(ranging from 12 to 66 months
postoperatively). These figures lead
us to believe that mortally ill pa
tients should not always be denied
the opportunity for a transplant
because of their poor preoperative
status.
This is not to imply complete
endorsement of the policy that
donor hearts should always go to
the sickest patients. We support the
policy stated above, namely that
potential recipients require system
atic evaluation to exclude those
with noncardiac disease or those
unlikely to be compliant, so that
maximal benefit is achieved from
the limited number of donor hearts.
Clearly, the risk must be higher in
the cohort of patients presented in

this communication, but we were
surprised at the salvage rate
achieved. This was due not only to
remarkable intraoperative and post
operative care by the many individu
als involved, but also perhaps to
some extent to the short interval
between the onset of significant
cardiac disease and the transplanta
tion procedure. The results may
also reflect the complete reversibili
ty of secondary organ damage once
adequate cardiac output is achieved.
We conclude that in patients with
end-stage cardiogenic shock who
are being sustained in an intensive
care setting, cardiac transplantation
is a reasonable consideration. These
patients seem to do as well postop
eratively as do those who are treat
ed on a more elective basis and
therefore should not always be de
nied the opportunity of definitive
treatment.
We gratefully acknowledge the assis
tance of Carole Magnan, RN, and Si
mone Sirois, RN, in gathering data
included in this report.
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Small-Bowel Carcinoid Presenting
in Association With a Phytobezoar
J.W. Lorimer, MD, FRCSC;* M.W. Allen, MD;t H. Tao, MD, FRCPC;$ B. Burns, MD, FRCPC§
An unusual case of a recurrent, postoperative, small-bowel obstruction is presented.
The obstruction was due to a phytobezoar proximal to the site of a primary carcinoid
of the small bowel. The radiologic findings of a mobile, intraluminal filling defect
and a more distal, fixed mural mass are reviewed. The cause of the recurrent
obstruction was likely a “ball-valve” effect of the phytobezoar at the site of stenosis
caused by the carcinoid. This case emphasizes the value of small-bowel imaging in
repeated small-bowel obstruction.
On decrit un cas inhabituel de recidive d’une obstruction postoperatoire du grele.
L’obstruction etait causee par un phytobezoard proximal au foyer d’un carcinoide
primitif de l’intestin grele. L’observation radiographique d’un defaut de remplissage
intraluminal mobile et d’une tumeur murale fixe plus eloignee est passee en revue.
La cause probable de Tobstruction recidivante etait l’effet de “soupape a flotteur” du
phytobezoard au point de stenose cause par le carcinoide. Ce cas met en lumiere
Timportance des techniques d’imagerie du grele lors d’obstructions a repetition.

is an unusual cause
A carcinoid
of small-bowel obstruction, as

is a phytobezoar. Bezoars of vegeta
ble origin are usually associated
with previous gastric resection, oc
curring as a consequence of the
disturbed gastric motility and de
creased gastric acidity. Bezoars are
also associated with ingestion of
large amounts of roughage, notably
persimmons.1-3 On review of the
literature, it has been our impres
sion that phytobezoars forming in
association with other chronic sub

acute obstructions have been rare,
although in this context adhesions,
tumours, polyps and Meckel’s diver
ticula have been reported.4 In this
report we describe a case of inter
mittent small-bowel obstruction
with a phytobezoar proximal to the
site of a partially constricting smallbowel carcinoid.
Case Report

A 60-year-old man presented with

From the *Department o f Surgery, Ottawa General Hospital, Ottawa, Ont.
fResident, Department o f Surgery, University o f Ottawa, Ottawa
fDepartment o f Radiology, Ottawa Civic Hospital, Ottawa
§Pathoiogist, University o f Ottawa, Ottawa
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a 6-week history of crampy mid
abdominal pain. This typically oc
curred twice per week, 1 hour after
a meal, and lasted about 1 hour.
Relief was usually heralded by a
loose brown bowel movement. His
wife had noted loud bowel sounds
during these episodes. During the 6
weeks he had lost 3.2 kg but
otherwise felt well. On the day of
admission the pain was worse than
usual and had persisted for several
hours.
He had been admitted to hospital
six times in the past 8 years for
small-bowel obstruction, including
two obstructions in the previous 3
months. His only past surgery was
an appendectomy at 37 years of
age. There was no history of unusu
al ingestion of fibre.
On examination this moderately
obese man had a heart rate of 68
beats/min, a blood pressure of
180/115 mm Hg, a respiratory rate
of 20/min and a temperature of
36°C. The general physical exami
nation was unremarkable. On ab
dominal examination distension,
normal bowel sounds and mild right
lower quadrant tenderness without
guarding were noted. Plain abdomi
nal radiographs revealed multiple
air-fluid levels. The admitting com
plete blood count, electrolyte levels,
renal function and glucose level
were all within normal limits.
Initially he was treated conserva
tively with nasogastric suction and
intravenous fluids. After 48 hours
the obstruction had not resolved
and a small-bowel antegrade enema
CJS, VOL. 34, N O . 4, A U G U S T 1991
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was performed. This study revealed
two abnormalities in the middle
portion of the small bowel. There
was a mobile intraluminal filling
defect (Fig. 1). Just distal to the
intraluminal filling defect was a
mural mass protruding into and
partly occluding the lumen (Figs. 2
and 3).
At laparotomy on the following
day a large number of adhesions
were lysed from his previous appen
dectomy. A constricting neoplasm
was discovered 100 cm from the
ileocecal valve. There was associat
ed thickening of the small-bowel
mesentery in that region. A wide
local excision was performed, with a
deep mesenteric resection. Also in
cluded in the resected specimen was
a phytobezoar which was found just
proximal to the tumour (Fig. 4). A
primary stapled anastomosis was
performed and his recovery was
uncomplicated.
The operative specimen (Fig. 5),
a segment of small bowel, included
a tumour which had narrowed the
lumen by 50%. It was a submucosally based carcinoid with extension
into the mucosa and the sub
mucosa. Four of five regional
lymph nodes recovered were posi
tive for cancer cells. The tumour
stained positive for neuron-specific
enolase, a sensitive marker for tu
mours of neuroendocrine origin.
The tumour was also positive for
the chromogranin stain which la
bels the dense core granules charac
teristic of neuroendocrine tumours.
A positive low-molecular-weight cytokeratin stain and a negative carcinoembryonic antigen stain indicat
ed that this tumour likely had an
epithelial nonadenomatous origin.
These tests all confirmed the diag
nosis of carcinoid.

instructive. The lesion presented as
an intermittent small-bowel obstruc
tion for an unknown length of time,
possibly as long as 8 years. The
obstructions had always resolved
with conservative management and
were presumed to be due to adhe
sions from his previous appendecto
my. A previous enteroclysis, per
formed 3 months before surgery,
had been considered normal. The

intermittent nature of the obstruc
tion could be accounted for by the
phytobezoar acting as a ball-valve
at the stenosis caused by the car
cinoid. Alternatively, the phytobe
zoar may have periodically broken
down and reformed, resulting in
intermittent obstruction. A similar
picture was described by Weinerman and colleagues in 1967.5 They
found a fruit-pit bezoar that had

FIG. 1. Intraluminal filling defect that was mobile during examination.

Discussion
This case was both unusual and
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FIG. 2. Mural mass encroaching on lumen of small bowel.

SMALL-BOWEL CARCINOID AND PHYTOBEZOAR

been causing recurrent obstruction
of the lumen of a normal terminal
ileum for over 44 years.
As an instructive case it reminds

us that not all recurrent small-bow
el obstructions in patients who have
had previous operations are due to
post-laparotomy adhesions. Also, in

the patient who is managed conser
vatively for a small-bowel obstruc
tion, perhaps greater emphasis
should be placed on post-resolution
small-bowel imaging, as this is the
only way to discover the occasional
obstruction due to an unusual
cause.
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T h e Natural History of Suspected
Scaphoid Fractures
Rick Zarnett, MD, FRCSC; Claude Martin, MD; Thomas W. Barrington, MD, FRCSC;
Dennis C. Evans, MD, FRCSC; Ian J. Harrington, MD, FRCSC; Gianni Maistrelli, MD, FRCSC;
Barry W. Malcolm, MD, FRCSC
Clinically suspected scaphoid fractures are common injuries. The authors
prospectively followed up, by serial radiography and bone scanning, 23 patients who
had a history of trauma to the carpus and associated localized tenderness to the
anatomic “snuff box”: in 15 patients the radiographs and bone scans were negative;
in 5 the radiograph was equivocal and the bone scan positive. The authors
concluded that patients with clinically suspected scaphoid fractures and negative
radiographs can be treated symptomatically without immobilization in a cast.
Patients with equivocal radiographs should be assumed to have a fractured scaphoid
and treated accordingly.

Les fractures scapholdes diniquement soupfonnees sont des blessures frequentes.
Les auteurs ont suivi de fa?on prospective, par radiographies seriees et scintigra
phies osseuses, 23 patients vus pour traumatisme carpien et sensibilite localisee
associee. Chez 15 patients, les radiographies et scintigraphies osseuses se sont
revelees negatives; 5 patients avaient des radiographies equivoques et des scintigra
phies positives. Les auteurs concluent que les fractures scaphoides soupconnees
diniquement peuvent etre traitees de fa?on symptomatique, sans immobilisation
dans un platre, quand les radiographies sont negatives. Les patients qui presentent
des radiographies equivoques devraient etre presumes souffrir de fractures et traites
en consequence.

he scaphoid is the most com
monly fractured carpal bone.
The true incidence of clinical frac
tures of the scaphoid, in which the
initial x-ray films appear normal or
are nondiagnostic but in which a
fracture is later demonstrated, is
controversial.12 Duncan and Thurs
ton3 reviewed 108 patients who had
clinical scaphoid fractures and were
unable to demonstrate any case of a
scaphoid fracture becoming visible
after a period of immobilization.
Failure to recognize and treat these

T

fractures early are among the fac
tors said to contribute to delayed
and nonunion. It has, therefore,
been recommended that patients
with clinical evidence of a scaphoid
fracture and negative x-ray films be
immobilized in a scaphoid cast and
reviewed at 10- to 14-day intervals
until the wrist is either asymptom
atic or a fracture has been demon
strated radiologically.3 The purpose
of this study was to determine the
accuracy of the initial physical ex
amination in evaluating patients
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with suspected scaphoid fractures
and to determine the natural history
of this injury.

Patients and Methods
All patients seen in the emergen
cy department of the Toronto East
General & Orthopaedic Hospital
Inc. and referred to the orthopedic
service with symptoms and signs of
a fractured scaphoid were consid
ered for entry into the study. Pa
tients were collected and studied
prospectively over a 6-month peri
od.
Patients were excluded if x-ray
films demonstrated any fracture (ei
ther in the hand, carpus or distal
radius), or if the patient had a
history of significant carpal injury.
Four standard radiographs, as de
scribed by Russe,4 were obtained
and interpreted by two independent
observers. Radiographs were report
ed as either negative or equivocal.
Equivocal radiographs were defined
as ones in which either observer
suspected a fracture, but in which
the films were nondiagnostic (no
fracture was clearly visible).
All patients were immobilized in a
scaphoid plaster leaving the interphalangeal joint of the thumb free.
Three-phase radionuclide imaging
was performed using technetium-99m dimethylene phosphonate
and an all-purpose collimator. A
single anterior view of the two
palms and wrists was obtained.

SCAPHOID FRACTURES

Scans were performed as early as
possible but no sooner than 48
hours after the injury. The bone
scans were interpreted as normal
when there was symmetrical activity
in both wrists, the same activity
present over the distal end of the
radius and ulna, and even activity
over the palm.35 Abnormal scans
were diagnosed when asymmetry
was noted between both hands or
between a focal area to adjacent
bones. Patients were followed up by
the consulting orthopedic surgeon,
clinically and radiographically, until
the fracture united or the symptoms
resolved. The results of bone scan
ning were not made available to the
treating physician until the conclu
sion of the study.

Discussion
Although the scaphoid is the
most commonly fractured carpal
bone, early recognition is some
times difficult. The incidence of
false-negative radiographs, reported
to range from 0 to 27%2 is contro
versial. In spite of this, Leslie and
Dickson1 believed that the true inci
dence of fractures that are not
visible initially is low and has been
exaggerated.
Radionuclide imaging has been
shown to be highly specific in de
tecting scaphoid fractures.6-9 Ganel
and colleagues5 demonstrated that a
normal bone scan excluded a frac-

ture of the scaphoid and that all
fractures not apparent on initial
radiographs were associated with an
abnormal scan.
In this study, all patients with
negative initial radiographs also had
negative bone scans. Symptoms in
these patients, resolved within 4 to
6 weeks. No fractures were visible
on subsequent radiographs. In each
patient who had an equivocal ini
tial radiograph, the bone scan was
positive. In each of these eight pa
tients, follow-up radiographs dem-

Findings
Twenty-three patients (11 male,
12 female) with clinical scaphoid
fractures and negative radiographs
qualified for inclusion into the
study. They ranged in age from 15
to 69 years (mean 30 years).
The patients were divided into
two groups: group A — 18 patients
with negative radiographs; group B
— 5 patients with equivocal radio
graphs. Bone scanning was per
formed on all patients at an average
of 5 days after injury.
In group A, all patients had a
negative bone scan. No fractures
were seen on subsequent follow-up
films. In all five patients in group B,
the bones scans were positive and
the follow-up films demonstrated a
fracture of the scaphoid bone, usu
ally at 4 to 6 weeks after injury
(Fig. 1).
In five patients from group A,
increased focal activity caused by
wrist fractures in bones other than
the scaphoid was seen (Fig. 2).
Three patients had increased activi
ty localized to the trapezium, one to
the distal radius and one to the
radial styloid.

beu 9veo
FIG. 1. (Top) Initial radiograph in this
47-year-old woman was interpreted as
equivocal for fracture in proximal pole
of scaphoid. (Bottom) Bone scan 5 days
after injury clearly demonstrates frac
tured scaphoid.

PALNAR
FIG. 2. (Top) Initial radiograph in this
24-year-old man failed to demonstrate
any abnormalities. (Bottom) Bone scan
3 days after injury demonstrated frac
ture in styloid process of radius.
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onstrated a fractured scaphoid.
We agree with Duncan and
Thurston3 that the true incidence of
fractured scaphoid in patients with
initially negative radiographs is
quite low. Certainly a great number
of patients with this relatively be
nign injury are “over treated.”
In conclusion, bone scanning is

an extremely accurate and reliable
method of detecting scaphoid frac
tures early. Patients without evi
dence of a scaphoid fracture on
initial x-ray films, but with a clini
cally suspected fracture, can be
treated symptomatically, without
plaster immobilization. Those pa
tients in whom the initial radio-

graphs are nondiagnostic or equivo
cal, should be assumed to have a
fractured scaphoid and treated as
such.
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T o x ic Megacolon Associated
With Anticancer Chemotherapy
C.J. de Gara, MB, BS, MS(Lond), FRCS(Edin), FRCS, FRCSC;* N. Gagic, MD, FRCSC;*
A. Arnold, MB, BS, FRCPC;t T. Seaton, MD, FRCPCI
The majority of gastrointestinal side effects associated with anticancer
chemotherapy are relatively mild and self-limiting and can be managed empirically.
However, severe side effects, such as necrotizing enterocolitis and ischemic colitis,
sometimes do occur after chemotherapy. The authors present a case of toxic
megacolon associated with anticancer chemotherapy. This is a relatively uncommon
but potentially lethal complication of ulcerative colitis.

La majorite des reactions indesirables gastro-intestinales reliees a la chimiotherapie
anticancereuse sont relativement benignes, evoluent spontanement vers la guerison
et peuvent etre traitees de fa?on empirique. Toutefois, des reactions indesirables
graves telles que l’enterocolite necrosante et la colite ischemique surviennent
parfois apres une chimiotherapie. Les auteurs signalent un cas de megacolon
toxique relie a une chimiotherapie anticancereuse. II s’agit la d’une complication
rare mais possiblement letale de la colite ulcereuse.

C

olonic responses to injury are
diarrhea, mucus discharge,
bleeding and dilatation. Diarrhea
may be caused by the maturation
arrest o f intestinal epithelium,
which may be induced by many
antineoplastic agents.1’2 A variety of
colitis syndromes occur in associa
tion with anticancer chemotherapy.
Neutropenia enterocolitis (typhlitis
or ileocecal syndrome) is a frequent
ly fatal complication of the treat
ment of hematologic malignant dis
ease. The findings are limited to the
ileum, cecum and ascending colon,
and symptoms include nausea, vom
iting, abdominal pain, diarrhea, melena and high fever.3 Pseudomem
branous colitis (Clostridium difficile

colitis) sometimes occurs in patients
receiving chemotherapy.4
Dosik and colleagues5 suggested
that pseudomembranous colitis,
agranulocytic colitis and acute isch
emic colitis occurring in patients
who have received antineoplastic
and antimicrobial regimens repre
sent the spectrum o f disease associ
ated with necrotizing colitis.
We present a case o f toxic mega
colon in a patient who had recently
undergone a course o f chemothera
py and antimicrobial therapy.

Case R eport
On Mar. 20, 1989 a 44-year-old
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premenopausal woman underwent a
segmental mastectomy for an infil
trating ductal breast carcinoma,
measuring 3 cm in diameter. The
tumour was estrogen receptor-posi
tive, and three o f the five lymph
nodes examined were positive for
cancer cells. Her history provided
no suggestion o f inflammatory
bowel disease. On Apr. 14, after
pretreatment with prochlorperazine
(10 mg) and decadron (8 mg), taken
orally, she received epirubicin 125
mg (70 m g /m 2) and 5-fluorouracil
900 mg (500 m g /m 2) intravenously
(repeated on days 1 and 8) and
cyclophosphamide 125 mg (75
m g /m 2) taken orally daily for 14
days, repeated monthly. By May 11
the patient had experienced mild
gastrointestinal symptoms, includ
ing hemorrhoids, diarrhea and mu
cositis. She received her fifth cycle
o f chemotherapy on Aug. 10 and 1
week later was admitted with febrile
neutropenia. This was treated with
piperacillin, tobramycin and van
comycin. Escherichia coli was cul
tured from the urinary tract. De
spite the crampy abdominal pain
and diarrhea, stool culture was neg
ative, as was culture for C. difficile
toxin. Colonoscopy to 60 cm re
vealed diffuse ulceration, and the
biopsy specimens showed evidence
o f acute and chronic nonspecific
inflammation. Successful manage
ment with intravenously adminis
tered metronidazole allowed the pa
tient to be discharged home on
Sept. 1. She received no further
CJS, VOL. 34, NO. 4, A U G U S T 1991
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courses of chemotherapy. On Sept.
18 she was readmitted as an emer
gency patient with increasing stool
frequency, severe abdominal pain
and distension. She was distressed
and diaphoretic but normotensive;
she exhibited sinus tachycardia
(pulse rate of 140 beats/min) and
had a temperature of 37.5°C. The
hemoglobin level was 65 g/L , and
she had a relative leukopenia of 5.4
X 109/L . The serum electrolyte
levels and coagulation screen re
sults were within the normal range,
but the serum albumin level mea
sured 13 g/L and the glucose level
20 mmol/L. The results of the
blood cultures were negative. Ab
dominal radiographs demonstrated
a dilated transverse colon measur
ing 13 cm (Fig. 1). In the intensive
care unit intravenous fluids, ste
roids (Solu-Medrol) and antibiotics
(ampicillin, metronidazole, to
bramycin) were started.
Serial abdominal films, obtained
on Sept. 22, showed free intraperitoneal gas. At emergency lap
arotomy the entire thin-walled fria
ble colon was found to be dilated,
but no perforation site was obvious,
nor was there any fecal soiling. A
subtotal colectomy with a Brook
ileostomy and stapled (TA-90
4.8-mm staples; Auto Suture Cana
da, St-Laurent, Que.) closure of the
rectal stump was carried out. Dur
ing the colonic resection some fecal
spillage occurred. Histologic exami
nation revealed an ulcerated hemor
rhagic mucosa of the transverse,
descending and sigmoid colons and
chronic inflammatory cells within
the submucosa and muscle layers.
Pseudopolyps were present. There
were no granulomas. The findings
were consistent with the diagnosis
of toxic megacolon.
The postoperative course was
complicated by recurrent bouts of
septicemia, neutropenia, candidemia
(requiring treatment with intrave
nous amphotericin), azotemia and
340
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liver dysfunction. On day 10 postoperatively, 200 mL of fluid drained
from the lower end of the wound.
Radiography after a Gastrografin
enema confirmed that disruption of
the stapled rectum had occurred.
On Oct. 14 a proctectomy was
performed, and the perineum was
packed open. Histologic examina
tion of rectal and anal specimens
revealed multifocal ulceration and
degenerative changes of the surface
epithelium. A few inflammatory
cells and early fibrosis were present
in the lamina propria.
After this second surgical proce
dure improvement was slow but
steady. The patient was discharged
approximately 6 months after re

ceiving the first course of chemo
therapy.

Discussion
In 1950 Marshak, Lester and
Friedman6 first coined the term
toxic megacolon. In 1955 Truelove
and Witts7 defined the criteria for
toxic megacolon: an erythrocyte
sedimentation rate more than 30
mm/h, diarrhea (more than six
bowel movements daily), hematochezia, fever, tachycardia and a
colonic diameter greater than 9 cm
demonstrated radiologically. Toxic
dilatation of the colon occurs in 2%
to 8% of all incidents of ulcerative

FIG. 1. Abdominal radiograph of transverse colon, showing dilatation measuring 13
cm.

TOXIC MEGACOLON AND CHEMOTHERAPY

colitis.8 In as many as 30% of
patients, toxic megacolon may be
the first manifestation of the dis
ease.9 Toxic megacolon may affect
patients at any age; the youngest
patient reported was 12 years old. A
major centre may expect to see two
to three patients per year with this
condition.10
Factors predisposing to toxic me
gacolon include hypokalemia, bari
um enema, colonoscopy, the admin
istration of opiates, anticholinergic
and antidiarrheal agents, and C.
difficile.11 Our patient, who present
ed with the classic signs of toxic
megacolon, had many of these pre
disposing factors. She had under
gone anticancer chemotherapy and
had neutropenia, symptomatic man
agement of diarrhea with Lomotil,
colonoscopy and antibiotic therapy.
It is known that 5-fluorouracil can
cause colitis12 and mucositis.13 Epirubicin is an analogue of dox
orubicin and was developed primari
ly to avoid the cumulative cardiotoxic effects of doxorubicin.14 In a
recent communication Hickish and
colleagues15 found that the major
toxic side effect of epirubicin was
mucositis, which occurred at doses
of 120 m g/m 2. Below this dose the
agent was well tolerated. By com
parison, our patient received a rela
tively low dose, 70 m g/m 2, and had
mucositis before toxic megacolon.
A case of toxic megacolon has been
reported in association with metho
trexate use for the treatment of
psoriasis.16 A 10-year review of the
literature did not reveal any other
cases in which toxic megacolon was
associated with anticancer chemo
therapy.
Toxic megacolon remains a po
tentially lethal condition, having an
overall death rate of 20%. Binder,
Patterson and Glotzer,17 reviewing
497 patients, found that only 29%
were managed successfully on medi

cal therapy alone, and in that group
there was an associated 30% death
rate. Furthermore, Sirinek and col
leagues18 found that 50% of pa
tients who were successfully ma
naged medically ultimately required
colectomy. However, surgery is not
without risks as was shown by
Strauss and associates.10 They re
viewed 31 series of patients (604
patients) reported between 1955
and 1975. The perforation rate was
42%, and the overall surgical death
rate was 20%. Surgery in the ab
sence of perforation carried a 9%
mortality, but in the presence of a
colonic perforation, the rate rose to

41% . 10
The fate of the retained rectum in
patients who undergo a subtotal
colectomy and ileostomy for toxic
megacolon remains a vexing ques
tion. The choice between a subtotal
colectomy and proctocolectomy is
difficult. Emergency proctocolecto
my in the severely ill patient is a
considerable undertaking and re
moves the chance of restoring intes
tinal continuity at a later date.
Alternatively, retaining the rectum
with a subtotal colectomy permits
ongoing inflammation. In a recent
study by Heppell and colleagues19
of 65 patients, of whom 22 had a
rectal preservation procedure for
toxic megacolon in association with
ulcerative colitis, 25% subsequently
required a proctectomy. Of the 12
patients who required surgery for
toxic megacolon secondary to
Crohn’s colitis, 83% required proc
tectomy.
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D N A Flow Cytometry of Large-Bowel
Biopsies Showing That Adenoma Tissue
Predicts the Ultimate Nature
of the Lesions
J.V. Frei, MD, PhD; M.M. Troster, MD; H.M. Cramer, MD; V.J. Martinez, BA, RT; M. Cook, BA, RT
Ploidy of neoplastic large-bowel cells in lesions from which biopsies showed only
adenoma tissue by histopathologic examination was investigated retrospectively by
DNA flow cytometry. Biopsy and resected-specimen blocks gave interpretable ploidy
profiles from 83 lesions. The expectation that adenomas will show diploidy in
biopsies and that adenocarcinomas will show aneuploidy in biopsies was fulfilled in
80% of the lesions. In addition, four lesions with diploid biopsies were polyps with
minimal invasion. Thus, diploidy would have correctly predicted that local resection
was adequate treatment for 62 lesions and conversely that cancer resection was the
appropriate treatment for 8 lesions, for an overall predictive success rate of 87%. In
conjunction with endoscopic, radiologic and other data, DNA flow cytometry of
biopsies from apparently benign large-bowel lesions could become a useful addition
to therapeutic decision-making.

On a etudie de fapon retrospective a la cytometrie de debit du DNA l’heteroploldie
des cellules neoplasiques du gros intestin lors de lesions ou les biopsies n’avaient
revele que du tissu adenomateux. Les biopsies et les prelevements de resection ont
permis d’etablir les profils chromosomiques de 83 lesions. La presomption que les
biopsies d’adenomes seraient diploides et que les adenocarcinomes seraient aneuploides s’est verifiee dans 80 % des cas. De plus, quatre lesions avec biopsies
diploides etaient des polypes avec envahissement minimal. En consequence, en
s’appuyant sur la dipioldie, on aurait pu prevoir correctement qu’une resection
locale etait un traitement adequat pour 62 lesions et, a 1’oppose, qu’une resection de
cancer etait indiquee dans 8 cas, pour un taux de succes previsionnel global de 87 %.
En association avec l’endoscopie, la radiographie et d’autres donnees, la cytometrie
de debit du DNA des biopsies provenant de lesions apparemment benignes du gros
intestin pourrait s’averer une addition utile au processus de decision therapeutique.
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s a result of the description of
the polyp-cancer sequence in
the large bowel by Morson and
associates12 in 1 9 7 4 -7 5 and the
observation that these lesions usu
ally progress slowly over decades, it
was realized that neoplasia in its
early stages could be cured by local
resection.3 A biopsy specimen of
such lesions obtained before resec
tion may show only adenomatous
tissue without invasion of the muscularis mucosae, which is the cur
rent criterion for malignancy. Some
of these tumours will show invasive
malignant disease in another part of
the lesion.
A biopsy is often performed to
detect malignant disease of relative
ly large lesions (diameter greater
than 2 cm) that appear benign
endoscopically, radiologically and
by inspection and palpation. Studies
of such lesions indicate that be
tween 9% and 24% of them are
malignant.4'6
The advent of DNA flow cytome
try offers the possibility that exami
nation of benign biopsy tissue may
aid in identifying the nature of the
lesion. The examination by DNA
flow cytometry of over 2000 colo
rectal neoplasms has been reported
in the literature7'31 (Table I). The
overall observation was that only

A
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18% of 426 adenomas, but 63% of
662 adenocarcinomas, displayed
aneuploidy by this technique. This
suggests that DNA flow cytometry,
in combination with histopathologic
techniques, would predict the pres
ence of a malignant lesion better
than morphologic methods alone.
This could be especially useful for a
biopsy specimen showing adenoma
tissue histologically but aneuploidy
by DNA flow cytometry. We exam
ined this proposition in a retrospec
tive study.

K igrials and Methods
Case Selection
The Department of Pathology re
cords of the three teaching hospi
tals at the University of Western
Ontario (University Hospital, Victo
ria Hospital and St. Joseph’s Hospi
tal) were searched for cases of colo
rectal neoplasms in which a biopsy
showing an adenoma — a neoplasm
without invasion of the muscularis
mucosae — was followed by a re
section of the lesion with an at
tempt at cure. Only cases in which
the biopsy specimen clearly origi
nated from the lesion that was later
resected were included. In some
cases several biopsy specimens
showed only adenoma tissue pre
ceding resection. All histologic
types of adenomas, except those
with severe anaplasia, such as sig
net ring formation, were included.
The paraffin blocks of biopsy speci
mens and of the resected lesions
were retrieved from storage for

DNA analysis by flow cytometry. In
all, 83 lesions were examined; there
were 123 biopsy blocks (average
1.48 per lesion, range from 1 to 6)
and 229 resection blocks (average
2.76 per lesion, range from 1 to 8)
that gave interpretable analyses.
DNA Flow Cytometry
We carried out DNA flow cy
tometry on paraffin blocks of each
lesion (biopsy or resection speci
mens), using a modification of the
method described by Hedley and
colleagues.3233 Briefly, 50-^01 sec
tions of each block were deparaffinized, rehydrated through an alco
hol series to water, pepsinized brief
ly, vortexed and filtered through a
37-ym nylon mesh to isolate indi
vidual nuclei. These were stained
with 4'-6-diamidino-2-phenylindole
(DAPI), and the DNA content of
about 50 000 nuclei from each
block was measured in the ICP 22A
flow cytometer (Ortho Diagnostic
Systems, Markham, Ont.) and dis
played on an Ortho 2140 analyser.
Apparent peaks were bracketed on
the histograms obtained and the
nuclei in each counted. Before each
day’s run the instrument was cali
brated with calf thymocytes (Ortho)
to set the diploid peak at channel
200 on the DNA scale. This was
repeated at the end of the run.
Interpretation
The printout of histograms was
initially evaluated blindly by one
author (J.V.F.). An interpretable

Table I. Aneuploidy in Colorectal Neoplasia: 25 Reports in Which DNA Flow Cytometry Was Used
Adenocarcinomas
Adenomas*
No. of lesions
Aneuploidy, %

Dukes’ stage

TA

TVA

A

B

C

232
13

194
24

225
46

718
58

719
74

*TA = tubular, TVA = tubulovillous and villous.
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graph was considered to be one in
which there were at least two clear
ly visible peaks, one at or just
below the pre-set 200 value (diploid
peak) and another at or below twice
that value. The lowering of some
DNA values in nuclei retrieved from
paraffin blocks was probably caused
by formalin fixation.33
The DNA index (DI) of the tetraploid peak was then calculated by
dividing its peak value by that of
the diploid peak value. It was ac
cepted as tetraploid (consisting of
cells in the G2 and M phases of the
cell cycle and of doublets of diploid
nuclei) if the DI was 2.00 ± 5%; if
the DI was below 1.90, it was
recalculated from the computer-pro
duced mean values of the peaks; in
all instances it was found to be in
the above range (Fig. la).
The percentage of nuclei in the
tetraploid peak was calculated from
the total number of nuclei in the
diploid and tetraploid peaks. This
percentage ranged between 2 and
24. The tetraploid peak was consid
ered to be a reflection of the pro
portion of cycling cells, albeit inac
curate, because it also measured an
unknown proportion of nuclear
doublets. When it was 25% or high
er, it was considered to represent a
tetraploid or near-tetraploid cell line
(one adenoma, two blocks, Fig. lb).
Calculations of the S phase of the
cell cycle were not attempted. Addi
tional peaks were seen in some
histograms. All were between the
diploid and the tetraploid peaks
(Fig. lc). They were considered to
represent aneuploid cell lines if the
DI of their peak was at least 10%
higher than that of the diploid peak
or 10% lower than that of the
tetraploid peak. In common with
other reports,7-31 therefore, an
aneuploid cell line was considered
to be present if two conditions were
satisfied: the presence of a distinct
peak additional to the diploid and
tetraploid peaks, and a DI differing

DNA FLOW CYTOMETRY

Occasionally there were double
peaks in the diploid or tetraploid
region that differed by less than

by 10% or more from that of the
normal cell nuclei present in the
paraffin blocks.
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10% from each other (Fig. Id).
These were considered to belong to
the normal cell population and to be
the result of uneven autolysis or
fixation of the specimen.33 In the
calculation of the ratios they were
added together.
In some instances there was a
fourth peak with a DI higher than
the normal tetraploid peak. This
type of peak always had a DI twice
that of the corresponding aneuploid
peak and was considered to repre
sent the aneuploid cell line cells in
the G2 and M phases of their cell
cycle as well as aneuploid nuclear
doublets. The percentage of aneu
ploid nuclei in this peak was calcu
lated as for the diploid nuclei, and
in only one instance did it exceed
24%.
As quality control, 20 consecu
tive coefficients of variation (CVs),
calculated by the flow-cytometer
computer, were examined for each
of the diploid, tetraploid and aneu
ploid groups of peaks. The CVs
were 5.13 ± 1.45, 4.11 ± 0.81 and
4.67 =t 1.63 in these groups respec
tively. Because these values are not
significantly different, the technical
quality of the analyses was not
affected by the ploidy status.
Statistical Analyses

FIG. 1. DNA flow cytometry profiles traced directly from computer histograms:
(a) normal tracing showing normal diploid and tetraploid peaks; (b) tetraploid cell
line with 26% of cells in tetraploid peak; (c) distinct aneuploid peak between normal
diploid and tetraploid peaks; (d) a “split” diploid peak considered to be artifact of
autolysis and fixation.

The x 2 test and other analyses
were done with the statistical pack
age of the University Hospital com
puter system.

Table II. Ploidy of Biopsy Specimen Compared With Nature of Resection Specimen

Results

Biopsy specimen
Diploid

Aneuploid

Resection specimen

No.

•/«*

No.

•/«*

of lesions

Adenoma
Adenocarcinoma

58t
io t
68

70
12

7§
8

8
10

65
18

Total

15

83

'Percentage of all lesions.
tOne aneuploid at resection (1%), one tetraploid at resection (1%).
JFour with stalk invasion only (5%), one aneuploid at resection (1%), two adenocarcinomas
aneuploid at resection.
§Three diploid at resection (4%).

Interpretable histograms of DNA
flow cytometry were obtained from
352 paraffin blocks containing neo
plastic tissue and representing 83
lesions. Histograms of at least one
biopsy specimen and one resection
block from each lesion were
analysed.
The ploidy of the biopsy speciCJS, VOL. 34. NO. 4. AUGUST 1991
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men was compared with the nature
of the resected specimen (Table II).
The distribution of ploidy between
adenomas and adenocarcinomas
showed a significant difference (p <
0.01). Biopsy specimens were found
to be diploid in 58 adenomas and
aneuploid in 8 adenocarcinomas, for
a total of 66 (80%) of the 83 lesions
in which ploidy correctly indicated
the type of lesion.
The 10 adenocarcinomas in
which the biopsy specimens were
found to be diploid represent a 12%
false-negative ploidy result within
the context of this investigation. Of
these 10 adenocarcinomas, 4 were
polyps with invasion of the head
only, which are curable by polypec
tomy.34-37 Thus, the number of op
erational false-negative biopsy re
sults is reduced to 6 (7%). Of the
remaining adenocarcinomas, two
were found to be aneuploid at resec
tion. Of the patients with adenocar
cinomas found to be diploid at
biopsy and resection, the biopsy
specimens in one patient showed
villous adenoma tissue present for
over 28 years before resection of a
Dukes’ stage B adenocarcinoma.
The patient was alive with metastases 1 year later. The second, also a
patient with Dukes’ stage B adeno
carcinoma, was alive with metastases 1 year later, but there was no
previous history of that lesion. The
third, a patient with Dukes’ stage A
adenocarcinoma, was alive and well
2 years later without evidence of
metastases. The fourth patient also
had a Dukes’ stage A adenocarcino
ma.
There were seven cases of adeno
mas in which the biopsy specimens
were aneuploid, an 8% false-positive
result. The paraffin blocks in three
of these cases were found to be
diploid at resection.
The biopsy or resection speci
mens of 19 lesions showed aneuploidy (Table III). The comparison
of ploidy between biopsy and resect
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mas and in diploid cell lines (Table
IV).

ed specimens showed that in eight
specimens (42%) the biopsy and the
resection blocks showed aneuploidy
with the same DI. This suggests
that the same single aneuploid cell
population was present. One of the
adenocarcinomas, however, was
heteroploid, showing two different
aneuploid peaks in the biopsy and
resection specimens. Of the remain
ing specimens, four (21%) showed
either different aneuploid DI in the
biopsy and resection specimens or
two different aneuploid cell popula
tions in the lesion, representing
aneuploid heteroploidy. Seven spec
imens (37%) were aneuploid only in
the biopsy specimens or the resec
tion blocks. This could also repre
sent heteroploidy, with a diploid
and an aneuploid cell population
present in the lesion. The difference
in distribution of the variants be
tween adenomas and adenocar
cinomas was not significant (p <

Discussion
The working hypothesis of this
investigation was that the ploidy of
biopsy specimens from large-bowel
lesions showing adenoma tissue his
tologically would differentiate ade
nomas (diploid biopsy specimens)
from adenocarcinomas (aneuploid
biopsy specimens) at resection. This
seemed feasible because a survey of
2088 lesions reported in the litera
ture7' 31 showed that 82% of adeno
mas were diploid and 63% of adeno
carcinomas were aneuploid. These
observations also indicated that
there would be false-negative (dip
loid in adenocarcinomas) and false
positive (aneuploid in adenomas)
ploidy readings of biopsy speci
mens. In spite of that, the predictive
values of the biopsy ploidy readings
could be better discriminators than
histopathologic methods alone,
which, when showing only adenoma
tissue, will not predict whether the
lesion is an adenoma or an adeno
carcinoma.
DNA flow cytometry was per
formed on appropriate archival par
affin blocks from 83 neoplastic
large-bowel lesions. The results
supported the hypothesis in 80% of
the cases: diploid biopsy specimens

0 . 2).
The nuclei in the tetraploid peak
are derived from cells in the G2 and
M phases of the cell cycle as well as
from an unknown contribution of
diploid nuclear doublets. Their per
centage appears to reflect the pro
portion of cycling cells. In adeno
carcinomas and in aneuploid cell
lines there was a significantly high
er proportion of nuclei in the tetra
ploid peak (p < 0.03 and p <
0.001 respectively) than in adeno

Table III. Ploidy Correlation Between Biopsy and Resection Specimens
Resection specimen
Ploidy
Both specimens aneuploid
Same DI*
Different D lf
Biopsy specimen aneuploid, resection
specimen diploid
Biopsy specimen diploid, resection
specimen aneuploid
*DNA index (peak value/diploid value).
tA t least one block different.
^Tetraploid at resection.
§0ne had two aneuploid peaks.
TlOne with invasion of head only.

Adenoma

Adenocarcinoma

Total
No.

%

3
1

5§
3

8
4

42
21

3

01

3

16

1t

3

4

21

DNA FLOW CYTOMETRY

indicated adenomas, and aneuploid
biopsy specimens indicated adeno
carcinomas (Table II). Also, the
ploidy of large-bowel adenoma biop
sy specimens was found to be repre
sentative of the whole lesion.
In addition, four lesions with dip
loid biopsy specimens were polypoid
adenomas with stalk invasion,
which, if completely removed endoscopically or by local resection, did
not require a subsequent cancer
operation.34-37
Thus, the overall success of the
working hypothesis in terms of
local resection compared with for
mal cancer operation was 70 of 83
cases (84%) in this survey. This
represents an improvement over
histopathology alone. In practical
terms, of course, DNA flow cytome
try would not be the sole criterion
by which to make a surgical deci
sion but would be used in addition
to endoscopic, radiologic and other
clinical information.
The remaining 13 cases in this
survey fell into two categories.
First, six of the biopsy specimens of
adenocarcinomas were found to be
diploid, a false-negative rate of 7%.
Two of these adenocarcinomas were
found to be aneuploid at resection.
Both were Dukes’ stage A tumours,
and the patients are alive without
metastases 3 years later. In the
remaining four cases, all resection
blocks showed diploidy. Two le
sions were Dukes’ stage A and two
Dukes’ B adenocarcinomas. One of
the former patients is alive and well
2 years after the resection without
evidence of metastases; the other
died 2 months after surgery and no

autopsy was performed. Of the two
patients with Dukes’ stage B adeno
carcinomas, one had a 28-year his
tory of biopsies showing villous
adenoma tissue, but 1 year after
resection, metastases were present;
the other had metastases 2 years
after resection. If the four microinvasive (Dukes’ stage A) adenomas
are added, this series shows that 8
of the 10 adenocarcinomas with
diploid biopsy specimens were
Dukes’ stage A and 2 were Dukes’
stage B; the average adenocarcin
oma of large bowel is seen at
resection at a later stage.18 Also, 7
of the 10 were found to be diploid
at resection, and patients with such
adenocarcinomas have been shown
previously to have longer survival
than those with aneuploid le
sions.7'11’15'16
It is generally appreciated that
diploidy, as determined by DNA
flow cytometry, may in some in
stances be aneuploidy with a DI
that cannot be differentiated from
diploidy. Some use the term “near
diploidy.” However, this appears
not to affect the discriminating
power of this technique as it was
used in this study.
In terms of the type of aneu
ploidy observed, there were 19
specimens in which at least one
block of the biopsy or resection
specimen showed an aneuploid peak
(Table III). All aneuploid peaks had
DIs between diploidy and tetraploidy, except one case in which it was
tetraploid. Five of the 19 specimens
(26%) showed two separate aneu
ploid peaks. One of these was an
adenoma. These lesions can be la

Table IV. Estimates of Proliferative Fraction
Percentage ol cells in tetraploid peak
Paraffin blocks

2-10

11-15

16-24

Adenomas
Adenocarcinomas
Diploid
Aneuploid

220
26
230
16

46
8
48
6

10
5*
7
8*

’ Twenty-seven percent in one aneuploid cell line.

/rvalue
< 0 .0 3
< 0.001

belled as heteroploid, and they
are similar in type to, but some
what lower in rate than, adenocar
cinomas reported in the litera
ture.1418 The lower incidence of
heteroploidy that was found in this
study is consistent with the overall
lower Dukes’ stage of the adenocar
cinomas studied.
Another type of heteroploidy, in
which some specimens are partly
diploid and partly aneuploid, may be
present (Table III). There were
seven specimens (37% of aneuploid
specimens) in which the biopsy
specimen was aneuploid and the
resected specimen diploid or vice
versa.
Ploidy, therefore, appears to
progress from diploidy to aneu
ploidy and then to aneuploid het
eroploidy as adenomas convert to
adenocarcinomas.
In 246 of the 352 paraffin blocks
it was possible to estimate the pro
liferative fraction of the neoplastic
population by determining the per
centage of cells in the tetraploid
peak (230 diploid and 16 aneuploid
specimens, Table IV). There was a
significantly higher percentage of
this proliferative fraction in adeno
carcinomas (p < 0.03) and in aneu
ploid specimens (p < 0.001). This
finding is consistent with those
from other reports in the litera
ture3839 but should be interpreted
with caution. First, as noted above,
the tetraploid peak contains not
only cells in the G2 and M phases of
the cell cycle but also an unknown
proportion of nuclear doublets. Sec
ond, the majority of the specimens
evaluated were diploid (93%); in
them, neoplastic cells are not differ
entiated from non-neoplastic cells,
thus lowering any increased neo
plastic proliferative cell fraction to
an unknown degree. To be useful,
the technique used in estimating
the proliferative fraction to evaluate
neoplasia will require technical im
provement.
CJS, VOL. 34, NO. 4, AUGUST 1991
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ORIGINAL ARTICLES

UNA Content and Estrogen Receptors
in Primary Carcinoma of the Breast
B.J. Fernandes, MD, FRCPC;* X.Y. Yao, MD;* Y. Hao, MD;t D.J. Sutherland, MD, FRCPC;*
S. Sidlofsky, MD, FRCSC;§ M.E. Blackstein, MD, FRCPCH
DNA content and estrogen-receptor status were studied in 54 consecutive patients
with primary breast carcinoma. Estrogen-receptor determinations were performed by
immunohistochemical assay on frozen sections with a monoclonal antibody against
the estrogen-receptor molecule and by biochemical analysis with a dextran-coated
charcoal method. Nuclear DNA content was measured by flow cytometry performed
on formalin-fixed, paraffin-embedded sections.
Seventy-two percent of tumours were positive for estrogen receptors by
immunohistochemical assay and 67% by biochemical assay. Comparison of the
qualitative results of immunohistochemical and biochemical estrogen-receptor
determinations revealed a strong correlation between the two assays, with
agreement in 90% of the cases (p < 0.001). Regression analysis showed only a weak
relationship between the quantitative results of the two assays.
DNA analysis was performed in 51 cases, and 54% demonstrated aneuploid
stemlines by flow cytometry. An association was demonstrated between aneuploidy
and low levels of estrogen receptor. The association was highly significant with the
immunohistochemical assay but not with the biochemical assay.
The authors’ results suggest that immunohistologic determinations of estrogen
receptor status may better reflect the biologic features of the tumour cells. However,
improved standardization in reporting the results is necessary if the test is to have
widespread use.

Le contenu en DNA et la presence de recepteurs d’estrogene ont ete etudies chez 54
patientes souffrant d’un carcinome primitif du sein. La determination des recepteurs
d’estrogene a ete effectuee par dosage immunohistochimique des coupes en
congelation a l’aide d’un anticorps monoclonal contre les recepteurs d’estrogene, et
par analyse biochimique utilisant une methode au charbon enrobe de dextran. La
teneur en DNA nucleaire a ete mesuree par cytometrie de debit effectuee sur des
coupes fixees au formol et incluses dans la paraffine.
Soixante-douze pourcent des tumeurs etaient positives pour les recepteurs a
estrogene par la methode immunohistochimique et 67 % par la methode biochimi
que. La comparaison des resultats qualitatifs obtenus par les methodes immunohis
tochimique et biochimique revele une forte correlation entre les deux techniques,
avec un accord dans 90 % des cas (p < 0,001). L’analyse de regression ne montre
qu’un faible rapport entre les resultats quantitatifs des deux methodes.
L’analyse du DNA a ete effectuee dans 51 cas et 54 % ont montre une aneuploidie
a la cytometrie de debit. Une relation a ete demontree entre l’aneuploidie et de
faibles taux de recepteurs a estrogene. Ce rapport etait hautement significatif pour
le dosage immunohistochimique mais il ne l’etait pas pour le dosage biochimique.
Les resultats obtenus par les auteurs indiquent que la determination immunohis
tochimique des recepteurs a estrogene reflete peut-etre mieux les caracteristiques
biologiques des cellules tumorales. Toutefois, il y a lieu de standardiser la facon de
rapporter les resultats si Ton veut que ce test soit largement utilise.

nvestigations into the cellular as
pects o f breast cancer have re
vealed much useful data that have
contributed to the management of
these patients.1 Among the many
prognostic factors known to influ
ence the behaviour o f breast cancer,
the steroid hormone-receptor status
and nuclear DNA content have re
ceived increasing attention. The
hormone dependence o f human
breast cancers has been shown to
be related to prognosis.2 Both the
estrogen receptor (ER) and the pro
gesterone receptor (PR) have prov
en valuable and independent prog
nostic factors.3 The analysis o f ste
roid receptors in breast-cancer spec
imens is now a routine procedure in
clinical oncology.
In recent years nuclear DNA con 
tent has emerged as an important
prognostic parameter. The presence
of cell populations with abnormal
(aneuploid) DNA content can fre
quently be detected in breast cancer
by flow cytometry and is a predictor
o f shorter disease-free survival.4
Aneuploidy has also been associated
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with more extensive nodal involve
ment and a higher risk of relapse.4
We have studied the relationship
between DNA ploidy as determined
by flow cytometry and hormonereceptor status in specimens of
breast cancer. Such a relationship is
of interest because of the influence
of each of these parameters on the
prognosis of breast cancer.

Materials and Methods
Fifty-four consecutive patients
with primary breast cancer who
presented to Mount Sinai Hospital
between May and December 1988
were studied. In all cases tissue was
submitted to the pathology depart
ment for routine histologic exami
nation. In addition, fresh tissue was
submitted for analysis of ERs by the
dextran-coated charcoal (DCC) and
immunohistochemical (ER-ICA [es
trogen-receptor immunocytochemical assay]) methods. The two assays
were performed independently in
different laboratories, and the re
sults were reported without knowl
edge of the results from the other
group. The paraffin sections were
reviewed from all cases to confirm a
diagnosis of primary carcinoma of
the breast. DNA content was mea
sured by flow cytometry performed
on paraffin-embedded tissue.

fered saline (PBS) for 15 minutes,
rinsed in PBS, transferred to cold
methanol ( —20°C) for 5 minutes,
placed in cold acetone ( —20°C) for
3 minutes and finally rinsed twice in
PBS at room temperature for 5
minutes. The sections were then
placed in a glycerol and sucrose
specimen-storage medium and
stored at —20°C for up to 1 week.
At the time of immunocytochemical
staining the sections were brought
to room temperature in two
5-minute rinses of PBS. One section
was stained with a primary mono
clonal anti-ER antibody, and the
other section was stained with a
control antibody. After incubation
for 30 minutes, a bridging goat
antimouse antibody was added fol
lowed by peroxidase-antiperoxidase
complex, and the colour was devel
oped with diaminobenzidine. As a
counterstain, 1% hematoxylin was
used, and the sections were mount
ed in xylol and examined under a
microscope (Fig. 1). The presence
and distribution of tumour was
noted on hematoxylin and eosinstained sections cut adjacent to the
ER-ICA-stained sections. On the

ER-ICA-stained sections 500 con
secutive tumour cells were counted,
and the intensity of staining was
graded from 0 to 4+, with 0 indicat
ing that no staining was present.
An H (histochemistry) score was
obtained from the following formula
proposed by McCarthy and associ
ates:5 H = (i + 1) X Pi, where i is
the intensity grade and P is the
percentage of cells. Thus, the po
tential range of the H score was 0
to 500, with 0 indicating that all
cells were completely negative.

Estrogen-Receptor Assay by the
Dextran-Coated Charcoal Method
A 1-cm3 specimen of tissue adja
cent to the tumour, determined at
the time of frozen-section diagno
sis, was snap frozen in liquid nitro
gen. The tissue was pulverized at
liquid-nitrogen temperature, sus
pended at 0°C in TRIS, ethylenediaminotetra-acetic acid, dithiothreitol (TED) buffer, containing 10
mM TRIS, 1.5 mM ethylenediaminotetra-acetic acid (EDTA),
0.5 mM dithiothreitol and 3 mM

lb

Estrogen-Receptor Assay by
Histochemistry
Two adjacent 5-/im cryostat sec
tions were cut at the time the
frozen-section diagnosis was per
formed on the tumour. The speci
men was processed according to the
instructions supplied with the Ab
bott ER-ICA Monoclonal Kit. (Es
trogen Receptor Immunocytochemical Assay; Abbott Laboratories,
North Chicago, 111.). Briefly, the
sections were immediately fixed in
3.7% formaldehyde-phosphate-buf
350
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FIG. 1. Section of breast carcinoma stained for estrogen receptors (ERs) by
immunohistochemical assay (ER-ICA). Note range of staining intensity in cell
nuclei (hematoxylin counterstain, original magnification X 625).

DNA AND ESTROGEN RECEPTORS IN BREAST CANCER

sodium nitrite and sonicated with
three 5-second pulses from a Polytron homogenizer (Sybron Chemi
cals Canada Ltd., Rexdale, Ont.) at
setting 6 (with 30-second intervals
for cooling). The cytosol, free of
supernatant lipid, was collected
after ultracentrifugation at 100 000
X g for 60 minutes.
The steroid receptor assays were
performed in duplicate on freshly
prepared cytosols and measured
specifically displaceable binding of
labelled steroid by a DCC method.
The labelled species were (2 nM)
estradiol-170 for ER and R 5020
(progesterone analogue; Dupont
Canada, Inc., Montreal) for PR. The
nonlabelled competitors were (100
nM) estradiol-170 for ER and R
5020 for PR determinations. After
incubation overnight at 0°C, free
and loosely bound steroid was re
moved by incubation with DCC (Norit A 10% [Fisher Scientific, Don
Mills, Ont.]), dextran T 70, 0.05%
in PBS, diluted 1:20 in TED buffer

0

5

10
Channel

before use) for 15 minutes. After
centrifugation to remove the DCC,
the difference between the counts
of cytosol without added unlabelled
steroid (a) and counts with a
100-fold excess of nonlabelled com
petitor (b) was used to determine
the amount of specific binding (a —
b). This difference was expressed in
femtomoles per milligram by nor
malization with the protein concen
tration in the individual cytosols.
Receptor positivity was defined as
equal to or greater than 10
fmol/mg cytosol protein. Levels be
tween 5 and 10 were considered
equivocal.

DNA Ploidy Analysis
Paraffin sections 50 fim thick
were cut from blocks containing a
large proportion of tumour cells.
The sections were dewaxed in xy
lene, rehydrated in a sequence of
100%, 95%, 70% and 50% ethanol

15
Num ber

20

25

30

X101

FIG. 2. DNA histogram of breast carcinoma obtained from paraffin-embedded
sections shows normal diploid G0G, peak (D) and aneuploid G0G! peak (A).

and then left overnight in distilled
water. The tissue was resuspended
in 1.5 mL of 0.5% pepsin (Sigma
Chemical Co., St. Louis, Mo.) in
saline adjusted to pH 1.5 with 1 M
hydrochloric acid and incubated at
37°C for 30 minutes. The sample
was filtered through 53-/um mesh,
layered on top of a double sucrose
gradient (1.5 M and 1.75 M) and
centrifuged for 40 minutes at 625
X g. The pellet was resuspended in
1 mL of minimal essential medium
and 10% fetal calf serum and centri
fuged. The cells were then resus
pended in TRIS buffer (pH 7.0)
containing 5 mM magnesium chlo
ride, 0.3% NP-40 (Nonidet P-40;
Sigma Chemical Co.), 1 m g/m L
RNase and 0.05 m g/m L propidium
iodide. The sample was incubated at
37°C for 30 minutes in the dark
and then centrifuged at 250 X g for
5 minutes. The pellet was then
resuspended in the TRIS buffer as
above (but without RNase) to give a
final concentration of 2 to 3 X 106
cells/mL. The sample was syringed
through a 25-gauge needle and fil
tered through a 37-|rm mesh before
the DNA content was measured on
an EPICS-C flow cytom eter
(Coulter Electronics, Hialeah, Fla.).
Chick erythrocytes were added to
all samples to measure the relative
propidium-iodide staining of each
specimen and thus to establish the
diploid Gi peak on each specimen.
Duplicate samples without added
chick erythrocytes were run to de
termine cell-cycle distribution based
on DNA.
At least 10 000 events were
counted per specimen at a flow rate
of 1000 events per second. A tu 
mour was considered to have an
aneuploid stemline when a distinct
peak was observed separate from
the diploid peak (Fig. 2). Tetraploid
tumours were also considered as
aneuploid.
Although an internal standard is
of limited use in this method, it has
CJS, VOL. 34, NO. 4, AUGUST 1991
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been shown that cellular DNA con
tent obtained from fresh tissue and
corresponding paraffin-embedded
material is unaffected by fixation
and that DNA ploidy can be accu
rately determined in relation to the
diploid Gi peak that is invariably
present.6

Statistical Methods
The two-way tables were
analysed by the x2 test or Fisher’s
exact test as appropriate. The rela
tionship between quantitative ER
ICA and DCC methods was exam
ined by linear regression analysis.
The significance of aneuploidy in

relation to the quantitative ER-ICA
and DCC results was determined by
the f-test.

Results
By ER-ICA analysis, 72% (39 of
54) of the tumours were positive for
ERs. The H scores ranged from 0 to
420. Positive staining was easy to
detect, and there was excellent
agreement among observers when
assessing the intensity of staining.
We did not encounter problems
with background staining when the
manufacturer’s instructions were
followed closely. Staining was local
ized in the nucleus, and no staining

Table 1. Comparison of Estrogen-Receptor Measurements by Immunohistochemical Assay
(ER-ICA) and Dextran-Coated Charcoal (DCC) Assay (Qualitative)*
DCC
Positive

Negative

Total

Positive
Negative

35
1

4
14

39
15

Total

36

18

54

ER-ICA

'N u m b e rs = number of specimens.

FIG. 3. Relationship between ER-ICA and dextran-coated charcoal (DCC) assay
measurements of ERs (quantitative).
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was demonstrated in the cytoplasm.
Some tumours demonstrated con
siderable heterogeneity in staining
intensity between individual cells.
When the DCC assay method was
used, 67% (36 of 54) of the speci
mens were positive for ERs. All
assays with a cytosol protein con
tent greater than 1 mg/mL were
considered technically valid. Four
specimens gave equivocal results
(ER levels between 5 and 10
fmol/mg); three were negative and
one was positive in the ER-ICA. By
the DCC assay method, 59% (32 of
54) of the specimens were positive
for PR. Four cases gave equivocal
results.
The results comparing the quali
tative ER-ICA and DCC assay were
tabulated (Table I). There was
agreement about 49 (91%) of 54
specimens, and statistical analysis
demonstrated that this agreement
was highly significant (p < 0.001,
Fisher’s exact test.)
The semiquantitative H score of
the ER-ICA method and the molar
concentration of the ERs as deter
mined by the DCC assay were com
pared (Fig. 3). Linear regression
analysis produced a slope, b =
0.83, which indicated a statistically
significant linear relationship be
tween measurements from the two
methods (p < 0.005). However,
since the R squares were small
(0.305) the relationship was not
strong. Using 10 fmol/mg as the
threshold for DCC assay, we could
not establish a useful cutoff point
as a threshold for ER-ICA.
In three cases, DNA ploidy analy
sis could not be performed because
of excessive background and debris
in the preparation. Of the 51 cases
that were suitable for analysis, 54%
(28 of 51) showed an aneuploid
stemline. The mean coefficient of
variation (CV) was 3.9 with a range
of 3.3 to 7.6. Four cases had CVs
greater than 7.6 (8.1, 8.3, 8.5,
11.8) but did not show a discrete

DNA AND ESTROGEN RECEPTORS IN BREAST CANCER

peak separate from the diploid
peak. These “wide CV” histograms
were considered as diploid for anal
ysis. Of the cases that were aneuploid, 24 were hyperdiploid or tetraploid and 4 were hypodiploid. Two
cases demonstrated double aneuploid stemline peaks. The range of
the DNA index was 0.45 to 3.49.
The range for the S phase was 7.7%
to 47%.
The relationship between DNA
aneuploidy and the quantitative
level of ERs in the tumour as
detected by the ER-ICA and DCC
methods was also explored (Fig. 4).
There was a negative correlation
between the presence of aneuploidy
and the level of ERs, with diploid
tumours having higher levels. This
association is seen when the ER
level is measured by both the ER
ICA and DCC methods. However,
statistical analysis indicated that the
association between DNA and ER
ICA was highly significant, with a t
value of 2.78 (df = 49, p < 0.01),
but was not significant for DNA and
DCC, with a t value of 1.27 (df =
49, p < 0.20).
The correlation between DNA
aneuploidy and quantitative ER-ICA
was also assessed (Table II). When

quantitative ER-ICA was classified
into four categories of increasing
values, diploid stemlines occurred
more frequently in the high-level
ER-ICA categories. Statistical anal
ysis indicated that there was a sig
nificant correlation between DNA
and quantitative ER values as deter
mined by ER-ICA (x2 = 8.246, p <
0.04).

is necessary to understand these
properties clearly to provide the
best management, and advances in
these aspects have occurred with
the advent of ER and nuclear DNA
analysis.
In the past, ERs have most fre
quently been detected by ligand
binding, and the DCC method has
been most popular for separating
bound and free hormone.3 However,
DCC ligand assay has several draw
backs: (a) there is no assurance that
the tissue sent for receptor analysis
contains malignant cells; (b) the
presence of estrogen hormones in
biopsy tissue or the presence of
other proteins that bind hormones
may interfere with the results; (c)
the method detects “free” and not
“bound” ERs, which can only be

Discussion
There is considerable variation in
the natural history of breast cancer,
reflecting a heterogeneity of the
biologic properties of the cells in
volved in this disease.1’7 Because
the prognosis for these patients is
dependent on the cellular biology, it

Table II. Results o f ER-ICA b y DNA P lo id y (Q uantitative)
Q uantitative ER-ICA values
DNA
A neuploid
Frequency
Row, %
C olum n, %
D iploid
Frequency
Row, %
C olum n, %

0 -9 9 .9

1 0 0 .0 -1 9 9 .9

2 0 0 .0 -2 9 9 .9

> 29 9 .9

Total

17
60.71
77 .2 7

4
14 .2 9
4 4 .4 4

3
10.71
3 0 .0 0

4
14.29
4 0 .0 0

28

5
21 .7 4
22 .7 3

5
2 1 .7 4
5 5 .5 6

7
30 .4 3
7 0 .0 0

6
26 .0 9
60 .0 0

23

22

9

10

10

51
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FIG. 4. Boxplots of quantitative ER measurements with ER-ICA (A) and DCC assay (B) by DNA ploidy. a = aneuploid,
d = diploid.
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extracted with buffers of high ionic
strength; and (d) the results may be
affected by the method used to
homogenize tissue, the composition
of the DCC slurry and the condi
tions under which bound and free
ligand are separated. However, li
gand binding has the advantage of
long clinical usage, and most of the
available data that relate ER con
centration to clinical information
are based upon ligand-binding de
terminations.3
The development of a monoclonal
antibody against the ER molecule
has resulted in the application of
immunohistochemical methods for
the analysis of ERs.8 This method
has the advantage of direct visual
ization of tumour cells and the
detection of isolated positive cells
within heterogeneous populations.
In this study, 72% of cases were
positive for ERs by the ER-ICA, and
67% of cases were positive by the
DCC assay. These results are com
parable to those obtained in large
studies on women with primary car
cinoma of the breast,9-14 although
there is a wide range among the
different studies. This variation may
be a result of differences in age and
other demographic data between
the study groups. In our study
there was a slightly higher inci
dence of false-negative results in
the DCC group (4 of 18, compared
with 1 of 15, Table I), and although
the numbers are small the results
suggest that the ER-ICA may be a
more sensitive method to detect
ERs. Some studies have demon
strated fewer false-negative results
with the ER-ICA,5 but others have
demonstrated more false-negative
results with this technique.11
Because of the heterogeneity of
staining for ERs by tumour cells, it
is generally accepted that a system
for numerical grading of staining
intensity is required to obtain a
semiquantitative value for ER-ICA.
Different workers have used ranges
354
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of 0 to 3+ ,1114 0 to 4+,5'11 A to C,9
0 to + + + 10 or weak, moderate and
strong12 for positive staining in as
sessing staining intensity. These
ranges need to be standardized if
studies from different centres are to
be compared. We have used a range
of 0 to 4+ and have found this easy
to apply and expressive of the dif
ferent shades of staining encoun
tered. In the future, evaluation of
staining intensity by automated
image analysis may replace manual
estimation.15
In reporting positive results of
ER determinations by DCC ligand
assay a threshold of 10 fmol/mg
cytosol is generally regarded as the
cutoff point, although this may vary
between 3 and 20 fmol/mg cytosol
in different centres.3 The validity of
these thresholds has been estab
lished by clinical correlation with
response to treatment and course of
the disease.3 There is no consensus
on a threshold for reporting results
of the ER-ICA. Some workers have
considered any positive staining
(threshold of 1) as positive,1214
while others have used greater than
10% of cell staining as positive.10
Using a range of 0 to 4 for staining
intensity and counting 100 cells,
one group reported a threshold of
70,5 while another group, using an
identical method for semiquantita
tion, reported a threshold of 100.13
It is clear that additional long-term
studies relating the level of positivi
ty to therapeutic response are
necessary to determine the relation
ship between quantitative ER values
as determined by the ER-ICA and
the clinical response. We would
suggest that, when reporting re
sults obtained by ER-ICA, any posi
tive staining be reported as qualita
tively positive along with a semi
quantitative score and the indica
tion that semiquantitative decision
making thresholds are not known.
The proportion of aneuploid tu
mours in this study (54%) corre

sponds to that in previously pub
lished reports,16 although the range
in the literature is quite wide (40%
to 92%).17 For most tumours the
presence of aneuploidy is associated
with aggressive disease and poor
survival, and this association has
also been confirmed for carcinoma
of the breast.417 Since aneuploid
DNA content and ERs have oppos
ing effects on survival in breast
cancer, it would be expected that a
correlation exists between the pres
ence of aneuploid nuclei and the
absence of ERs, and this relation
ship has been demonstrated by an
other group.16 In this study we
demonstrated a highly significant
correlation between DNA aneu
ploidy and low quantitative levels of
ERs as determined by the ER-ICA
(Fig. 4, Table II). The correlation
between DNA aneuploidy and quan
titative ER levels determined by
DCC was not significant. These
results suggest that the quantitative
ER levels determined by ER-ICA
more accurately reflect the biologic
properties of the tumour cells than
the quantitative ER levels deter
mined by DCC. This is not surpris
ing, because it has been shown that
the majority of ERs in cells reside in
the nucleus18 and that the ER-ICA
measures only nuclear ER content.
Further long-term studies are re
quired to determine which quantita
tive assays more accurately predict
the outcome of disease.
In conclusion, this study has
demonstrated that qualitative ER
determinations by ER-ICA correlate
closely with those by DCC. The
quantitative ER-ICA and the DCC
assays show only a weak relation
ship. There is a statistically signifi
cant association between DNA
aneuploidy and lower quantitative
ER results by ER-ICA, but this
relationship is not statistically sig
nificant when a comparison is made
with ER quantitation by the DCC
assay.
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SESAP VI Question/Question SESAP VI
Item 244
Which of the following statements about cancer chemotherapy for patients over 70 compared with younger
patients is NOT true?
(A) Elderly patients may show greater toxicity to specific agents such as methotrexate
(B) The type of toxic reaction is similar for both groups
(C) The response rate is comparable for both groups
(D) The incidence of hematologic complications after treatment of certain tumors is greater among
elderly patients
(E) Elderly patients must be in better general health than younger patients to tolerate chemotherapy

For the question above select the one answer that is best of the five given.
For the critique of Item 244 see page 388.
(Reproduced by permission from SESAP VI Syllabus; Surgical Education and Self-Assessment Program No. 6.
For enrolment in the Surgical Education and Self-Assessment No. 6, please apply to the American College of
Surgeons, 55 East Erie St., Chicago, IL 60611.)
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E tude pathologique du nevrome
de Morton
P. Vachon, MD;* M. Lemay, MD;t H-L. Bouchard, MD$
Le syndrome clinique du nevrome de Morton, decrit depuis plus d’un siede, cache
encore son etiopathogenie. Les etudes recentes semblent demontrer qu’il s'agit
d’une neuropathie compressive. Les changements histologiques de nerfs digitaux
reseques pour traiter ce syndrome ont ete compares a l’histologie de nerfs digitaux
preleves lors d’autopsies de personnes asymptomatiques.
Les resultats montrent qu’environ un tiers des nerfs digitaux «malades» ont une
apparence histologique normale. Alors pourquoi les reseque-t-on?

The clinical syndrome of Morton’s nephroma was described over a century ago, but
its etiopathology remains unknown. Recent studies suggest that it may be induced
by compression neuropathy. Histologic changes in digital nerves resected for
therapeutic purposes were compared with histologic findings of digital nerves
sampled at autopsy of asymptomatic subjects.
Results show that approximately one-third of resected “diseased” digital nerves
were histologically normal. The authors question the therapeutic approach, which
consists of resecting the nerves.

a metatarsalgie de Morton, plus
frequente chez la femme, cor
respond a une entite clinique qui se
manifeste par une douleur locale
augmentee par le port de souliers
etroits, par la marche ou la station
debout prolongee.
Decrit pour la premiere fois au
milieu du siecle dernier par Durlacher,1 ce syndrome clinique cache
toujours son etiopathogenie. Mor
ton2 fut le premier a suggerer la
resection de l’articulation metatarsophalangienne comme traitement
chirurgical.
II y a 50 ans Betts3 publiait les
resultats du traitement par l’exci

L

sion du nerf commun digital chez
une serie de 19 patients.
Plus tard, Nissen4 et Scotti5 expliquaient que l’ischemie secondaire
a Tarteriosclerose des vaisseaux di
gitaux etait responsable de la degenerescence nerveuse et de la dou
leur.
D’autres auteurs dont Kopell et
Thompson,6 Lassman, Lassman et
Stockinger7 Ochoa8 et Gauthier9 ont
suggere qu’il s’agissait d’une neuro
pathie compressive. Ce dernier a
obtenu de bons resultats (83 %) par
decompression simple sans neurectomie sur 206 patients.
La presente etude avait pour but

Du departement de chirurgie, Le Centre Hospitalier de I'Universite Laval, Sainte-Foy (Que.)
‘'Resident senior en orthopedie, L ’Universite Laval, Sainte-Foy
fPathologiste, Hotel-Dieu de Quebec
fO rthopediste. Hotel-Dieu de Quebec
Accepte p o u r publication le 3 mai, 1990
Les demandes de tires a part doivent etre adressees a : LF H. L. Bouchard, Departement de
chirurgie, L ’Hotel-Dieu de Quebec, 11 Cote du Palais, Quebec, QC G1R 2J6
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d’observer les changements his
tologiques de nerfs digitaux
reseques chez des patients operes
pour une metatarsalgie de Morton.
Les changements histologiques
ont ete compares a ceux d’un
groupe temoin.

Materiel et methode
Les dossiers de 13 femmes et 2
hommes operes entre 1982 et 1986
ont ete revus. Ces 15 patients avaient ete operes par trois chirurgiens
differents qui ont tous utilise une
approche dorsale hormis un seul
cas (plantaire).
L’age de ces patients variait de
17 a 61 ans avec une moyenne de
43 ans.
Les lames histologiques des
pieces de resection ont ete revues
avec soin. Une attention toute particuliere a ete portee au perinerve,
aux vaisseaux endoneuraux, aux
depots hyalins et a la sclerose endoneurale.
Les changements histologiques10
observes ont alors ete cotes de la
fagon suivante (tableau I ) : soit de 1
a 3 selon l’epaisseur du perinerve,
soit de 1 a 2 selon que la lumiere du
vaisseau endoneural etait permeable
ou obstruee et la presence ou l’abTableau I. Mesure des changements
histologiques
Epaissisement du perinerve:
1 leger
2 modere
3 marque
Vaisseaux endoneuraux:
1 permeables
2 obstrues
Depots hyalins et sclerose endoneurale :
1 present
0 absent

NEVROME DE MORTON

sence de depots hyalins et de scle
rose endoneurale fut notee.
Ont ete utilises comme groupe
temoin, huit hommes et sept
femmes decedes a un age moyen de
57 ans (de 21 a 86 ans) n’ayant
aucun antecedent de metatarsalgie
anterieure consigne au dossier.
Des prelevements de nerfs communs digitaux au 2e et 3e espace
intermetarsien de chaque pied autopsie furent effectues par approche
plantaire (fig. 1) et conserve au
formol avant d’etre soumis au mi
crotome puis colores de fagon stan
dard avec hematoxyline-eosine et
safran.
Les lames furent ensuite ex
aminees au microscope optique et
les changements histologiques ob
serves furent cotes et compiles
selon la methode decrite plus haut.
Cinquante-quatre nerfs ont ainsi
ete preleves avec une repartition par
pied et par espace intermetatarsien
similaire aux specimens chirurgicaux (tableau II).
Resultats
Lors de la revision des lames de
pieces chirurgicales, 14 nerfs ont

FIG. 1. Prelevement lors d’autopsie
par approche plantaire.

pu etre identifies et examines.
Quatre nerfs etaient d’apparence
normale, soit 28,5 % des cas. Parmi
les 10 autres nerfs, un epaississement du perinerve fut observe dans
neuf cas (fig. 2), quatre specimens
montraient des vaisseaux endoneuraux peu permeables et 3
nerfs presentaient de fagon in
homogene de la sclerose en
doneurale et des depots hyalins
(tableau III).
Dans le groupe temoin constitue
du materiel d'autopsie, 49 nerfs sur
54 specimens ont ete identifies et
examines en microscopie optique.
Vingt-trois nerfs etaient anormaux
a l’histologie et les changement
observes se repartissaient de la
fagon suivante : epaississement du
perinerve dans 20 cas (87 %) perme-

ablite reduite des vaisseaux endoneuraux dans 12 cas (53 %) et
zone de sclerose endoneurale et
depots hyalins dans 11 (tableau IV).
Aucune difference significative
n’a ete retrouvee entre le pied droit
ou gauche ou l’espace intermetatar
sien concernant ces observations
histologiques.
Lorsque Ton compare les obser
vations faites dans les deux
groupes, on remarque que les
changements histologiques sont
equivalents dans les deux cas.
L’epaississement du perinerve est
le changement le plus frequemment
observe parmi les nerfs anormaux
des deux groupes et pourrait etre
une fagon pour le nerf de repondre
a un traumatisme mecanique repetitif ou a une compression chro-

T a b le a u II. R epartion des s p e c im e n s exam ines
S p e cim e n s c h iru rg ic a u x
Pied

S p e c im e n s d 'a u to p s ie

2" E IM *

3 ‘ EIM

2" E IM

3 ' E IM

T o ta l

D roit
Gauche

3
5

3
4

6
9

15
13

13
13

28
26

Total

8

7

15

28

26

54

T o ta l

’ Espace in term etatarsien.

FIG. 2. Augmentation importante de l’epaisseur du perinerve (P) (grossissement X

100).
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nique.11 Le tableau V resume cette
comparaison.

Discussion
Dans cette etude, pres de 30 %
des nerfs excises pour metatarsalgie
de Morton ont une histologie normale en microscopie optique. II est
surprenant de constater que le pro
tocole operatoire mentionne souvent une apparence macroscopique
de nevrome lors de la chirurgie.
Dans les cas ou le nerf est nor
mal, Ton pourrait se demander si le
diagnostic initial de nevralgie de
Morton n’etait pas errone. Mais si
ce diagnostic a ete etabli adequatement, une autre question surgit a
Tableau III. O b s e rv a tio n s h is to lo g iq u e s *
Observation

Nombre

E p a is s is s e m e n t du p e rin e rv e

1

2

2
3
V a is s e a u x e n d o n e u ra u x

1
2
D e p o ts h y a lin s et s c le ro s e

1

4
3
2
2
3

'S p e c im e n s c h iru rg ic a u x a n o rm a u x = 10.

Tableau IV. O b s e rv a tio n s h is to lo g iq u e s *
Observation

Nombre

H y p e rp la s ie p e rin e rv e u s e

1
2
3
V a is s e a u x e n d o n e u ra u x

1
2
D e p o ts h y a lin s et s c le ro s e
e n d o n e u ra le
1

8
6
6
7
5

11

'S p e c im e n s a u to p s iq u e s a n o rm a u x = 2 3 .

l’esprit: pourquoi soulage-t-on un
patient par resection d’un nerf nor
mal? La section du ligament intermetatarsien9 lors de l’approche dorsale joue peut-etre un role dans
l’etiopathogenie de la metatarsalgie
de Morton.
En ce qu’a trait au groupe
temoin, on remarque que meme en
l’absence d’antecedents de metatar
salgie, 47 % des patients presentaient des changements histologiques
lors de l’etude. II est plus que
probable que certains changements
histologiques sont physiologiques
et traduiraient peut-etre un proces
sus d’adaptation a une compression
chronique (hyperplasie periner
veuse).12'13 D’ailleurs, comme le
mentionne Lassman,14 l’hyperplasie
perinerveuse est une trouvaille frequente et caracteristique des neu
ropathies compressives peripheriques.
De plus, on doit noter qu’aucune
trace de tissu inflammatoire n’a ete
retrouvee a l’examen des lames. La
comparaison de ces deux groupes
nous permet d’affirmer qu’aucun
changement specifique au nevrome
de Morton n’est retrouve en micro
scopie optique.
L’excision du nerf commun digi
tal etant simple et presque sans
complications, la majorite des chirurgiens ne s’interrogent done pas
sur l’opportunite de changer leur
approche.
Or, les etudes recentes,14-16 grace
aux observations histologiques ainsi
qu’aux etudes de conduction nerveuse de Guiloff, Scadding et Klenerman,16 semblent nous orienter
vers une etiopathogenie de neuro-

N o m b re id e n tifie
N e rfs a n o rm a u x , no (% )
H y p e rp la s ie p e rin e rv e u s e
V a is s e a u x e n d o n e u ra u x
S c le ro s e e n d o n e u ra le
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A proven, effective, generally well
tolerated regimen that prolongs survival.
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SINCE LEUC0V0RIN MAY ENHANCE THE TOXICITY OF FLUOROURACIL. LEUCOVORIN/ FLU0R0URACIL

well-controlled studies in pregnant woman. Because anim al reproduction studies are not always predictive of

COMBINATION THERAPY FOR ADVANCED COLORECTAL CANCER SHOULD BE ADMINISTERED UNDER

human response, this drug should be used during pregnancy only if clearly needed.

THE SUPERVISION OF A PHYSICIAN EXPERIENCED IN THE USE OF ANTIMETABOLITE CANCER

Nursing Mothers

CHEMOTHERAPY PARTICULAR CARE SHOULD BE TAKEN IN THE TREATMENT OF ELDERLY OR
DEBILITATED COLORECTAL CANCER PATIENTS AS THESE PATIENTS MAY BE AT INCREASED RISK OF
SEVERE TOXICITY. DEATHS FROM SEVERE ENTEROCOLITIS. DIARRHEA AND DEHYDRATION HAVE BEEN
REPORTED IN ELDERLY PATIENTS RECEIVING LEUCOVORIN AND FLUOROURACIL. CONCOMITANT
GRANULOCYTOPENIA AND FEVER WERE PRESENT IN SOME BUT NOT ALL OF THE PATIENTS.

ACTIONS, CLINICAL PHARMACOLOGY
LEDERLE LEUCOVORIN Calcium (calcium folinate), the calcium salt o f fo lin ic acid (citrovorum factor), is a
mixture of the diastereoisomers of the 5-form yl derivative of tetrahydrofolic acid. The biologically active
component of the m ixture is the (-)-L-isom er. It is a metabolite of fo lic acid and an essential coenzyme for
nucleic acid synthesis.
LEUCOVORIN is a reduced form of fo lic acid, w hich is readily converted to other reduced fo lic acid derivatives
(e.g., tetrahydrofolate). Because it does not require reduction by dihydrofolate reductase as does folic acid,
LEUCOVORIN is no t affected by blockage of this enzyme by folic acid antagonists (dihydrofolate reductase
inhibitors). This a llow s purine and thym idine synthesis, and thus DNA, RNA, and protein synthesis, to occur.
LEUCOVORIN may lim it METHOTREXATE action on normal cells by com peting with METHOTREXATE for the
same transport processes into the cell. LEUCOVORIN rescues bone m arrow and gastrointestinal cells from
METHOTREXATE but has no apparent effect on pre-existing METHOTREXATE nephrotoxicity.
LEUCOVORIN is extensively converted to 5-methyltetrahydrofolate in the intestine prior to absorption. In this

It is not known whether this drug is excreted in hum an m ilk. Because many drugs are excreted in human
m ilk, caution should be exercised when LEUCOVORIN is adm inistered to a nursing mother.

Pediatric Use
See Drug Interactions.

ADVERSE REACTIONS
Allergic sensitization has been reported follow ing both oral and parenteral administration of folic acid.
In combination regim ens, the toxicity profile of 5 FU is enhanced by LEUCOVORIN. The m ost common
manifestations are mucositis, stom atitis, leukopenia, and/or diarrhea which may be dose-lim iting. In clinical
trials with this drug com bination these toxicities were found to be reversible with appropriate modification
of 5 FU administration,

SYMPTOMS AND TREATMENT OF OVERDOSAGE
Folic acid is a water soluble vitam in converted in the body by the action of folate reductase
to folinic acid (LEUCOVORIN) w hich is rapidly elim inated in the urine.
Folic acid has low acute and chronic toxicity in man. No adverse effects have been
noted in adults after the ingestion of 400 mg/day for 5 m onths or 10 mg/day for 5 years.
Excessive am ounts of LEUCOVORIN may nullify the chemotherapeutic effect of
folic acid antagonists.

form , it is a major com ponent of the total active hum an serum folate. Oral absorption is saturable at doses

DOSAGE AND ADMINISTRATION

above 25 mg.
LEUCOVORIN enhances the cytotoxicity of fluoropyrim idines such as 5-fluorouracil (5 FU) by their

used after reconstitution for intravenous or intramusculuar adm inistration. The liquid injection 350 mg/35 mL

LEDERLE LEUCOVORIN Calcium for Injection cryodesiccated powder 50 mg/vial and 350 m g/vial may be

complex with thym idylate synthase, and thereby, decreasing intracellular levels of that enzyme and the product

is used for intravenous or intramusculuar adm inistration.
When LEDERLE LEUCOVORIN C alcium is used for LEUCOVORIN pre-treatment followed by 5-fluorouracil (5

thymidylate. The cell then dies as a result of thym ine starvation.

FU) in the treatment of patients w ith advanced colorectal cancer, intravenous administration is employed.

metabolites, methylene tetrahydrofolate and fluorodeoxyuridine monophosphate, form ing a stable ternary

INDICATIONS
For pre-treatment follow ed by 5-fluorouracil to prolong survival in the palliative treatment of patients with
advanced colorectal cancer.

CONTRAINDICATIONS

Because of the Ca44 content of LEUCOVORIN solutions, no more than 160 mg of LEUCOVORIN should be
injected intravenously per minute.

Dosage
a) Advanced Colorectal Cancer
LEUCOVORIN is adm inistered at 200 m g /n f by slow intravenous injection immediately prior to dosing

Not to be adm inistered for the treatment of pernicious anemia or other megaloblastic anemias where Vitamin
B.? is deficient. A hem atologic remission may occur while neurologic manifestations continue to progress.

WARNINGS
Cryodesiccated powder reconstituted with Bacteriostatic Water for Injection containing benzyl alcohol should
on ly be used at doses below 10 m g/m ?. (See PRECAUTIONS.)
Treatment-related deaths have been sporadically reported in patients treated with LEUCOVORIN plus
fluorouracil com bination therapy regim ens. In general, diarrhea or stom atitis/m ucositis are the first indications
that severe and potentially life-threatening toxicity could develop. Patients w ho experience these symptoms

with 370 m g /n f 5 FU (fluorouracil) by slow intravenous injection, for five consecutive days.
This 5 day treatment course may be repeated at 4 week (28 day) intervals, provided that the patient has
completely recovered from the to xic effects of the prior treatment course.
In subsequent treatment courses, the dosage of fluorouracil should be adjusted based on patient tolerance
of the prior treatment course. The daily dosage of fluorouracil should be reduced by 20% for patients who
experienced moderate hem atologic or gastrointestinal toxicity in the prior treatment course, and by 30% for
patients w ho experienced severe toxicity. For patients who experienced no toxicity in the prior treatment
course, fluorouracil dosage may be increased by 10% . LEUCOVORIN dosages are not adjusted for toxicity.

w h ile receiving any com bination therapy regim en incorporating LEUCOVORIN plus fluorouracil should be
carefully followed and further therapy should be withheld until these sym ptom s resolve.
LEUCOVORIN enhances the toxicity of fluorouracil. When these drugs are administered concurrently in the
palliative therapy of advanced colorectal cancer, the dosage of fluorouracil must be reduced. Although the

AVAILABILITY
Single Dose Vials of 10 mg/mL
Single 35 m L vial. Each vial contains 350 mg LEUCOVORIN as LEUCOVORIN Calcium in solution. Product

toxicities observed in patients treated with the com bination of LEUCOVORIN plus fluorouracil are qualitatively

Code 4545-23.

sim ila r to those observed in patients treated w ith fluorouracil alone, gastrointestinal toxicities (particularly
stom atitis and diarrhea) are observed more com m only and may be m ore severe in patients receiving the

Vials of Cryodesiccated Powders
(50 mg/Vial, 350 mg/Vial)

combination. (See PRECAUTIONS).
Therapy with LEUCOVORIN/fluorouracil must not be initiated or continued in patients who have sym ptom s of
gastrointestinal toxicity of any severity, until those symptoms have resolved. Patients with diarrhea must be
monitored with particular care until the diarrhea has resolved, as rapid clinical deterioration leading to death can
occur. Elderly o r debilitated patients are at greater risk for severe toxicity receiving this therapy.

PRECAUTIONS
Because of the Ca44 content of LEUCOVORIN solutions, no more than 160 m g of LEUCOVORIN should be
injected intravenously per minute.
If the cryodesiccated powder is reconstituted w ith Bacteriostatic Water for Injection containing 0.9% benzyl
alcohol, doses greater than lO m g/rrY are not recommended due to the benzyl alcohol content. If greater doses
are required (see DOSAGE & ADMINISTRATION), LEUCOVORIN C alcium for Injection (cryodesiccated powder)
should be reconstituted w ith Sterile Water for Injection USP and used im mediately, or the preservative-free
liq u id form, LEUCOVORIN Calcium Injection, should be used.

Drug Interactions:
Folic acid in large am ounts may counteract the antiepileptic effect of phenobarbital, phenytoin and prim idone,
and increase the frequency of seizures in susceptible children.
Preliminary anim al and human studies have shown that small quantities of systemically adm inistered
LEUCOVORIN enter the CSF prim arily as 5-methyltetrahydrofolate and, in humans, remain 1-3 orders of
magnitude lower than the usual METHOTREXATE concentrations follow ing intrathecal adm inistration.

I.

10 x 10 m L vials. Each 10 m L vial contains 50 m g of LEUCOVORIN as LEUCOVORIN

Calcium. Product Code 5330-72.
II. Single 30 m L vials. Each 30 m L vial contains 350 m g of LEUCOVORIN as
LEUCOVORIN Calcium. Product Code 4645-77.
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® LEDERLE LEUCOVORIN is a registered trade mark of Cyanamid Canada Inc.

However, high doses of LEUCOVORIN may reduce the efficacy of intrathecally administered METHOTREXATE.

AN ORIGINAL
BRAND NAME MEDICINE

LEUCOVORIN m ay enhance the toxicity of fluorouracil. (see WARNINGS.)

Pregnancy - Teratogenic Effects
Reproduction studies have been performed in rats and rabbits at doses at least 50 times the hum an dose and
have revealed no evidence of harm to the fetus due to LEUCOVORIN. There are, however, no adequate and
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Compartment Syndrome After Surgery
in the Lithotomy Position
E.L. Macintosh, MD; R.J.W. Blanchard, MD, FRCSC
Compartment syndrome developed in five patients after prolonged surgery in the
lithotomy position. Four different surgeons performed the operations. Serious
morbidity resulted from the syndrome and could have been prevented by
consideration of the factors that predispose to its development: tight bindings; direct
pressure on the calves; and prolonged time in the lithotomy position. The
pathogenesis of compartment syndrome in this group of patients is discussed.

Un syndrome des loges est apparu chez cinq patients apres qu’ils eurent subi une
intervention chirurgicale prolongee en position de lithotomie. Une morbidity grave a
resulte de ce syndrome, lequel aurait pu etre prevenu si Ton avait prete attention
aux facteurs qui predisposent a son developpement: attaches serrees, pression
directe sur les mollets et prolongation du temps en position de lithotomie. La
pathogenese du syndrome des loges chez ce groupe de patient est commentee.

C

ompartment syndrome is a con
dition in which increased tissue
pressure within a limited space
compromises the circulation and
function of the contents of that
space.1 A prerequisite for the devel
opment of increased tissue pressure
is an envelope that restricts the
volume available to the enclosed
tissue.2 The muscles of the extremi
ties are enclosed in fascial compart
ments and, given the presence of
the appropriate inciting factors,
compartment syndrome will occur.
Compartment syndrome has been
reported after surgery in the lithot
omy position.3-5 In the cases we
report compartment syndrome oc
curred after general surgical proce

dures, resulting in serious morbidi
ty that could have been prevented.

Case Reports
Case 1

A 30-year-old man with a 9-year
history of Crohn’s disease was ad
mitted for elective surgery for se
vere perianal disease. At the time of
original diagnosis he underwent
ileal and sigmoid resections for enterovesical fistulas. Following this,
despite maximal medical therapy,
he suffered from multiple perineal
fistulas and ongoing perianal dis
ease. His medications included pred
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nisone, 5 mg daily, and Asacol. He
smoked occasionally but was other
wise healthy. He underwent a proc
tocolectomy and ileostomy lasting
5V2 hours. During the operation he
was in the lithotomy position, and
his legs were wrapped without ten
sion in tensor bandages and placed
in leg brace-type stirrups. During
the perineal dissection he was
placed in the Trendelenburg posi
tion. Steroids were administered in
travenously. Four hours after com
pletion of surgery the patient com
plained of pain in the left calf,
which appeared slightly reddened.
The following morning the left calf
was swollen and firm, the foot was
parasthetic, with no dorsiflexion
and minimal plantar flexion. The
dorsalis pedis pulse was present.
Deep vein thrombosis was a possi
ble diagnosis. A venogram could
not be obtained, but Doppler ul
trasonography of the proximal ve
nous system showed that the whole
system was patent. A vascular sur
geon was consulted, and compart
ment syndrome was diagnosed 24
hours after surgery. Fasciotomies
of the anterior and posterior com
partments of the left calf were per
formed. The muscle was viable. Al
though there was some recovery of
neuromuscular function, the patient
had residual left foot drop when
discharged. The foot drop resolved
completely over the next 6 months.
Case 2

A

29-year-old

man
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7-month history of ulcerative colitis
was admitted to hospital for an
elective construction of an ileal res
ervoir. He had undergone total co
lectomy and ileostomy 6 months
previously. He was placed in the
lithotomy position with his legs
wrapped in tensor bandages and in
leg brace-type stirrups for an ileo
anal pull-through procedure. The
operation lasted 8V2 hours; the pa
tient was in the Trendelenburg posi
tion for the majority of that time. In
the recovery room, 30 minutes after
surgery, he complained of severe
pain in his right calf. The right
anterior compartment was swollen
and tense. Dorsiflexion was absent,
and the lateral aspect of the right
foot was anesthetic. A dorsalis pedis
pulse was audible through a Dopp
ler stethoscope. A diagnosis of com
partment syndrome was made, and
the patient was immediately re
turned to the operating room. Fasciotomies of the right anterior and
posterior compartments were per
formed. Two days later myo
globinuria was noted. Adequate di
uresis prevented deterioration in
renal function. When the patient
was discharged from hospital, full
motor function had returned to the
right foot, but there was residual
paresthesia to the lateral aspect of
the foot. This has since resolved.
Case 3

A 25-year-old man with ulcer
ative colitis was admitted for elec
tive construction of an ileal pouch.
One year earlier, 6 months after the
initial diagnosis of ulcerative colitis,
the patient had undergone partial
colectomy and colostomy. Four
months later, he underwent a com
plete colectomy with preservation of
the rectal stump and Brooks’ ileos
tomy for disease unresponsive to
medical therapy. The patient was
otherwise well and was taking no
medications. He remained in the
360
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lithotomy position for 10 hours
while an ileoanal pouch was creat
ed. This procedure was complicated
by laceration of the urinary bladder
and transection of the right ureter
and left vas deferens, which re
quired repair by the urologist. Dur
ing the ileorectal anastomosis, the
urologic repair was disrupted and
repaired again. A loop ileostomy
was fashioned, and a suprapubic
catheter and right ureteric stent
were inserted. At the completion of
surgery in the operating room,
pressure marks were noted on both
calves, with the left appearing
worse than the right. In the recov
ery room the patient complained of
pain in the left calf, and the calf
compartments were noted to be
tense. Sensory and motor deficits
were present on the left side. The
right calf was tender but not tight,
and neuromuscular function was
normal. The patient was returned to
the operating room 2 hours after
completion of the ileal pouch proce
dure, and fasciotomies of the anteri
or and posterior compartments of
the left calf were done. Urine sam
ples taken in the recovery room
were positive for myoglobin. Postfasciotomy mannitol and bicarbon
ate diuresis was initiated and was
stopped 72 hours later when the
urine sample was negative for myo
globin. Renal function remained
normal. Over the next 10 days, with
the help of physiotherapy, motor
function improved. At the time of
writing, 1 month postoperatively,
plantar flexion was normal, dorsi
flexion was limited to 90% and the
patient had dysesthesia and edema
of the left foot.
Case 4

A 29-year-old man with a 3-year
history of ulcerative colitis was ad
mitted for an elective ileal pouch
procedure. The patient had been
taking prednisone, but it was

stopped 1 week before surgery. He
was otherwise well. He underwent
total colectomy and loop ileostomy
with creation of an ileoanal pouch,
for which he was placed in the
lithotomy position for 10 hours in
leg brace-type stirrups. In the re
covery room he complained of pain
in the right leg and was found to
have a swollen, firm anterior com
partment. Thirty minutes after the
operation, he was returned to the
operating room where both anterior
and posterior compartments in the
right calf were opened. Forty-eight
hours later there was normal sensa
tion and normal active range of
movement. His recovery was
smooth.
Case 5

A 60-year-old woman was admit
ted for takedown of a colostomy
and colorectal anastomosis. She
had been admitted 4V2 months be
fore with a pelvic mass and colovaginal fistula. At laparotomy she was
found to have a perforated colonic
diverticulum, so sigmoid resection
was done, with abscess drainage
and stapling of the rectal stump.
Her medical history included hyper
tension, treated with methyldopa,
and deep vein thrombosis of the left
leg 1 year before this admission. At
the time of colostomy takedown she
was not taking any antithrombotic
agents. There was no history of
peripheral vascular disease. Subcu
taneous heparin was administered
pre- and postoperatively, and the
legs were placed in antiembolic
stockings for the operative proce
dure. The patient was in the lithoto
my position in leg brace-type stir
rups for the 9-hour procedure. The
rectal dissection was difficult, re
sulting in two bladder lacerations.
These were recognized and re
paired, but the attempted restora
tion of gastrointestinal continuity
was abandoned.

COMPARTMENT SYNDROME AFTER SURGERY

Immediately upon awakening in
the recovery room, the patient com
plained of severe pain in both of her
lower extremities. The calves were
tense, there was bilateral foot drop,
and both feet were paresthetic. A
neurologist and vascular surgeon
were consulted. The diagnosis was
bilateral compartment syndromes.
The vascular surgeon elected to
observe the patient. By the next
morning the calves were firm, and
dorsiflexion was absent bilaterally.
Fasciotomies were performed 24
hours after completion of the lapa
rotomy. Diuresis with mannitol was
established for documented myo
globinuria. Renal function was pre
served and the myoglobinuria re
solved over 5 days. There was
motor recovery, and diminished sen
sation persisted in both feet. The
patient required orthotic supports
and a walker to ambulate 2 years
postoperatively.

Discussion
The pathogenesis of compart
ment syndrome relates to increased
local tissue pressure. The local
blood flow (LBF) is determined by
the local arteriovenous gradient
(Pa-Pv) and the local vascular re
sistance (R) according to the follow
ing formula: LBF = (Pa - Pv) H- R.
Within an affected compartment,
locally increased tissue pressure in
creases local venous pressure and
reduces the local arteriovenous gra
dient.2 When local blood flow is no
longer adequate to meet metabolic
demands, neuromuscular ischemia
develops, and loss of function and
viability result if these conditions
persist. A self-perpetuating cycle of
ischemia and tissue edema develops,
further increasing local tissue pres
sure.
Any factors that decrease com
partment size predispose to devel
opment of compartment syndrome;

the five patients we report all had
circumferential bindings on their
lower extremities, which contribut
ed to its development.
Limb compression leads to in
creased local tissue pressure by di
rect transmission of external pres
sure to that compartment. Patients
positioned in leg brace-type stirrups
support the weight of their lower
extremities on the brace device,
thereby mechanically compressing
the calf compartments. Four of the
cases we report occurred in young
men with heavy, muscular lower
limbs. We postulate that these pa
tients are predisposed to develop
ment of compartment syndrome be
cause of greater limb weight applied
directly to the compartments. Also,
these patients may have tighter,
less compliant fascial compartments
by virtue of their muscular develop
ment.
Tissue tolerance to compartment
hypertension varies. We report here
the second case in the literature of
bilateral compartment syndrome oc
curring in patients placed in lithoto
my position.5 The variability in tis
sue tolerance is related to several
factors: the absolute pressure ap
plied; the duration of compartment
hypertension; and local arterial
pressure in the compartment. We
have reported the development of
compartment syndrome in a patient
who underwent a 5V2-hour proce
dure in the lithotomy position. A
maximum safe time limit cannot be
defined.
The Trendelenburg position de
creases local arterial pressure and
also predisposes the patient to de
velopment of compartment syn
drome. Matsen2 has reported that
local arteriolar pressure decreases
0.78 mm Hg for each centimetre
the compartment is raised above the
right atrium. This translates into a
fall in local arteriolar pressure of 43
mm Hg if the calves are raised 55
cm above the level of the heart,

which is easily achieved with the
patient in the Trendelenburg posi
tion. However, placing the patient
in the Trendelenburg position may
decrease the duration of surgery if
it facilitates perineal dissection.
Other factors that diminish arterio
lar pressure are presence of periph
eral vascular disease and systemic
hypotension (e.g., secondary shock,
anesthetic agents).
Recognition of compartment syn
drome and prompt institution of
treatment are essential to minimize
morbidity and mortality. The most
effective treatment is decompres
sion of the space. All dressings
must be removed from around the
limb and the compartment posi
tioned level with the heart to maxi
mize the arteriovenous gradient.
Surgery is the only therapy for
established compartment syndrome,
and fasciotomy must be performed
in patients with demonstrable motor
or sensory loss. Appropriate alka
line diuresis must be instituted to
prevent development of myoglobinuric renal failure if there is
evidence of rhabdomyolysis.
Measures can be taken to prevent
development of compartment syn
drome in this group of patients.
• Do not apply tight bindings of
any nature to the legs of these
patients if they are to undergo
prolonged surgery in the lithotomy
position.
• Avoid placing direct pressure
on the calves by using leg-suspen
sion type stirrups. At our institution
we have now switched from the
leg-brace stirrup to the suspension
system, in which the weight is
transmitted to the patient’s feet,
thus avoiding direct compression of
the calf.
• Minimize the length of time
the patient is in the lithotomy and
Trendelenburg positions.
• Consider all factors that pre
dispose to development of compart
ment syndrome and be vigilant for
CJS, VOL. 34, NO. 4, AUGUST 1991
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signs and symptoms in these pa
tients.
• Serially examine the leg com
partments in patients who have un
dergone surgery in the lithotomy
position, and recognize compart
ment syndrome early to institute
prompt treatment and minimize
morbidity.
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BOOK REVIEWS
continued from page 310

ters replete with excellent tips on dayto-day management, but the latest data
are included on pathologic aspects (e.g.,
Hirschsprung’s disease). These together
with interesting historical reviews, and
appropriate photographs, illustrations
and tables make for a very readable
text.
The section of the book on the heart
and great vessels is an exception. Surgi
cal treatment is only mentioned in a
more medical summary of the subject.
The last two sections dealing with the
central nervous and the urogenital sys
tems are the most pragmatic. Causes,
pathologic features, clinical diagnosis,
treatment (including surgical) and prog
nosis are succinctly covered with a
certain loss of readability. No doubt the
resident preparing for rounds will like
these chapters.
There are notable omissions, espe
cially orthopedics. In addition, the lack
of specific mention of prenatal diagno
sis in many chapters is disappointing.
With the exception of Rickwood’s dis
cussion of prenatal surgery in obstruc
tive uropathies, the advent of exciting
intrauterine surgery is not considered.
Overall, this book is an essential
addition to the armamentarium of all
physicians involved in neonatal surgery
whether medical or surgical.
Steven Rubin, MD, FRCSC
Children’s Hospital of Eastern Ontario
401 Smyth Rd.
Ottawa, ON
K1H8L1
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BONE
TUMORS:
DIAGNOSIS,
TREATMENT, AND PROGNOSIS.
2nd edition. Andrew G. Huvos. 784 pp.
Illust. W.B. Saunders Company/Harcourt Brace Jovanovich, Inc., Philadel
phia. 1991. $162. ISBN 0 -7 2 1 6 2050-7

This second edition of Bone Tumors is
an updated and substantially revised
version of the first, which was pub
lished 10 years ago. It represents a
significant improvement over the initial
edition.
There are two additional chapters:
one on aneurysmal bone cysts and the
other on miscellaneous lesions includ
ing myositis ossificans and soft-tissue
tumours. Dr. Huvos has also included
samples of computed tomography and
magnetic resonance imaging and has
demonstrated their role in expediting
accurate staging of skeletal lesions.
Huvos has also included updated
statistics on treatment and prognosis.
It is in the area of management that
the book is weakest. This is easy to
understand because Huvos (Joes not
manage patients but looks at speci
mens. Readers would have benefited if
Huvos had had the portions of his text
devoted to treatment written by an
experienced musculoskeletal oncology
surgeon.
As a pathology text, however, the
book is excellent. It is easy to read, and
a concise picture of the relevant patho
logic features of particular tumours can

be found quickly and easily. The histo
logic illustrations, including electron
micrographs, are also well reproduced.
Radiographs are excellent and are ap
propriately represented.
Bone-tumour pathology often is per
ceived as a difficult hurdle for orthope
dic residents. There seems to be a
colossal amount of information that
must be processed and stored ready for
quick access. In fact, the amount of
information is not that great, and a
clear orthopedic text such as the one by
Andrew Huvos is an excellent means of
obtaining the information.
Fred Langer, MD, FRCSC
Mount Sinai Hospital
Ste. 476
600 University Ave.
Toronto, ON
M5G 1X5

VASCULAR SURGERY. 3rd edition.
Edited by Wesley S. Moore. 767 pp.
Illust. W.B. Saunders Company/Harcourt Brace Jovanovich, Inc., Philadel
phia. 1991. Price not stated. ISBN 0 7216-3512-1

This multiauthored text covers all as
pects of vascular surgery in a compre
hensive yet concise manner that is very
readable. All important aspects of vascontinued on page 380
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Outpatient Orthopedic Surgery:
a Retrospective Study of 1996 Patients
Patrick Kinnard, MD, FRCSC; Richard Lirette, MD, FRCSC
Outpatient surgical procedures performed at the Centre Hospitalier de l’Universite
Laval on 1996 patients (1091 men, 905 women) were studied retrospectively.
Lower-limb surgery accounted for 66.5% of the procedures. The mean age of the
1996 patients was 40.7 years. General anesthesia was used in 91.5% of the cases.
After surgery, the patients were discharged according to the criteria described by
Wetchler and Kortilla. The unanticipated hospital admission rate was 6.3% and the
complication rate was 1.3% with no life-threatening conditions. Proper selection and
preparation of the patient and strict criteria for safe discharge after day surgery are
mandatory for the patient’s safety and satisfaction.

On a procede a une etude retrospective des interventions chirurgicales effectuees, au
Centre hospitalier de l’Universite Laval, sur 1 996 patients consultants (1 091
hommes et 905 femmes). Dans 66,5 % des cas, on a pratique une intervention
chirurgicale sur les membres inferieurs. Les 1 996 patients avaient en moyenne 40,7
ans. On a administre une anesthesie generate dans 91,5 % des cas. Apres
l’intervention chirurgicale, on a libere les patients selon les criteres decrits par
Wetchler et Kortilla. Le taux des hospitalisations imprevues s’est etabli a 6,3 % et le
taux des complications, a 1,3 %, sans danger pour la vie. La selection et la
preparation appropriees du patient et l’observation stricte des criteres de liberation
securitaire apres une intervention chirurgicale de jour sont obligatoires pour la
securite et la satisfaction du patient.

They represented 53% of all the
orthopedic procedures performed at
our institution.
All patients scheduled for outpa
tient surgery were evaluated clini
cally and classified according to the
American Society of Anesthesiolo
gists (Table I).7
Preoperative laboratory work, al
though not mandatory,8 included,
for medicolegal reasons, measureTable 1. American Society of
Anesthesiology Classification
Class
1
II
III

IV

V

he concept of outpatient sur
gery is not new, but it is only
within the last decade that we have
seen an increase in outpatient surgi
cal procedures, which will soon ex
ceed the number of inpatient surgi
cal procedures.1’2
The lack of accessibility to hospi
talization, reduced costs of opera
tion, less disruption to the patient’s
personal life and avoidance of hos-

T

pital-acquired infections have con
tributed to the renewed interest in
outpatient surgery.3-6

Patients and Methods
The records of 1996 patients
treated at the Centre Flospitalier de
l’Universite Laval between June
1984 and June 1987 were reviewed.

From the Department o f Orthopedic Surgery, Centre Hospitalier de l ’Universite Laval, Quebec,
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Reprint requests to: Dr. Patrick Kinnard, Professor and head. Division o f Orthopedic Surgery,
Universite Laval, Centre Hospitalier de l ’Universite Laval, 2705 blvd. Laurier, Ste-Foy, PQ
C1V4G 2

Description
Healthy patient
Patient with a mild systemic
disease
Patient with a severe systemic
disease, not incapacitating and
controlled by medication
Patient with incapacitating
systemic disease which is a
constant threat to life
Moribund patient

Table II. Guidelines for Safe Discharge
Stable vital signs for f.5 h
No new signs or symptoms that may
threaten a safe recovery
Cessation of oozing or bleeding
No nausea or emesis
Good circulation and return of sensation in
the operated extremity when a tourniquet
was used
No evidence of swelling or impaired
circulation in an extremity when a cast
has been applied
Ability to void and to maintain orally
administered fluids
Ability to recognize time and place
Little or no dizziness
Ability to dress
Pain controlled by oral analgesics
Discharge information
Responsible adult physically and
intellectually capable of taking care of
the patient at home
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Table III. Outpatient Procedures
Anatomic area
Shoulder
Acrom ioplasty, acromioclavicular surgery
R otator-cuff repair
Recurrent-dislocation repair
M inor procedures
A rm /e lb o w
Hum erus plate removal, biopsy
Elbow epicondylectom y, arthrotomy
M inor procedures (bursectomy, ulnar-nerve release)
Forearm
Open reduction of fractures
Plate removal
M inor procedures
W rist/h an d
Bone gra ft for scaphoid nonunion
Bone procedure (osteotomy, partial arthrodesis)
Distal forearm fracture (closed or open)
M inor procedures (plate removal, Dupuytren’s contracture, carpal tunnel
syndrom e, trigger finger, metacarpal fractures, synovial cysts)
B ack/pelvis
Discography
Bone biopsy
H ip/thigh
Fem oral-plate removal (10 holes)
Sm all plate, pin, nail removal; biopsy
Knee
D iagnostic arthroscopy
Surgical arthroscopy
Lateral retinacular release
A rthrotom y
M inor procedures (wire removal, bursectomy)
Leg
Plate removal
M inor procedures (exostectomy, fasciotomy)
Ankle
Open reduction ankle fractures
A rth roto m y
M inor procedures (screw or plate removal; soft-tissue release)
Foot
Unilateral great-toe surgery (arthroplasty or osteotom y)
Unilateral lateral metatarsal osteotomy
Bilateral great-toe surgery
Bilateral metatarsal osteotomy
Miscellaneous (M orton's toe, hammer toes)
M ultiple procedures

239
116
48
49
26
103
9
54
40
33
3
29
1
240
16

18
14
192
23
17
6
67
11
56
747
157
343
164
32
51
70
45
25
121
16
18
87
323
122
26
25
6
144
30
1996

Total
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No.
procedures
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No. patients
hospitalized

No.
complications

32
15
9
6
2
4
4
~
2

5
3

1
1

11
2

2
0
1
1
1
-

2
2
2
14

1

7
7

27
2
9
4
8
4
1
1
-

5
2
2
1
25
13
-

A.

-

-

7

A

1

1

10
3
7
1
1
2
1

1
6
2

7

-

1
4
3

4

-

126

27

4

OUTPATIENT ORTHOPEDIC SURGERY

was 1.3%, and there were no lifethreatening conditions (Table IV).
The hospitalization rate was greater
in the shoulder and the hip/thigh
groups than in any other group. No
statistical differences were noted be
tween hospitalization, complication
rates, sex or American Society of
Anesthesiologists’ classification.

Discussion
Outpatient surgery has pro
gressed from simple procedures per
formed under local anesthesia to
more extensive procedures in pa
tients with complex medical prob
lems.5 If this type o f surgery is to
be successful, patients must be
properly selected and prepared for
the operation.
Patients whose physical status is
American Association of Anesthesi
ology class I or II and even medical
ly stable patients in class III are
acceptable at most outpatient facili
ties.5-12
Pre-existing medical problems
that are under good control do not
appear to increase the frequency of
complications after outpatient anes
thesia and surgery.5-6-12
Arbitrary restrictions based on
the age o f the patient may be

Table IV. Hospitalization and Complications
Details of
hospitalization
Hospitalization
Immediate
Pain
Faintness
Physician’s request
More extensive surgery
Delayed
Infection
Pulmonary em bolism
Complications (without
hospitalization)
Infection
Hematoma
Seroma
Wound dehiscence
Superficial phlebitis
Refracture after plate removal

No. of
patients
126
122
75
37
8
2
4
3
1
27
12
9
2
2
1
1

inappropriate because there is no
age-related increase in recovery
time or complications following out
patient anesthesia.5-6-12
Local, regional and general anes
thesia may be used for outpatient
surgery; the choice of anesthetic
technique is determined by surgical
requirements and the patient’s
physical status and preferences,5-10
but local and regional anesthesia
have specific advantages.13 Proce
dures o f more than 90 minutes are
acceptable because the relationship
between anesthesia time and recov
ery time is weak.5-14 The potential
need for a transfusion may no lon
ger be an absolute contraindication
to outpatient surgery.7
The laboratory data required de
pend on the patient’s age, state o f
health and drug history.5-6-8-14 Given
the potentially high incidence o f
side effects in the outpatient set
ting, a variety of tests and dis
charge criteria have been devised
(Table II).
There is some evidence that am
bulatory patients experience fewer
complications like pneumonia, cross
infection and pulmonary infection.15
In a review o f 32 000 outpatient
procedures, only 50 cases of infec
tion, 138 o f hemorrhage and 8 o f
phlebitis were noted.15 In our series
o f 1996 orthopedic outpatient pro
cedures we had similar results.
It must be noted that 50% o f the
hospitalizations required immediate
ly were because o f pain. However,
over the 3 years o f this study, we
experienced a substantial decrease
in the hospitalization rate. Injection
o f a long-acting local anesthetic
agent before departure, either into
the surgical wound or as a tempo
rary nerve block, such as a femoral
nerve block for knee surgery or
tibialis posterior nerve block for
foot surgery,16-17 alleviated the post
operative pain without known side
effects or complications.
The second largest complication

requiring hospitalization was faint
ing or a feeling o f faintness, but
changes in anesthetic and antalgic
drugs and more frequent use o f
regional anesthesia resulted in a
decrease o f this problem.
A major criticism o f this study is
that data obtained by retrospective
review are subject to many prob
lems because, unlike hospitaliza
tions, complications may be easily
overlooked. However, the small
number o f clinically detected cases
o f phlebitis and pulmonary em bo
lism may be explained in part by
early ambulation, even if no method
o f prophylaxis can be relied upon to
remove the fear o f deep vein throm
bosis and its consequences.18-20
The only pulmonary embolism in
our series occurred in a 22-year-old
man with no medical history who
underwent a diagnostic arthroscopy
o f 20 minutes’ duration. He was
hospitalized 8 days after his surgery
for chest pain and had a complete
recovery after anticoagulation ther
apy.
Due to the lack o f hospital facili
ties, there is a continued trend to
do ever more extended operations
on an outpatient basis and this
study is a step in that direction.
As the complexity o f patient con 
ditions and scheduled surgical pro
cedures increase, patient safety and
satisfaction will depend upon proper
selection, preparation, standardized
postoperative
discharge
criteria,
precise and clear discharge informa
tion and easy access for the patient
to the doctor.
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ACTION
In vitro studies demonstrate that the bactericidal
action of cefoxitin, a cephamycin derived from
cephamycin C, results from the inhibition of
bacterial cell wall synthesis. Evidence suggests
that the methoxy group in the 7a position is
responsible for the resistance of cefoxitin to
degradation by bacterial beta-lactamases.

INDICATIONS AND CLINICAL USES
TREATMENT

The treatment of the following infections when
due to susceptible organisms:
1 - Intra-abdominal infections such as peritonitis
and intra-abdominal abscess
2 - Gynecological infections such as endo
metritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and Serratia
spp.)
5 - Lower respiratory tract infections
6 - Bone and jo in t in fe c tio n s caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies
should be performed to determine the susceptib ilit y of th e c a u s a tiv e o rg a n is m (s ) to
MEFOXIN®. Therapy may be started while
awaiting the results of these tests, however,
modification of the treatment may be required
once these results become available.
Organisms particularly appropriate for therapy
with MEFOXIN® are:
Gram positive

Staphylococci, penicillinase producing and
non-producing
Streptococci excluding enterococci
Gram negative (beta-lactamase producing and
non-producing strains)

Escherichia coli
Klebsiella species (including K. pneumoniae)
Proteus, indole positive and negative
Haemophilus influenzae
Providencia species
Anaerobes

Bacteroides fragilis
MEFOXIN® may also be appropriate for the
treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
MEFOXIN® is not active against Pseudomonas
spp., most strains of enterococci, many strains
of Enterobacter cloacae, and m eth icillin r e s is ta n t s t a p h y lo c o c c i a n d L is te r ia
monocytogenes.
Clinical experience has demonstrated that
MEFOXIN® can be administered to patients who
are also receiving carbenicillin, gentamicin,
tobramycin, or amikacin (see PRECAUTIONS
and ADMINISTRATION).
PROPHYLACTIC USE

MEFOXIN® may be administered perioperatively (preoperatively, intraoperatively and postoperatively) to patients undergoing vaginal or
abdominal hysterectomy and abdominal surgery
when there is a significant risk of postoperative
infection or where the occurrence of post
operative infection is considered to be especially
serious.
In patients undergoing cesarean section, intra
operative (after clamping the umbilical cord)
and postoperative use of MEFOXIN® may
reduce the incidence of surgery related post
operative infections.

®Trademark Merck & Co., Inc.
Merck Frosst Canada Inc., R.U.

Effective prophylactic use depends on the time
of administration. MEFOXIN® usuallyshould be
given one-half to one hour before the operation.
Prophylactic administration should usually be
stopped within 12 hours. It has been generally
reported that continuing administration of any
antibiotic beyond 24 hours following surgery
increases the possibility of adverse reactions
but, in the majority of surgical procedures, does
not reduce the in cid e n ce of subsequent
infection.
If signs of postsurgical infection should appear,
specimens for culture should be obtained for
identification of the causative organism(s) so
that appropriate treatment may be instituted.

CONTRAINDICATIONS
MEFOXIN® is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.

WARNINGS
Before therapy with MEFOXIN® is instituted,
careful inquiry should be made to determine
whether the patient has had previous hyper
sensitivity reactions to MEFOXIN®, cepha
losporins, penicillinsorotherdrugs. MEFOXIN®
should be given with caution to penicillinsensitive patients.
There is some clinical and laboratory evidence
of partial cross-allergenicity between cephamycins and the other beta-lactam antibiotics,
penicillins and cephalosporins. Severe reactions
(including anaphylaxis) have been reported
with most beta-lactam antibiotics.
Pseudomembranous colitis has been reported
w ith v ir tu a lly a ll a n tib io tic s in c lu d in g
MEFOXIN®. This colitis can range from mild to
life threatening in severity. Antibiotics should
therefore be prescribed with caution in indi
viduals with a history of gastrointestinal disease,
particularly colitis. It is important to consider a
diagnosis of pseudomembranous colitis in
patients who develop diarrhea in association
with antibiotic use. While studies indicate that a
toxin produced by Clostridium difficile is one
primary cause of antibiotic-associated colitis,
other causes should also be considered.
Any patient who has demonstrated some form of
allergy, particularly to drugs, should receive
antibiotics including MEFOXIN® with caution.
If an allergic reaction to MEFOXIN® occurs,
adm inistration of the drug should be dis
continued. Serious hypersensitivity reactions
may require treatment with epinephrine and
other emergency measures.

PRECAUTIONS
The total daily dosage should be reduced when
MEFOXIN® is administered to patients with
transient or persistent reduction of urinary
output due to renal insufficiency (see DOSAGE
AND ADMINISTRATION) because high and
prolonged serum antibiotic concentrations can
occur from usual doses.
In patients treated with MEFOXIN® a false
positive reaction to glucose in the urine may
occur with Benedict's or Fehling's solutions but
not with the use of specific glucose oxidase
methods.
Using the Jaffe Method, falsely high creatinine
values in serum may occur if serum concen
trations of cefoxitin exceed 100 pg/mL. Serum
samples from patients treated with MEFOXIN®
should not be analyzed for creatinine if with
drawn within two hours of drug administration.
High concentrations of cefoxitin in the urine
may interfere with measurement of urinary 17hydroxy-corticosteroids by the Porter-Silber
reaction, and produce false increases of modest
degree in the levels reported.
Increased nephrotoxicity has been reported
fo llo w in g co n c o m ita n t a d m in istra tio n of
cephalosporins and aminoglycoside antibiotics.
Prolonged use of MEFOXIN® may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation ofthe patient's condition is
essential and if super-infection occurs during
therapy, appropriate measures should be taken.
Should an organism become resistant during
antibiotic therapy, another antibiotic should be
substituted.

Use in Pregnancy
The safety of MEFOXIN® in the treatment of
infections during pregnancy has not been
established. If the administration of MEFOXIN®
during pregnancy is considered necessary, its
use requires that the anticipated benefits be
weighed against possible hazards to the fetus.
Reproductive and teratogenic studies have been
performed in mice and rats and have revealed no
evidence of impaired fertility or harm to the fetus
due to MEFOXIN®.
There are no controlled studies in pregnant
women.
Nursing Mothers
Cefoxitin is excreted in human milk. Caution
should be exercised if use is indicated.
Children
In children 3 months of age or older, higher
doses of MEFOXIN® (100 m g/kg /d a y and
above) have been associated with an increased
incidence of eosinophilia and elevated SGOT.

ADVERSE REACTIONS
MEFOXIN® is generally well tolerated. Adverse
reactions rarely required cessation of treatment
and usually have been mild and transient.
Local Reactions
Throm bophlebitis has occurred with intra
venous administration. Some degree of pain and
tenderness is usually experienced after intra
muscular injections using water. Induration has
occasionally been reported.
Allergic
M a c u lo p a p u la r rash, u rtic a ria , p ru ritu s ,
eosinophilia, fever and other allergic reactions
including anaphylaxis have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can
appear during or after antibiotic treatment.
Nausea and vomiting have been reported rarely.
Blood
Eosinophilia, leukopenia, neutropenia, hemo
lytic anemia, and thrombocytopenia and bone
marrow depression have been reported. Some
individuals, particularly those with azotemia,
may develop positive direct Coombs tests
during therapy with MEFOXIN®.
Liver Function
Transient elevations in SGOT, SGPT, serum
LDH, and serum alkaline phosphatase and
jaundice have been reported.
Cardiovascular Function
Hypotension.
Renal Function
Elevations in serum creatinine and/or blood
urea nitrogen levels have been observed. As
with the cephalosporins, acute renal failure has
been reported rarely. The role of MEFOXIN® in
changes in renal function tests is difficult to
assess, since factors predisposing to prerenal
azotemia or to impaired renal function have
often been present.

TREATMENT OF OVERDOSE
Other than general supportive treatment, no
specific antidote is known. MEFOXIN® can be
eliminated by dialysis in patients with renal
insufficiency.

DOSAGE AND ADMINISTRATION
MEFOXIN® may be administered intravenously
or intramuscularly as required. (See complete
m o n o g ra p h on A D M IN IS T R A T IO N and
RECONSTITUTION.)
Intravenous Administration
The intravenous route is preferable for patients
with bacteremia, bacterial septicemia, or other
severe or life-threatening infections, or for
patients who may be poor risks because of
lowered resistance resulting from such debili
tating co n d itio n s as m alnutrition, trauma,
surgery, diabetes, heart failure, or malignancy,
particularly if shock is present or impending.
TREATMENT DOSAGE
Adults
The usual a d u lt dosage is 1 g or 2 g of
MEFOXIN® every 6 to 8 hours. Dosage and
routeof administration should be determined by

severity of infection, susce p tibility of the
causative organisms, and condition of the
patient. The usual adult dosages are shown in
the Table below.
Usual Adult Dosage
Type of
infection

Dally
Dosage

Frequency
and Route

Uncomplicated
forms* of infections such as
pneumonia,
urinary tract
infection, soft
tissue infection

3-4 g

1 g every 6-8 h
l.v. or I.M.

Moderately
severe or severe
infections

6-8 g

1 g every 4 h
or
2 g every 6-8 h I.V.

Infections
commonly
needing antibiotics in higher
dosage (e.g. gas
gangrene)

12 g

2 g every 4 h
or
3 g every 6 h I.V.

‘ Including patients in whom bacteremia is absent or
unlikely

Therapy may be started while awaiting the
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic
streptococcal infections should be maintained
for at least 10 days to guard against the risk of
rheum atic fever or glom erulonephritis. In
staphylococcal and other infections involving a
collection of pus, surgical drainage should be
carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN® may be used in patients w ith
reduced renal function but a reduced dosage
should be employed and it is advisable to
monitor serum levels in patients with severe
impairment.
In adults with renal insufficiency, an initial
loading dose of 1 g to 2 g should be given. After
a loading dose, the following recommendations
for maintenance dosage may be used as a guide:
MAINTENANCE DOSAGE OF
MEFOXIN® IN ADULTS
WITH REDUCED RENAL FUNCTION
RENAL
FUNCTION

DOSE

FREQUENCY

50-30

1-2 g

every 8-12 h

29-10

1-2 g

every 12-24 h

Mild
impairment

9-5

0.5-1 g

every 12-24 h

<5

0.5-1 g

every 24-48 h

In patients undergoing hem odialysis, the
loading dose of 1 - 2 g should be given after each
hemodialysis, and the maintenance dose should
be given as indicated in the Table above.
Neonates (Including Premature Infants), Infants
and Children (See WARNINGS for Neonates
under ADMINISTRATION in the com plete
monograph.)
Premature Infants
with Body Weights
Above 1500 g

20-40 mg/kg every 12 h I.V.

Neonates

0-1 week of age
1-4 weeks of age

A t p re se n t th e re is in s u ffic ie n t data to
recommend a specific dosage for children with
impaired renal function. However, if the adminis
tration of MEFOXIN® is deemed to be essential
the dosage should be modified consistent with
the recommendations for adults (see Table
above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of
MEFOXIN® is recommended as follows:
Vaginal or abdominal hysterectom y and
abdominal surgery
2 g adm inistered in tra m u scu la rly or in tra 
venously just prior to surgery (approximately
one-half to one hour before initial incision).
The second and third 2 g doses should be
administered at 2-6 hour intervals after the
initial dose.
Cesarean Section
The first dose of 2 g should be administered
intravenously as soon as the umbilical cord has
been clamped. The second and third 2 g doses
should be given intravenously or intram us
cularly four hours and eight hours after the first
dose.

AVAILABILITY
MEFOXIN® is supplied as sterile powder in
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3357 Ca - 2 g cefoxitin as sodium salt
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ADD-Vantage® vial
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ADD-Vantage® vial
For full details on preparation and adminis
tration with ADD-Vantage® vials - please
consult Product monograph.
Storage
MEFOXIN® in the dry state should be stored
below 30°C. The d ry m aterial as w ell as
solutions tends to darken, depending on storage
conditions; product potency, however, is not
adversely affected.
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Early and Late Complications
of Retroperitoneal Lymphadenectomy
in Testis Cancer
M.A.S. Jewett, MD, FRCSC; T. Wesley-James, MD, FRCSC
The complications arising from 100 consecutive retroperitoneal lymphadenectomies
done for nonseminomatous germ-cell tumours of the testis were reviewed. Thirty
procedures were performed with sparing of sympathetic nerve fibres. There were no
operative deaths. Complications were not stage-related, and the sympathetic
nerve-sparing procedure did not alter their frequency. Long-term follow-up in the
same cancer centre allowed documentation of all early and delayed complications as a
measure of burden of surgical therapy. Median follow-up for survivors was 44
months. Complications that resulted in delayed hospital discharge or further
operative intervention at any time were defined as major; all others, resulting in
minimal morbidity to the patient, were documented as minor. Injury to renal vessels
occurred in four patients intraoperatively. Delayed complications included
small-bowel obstruction requiring laparotomy (six patients), incisional hernia
requiring repair (two patients) and urethral stricture requiring urethroplasty (one
patient). There were 49 complications (14 major, 35 minor) in 35 patients. The
authors conclude that the majority of complications after retroperitoneal
lymphadenectomy are minor and cause little morbidity. This information is useful
when comparing surgery to alternative therapy with similar outcomes. The overall
burden of treatment becomes all-important in the selection of optimal therapy.

On a etudie les complications decoulant de 100 lymphadenectomies retroperitoneales consecutives, pratiquees pour des tumeurs testiculaires des cellules germinales
de type non seminomateux. Trente operations ont ete effectuees avec preservation
des fibres sympathiques. Aucune mortality operatoire n’a ete enregistree. Les
complications n’ont pas ete reliees au stade de la maladie et l’operation sauvegardant l’innervation sympathique n’en a pas modifie la frequence. La surveillance a
long terme des suites therapeutiques, dans un merae centre, a permis la verification
de toutes les complications immediates et retardees comme mesure des inconvenients de la chirurgie. La surveillance mediane des survivants a ete de 44 mois.
Les complications qui ont resulte en une hospitalisation prolongee ou ont entraine
des operations subsequentes ont ete considerees comme majeures; toutes les autres,
causes de morbidite minimale, ont ete jugees mineures. Des lesions des vaisseaux
renaux sont survenues, en cours d’operation, chez quatre patients. Les complica
tions retardees, comprenaient obstruction du grele necessitant une laparotomie (six
patients), hernie d’incision necessitant reparation (deux patients) et stenose uretrale
necessitant une uretroplastie (un patient). II y a eu 49 complications (14 majeures,
35 mineures) chez 35 patients. Les auteurs concluent que la majorite des
complications consecutives a une lymphadenectomie retroperitoneale sont mineures
et causent une faible morbidite. Cette information est utile pour comparer la
chirurgie a d’autres traitements donnant des resultats similaires. L’ensemble des
inconvenients d’un traitement est de premiere importance dans le choix d’une
therapie optimale.

he complete removal of tu
m our-bearing lymph nodes
from the retroperitoneum in early
stage nonseminomatous germ-cell
tumours of the testis results in a
surgical cure rate of 65% to 70%.1-3
This is one of the few tumour sites
in which surgery alone can cure
metastatic disease after it has
spread to regional lymph nodes.
Retroperitoneal lymphadenectomy
(RPL) is also performed as an adju
vant to chemotherapy for residual
abdominal tumour including carci
noma, teratoma and necrosis or
fibrosis. We carried out a retrospec
tive review to define our complica
tions of RPL and relate these to the
extent of disease.

T

Patients and Methods
One hundred consecutive patients
with primary nonseminomatous
germ-cell tumours of testis under
went transabdominal retroperitoneal
lymphadenectomy by the same urol
ogist (MASJ) between 1977 and
1988.
Patients were staged as follows:
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stage I — tumour confined to the
testis with or without epididymal
involvement; stage IIA — retroperi
toneal nodes below the diaphragm,
5 cm in diameter or smaller; stage
IIB — retroperitoneal nodes below
the diaphragm, more than 5 cm in
diameter; and stage III — supradia
phragmatic metastases or invasion
of visceral organs.
Clinical staging at the time of
diagnosis in the 100 patients was as
follows: stage I, 12 patients; stage
IIA, 41 patients; stage IIB, 21 pa
tients; and stage III, 26 patients.
The pathological and operative
staging was as follows: stage I, 22
patients; stage IIA, 18 patients;
stage IIB, 24 patients; and stage III,
6 patients.
The sympathetic nerves were
spared in 30 cases.4 Our current
policy is to attempt nerve-sparing
dissection in all cases. It was con
sidered in the last 41 cases, but was
precluded in 11 cases because of
the extent or location of tumour.
Bulky retroperitoneal disease did
not preclude nerve-sparing, because
eight stage IIB and three stage III
patients had this procedure per
formed successfully. All patients
were followed up for a minimum of
3 months or until death. Indications
for RPL included patients with clini
cal stage I disease who refused the
surveillance protocol or were con
sidered unsuitable for surveillance,
patients with clinical stage IIA dis
ease and patients with post
chemotherapy residual abdominal
mass (stage IIB or stage III). Pa
tients with marked elevation of the
serum markers, a-fetoprotein or
chorionic gonadotropin, or both,
after orchiectomy were treated pri
marily with chemotherapy.
The chemotherapy consisted of
platinum-based multidrug regimens
including vinblastine, bleomycin,
cis-platinum, Adriamycin, cyclo
phosphamide and etoposide. The
majority received vinblastine-

Adriamycin-bleomycin (VAB) com
bination with cis-platinum for three
courses.5 Abdominal radiotherapy
(25 to 30 Gy) was given preoperatively to patients with low-stage
testicular tumours managed be
tween 1977 and 1980. Preoperative
therapy was given to 64 of the 100
patients — chemotherapy alone in
38, radiotherapy alone in 22, and
both chemotherapy and radiothera
py in 4 patients. Surgical complica
tions were conservatively defined as
major or minor. Only those compli
cations that resulted in delayed hos
pital discharge (routine hospitaliza
tion for RPL is 7 days) or further
operative intervention at any time
were defined as major. All other
complications resulting in minimal
morbidity to the patient were docu
mented and included as minor.
Retroperitoneal lymphadenectomy was performed transabdominally6 in all patients, with the recently
described sympathetic nerve-sparing
procedure4 in 30 patients. The lim
its of dissection were as follows: the
inferior border of the superior mes
enteric artery extended bilaterally at
a level 1 to 2 cm above the renal
arteries superiorly; the ureters later
ally; the midpoint of the ipsilateral
external iliac artery and the bifurca
tion of the contralateral common
iliac artery including the aortic bi
furcation inferiorly.

Results
There were 49 complications (14
major, 35 minor) in 35 patients
(Tables I and II). Fourteen major
complications occurred in 13 pa
tients and minor complications oc
curred in 24 patients. Two patients
had both major and minor compli
cations. Major and minor complica
tions occurred in all stages and did
not appear to be stage-related (Ta
bles III to V). The major complica
tion rate in patients who did not

undergo nerve-sparing dissection
(17%) (Table III) was higher than
that in patients who had nerve-spar
ing dissection (3%) (Table IV), but
the difference was not significant
(Table V). Of patients who received
chemotherapy, radiotherapy or chem oradiotherapy preoperatively,
complications occurred in 33%, 46%
and 75% respectively (Table VI).
The majority of patients operated
on later in the study had no preop
erative therapy (Table VII). Patients
who did not undergo nerve-sparing
dissection but who received radio
therapy preoperatively now would

.

Table 1 Early and Late M ajor
C om plications of Retroperitoneal
Lym phadenectom y in 100 Patients
Type of complication

No. of
complications

Sm all-bowel obstruction
requiring laparotom y
Ischemic damage to
kidney
Incisional hernia requiring
repair
Urethral stricture requiring
urethroplasty
Drainage of psoas
hematoma
Total

6
4
2
1
1
14

Table II. Early and Late M inor
C om plications
Type of complication

No. of
complications

Wound infection
Lymphocele requiring
aspiration
Pneumonia
Prolene suture irritation
requiring suture
removal
Lymphedema of leg
Gastrointestinal bleeding
Ascites
Partial ureteral obstruction
Urethral stricture
Small-bowel obstruction
resolving
spontaneously
Prolonged ileus
Epididymitis
Pyelonephritis
Atelectasis
Pleural effusion requiring
aspiration
Total

7
3
3

3
3
3
2
2
2

2
1
1
1
1
1
35
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not receive irradiation preoperatively. Approximately 40% of both
nerve-sparing and non-nerve-spar
ing groups received chemotherapy
preoperatively.
There were no operative deaths.
Two patients died of metastatic dis
ease, 1 and 2 months after surgery.
Eleven patients had died of cancer

at the time of writing (median sur
vival 8 months, range from 1 to 77
months). The median follow-up for
survivors is 44 months (range from
3 to 136 months).
Intraoperative complications were
unusual (4%) and consisted of renalvessel injuries including renal-artery
laceration (two), renal-vein lacera

Table III. Stage-Related Complication Rate in Non-Nerve-Sparing Retroperitoneal
Lymphadenectomy
Minor complicationsf

Major complications*
Pathologic
stage
1
IIA
IIB
III
TotalJ

Patients

Patients

No. ol
patients

No.

No.

%

No.

No.

%

22
18
24
6

4
0
7
2

4
0
6
2

18
0
25
33

12
3
13
0

7
3
10
0

32
17
42
0

70

13

12

17

29

20

29

' x 2 not valid,
t p = 0.545.
^Overall complication rate was 43% (30 of 70; two patients had both major and minor
complications).

tion (one) and severe renal-artery
spasm (one). All hilar injuries were
recognized intraoperatively and re
paired primarily. All resulted in
total or partial infarction of one or
both kidneys. One patient required
delayed nephrectomy for persistent
hypertension due to renal ischemia.
No patient had an elevated creati
nine level after convalescence, and
dialysis was never necessary.
Immediate postoperative compli
cations were minor. Delayed postop
erative complications can occur at
any time and were frequently late.
They included small-bowel obstruc
tion, incisional hernia, urethral
stricture, psoas hematoma, lym
phedema of the leg and irritative
incisional Prolene suture. Of the six
patients who underwent laparotomy
for small-bowel obstruction, three
had had chemotherapy preopera
tively and two had had radiotherapy
preoperatively. The average interval
to laparotomy was 19.2 months.

Table IV. Stage-Related Complication Rate in Nerve-Sparing Retroperitoneal Lymphadenectomy
Major complications *

Minor complications*

Patients

Patients

Pathologic
stage

No. of
patients

No.

No.

%

No.

No.

%

I
IIA
IIB
III

10
11
8
1

1
0
0
0

1
0
0
0

10
0
0
0

4
1
0
1

2
1
0
1

20
10
0
100

30

1

1

3

6

4

13

Totalt

* x 2 not valid.
tOverall complication rate was 17% (5 of 30).

Table V. Combined Stage-Related Complication Rate
Major complications*
Pathologic
stage
I
IIA
IIB
III
Totals

Minor complicationsf

Patients

Patients

No. of
patients

No.

No.

%

No.

No.

%

32
29
32
7

5
0
7
2

5
0
6
2

16
0
19
29

16
4
14
1

9
4
10
1

28
14
31
14

100

14

13

13

35

24

24

* x 2 not valid. Comparison by type of surgery according to Fisher's exact test (two-tailed), p =
0 . 101 .
+ x 2, P = 0.311. Comparison by type of surgery according to Fisher's exact test (two tailed), p =
^Overall complication rate was 35% (35 of 100).
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Discussion
Retroperitoneal lymphadenecto
my is a major operation. It was
associated with a 35% morbidity in
the present series but no operative
deaths. These results are in con
trast to those of other series,7-9
which have noted operative mortali
ty rates of 1.3% and overall morbid
ity rates of 12% to 33%. Our rela
tively high morbidity rate is not
directly comparable because we
have included several delayed com
plications. Delayed complications
included small-bowel obstruction
and Prolene-suture irritation. Past
series have not considered this
group. Patients were followed up
regularly in a regional cancer treat
ment centre and follow-up was com
plete.
Retroperitoneal lymphadenecto
my can be performed by either the
thoracoabdominal approach4 or the

COMPLICATIONS OF RETROPERITONEAL LYMPHADENECTOMY

transabdominal midline approach.8
There is no reported difference in
the morbidity rate using either ap
proach.7-9
More advanced disease was not
associated with a corresponding in
crease in operative morbidity (Table
VI). A similar lack of increased
morbidity was noted by Sago, Ball
and Novicki.8 Others7-9 found an
increase in morbidity with bulky
retroperitoneal disease. The differ
ence noted between these series and
ours may be accounted for by a
greater use of chemotherapy preoperatively in all our cases of bulky
retroperitoneal disease (stages IIB
and III). Skinner, Melamud and
Lieskovsky7 performed RPL after
most of their stage B3 and C pa
tients received chemotherapy, but
only stage III patients received che
motherapy preoperatively in Dono
hue and Rowland’s series.9 In both
of these series all patients with
bulky disease (stages IIB and III)
would have received chemotherapy
before RPL as in our treatment
protocol. The addition of chemo
therapy not only results in cure in
some patients but also in better
definition of tissue planes, easing
the removal of residual disease. Javadpour and colleagues10 have re
ported prohibitive complications in
initial cytoreductive surgery in
those with bulky disease.
Preoperative treatment with che
motherapy or radiotherapy, or both,
and their effect on morbidity could
not be analysed statistically due to
small numbers. Patients in the early
T a b le V I.

part of our series received 25 to 30
Gy to the retroperitoneum preoper
atively, as part of a treatment proto
col at that time. Currently, only
those who progress on combination
chemotherapeutic regimens are irra
diated in an attempt to salvage the
patient. Interestingly, there was no
difference between the incidence of
small-bowel obstruction in those
who received radiotherapy and
those who did not. The posterior
peritoneum was reapproximated in
all cases of RPL, but meticulous
suture closure of the re 
troperitoneum has reduced this
complication. If one excludes the
irradiated group, there was only a
mild increase in complications in
those receiving chemotherapy pre
operatively (34%) compared with
those who did not (22%). We be
lieve that this apparent mild in
crease in morbidity with chemother
apy is more than compensated for
by the decrease in mortality with
chemotherapy in those with bulky
disease.
Bleomycin pulmonary toxicity did
not result in any morbidity or mor

T a b le V II.

Preoperative Treatment in Relation to Type of Dissection Used for Retroperitoneal
Lymphadenectomy
P ro ced u re

P re o p e ra tiv e
th e ra p y

N o. of
p a tie n ts

Chemotherapy
Radiotherapy
Chemoradiotherapy
None
Total

39
24
4
33
100

N e rv e -s p a r in g

N o n -n e rv e -s p a rin g

N o.

%

No.

%

11
0
18

37
3
0
60

28
23
4
15

40
33
6
21

30

100

70

100

1

Analysis of Complications of Retroperitoneal Lymphadenectomy by Preoperative Therapy
M a jo i c o m p licatio n s

P re o p e ra tiv e
th e ra p y

tality in our series. Preoperative
therapy with bleomycin can result
in pulmonary fibrosis and oxygen
diffusion defects during anesthe
sia.11 Preoperative arterial blood
gases and pulmonary function tests
were done in all patients who re
ceived bleomycin chemotherapy pre
operatively. Intraoperative mainte
nance of the patients on a lower
percentage of inspired oxygen and
careful control of intravenous fluids
to maintain a slightly dry fluid
balance has resulted in minimal
morbidity from bleomycin pulmo
nary toxicity intraoperatively or
postoperatively.
With improvement in knowledge
of the anatomy and physiology of
ejaculation, recent RPLs have been
described in which the retroperito
neal sympathetic nerves are spared.4
This has resulted in success in
maintaining emission postoperative
ly. In our series, the nerve-sparing
procedure for RPL was associated
with a lower major complication
rate, although the difference was
not statistically significant. There
may be a lower morbidity rate with

N o. of
p a tie n ts

M in o

c o m p lic a tio n s

P atien ts

T o ta l p a tie n ts
w ith c o m p lic a tio n s

P a tie n ts

No.

%

N o.

No.

%

N o.

%

Chemotherapy
Radiotherapy
Chemoradiotherapy

39
24
4

4
4
2

4
3
2

10
13
50

14
13
1

11
8
1

29
36
25

15
11
3

38
46
75

Total*

67

10

9

13

28

20

30

27

40

N o.

'Two patients had both major and minor complications.
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DIFLUCAN
(fluconazole/pfizer)

A N OPPORTUNISTIC WAY
TO TREAT FUNGAL INFECTION
PRODUCT INFORMATION
NAME OF DRUG
DIFLUCAN TABLETS
DIFLUCAN INTRAVENOUS INFUSION 2 mg/mL in 0.9% SODIUM CHLORIDE
(fluconazole)
THERAPEUTIC CLASSIFICATION Antifungal
ACTIONS: Fluconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C14-alpha-dem ethylation. Mammalian cell dem ethylation is much less sensitive to
fluconazole inhibition. The subsequent loss of norm al sterols correlates with the
accumulation of 14-alpha-methyl sterols in fungi and may be responsible for the fungistatic
activity of fluconazole.
INDICATIONS AND CLINICAL USE: DIFLUCAN (fluconazole) is indicated for the treatment
of: 1. Oropharyngeal and esophageal candidiasis. DIFLUCAN is also effective for the
treatm ent of serious systemic candidal infections, including urinary tract infection,
peritonitis, and pneumonia. 2. Cryptococcal meningitis. 3. Prevention of the recurrence of
cryptococcal meningitis in patients with acquired immunodeficiency syndrome (AIDS).
Specim ens fo r fungal culture and other relevant laboratory studies (serology,
histopathology) should be obtained prior to therapy to isolate and identify causative
organisms. Therapy may be instituted before the results of the cultures and other laboratory
studies are known; however, once these results become available, anti-infective therapy
should be adjusted accordingly.
CONTRAINDICATIONS: DIFLUCAN (fluconazole) is contraindicated in patients who have
shown hypersensitivity to fluconazole or to any of its excipients. There is no information
regarding cross hypersensitivity between fluconazole and other azole antifungal agents.
Caution should be used in prescribing DIFLUCAN to patients with hypersensitivity to other
azoles.
WARNINGS: Patients with baseline abnormal liver function tests and those who develop
abnormal liver function tests during DIFLUCAN (fluconazole) therapy should be monitored
for the development of more severe hepatic injury. Although serious hepatic reactions have
been rare and the causal association with DIFLUCAN uncertain, if clinical signs and
symptoms consistent with liver disease develop that may be attributable to fluconazole,
DIFLUCAN should be discontinued, (see ADVERSE REACTIONS).
Immunocompromised patients, especially those with AIDS, who develop rashes during
treatment with DIFLUCAN should be monitored closely and the drug discontinued if lesions
progress, (see ADVERSE REACTIONS).
PRECAUTIONS
Use in Pregnancy: There are no adequate and well-controlled studies in pregnant women.
DIFLUCAN (fluconazole) is not recommended in pregnant women unless the potential
benefit outweighs the potential risk to mother and fetus.
Use in Nursing Mothers: It is not known whether fluconazole is excreted in human milk.
Because many drugs are excreted in human milk, caution should be exercised when
DIFLUCAN is administered to a nursing woman.
Use in Children: The clinical use of DIFLUCAN in children below 13 years of age has not
been established.
Use in Elderly: DIFLUCAN was well tolerated by patients aged 65 years and over.
Drug Interactions
Cimetidine and Antacids Absorption of orally administered DIFLUCAN does not appear to
be affected by gastric pH. Cimetidine did not affect oral bioavailability of fluconazole to a
clin ica lly meaningful extent; reduction of about 13% in AUC (area under the plasma
concentration-time curve) and 21% in peak plasma concentration (Cmax) was observed.
Administration of magnesium/aluminum hydroxide formulation, just prior to DIFLUCAN
adm inistration had no clinically relevant effects on the absorption or elimination of
fluconazole in normal volunteers.
Cyclosporine DIFLUCAN administered at 100 mg daily dose does not affect cyclosporine
pharmacokinetic levels in patients with bone marrow transplants. There have been several
reports in the literature associating concomitant administration of high doses of DIFLUCAN
with an increase in cyclosporine plasma concentrations in renal transplant patients with or
w ith o u t impaired renal function. Therefore, when DIFLUCAN and cyclosporine are
coadministered, cyclosporine levels should be monitored and cyclosporine dose accordingly
adjusted.
Warfarin DIFLUCAN increased the prothrombin time after warfarin administration in healthy
males. Though the magnitude of change was sm all (12% ), careful m onitoring of
prothrombin time in patients receiving coumarin-type anticoagulants is recommended.
Hydrochlorothiazide Concomitant administration of m ultiple doses of DIFLUCAN and
hydrochlorothiazide was associated with increases in fluconazole plasma levels which were
not considered to be clinically significant.
Sulfonylurea-Oral Hypoglycemics The potential fo r hypoglycemia due to decreased
elimination and increased blood levels of sulfonylurea oral hypoglycemics (glibenclamide,
glipizide and tolbutamide) has been demonstrated with concomitant administration of
DIFLUCAN. Blood glucose levels should be m onitored closely and the dose of the
hypoglycemic agent should be adjusted as necessary.
Phenytoin Concomitant administration of DIFLUCAN at steady state and phenytoin at steady
state resulted in an increase of up to 75% in AUC phenytoin. Since phenytoin has a low
therapeutic ratio, phenytoin plasma levels should be closely monitored when DIFLUCAN is
coadministered. The dose of phenytoin should be adjusted to maintain therapeutic levels.
Rifam pin Concomitant administration of DIFLUCAN and rifampin resulted in a 25%
decrease in the AUC and a 20% shorter half-life of fluconazole. The dosage of fluconazole
should be increased by 25% when fluconazole is administered with rifampin.
Zidovudine (AZT) and/or Pentamidine lsethionate Though no formal interaction studies have
been completed for DIFLUCAN and concomitant zidovudine and/or pentamidine isethionate,

these drugs have been used together in patients with AIDS with no clinically important
difference in the pattern of adverse events.
Drug/Laboratory Test Interactions: None known.
ADVERSE REACTIONS: Sixteen percent of over 4000 patients treated with DIFLUCAN
(fluconazole) in clinical trials of 7 days or more experienced adverse events.
Treatment was discontinued in 1.5% of patients due to adverse clinical events and in 1.3%
of patients due to laboratory test abnormalities.
Adverse clinical events were reported more frequently in HIV infected patients (21%) than in
non-HIV infected patients (13%). However, the patterns of adverse events in HIV infected
and non-HIV infected patients were similar. The proportions of patients discontinuing
therapy due to clinical adverse events were similar in the two groups (1.5%). The two most
serious adverse clinical events noted during clinical trials with DIFLUCAN were: 1. Exfoliative
skin disorders 2. Hepatic necrosis Because most of these patients had serious underlying
disease (predominantly AIDS or malignancy) and were receiving multiple concomitant
medications, including many known to be hepatotoxic or associated with exfoliative skin
disorders, the causal association of these reactions with fluconazole is uncertain. Two cases
of hepatic necrosis and one exfoliative skin disorder (Stevens-Johnson syndrome) were
associated with a fatal outcome.
The following treatment-related clinical adverse events occurred at an incidence of 1% or
greater in 4,048 patients receiving fluconazole for 7 or more days in clinical trials: Nausea
3.7% Headache 1.9% Skin Rash 1.8% Vomiting 1.7% Abdominal Pain 1.7% Diarrhea
1.5% Other treatment-related clinical adverse events which occurred less commonly (0.2 to
<1%) are presented by organ system below:
Skin and Appendages: pruritus.
Musculoskeletal: myalgia.
Central and Peripheral Nervous System: convulsions, dizziness, paresthesia, tremor, vertigo.
Autonomic Nervous System: dry mouth, increased sweating.
Psychiatric: insomnia, somnolence.
Gastrointestinal: anorexia, constipation, dyspepsia, flatulence.
Liver and Biliary System: cholestasis, hepatocellular damage.
Special Senses: taste perversion.
Hematopoietic: anemia
General: fatigue, malaise, asthenia, fever.
LABORATORY TEST ABNORMALITIES
Liver Function: Clinically significant increases were observed in the following proportions
of patients: AST (SGOT) 1%, ALT (SGPT) 1.2%, Alkaline Phosphatase 1.2%, Total bilirubin
0.3%. The incidence of elevated serum transaminases was independent of age or route
(p.o. or i.v.) of administration but was greater in patients taking DIFLUCAN concomitantly
with one or more of the following medications: rifampin, phenytoin, isoniazid, valproic acid,
or oral hypoglycemic agents. Clinically significant increases also were more frequent in
patients who: 1) had SGOT or SGPT elevations greater than three times the upper limit of
normal (>3xULN) at the time of entering the study (baseline), 2) had a diagnosis of hepatitis
at any time during the study and, 3) were identified as alcohol abusers. The overall rate of
serum transaminase elevations of more than 8 times the upper lim it of normal was
approximately 1% in patients treated with DIFLUCAN during clinical trials. (See table below)
Percent
Number
Percent
Number*
Percent
Drugof
Percent
Drugof
Lab
Abnormal
Related
Patients
Abnormal
Related
Patients
Parameter
Baseline < 3xULN
Baseline > 3xULN
4.2
0.8
3007
9.4
3.8
2874
4.8
1.0
3.1
0.0
Non-Hepatitis Patients
Hepatitis Patients
3.9
0.8
2900
SGOT
160
10.6
1.9
4.4
1.0
2799
11.4
2.1
SGPT
140
Non-Alcohol Abuse
Alcohol Abuse
4.2
0.9
3018
42
9.5
2.4
SGOT
4.7
1.0
2899
10.0
2.5
SGPT
40
Never
Received
Received
I.V. Fluconazole
I.V. Fluconazole
4.2
0.9
144
2916
SGOT
5.6
1.4
4.7
1.0
2800
SGPT
139
5.0
0.7
< 65 Years Old
> 65 Years Old
4.3
0.9
2783
277
4.3
1.1
SGOT
4.8
1.0
3.9
1.2
2681
SGPT
258
'Note: Only patients who had measurements at baseline and during therapy were included.
Renal Function: Clinically significant increases were observed in the following proportions
of patients: blood urea nitrogen (0.4%) and creatinine (0.3%).
Hematological Function: Clinically meaningful deviations from baseline in hematologic
values which were possibly related to DIFLUCAN were observed in the following proportions
of patients: hemoglobin (0.5%), white blood cell count (0.5%), and total platelet count
( 0 . 6 % ).
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essentially complete (greater than 90%), and is independent of dose. Peak plasma
concentrations after oral administration are attained rapidly, usually within 2 hours of
dosing. Since oral absorption is rapid and almost complete, the daily dose of DIFLUCAN
(fluconazole) is the same for oral and intravenous administration. The terminal plasma
elimination half-life is approximately 30 hours (range 20-50 hours).
The daily dose of DIFLUCAN and the route of administration should be based on the
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COMPLICATIONS OF RETROPERITONEAL LYMPHADENECTOMY

nerve-sparing dissection which
might become more apparent with a
larger series. However, this would
reflect an increased operative expe
rience with RPL rather than any
inherent advantage of the nerve
sparing procedure. Nerve-sparing is
not attempted when eradication of
disease may be compromised by
attempting to spare the sympathetic
nerves.

Conclusions

to result in an increased complica
tion rate. This information is useful
when comparing surgery to alterna
tive therapy with similar outcomes.
Overall burden of treatment be
comes all-important in the selection
of optimal therapy.
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Is Age an Independent Variable
in the Morbidity and Mortality of Patients
With Colorectal Cancer? A Prospective Study
Hanoch Kashtan, MD; Moshe Z. Papa, MD, FRCSC; Hartley S. Stern, MD, FRCSC, FACS
The authors examine prospectively the results of a single surgeon (H.S.S.), using a
computerized database to determine the effect of age on morbidity and mortality in
the management of colorectal cancer. Computer input was performed by a nurse data
manager (20 minutes per patient), and data retrieval required approximately 30
minutes of computer time.
Between 1984 and 1989, 241 patients with primary colorectal cancer underwent
operation. The average age was 67.9 years (range from 31 to 94 years). The authors
compared 108 (44.8%) patients who were older than 70 years with 133 (55.2%)
patients who were 70 years of age or younger.
Rectal carcinoma was more common in the younger age group (41.3% v. 20.4%),
but right-sided carcinoma was more common in the older age group (36.1% v. 19.6%,
p < 0.001). Bleeding was more frequent in the younger patients than in the older
ones (51.9% v. 35.2%, p < 0.01). There was no difference between the two groups in
tumour staging, using the modified Dukes’ classification. The overall mortality was
2.5% and morbidity was 39.4%, with no significant differences between the groups.
The authors conclude that age should not be a determinant in consideration of
operation for colorectal cancer and that a personal computerized database facilitates
simple prospective studies.

Les auteurs ont examine les resultats obtenus par un chirurgien (H.S.) afin de
determiner, a partir d’une base de donnees informatisee, quels sont les effets de
l’age sur la morbidite et la mortalite reliees au traitement du cancer colorectal.
L’entree des donnees a ete effectuee par une infirmiere de recherche (20 minutes par
patient), et la recuperation des donnees a exige environ 30 minutes de temps
d’ordinateur.
Entre 1984 et 1989, 241 patients souffrant d’un cancer colorectal primitif ont ete
operes. Leur age moyen etait de 67,9 ans (ecart de 31 a 94 ans). Les auteurs ont
compare 108 patients (44,8%) dont l’age etait superieur a 70 ans, a 133 patients
(55,2%) qi etaient ages de 70 ans ou moins.
Les cancers du rectum etaient plus frequents dans le groupe moins age (41,3%
contre 20,4%), mais les cancers du cote droit etaient plus frequents chez le groupe
plus age (36,1% contre 19,6%; p < 0,001). Les saignements ont ete plus frequents
chez les patients plus jeunes (51,9% contre 35,2%; p < 0,01). On n’a observe aucune
difference entre les deux groupes en ce qui a trait au stade la maladie, d’apres la
classification de Dukes modifiee. La mortalite globale fut de 2,5% et la morbidite de
39,4%, sans qu’il n’y ait de differences significatives entre les deux groupes.
Les auteurs concluent qu’on ne devrait pas tenir compte de l’age dans la chirurgie
des cancers colorectaux et qu’une base de donnees informatisee facilite les etudes
prospectives simples.
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olorectal cancer is the second
commonest cause of death from
cancer in Western society.1 Its inci
dence has increased among the el
derly in recent years.2 A number of
reports have addressed the effect of
age on the surgical outcome of
colorectal cancer, but many are lim
ited by the biases associated with
retrospective reviews3"8 or by the
confounding variable inherent in
collective reviews of multiple sur
geons.2"689 In 1984 the senior au
thor (H.S.S.) began prospectively
collecting data on 700 variables of
the management of all his patients
who underwent abdominal colorec
tal surgery using a commercially
available “tailor-made” system, Me
tabase (Metasa, Wimbledon, UK).10
Using this system, we evaluated the
effect of age on morbidity and mor
tality in patients who underwent
surgery for colorectal cancer.

Patients and Methods
All patients admitted to the
Mount Sinai Hospital in Toronto
between 1984 and 1988 were evalu
ated prospectively. Data were gener
ated from a computerized database
(Metabase). The database, which is
designed for medical applications,
allows rapid data input as well as
rapid, accurate and straightforward
retrieval of results.
Computer input was performed
by a nurse data manager (20 min
utes per patient), and data retrieval
for this project required approxi
mately 30 minutes of computer
time.
The colon was prepared for elec-

AGE AND COLORECTAL CANCER

tive surgery with GoLYTELY, 3 to
4 L, the evening before the opera
tion, in combination with met
ronidazole and erythromycin orally
and gentamicin and metronidazole
intravenously. Mechanical prepara
tion was not used in emergency
cases but antibiotics were given
intravenously.
Right-sided tumours included
carcinomas of the cecum, ascending
colon, hepatic flexure and proximal
two-thirds of the transverse colon.
Left-sided tumours included car
cinomas of the distal one-third of
the transverse colon, splenic flex
ure, and descending and sigmoid
colons. Rectal tumours included
carcinomas below the peritoneal re
flection that demanded anterior or
abdominoperineal resection.
The anastomoses used were as
follows: right colonic — functional
end-to-end with linear staples; left
colonic or high anterior resection
— hand sewn; low anterior resec
tion — double stapling with linear
and circular staples.
Operative death rate was defined
as the overall death rate during the
entire hospitalization period. A
modified Dukes’ classification was
used for staging.11
Data were analysed by the x2 test
and by analysis of variance meth
ods with the SAS statistical pack
age.12

Results

cinoma was 19.6% in the younger
age group and 36.1% in the older
group. The incidence of rectal carci
noma was 41.3% in the younger
group and only 20.4% in the older
group (p < 0.001: Table I).
Sixteen (12.0%) of the 133 youn
ger patients were asymptomatic at
the time of diagnosis, compared
with 22 (20.4%) of the 108 elderly
patients (p = 0.06). Of those who
presented with symptoms, bleeding
was more common in the younger
group (69 of 133, 51.9%) than in
the older group (38 of 108, 35.2%)
(p < 0.01). There were no differ
ences in the incidence of abdominal
pain, change in bowel habit or
weight loss between the two
groups.
The results of the histologic stag
ing of the colonic disease in the 233
patients were tabulated (Table II).
There were no significant differ
ences between the two groups.
Twenty-four (18.2%) of 132 youn
ger patients and 12 (11.9%) of 101
older patients had distant metastases at the time of diagnosis.
Forty-eight (36.1%) of the youn
ger patients were operated upon

Discussion
One of the major achievements of
modern society is the increase in
life expectancy. The process of
aging and its effects have demanded
more attention from medicine in
general and from surgical disci
plines in particular. Coincident with
the increase in life expectancy, the
definition of “old” has changed. It
is widely accepted now that 70

Table I. Age and Tumour Location of 241 Patients With Colorectal Cancer
Group
< 70 yr
Location
Right colon*
Left colon
Rectum*
Total

There were 241 patients in the
study. The average age was 67.9
years (range from 31 to 94 years).
We compared 108 (44.8%) patients
older than 70 years with 133
(55.2%) patients 70 years old or
less. The sex distribution between
the two groups was not significant:
in the older group 55 (50.9%) pa
tients were men, and in the younger
group 70 (52.6%) were men.
The incidence of right-sided car

urgently, compared with 33 (30.6%)
of the elderly patients (NS).
Primary resection with or with
out colostomy was performed in
114 (85.7%) of the younger patients
and in 91 (84.3%) of the older
group (NS).
The overall morbidity was 39.4%,
with no significant difference be
tween the two groups (36.8% in the
younger group and 42.6% in the
elderly group). The overall death
rate was 2.5% (one patient in the
younger group [0.75%] and five
patients in the elderly group
[4.6%]). These differences ap
proached significance (p = 0.06).

> 70 yr

Total

No.

°/o

No.

%

No.

%

26
52
55

19.6
39.1
41.3

39
47
22

36.1
43.5
20.4

65
99
77

27.0
41.1
31.9

133

100.0

108

100.0

241

100.0

*p < 0 . 001 .
Table II. Age and Dukes' Staging of 233 Patients With Colorectal Cancer
Group
< 70 yr

> 70 yr

Total

Stage

No.

%

No.

«/o

No.

%

A
B
C
D

5
61
42
24

3.8
46.2
31.8
18.2

9
54
26
12

8.9
53.5
25.7
11.9

14
115
68
36

6.0
49.4
29.2
15.4

Total

132

100.0

101

100.0

233

100.0
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years is the “border-age.”3’4 Opera
tive results of colorectal surgery in
elderly patients are considered to be
worse than those in younger pa
tients.3'5’89 Therefore, it is not un
common to find that age is a major
determinant when deciding whether
or not to operate upon a patient,
and that the incidence of inoperabil
ity in some series is as high as
45%.6'7 In this study, using a com
puterized database, we prospective
ly evaluated the effect of age on the
operative results of patients who
had primary colorectal carcinoma
and who were all operated on by a
single surgeon in a tertiary referral
centre.
A comparison of the preoperative
variables between the two age
groups demonstrates a significant
difference in the location of the
tumour. Carcinoma of the rectum
was the most common site in the
younger patients, and carcinoma of
the right colon was predominant in
the elderly patients. This observa
tion has been noted previously by
others.13-15 Several explanations
have been proposed, including the
greater influence of environmental
factors on the right colon, and the
increased number of endoscopic
polypectomies being performed in
the left colon.
More elderly than younger pa
tients were asymptomatic at the
time of diagnosis, a difference that
approached significance. In patients
who were symptomatic, bleeding
was more common in the younger
group. This difference may be attri
buted to the difference in the tu
mour location (rectal cancer was
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more frequent in the younger
group).
There was no apparent delay in
diagnosis in the over-70 age group,
because tumour staging at the time
of operation was similar in both
groups. Indeed, the fewer number
of metastases in the older patients
suggests that the diagnosis may
have been made earlier in this
group.
The results of operations were
similar in both groups. The number
of primary resections, morbidity and
mortality did not differ between the
two. The 2.5% overall death rate is
at the lower end of the range
usually reported.2-9
A patient was deemed unsuitable
for surgery on the basis of severe
intercurrent disease or the presence
of diffuse metastases. Age itself was
not a factor in this decision.
The senior author (H.S.S.) has
been using the database system for
5 years with no significant prob
lems. Data input can be done quick
ly (20 minutes per patient) by a
nurse data manager. Retrieval of all
of the variables examined in this
analysis was also rapidly and effi
ciently performed.
The authors believe that two con
clusions can be drawn from this
study. First, our results support the
concept that advanced age is not an
independent variable in determining
outcome in the management of co
lorectal cancer. Second, the use of a
comprehensive computerized data
base enhances the ability of clini
cians to prospectively address clini
cally relevant questions in their
practice.
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Hepatic Artery Pseudoaneurysms
in Acute Pancreatitis
J.M. Walton, MD, FRCSC; R.J. Abraham, MD; B.J. Perey, MD, FRCS(Glas), FRCSC;
J.H. MacGregor, MD, FRCPC; D.R. Campbell, MD, FRCPC

►
*
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The authors present a case of multiple intrahepatic pseudoaneurysms complicating
acute gallstone pancreatitis, and they review the relevant literature. The
complementary roles of ultrasonography, computed tomography and arteriography
are illustrated.
Although necrotizing vasculitis with resultant aneurysmal changes in
peripancreatic vessels is a recognized complication of chronic pancreatitis, similar
pseudoaneurysms have rarely been described in association with acute pancreatitis.

-> ►

r1

Les auteurs decrivent un cas de pseudo-anevrismes intrahepatiques multiples qui
sont venus compliquer une pancreatite lithiasique aigue et ils passent en revue les
publications pertinentes. Les roles complementaires de l’echographie, de la tomodensitometrie par ordinateur et de l’arteriographie sont illustres.
Meme si la vasculite necrosante avec formation d’anevrismes dans les canaux
peripancreatiques est une complication connue de la pancreatite chronique, des
pseudo-anevrismes similaires sont rarement decrits en rapport avec une pancreatite
aigue.

►
epatic artery aneurysms occur
rarely. When they are symp
tomatic, they can present with a
classic triad of upper abdominal
pain, gastrointestinal bleeding and
obstructive jaundice.1 They are
most commonly extrahepatic (75%)
and often present with rupture
(80% to 85%); the subsequent mor
tality ranges from 30% to 40%.2,3
The causes of hepatic artery aneu
rysms include atherosclerosis, fibromuscular dysplasia, inflamma
tion of the vessel wall, intra-arterial
chemotherapeutic agents, septic
emboli and accidental or iatrogenic
trauma.14’5

H

A
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'*

v
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Case Report
A 68-year-old woman was admit
ted to a regional hospital with lowgrade fever, abdominal pain and
vomiting. She had a 10-year history
of intermittent abdominal pain with
no hospitalization. Examination on
admission revealed mild epigastric
tenderness. Laboratory findings in
cluded a leukocyte count of 17.7 X
109/ L (normal, 4.5 to 10.5 X
109/L ) and the following levels:
serum amylase 1109 U/L (normal,
13 to 83 U/L), hemoglobin 137
g /L (normal, 115 to 155 g/L),
serum sodium 127 mmol/L (nor

►
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mal, 138 to 145 mmol/L), serum
potassium 2.5 mmol/L (normal,
3.8 to 4.9 mmol/L), serum aspar
tate aminotransferase 172 U /L
(normal, 8 to 29 U/L), serum glu
cose 15.5 mmol/L (normal, 3.6 to
5.83 mmol/L) and room air partial
pressure of oxygen (Po2) 47 mm
Hg. Ultrasonography revealed
cholelithiasis, a diffusely enlarged
pancreas and a normal liver.
She was admitted to the intensive
care unit with the diagnosis of
gallstone pancreatitis and was treat
ed with intravenous rehydration,
nasogastric suction and analgesics.
Her symptoms regressed, her serum
amylase levels returned to normal,
and by day 8 she was on a full diet.
On day 10 recurrent epigastric pain,
radiating to her back, and hypoten
sion developed. Repeat tests gave
the following results: serum amy
lase 582 U /L, hemoglobin 82 g /L ,
leukocyte count 14.7 X 109/L ,
serum lactic dehydrogenase 562
U /L (normal, 50 to 150 U/L) and
serum aspartate aminotransferase
89 U /L. She was given 2 units of
packed red blood cells and trans
ferred to our centre with the diag
nosis of acute hemorrhagic pan
creatitis. Repeat abdominal ul
trasonography demonstrated chole
lithiasis and a poorly defined hypoechoic mass in the right hepatic
lobe (Fig. 1). The computed tomog
raphy (CT) scan revealed an en
larged pancreas, which had an out
line compatible with acute pan
creatitis, and a mass in the right
lobe of the liver, which contained a
CJS, VOL. 34, NO. 4, AUG UST 1991
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large area of increased attenuation
(Fig. 2). Enhanced CT scanning
revealed a spherical vascular lesion

inferior to the high-density lesion
(Fig. 3). Selective hepatic arteriog
raphy demonstrated that the right

FIG. 1. Real-time ultrasonographic image shows poorly de
fined mass in posterior segment of right lobe of liver. There is
irregular hypoechoic centre (open white arrow).

FIG. 3. Enhanced CT scan at level slightly caudal to that
shown in Fig. 2 demonstrates intensely enhancing mass
(straight arrow) arising from vessel (curved arrow), indicating
pseudoaneurysm.
378
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hepatic artery arose from the supe
rior mesenteric artery. The right
hepatic artery had multiple pseu-

FIG. 2. Unenhanced computed tomography (CT) scan shows
high-density mass in right lobe of liver corresponding to
hypoechoic mass shown in Fig. 1. This is consistent with
hematoma of recent origin (straight arrow). Small amount of
free fluid is present in peritoneal cavity (curved arrows).

FIG. 4. Selective superior mesenteric artery injection opacifies
anomalous right hepatic artery and demonstrates multiple
pseudoaneurysms (straight arrows) of intrahepatic portion of
artery. Intrahepatic hematoma results in avascular area with
associated vascular displacement (curved arrows) visible in
right lobe of liver.

PSEUDOANEURYSMS IN ACUTE PANCREATITIS

doaneurysms, the largest having a
diameter of 3 cm (Fig. 4). The left
hepatic artery arose from the celiac
axis and was severely attenuated.
There was no active bleeding at the
time of angiography, and the portal
vein was patent.
The right hepatic artery was oc
cluded using transcatheter emboli
zation with two Gianturco 3-mm
steel coils. Subsequent CT scans
showed progressive resolution of
the intrahepatic hematoma and no
further evidence of aneurysms. The
patient was discharged symptomfree after a 4V2-week hospital stay.
She returned 5 weeks later for a
cholecystectomy. A cholangiogram
obtained intraoperatively was nor
mal. The porta hepatis and liver
were also noted to be normal to
inspection and palpation. There
were no complications of the chole
cystectomy.

Discussion
Approximately 10% of patients
with chronic pancreatitis demon
strate aneurysmal changes in the
peripancreatic vessels.6 In order of
decreasing frequency, these pseu
doaneurysms involve the splenic,
pancreaticoduodenal and gastro
duodenal arteries.7-14
An English literature review re
vealed 12 cases of hepatic artery
pseudoaneurysms associated with
pancreatitis. Only one definite case
of acute gallstone pancreatitis with
hepatic artery pseudoaneurysm was
reported. The pseudoaneurysm was
in the extrahepatic portion of the
left hepatic artery and was associat
ed with a pancreatic abscess.15 In
another study a hepatic artery pseu
doaneurysm was seen on arteriogra
phy, but the report did not state
whether it was associated with
acute or chronic pancreatitis.16
Burke and associates17 described
one case involving the intrahepatic

portion of the left hepatic artery
associated with recurrent pancreatic
abscesses. This appears to be a case
of acute relapsing pancreatitis in
which the pseudoaneurysm devel
oped over a period of months. Nine
other cases of hepatic artery pseu
doaneurysms have been described
in association with chronic pan
creatitis.4'6'8'18-22
Although multiple intrahepatic
true aneurysms have been described
in association with connective-tis
sue disorders,23'24 this appears to be
the first report of multiple pseudoa
neurysms forming within the liver
parenchyma that were associated
with pancreatitis. The necrotizing
vasculitis associated with pancreati
tis is thought to be secondary to
the digestive effects of elastase on
the wall of the arteries.25 The nu
merous lesions and their distribu
tion in the present case suggests
the destructive potential of enzymerich pancreatic fluid in sites remote
from the inflamed pancreas. It is
conceivable in our case that elastase
migrated along the right and left
hepatic arteries to damage the in
trahepatic vessels.
The early detection of hepatic
pseudoaneurysms by real-time and
doppler ultrasonography and by bo
lus-enhanced CT has been de
scribed.151719'22 However, selective
arteriography not only confirms the
diagnosis but also may detect addi
tional lesions not demonstrated by
other methods. Arteriography also
allows for definitive therapy by
transcatheter embolization.16
This appears to be the first re
ported case of multiple pseudoaneu
rysms of the intrahepatic portion of
the hepatic artery in association
with acute pancreatitis.
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cular surgery — anatomy, embryology,
pathophysiology, diagnosis, natural his
tory and management — are clearly
addressed. Each chapter covers the per
tinent information in an authoritative
manner and is accompanied by a series
of questions and answers that provide
the reader with immediate self-assess
ment and feedback. The bibliographies
are pertinent, extensive and current,
allowing the reader easy access to addi
tional information.
New chapters have been added to
this edition on the anatomy, physiology
and pharmacology of the arterial wall,
on the natural history of chronic lowerextremity ischemia, on reconstruction
of the supra-aortic trunks and verte
brobasilar system, on endovascular sur
gery, and on acute arterial occlusion
and the reperfusion injury. The chap
ters on nonatherosclerotic vascular dis
ease, hemodynamics of atherogenesis,
hemostasis and thrombosis, and he
modynamics for the vascular surgeon
are clear and concise, providing ade
quate information for the vascular train
ee and practising surgeon.
Each of the surgical chapters in
cludes the natural history, diagnosis,
preoperative evaluation, operative tech
nique and complications. The descrip
tions of the operative techniques are
not extensive but are frequently accom
panied by diagrams sufficient for a clear
understanding. Early and late results of
operative treatment are documented
usually by life-table graphs. Acute and
chronic venous disease, lymphedema,
portal hypertension, hemoaccess and
amputations all receive appropriate em
phasis.
This is an excellent, comprehensive,
practical text on vascuiar surgery which
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should be read thoroughly by all train
ees, as well as practising vascular sur
geons. The editor has indeed achieved
the objective of a textbook in vascular
surgery — to be comprehensive and
current yet enjoyable and easy to read.
A.R. Downs, MD, FRCSC, FACS
Professor of surgery
Faculty of Medicine
University of Manitoba
GC405 Health Sciences Centre
820 Sherbrook St.
Winnipeg, MB
R3A 1R9

ATLAS OF PULMONARY SURGICAL
PATHOLOGY. Thomas V. Colby,
Charles Lombard, Samuel A. Yousem
and Masanori Kitaichi. 380 pp. Illust.
W.B. Saunders Company/Harcourt
Brace Jovanovich, Inc., Philadelphia.
1991. $172. ISBN 0 -7 2 1 6 -2 8 9 3 -1

The major strides taken in thoracic
surgery over the past 20 years include
the double-lung transplant. A less ac
claimed, but critically useful, byproduct
of these advances has been the easy
availability of “open lung biopsies” for
diagnostic purposes. This in turn has
revolutionized the scope of pulmonary
pathology, leaving the surgical patholo
gist scrambling to recognize the myriad
new entities that have been described.
The Atlas o f Pulmonary Surgical Pa
thology is an addition to a growing list
of textbooks that document the expand
ing field of pulmonary pathology.
This volume is handsomely bound
with superb production values, match
ing any good illustrated “coffee-table”
book. It has a short introduction, which

suggests approaches to the biopsy in
different clinical situations and ends
with helpful hints on diagnosing local
ized and diffuse lung lesions. The bulk
of the book consists of illustrations of
abnormal histologic features accompa
nied by a short commentary. There is a
reasonable balance of black-and-white
and coloured illustrations — the latter
being more expensive to reproduce but
having greater impact. The photomicro
graphs are well reproduced, although in
some colour illustrations there is an
annoying increase in the background
density.
The spectrum of cases presented is
impressive and illustrates the breadth of
experience brought to the subject by
the authors. The majority of diseases
likely to be encountered by the average
general surgical pathologist is certainly
covered in this book. The images are
well chosen and the pictures composed
to illustrate the dominant facets of the
lesion at the light-microscope level. The
written text is succinct, provides useful
information and complements the illus
trations appropriately.
Interstitial lung disease, a perplexing
subject to many pathologists, is well
covered. The section on infectious dis
ease is encyclopedic and should be of
considerable assistance, especially when
dealing with specimens from patients
with acquired immunodeficiency syn
drome. There are many illustrations of
bronchiolitis obliterans organizing
pneumonia (BOOP), which appropriate
ly reflects the many facets of this lesion
in different clinical conditions. The de
scription of lymphoreticular tumours
could benefit from a review of immunocontinued on page 384
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Appendicular Abscess Presenting
as Neoplastic Ileocecal Obstruction
C. Rosati, MD;* S.N. Huang, MD, FRCPC;f J. Ali, MD, FRCSC, FACS*
Most complications after appendectomy occur within weeks of the operation. The
authors present a case in which an appendicular abscess presented more than 18
years after appendectomy for acute appendicitis. The abscess simulated a neoplastic
obstructive process, and a communication was demonstrated between the cecum and
the abscess cavity through the appendiceal stump.

La plupart des complications de l’appendicectomie surviennent dans les quelques
semaines qui suivent l’operation. Les auteurs presenter^ un cas, ou un abces
appendiculaire est apparu, plus de 18 ans apres une appendicetomie pour
appendicite aigue. L’abces a pris l’apparence d’une formation tumorale obstructive,
et une communication a ete demontree entre le coecum et la cavite d’abces, a travers
le moignon appendiculaire.

ppendectomy is the most fre
quently performed emergency
surgical procedure. Although the
death rate is quite low, complica
tions resulting from appendectomy
are reported in up to 20% of pa
tients.1 Most of these complications
occur within 10 days but may occur
weeks after appendectomy. The
case report that follows is unusual,
because the complication occurred
18 years after appendectomy, and
the clinical and radiologic signs
suggested a neoplastic process.

A

Case Report

A 37-year-old man, a competitive
marathon runner with a history of
asthma, was seen complaining of

gradual onset of vague right flank
and abdominal pain of 48 hours’
duration. The pain was described as
constant, nonradiating and progres
sively more severe over the 48-hour
period. Associated symptoms in
cluded nausea, anorexia, fever (tem
perature 38.3°C) and chills. There
was no vomiting, and his last bowel
movement was the day before pre
sentation. The patient denied any
history of a similar illness and,
apart from his asthma, was in good
general physical health.
His medical history revealed that
he had undergone an appendectomy
18 years earlier. He had also had a
brief episode of bleeding per rec
tum, which was investigated by co
lonoscopy, and an episode of hema
turia, which was investigated by

From the *Department o f Surgery and f Department o f Pathology, University o f Toronto,
Toronto, Ont.
Accepted for publication June 11, 1990
Reprint requests to: Dr. J. Ali, Department o f Surgery, University o f Toronto, 100 College St
Toronto. ON M5G 1L5

intravenous pyelography and cys
toscopy 3 years previously. The
results of all of these investigations
were negative, and his symptoms
were attributed to long-distance
running.
The patient had no known aller
gies. At the time of presentation he
was taking theophylline (Theo-Dur,
300 mg twice daily), fenoterol inha
lations (Berotec, four times daily)
and Pulmocare nutrient (Ross Labo
ratories, Montreal, Que.).
The results of examination of the
head, neck, chest and cardiovascu
lar and central nervous systems
were unremarkable. Examination of
the abdomen revealed a slightly
distended muscular abdomen with a
healed scar in the right lower quad
rant from the previous appendecto
my. There was maximal tenderness
over the scar with voluntary guard
ing, and a solid mobile intra
abdominal mass was palpated at the
point of maximal tenderness. No
other abnormalities were noted. The
rectal examination revealed soft
stool, which tested negative for oc
cult blood.
The initial laboratory investiga
tions gave the following results:
hemoglobin level 152 g /L , leuko
cyte count 11.1 X 109/L , platelet
count 273 X 109/L , serum sodium
level 140 mmol/L, serum potassi
um level 3.8 mmol/L, serum chlo
ride level 103 mmol/L, serum glu
cose level 5.4 mmol/L, blood urea
nitrogen level 4 mmol/L urea,
serum creatinine level 100 /^mol/L
and serum amylase level 92 U /L.
CJS, VOL. 34, NO. 4, AUGUST 1991
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Urinalysis results were negative.
Three views of the abdomen re
vealed a nonspecific pattern of gas
that was consistent with possible
early intestinal obstruction. The pa
tient was admitted to hospital for
further investigation of the tender
mass in the right lower quadrant.
Subsequent investigation by abdominopelvic ultrasonography and
computed tomography (Fig. 1) indi
cated a mass lesion measuring 5 X
4 X 3 cm surrounding the terminal
ileum, with the presence of contrast
medium in the central portion of
the mass. Similarly, a small-bowel
radiography series revealed the
presence of an extrinsic circumfer
ential mass at the terminal ileum
(Fig. 2). The differential diagnosis
included lymphoma, carcinoid, mes
enchymal tumour and an inflamma
tory mass arising in the terminal
ileum or cecum.
Because of the marked narrowing
of the terminal ileum and the clini
cal features of imminent obstruc
tion, a laparotomy was performed

through a midline incision. A mass
lesion surrounding the terminal
ileum was found. Its gross appear
ance was suggestive of malignant
disease, involving the terminal
ileum and cecum (Fig. 3). There
were several soft mesenteric lymph
nodes, one of which was sampled;
the quick section was found to be
negative for malignant cells. A right
hemicolectomy was performed.
The p atien t’s postoperative
course was complicated by a pro
longed ileus, which resolved with
nasogastric suction and intravenous
administration of fluids. The pa
tient was discharged from hospital
in good condition 14 days postoperatively.

Pathological Diagnosis

in the mass was a well-defined cavi
tary lesion and a short tubular
structure that communicated direct
ly with the cecum (Fig. 4). The ileal
and cecal mucosa was intact, but

FIG. 2. Small-bowel series demon
strates extrinsic mass (arrow) sur
rounding narrowed terminal ileum.

Surrounding the terminal ileum
and the cecum was an acute inflam
matory pericecal mass, 2 to 3 cm in
diameter, which was compressing
the terminal ileum. Contained with

FIG. 3. Operative appearance of mass
involving terminal ileum and cecum at
laparotomy suggests malignant lesion.

FIG. 1. Computed tomography scan of abdomen shows mass lesion surrounding
terminal ileum with a narrowed central lumen containing contrast medium (arrow).
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FIG. 4. Probe shows communication
between cecum and large abscess cavity.

APPENDICULAR ABSCESS

there was moderate edema. Micro
scopic sections of the tubular struc
ture demonstrated acute ulcerative
and suppurative inflammation, with
total effacement of the mural struc
ture. The wall of the proximal por
tion of the tubular structure con
tained two muscle layers that were
in continuity with the outer muscu
lar layers of the cecum. Acute fibrinopurulent inflammation was in
tense; an abscess surrounded the
short tubular structure, and the
inflammation had spread to the pe
ricecal serosal tissues. The results
of histologic examination of the
bowel specimen excluded other in
flammatory bowel disorders, includ
ing Crohn’s disease and ulcerative
colitis.

Discussion
Although the death rate from
appendectomy ranges from 0% to
1.2%,2 complications occur fre
quently.1 Factors influencing the
possibility of complications include
delay in diagnosis, appendiceal rup
ture, method of management of the
appendiceal stump and the patient’s
age.1-6
Complications resulting from ap
pendectomy include simple wound
infection, free perforation, pelvic or
hepatic abscess, ureteric or intesti
nal obstruction, portal pyelothrombophlebitis or death; these compli
cations tend to occur in the early
postoperative period.1’7 Significant
delayed complications include infer
tility following appendiceal perfora
tion,8 and intussusception.9
Treatment of the appendiceal
stump has been reported to influ
ence the type of complication. Com
plications after simple ligation of
the stump have included intestinal
obstruction secondary to adhesions,
fecal fistula, stump sloughing, ab
scess formation, free perforation
and generalized peritonitis.4’1011

After inversion of the appendiceal
stump complications have included
hemorrhage and stump abscess.
Postoperative abscess formation is
common with both of these meth
ods and the complication rates are
similar. The issue remains contro
versial, and to date there has been
no prospective evaluation compar
ing the two methods or situations
in which one method would be
preferable to the other.
Review of this patient’s operative
report at the time of appendectomy
indicated that a purulent retrocecal
appendix was found, and the base
of the appendix was crushed, ligat
ed and buried with a purse-string,
chromic catgut suture. The lumen
of the appendix was patent at the
base, and the inflammatory process
was most marked at the distal end
of the appendix. There was no
suggestion of a chronic inflammato
ry process such as Crohn’s disease
in the specimen removed or in the
right hemicolectomy specimen re
moved during the recent admission.
The reported incidence of abscess
formation in the postoperative peri
od ranges from 1.4% to 18%; most
abscesses occur between 5 and 10
days postoperatively14 and are more
common after appendectomy for a
perforated appendix. Rupture of an
appendiceal stump that leads to
abscess formation occurs in approx
imately 0.5% of appendecto
mies.101213 These patients are clini
cally well for approximately 5 to 7
days and then present with signs of
generalized peritonitis. There is
usually an associated disruption of
the purse-string suture in the
cecum and an intact ligature on the
appendiceal stump. Fecal fistula is
uncommon unless the stump itself
has become necrotic. The present
case is unique in that the abscess
was diagnosed more than 18 years
after the appendectomy, and there
was no clinical evidence of a compli
cation in the immediate postopera

tive period. The patient was dis
charged from hospital 5 days after
his initial appendectomy. We are
not aware of any previously report
ed periappendiceal abscess present
ing this long after an appendecto
my. The history and pathological
findings suggest that the periappen
diceal abscess may have resulted
from an appendiceal stump abscess,
which became organized and pre
sented as an inflammatory mass
producing obstructive symptoms
from extrinsic compression.
The right hemicolectomy was
performed in this case because of
the gross appearance, which sug
gested a malignant process, despite
a negative result from the quickfrozen section of the mesenteric
lymph node. McVay14 in 1964 sug
gested a relationship between ap
pendectomy and subsequent devel
opment of malignant disease. This
presumed protective effect of the
appendix against malignant disease
has since been disproven.15
Our case demonstrates that a
periappendiceal abscess can present
several years after appendectomy
and that the clinical and gross
findings may be difficult to differen
tiate from those of a malignant
condition.
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logic aspects and a mention of the
International Working Formulation for
Classification. I found the short sec
tions on normal-appearing biopsies and
nondiagnostic changes most useful be
cause they are not covered in most
conventional textbooks.
This text does not mention ancillary
studies in diagnostic histopathology
such as ultrastructure, immunohistochemistry and in-situ hybridization, but
it does not claim to be a comprehensive
textbook. The lack of radiologic corre
lations is also a shortcoming in any
book on lung diseases. Fine-needle aspi
ration and bronchiolar-alveolar lavage,
both useful diagnostic modalities in
lung disease, are also not covered.
In the final analysis, this atlas must
be judged on the usefulness of the
illustrations. The authors have intended
this book as a “cookbook” for surgical
pathologists to assist in the diagnosis of
lung biopsies. It succeeds admirably in
this and can be recommended as a
useful book for the busy surgical pa
thologist faced with a difficult lung
biopsy. It could also be of assistance to
the clinical respirologist or thoracic
surgeon who has an interest in learning
more about pulmonary histopathology.
Bernard Fernandes, MD, FRCPC,
MRC Path, FRCPA
Mount Sinai Hospital
University of Toronto
600 University Ave.
Toronto, ON
M5G 1X5
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SURGERY OF THE EAR. 4th edition.
Edited by Michael E. Glasscock III and
George E. Shambaugh Jr. 640 pp. IIlust. W.B. Saunders Company, London/Harcourt Brace Jovanovich, Inc.,
Philadelphia; HBJ-Holt-Saunders Dis
tribution Services, Toronto. 1990.
Price not stated. ISBN 0 -7 2 1 6 2063-9

This is the fourth edition of a compre
hensive textbook of otologic surgery
begun by George E. Shambaugh in
1959. It is timely because of the numer
ous changes that have taken place in
otology in the 10 years since the third
edition was released.
The basic format of the three previ
ous editions has been retained. The
book starts with a section devoted to
embryology, anatomy and diagnostic
procedures. This is followed by sections
dealing with infectious disease, surgery
for deafness and neuro-otologic sur
gery. The final section deals with surgi
cal anatomy as learned through tempo
ral bone dissection. The authors should
be commended for retaining the histori
cal vignettes that begin each chapter.
This adds immeasurably to the interest
and appeal of the text and sets it apart
from its competitors.
Notable additions to this edition are
chapters dealing with acoustic and fa
cial-nerve monitoring, skull-base sur
gery and implantable hearing devices.
The section dealing primarily with neu

ro-otologic procedures has been up
graded and expanded. Magnetic reso
nance imaging has been added to the
diagnostic armamentarium. The grading
system for facial-nerve recovery, devel
oped by the facial-nerve disorders com
mittee of the American Academy of
Otolaryngology — Head and Neck Sur
gery, has also been included. The fenes
tration operation for otosclerosis has
been reduced from a full chapter to a
brief historical description.
No text can fully cover all aspects of
such a diverse subject. The use of lasers
in otologic surgery is barely mentioned.
I would also like to have seen a much
more comprehensive discussion of the
various types of biocompatible ossicular
implants, currently an area of consider
able controversy.
This text is designed primarily for
students of otology, whether in the
early phases of residency training or as
practising otolaryngologic surgeons.
However, its content should appeal to
any surgical specialities involved in the
treatment of head and neck disorders. It
is particular importance to those with
an interest in the development of the
operating microscope. It remains an
indispensable addition to the library of
the otologic surgeon.
R.R.F. Ruby, MD, FRCSC, FACS
Department of Otolaryngology
St. Joseph’s Hospital
The University of Western Ontario
London, ON
N6A 4V2
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Neuroendocrine Tumour of the Inferior
Vena Cava
York Hsiang, MB, FRCSC; Peter D. Fry, MD, FRCSC
Malignant tumours of the inferior vena cava (IVC) are rare. Secondary involvement
of the IVC by adjacent retroperitoneal tumours is more common than the occurrence
of leiomyosarcomas of the IVC. The authors present a case of a secondary
neuroendocrine tumour of the infrarenal vena cava that presented with pulmonary
emboli. To their knowledge this presentation has not been reported previously. The
tumour was technically resectable and reconstruction of the IVC was not required.
No primary tumour was identified. As palliative treatment, an aggressive surgical
approach is recommended when the primary tumour is controlled or is not readily
identified.
Les tumeurs malignes de la veine cave inferieure (VCI) sont rares. L’atteinte
secondaire de la VCI par des tumeurs retroperitoneales adjacentes est plus frequente
que la survenue d’un leiomyosarcome de la VCI. Les auteurs decrivent un cas de
tumeur neuroendocrine secondaire de la veine cave sous-renale qui s ’est presentee
sous la forme d’une embolie pulmonaire. A leur connaissance, ce tableau n’a pas ete
decrit precedemment. II a ete techniquement possible de resequer la tumeur, et la
reconstruction de la VCI n’a pas ete necessaire. Aucune tumeur primitive n’a ete
identifiee. Comme traitement palliatif, une chirurgie etendue est recommandee
quand la tumeur primitive est inactivee ou quand elle n’a pu etre identifiee.

n unusual case of neuroendo
crine tumour involving the
lower inferior vena cava (IVC) is
reported. We could find no formal
guidelines for management in the
literature, and we advocate an ag
gressive surgical approach if feasi
ble.

A

Case Report
A 61-year-old woman presented
with a 2-day history of shortness of
breath on exertion. There was no
associated chest pain, cough, or
hemoptysis. Her medical history

was negative for trauma or disor
ders of the venous system. She had
complained of lumbosacral discom
fort 1 year previously, but this was
attributed to sciatica. On physical
examination she was in no distress.
Her temperature was 36°C, pulse
80 beats/min, blood pressure
110/70 mm Hg and respiratory
rate 24/min. She had crepitations
bilaterally in the lung bases and a
suggestion of fullness in the right
lower quadrant. The results of the
examination of her extremities were
unremarkable except for stasis der
matitis involving her right leg.
The results of the laboratory

tests were as follows: hemoglobin
level 146 g/L ; leukocyte count,
10.0 X 109/L, with normal differ
ential, normal sinus rhythm on elec
trocardiography and a normal chest
radiograph. Blood gas levels with
the patient breathing room air were
as follows: pH 7.48; partial pressure
of carbon dioxide (Pco2)31 mm Hg;
partial pressure of oxygen (Po2) 60
mm Hg; bicarbonate 23 mmol/L. A
ventilation-perfusion lung scan
showed multiple perfusion defects
bilaterally, consistent with pulmo
nary emboli. The patient was fully
heparinized. Bilateral nuclear medi
cine venograms showed an obstruc
tion of the IVC with large venous
collaterals (Fig. 1). Abdominal and
pelvic ultrasonography disclosed a
mass, measuring 4.5 X 4.5 X 6 cm,
at the level of the right psoas major
muscle, lying posterior to the iliac
vessels. The mass lay within the
lumen of the IVC and extended to
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FIG. 1. Bilateral nuclear medicine ve
nogram showing lack of isotope up
take into inferior vena cava (IVC).
Large collateral vein (C) is visualized.
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the level of the renal veins (Fig. 2).
A computed tomography (CT) scan
(Fig. 3) confirmed the size of the
mass and showed that it extended
into the pelvic soft tissues and
upper sacral foramina. Because of
the abdominal mass and potential
tumour emboli, a Greenfield IVC
filter was inserted into the suprare
nal cava. A CT-guided needle aspi

ration biopsy was performed, but
the results were nondiagnostic.
Aortography (Fig. 4) revealed a tu
mour blush and feeding vessels
from the right common and exter
nal iliac arteries. Follow-up ventila
tion-perfusion lung scanning, per
formed 1 week after starting the
patient on heparin, showed marked
resolution of the perfusion defects,

FIG. 2. Abdominal ultrasonogram showing tumour (T) in IVC.

FIG. 3. Computed tomography scan of abdomen showing tumour (T) obstructing
and distending IVC, with extension into psoas muscle (M). Ao = aorta.
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suggesting blood rather than tu
mour pulmonary emboli.
One week after admission the
patient’s dyspnea had improved
markedly, although she continued
to experience nonlocalizing discom
fort in her back. Surgery was rec
ommended for diagnostic and thera
peutic reasons.
At operation the tumour ap
peared partially encapsulated; it was
embedded in the IVC and extended
into the pelvic soft tissues (Fig. 5).
There was no other intra-abdominal
or retroperitoneal condition. An enbloc excision of all gross tumour,
including the infrarenal right com
mon iliac vein and right external
iliac vein, was performed, but the
IVC filter was retained intact. The
postoperative course was smooth,
with no evidence of venous obstruc
tion. The final pathology report
identified a neuroendocrine tumour,
likely metastatic carcinoid, which
stained positively for gastrin (Fig.
6). The tumour extended to the
resection margin. Adjuvant exter
nal-beam radiotherapy was adminis
tered 3 months after the operation.
At the 5-month follow-up examina
tion, the patient was completely
asymptomatic, although she had a
small residual pelvic mass. The
serum gastrin level was 28 ng/m L
(normal less than 130 ng/L);

FIG. 4. Aortogram demonstrates ex
tensive vascularity of tumour.

NEUROENDOCRINE CAVAL TUMOUR

5-hydroxyindoleacetic acid quantita
tion gave normal results.

Discussion
Tumours of the IVC are rare.
Leiomyosarcoma is the most com
mon primary IVC tumour and was
initially described by Perl as an
autopsy finding in 1871.1 Recently,
Bruyninckx and Derksen2 reviewed
the literature on this rare tumour.
They found 70 patients, with a
striking female predominance (5:1).
The tumours were classified accord
ing to location, the most common
site being the lower third of the IVC
or inferior to the renal veins. Tu
mours in this location are ideally
suited for resection, since restora
tion of the IVC is not essential
because there is chronic occlu
sion.2-3 Surgical extirpation is the
main form of treatment, because
these tumours, which are often of
low grade, are usually not suscepti
ble to radiotherapy or chemothera-

FIG. 5. Artist’s concept of tumour,
lying within IVC and extending into
soft tissues. Ureter, gonadal vein and
accessory renal arteries are retracted.
Note spatial relationship of tumour to
renal veins and IVC filter.

py.4 Multimodality therapy, which
was suggested by Antman and asso
ciates,5 may provide 3-year survival
periods for increasing numbers of
patients with retroperitoneal sarco
mas; however, there is no evidence
so far to substantiate successful
results when multimodality therapy
is used for IVC tumours.
Secondary tumours involving the
IVC are more common than primary
tumours; they usually arise as a
result of direct invasion from tu 
mours located in retroperitoneal or
gans, such as renal-cell tumour,
neuroblastoma, Wilms’ tumour, re
troperitoneal sarcomas, and those
located at other sites, such as hepa
tocellular carcinoma and bony tu
mours. Usually, retroperitoneal tu
mour extension into the IVC is
considered a poor prognostic fac
tor.6 However, Skinner, Pfister and
Colvin7 suggested, in their series of
11 patients, that an aggressive sur
gical approach could lead to im
proved survival.
The retroperitoneal neuroendo
crine tumours, pheochromocytomas
and paraganglionomas, may also
invade the IVC directly. The latter
most commonly arise from the

FIG. 6. Poorly differentiated neuroen
docrine tumour stained with monoclon
al antibody for gastrin (G) (original
magnification X 200).

organ of Zuckerkandl but can occur
anywhere along the sympathetic
chain or dome of the bladder.8
There have been eight documented
cases of pheochromocytomas in
volving the IVC.9 Two of these were
caused by local invasion of malig
nant cells, according to the criteria
proposed by Davis, Peart and van’t
Hoff.10
Carcinoids, the most common
neuroendocrine tumours, can arise
anywhere in the gastrointestinal
tract or in other sites containing
neuroendocrine tissue, including
the liver and pancreas. Most com
monly they metastasize by direct
invasion or by hematogenous
routes.8 Surgical resection is the
preferred method of treatment, but
adjunctive radiotherapy and chemo
therapy may be beneficial in pa
tients who have incompletely resect
ed or recurrent tumours.11
Our patient had a secondary car
cinoid involving her IVC, although
she had many features highly sug
gestive of a primary IVC tumour.
Her tumour appeared to arise di
rectly from the lower third of the
IVC with extension into the soft
tissues. It was likely slow-growing,
judging by the collateral develop
ment and lack of venous obstruc
tion following resection. It did not
produce tumour emboli, a typical
finding in most IVC tumours.12 Intraoperatively, there was no evi
dence of tumour arising from the
adrenal glands or the organ of
Zuckerkandl. Neuroendocrine tu
mours are potentially capable of
elaborating multiple peptide hor
mones, including gastrin, calcitonin
and catecholamines.8 Not surpris
ingly, this tumour stained positive
for gastrin, although it was func
tionally inactive.
To our knowledge, a neuroendo
crine tumour directly invading the
IVC has not been described in the
literature. Thus, there are no clear
guidelines for management. We beCJS, VOL. 34, NO. 4, AUGUST 1991
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lieve that these secondary tumours
should be managed like a primary
IVC tumour: en bloc resection when
feasible, in view of the similar clini
cal and gross pathologic character
istics, provided the primary tumour
has been controlled or cannot be
identified by the usual means.
We thank the British Columbia Health
Care Research Foundation.
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Item 244
Intense chemotherapeutic regimens have until recently been withheld
from elderly patients, because of the fear that toxic side effects would be
more severe. However, the elderly tolerate these drugs as well as
younger patients in similar condition. Some agents appear to be more
toxic in certain tumors, eg, methotrexate in acute leukemia. Age per se
should not be a contraindication to chemotherapy.
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Association

of Urolo

The 16th annual meeting of the
Quebec Association of Urologists
will be held at the Hilton Hotel,
Quebec, Nov. 14-17, 1991. For further
information please contact: Ms Jacque
line Deschenes, Quebec Association of
Urologists, 2 Complexe Desjardins,
East Tower, Door 3000, Montreal, PQ
H5B 1G8; phone: (514) 844-9523.

Oncologic Breast Surgery and
Reconstruction
A conference on the esthetic ap
proach to oncologic breast surgery
and reconstruction, with AMA cate
gory I study credits, will be held on
Oct. 5, 1991, at the Etobicoke Gen
eral Hospital, Rexdale (Toronto),
Ont. Further information may be
obtained from: Continuing medical
education, Faculty of Medicine, Uni
versity of Toronto, Medical Sciences
Building, Toronto, ON M5S 1A8;
phone: (416) 978-2718.

BREATHING
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This list is an acknowledgement of
books received. It does not preclude
review at a later date.
Cette liste enumere les livres regus.
Elle n’en exclut pas la critique a
une date ulterieure.

Handbook of Congenital and Early
Onset Hearing Loss. Michael H.
Fritsch and Annemarie Sommer. 170
pp. Illust. Igaku-Shoin Medical Publish
ers, Inc. New York. 1991. Price not
stated. ISBN 0 -8 9 6 4 0 -1 8 4 -7

Trauma. 2nd edition. Edited by Ernest
E. Moore, Kenneth L. Mattox and David
V. Feliciano. 1059 pp. Illust. Appleton
& Lange, Norwalk, Conn. 1991. $150
(US). ISBN 0 -8 3 8 5 -9 0 0 7 -1
Woodward’s Postgastrectomy Syn
dromes. 2nd edition. Edited by Michael
P. Hocking and Stephen B. Vogel. 195
pp. Illust. W.B. Saunders Company/Harcourt Brace Jovanovich, Inc.,
Philadelphia. 1991. Price not stated.
ISBN 0 -7 2 1 6 -2 2 0 9 -7

FACT
Smoking is the single largest
preventable cause of death in
Canada.

FACT
Over 27,000 Canadians will
die of respiratory disease this
year alone.
Support
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Surgical Pathophysiology. Edited by
Ansgar O. Aasen and Bo Risberg. 452
pp. Illust. Harwood Academic Publish
ers, New York. 1990. $95 (US). ISBN
3-7186-5038-X

One in every five Canadians
has some form of respiratory
problem.

THIS

Surgery Annual: 1991. Volume 23,
Part 2. Edited by Lloyd M. Nyhus. 186
pp. Illust. Appleton & Lange, Norwalk,
Conn. 1991. $75 (US). ISBN 0 -8 3 8 5 8744-5

FACT

BE

The Spinal Cord Injured Patient: Com
prehensive Management. Edited by
Bok Y. Lee, Lee E. Ostrander, George
Van B. Cochran and William W. Shaw.
341 pp. Illust. W.B. Saunders Company/Harcourt Brace Jovanovich, Inc.,
Philadelphia. 1991. Price not stated.
ISBN 0 -7 2 1 6 -5 6 9 9 -4
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Cancer, Diagnostics, and Chemothera
py: a Reference Manual. Cynthia Chernecky. 183 pp. W.B. Saunders Company/Harcourt Brace Jovanovich, Inc.,
Philadelphia. 1991. Price not stated.
ISBN 0 -7 2 1 6 -3 1 8 7 -8
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AGE-RELATED BREAST DIAGNOSIS. E.E. Sterns. Department of
Surgery, Queen’s University and the Kingston General Hospital,
Kingston, Ont.
Diagnosis of breast problems is difficult particularly in premenopausal
women. To assess the relationship between symptoms and clinical
findings, data on 3335 women seen on 7296 visits were prospectively
recorded and evaluated in three age groups (< 41, 41 to 60, > 60
years). Symptoms, clinical findings and pathology were significantly
different in each age category. The most common symptom in young
women was a localized mass, in middle-aged women nodularity and pain
and in older women a localized mass and pain. Overall, more than half
the clinical evaluations were normal. Cancer was suspected in 0.4% of
women under 41, 3% between 41 and 60 and 13% over 60. The
presenting problem and clinical diagnosis were often at variance. The
majority with nodularity, pain and nipple discharge were clinically
normal. Seven hundred eighty-six biopsies were performed in 22% of
patients. Fibroadenomas were most common in the young, fibrocystic
change in the 40 to 60 group and cancer in those over 60. Cancer was
diagnosed in 6% of biopsies in young women, 29% between 41 and 60
and 55% of those over 60. Cyst aspiration was performed in 12% of
patient visits in the 40 to 60 group. Clinical and mammographic
sensitivity in cancer diagnosis improved with age. Referral because of
mammographic abnormality is increasingly common. One hundred
fifty-eight had mammograms suspicious for cancer. Biopsy confirmed
malignancy in 37%. The findings suggest that most patients referred to
a specialty clinic are normal or have benign breast changes. Biopsy,
particularly in premenopausal women, is avoidable if clinical, radiologic
and cytologic expertise is available. Such review is essential as more
asymptomatic patients enrol in screening programs.
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TOTAL MASTECTOMY IS NOT MANDATORY TREATMENT FOR
BREAST RECURRENCE FOLLOWING LUMPECTOMY ALONE. D.
McCready, E. Fish, G. Hiraki, T. Ross, J. Wall, L. Lickley. Women’s
College Hospital, University of Toronto, Toronto, Ont.
The purpose of this study was to determine the treatment strategy that
offered the best rate of local control for isolated local breast cancer
recurrences following lumpectomy without radiation. There is little in
the literature that addresses this situation. We reviewed 355 breast
cancer patients who were initially treated with a lumpectomy (± axillary
dissection) but no radiotherapy. There were 79 local breast recurrences
and these patients underwent either a repeat partial (PM) or total
mastectomy (TM), and 24 (5 TM, 19 PM) received radiotherapy (XRT).

No.

5-yr local control*

PM + XRT
TM + XRT

19
5

82%
52%

TM
PM

28
27

60%
32%

Treatment of recurrence
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*p = 0.01
Wilcoxon

The size of the recurrence did not differ significantly between groups.
Twenty-five patients (32%) were given chemotherapy or tamoxifen.
Local control was the absence of any further breast or chest-wall
recurrence. Median follow-up from the first recurrence was 69 months.
These data show that treatment of a breast recurrence with PM + XRT
is a viable alternative to total mastectomy since this group had excellent
local control. Re-resection alone (PM) provided significantly poorer
results. The decreased local control for TM + XRT is based on only five
patients and may reflect selection bias. Neither chemotherapy nor
tamoxifen improved local control. We conclude that local breast cancer
recurrences following lumpectomy alone do not necessarily require total
mastectomy and can often be treated with re-excision and XRT.
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INFLUENCE D UNE DEUXIEME NEOPLASIE SUR LA SURVIE
D’UN CANCER DU SEIN. A.B. Peloquin, M. Poljicak, M. Falardeau,
D. Gravel, R. Moisescu, L. Peloquin. Departement de chirurgie,
Hopital Notre-Dame, Universite de Montreal, Montreal (Que.)
On pourrait craindre un taux moins eleve de survie chez les patientes
atteintes de cancer du sein qui font au cours de leur vie une ou deux
autres neoplasies. II n’y a rien a ce sujet dans la litterature.
Une etude retrospective de 1 510 cas de neo du sein (1960-1980)
nous permit de comparer deux groupes: 1 353 cas ayant eu un neo du
sein seulement (N.S.) et 157 cas ayant en plus fait un autre cancer
(N.M.) vg col uterin, colon, ORL,... Les N.M. sont plus agees de 2 ans.
L’etat hormonal (pre et post-menopause est identique dans les deux
groupes (p = 0,1768). Dans les N.M. il y a moins de T3 et plus de T1 (p
= 0,0288) et on retrouve moins d’envahissement ggl. (p = 0,0242). Le
stade des N.M. montre autant de stade II, moins de III et plus de 1 (p =
0,0041). Le type histologique est le meme dans les deux groupes (p =
0,3158) tout comme le type de traitement chirurgical (p = 0,8759) et
adjuvant.
La survie ne tenant compte que de la mortalite par neo du sein est a
10 ans de 54 % (N.S.) et de 78 % (N.M.) (p = 0,0000). La survie tenant
compte de la mortalite par neo du sein et par l’autre cancer est de 54 %
(N.S.) et 64 % (N.M.) (p = 0,0008). La survie par stade (mortalite par
neo du sein) montre aussi une survie meilleure pour les N.M.
Ainsi a 10 ans, stade I : 75 % (N.S.) et de 90 % (N.M.) (p = 0,0332),
stade II : 59 % (N.S.) et de 78 % (N.M.) (p = 0,0015), stade III : 33 %
(N.S.) et de 59 % (N.M.) (p = 0,0118).
Les patientes a neo multiples ont done un neo du sein dont le
pronostic semble plus favorable que chez celles qui ne font qu’un cancer
du sein isole.
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DETECTION OF SQUAMOUS CELL CANCER AND PRE-CANCEROUS LESIONS BY IMAGING OF TISSUE AUTOFLUORESCENCE.
A. Kluftinger, N.L. Davis, N. Quenville, S. Lam, J. Hung, B. Palcic.
Vancouver General Hospital and British Columbia Cancer Agency,
Vancouver, BC
When activated by the appropriate wavelengths, most human tissues
will exhibit low levels of fluorescence even in the absence of photoactive
drugs. This autofluorescence has been shown to differ between normal

ABSTRACTS

and malignant tissues. This study investigates the utility of fluorescence
imaging in the oral cavity in an animal model. Premalignant and
malignant changes were induced in the cheek-pouch squamous epitheli
um of adult Syrian hamsters. The pouches were examined with a
specifically designed image-intensified camera system, which recorded
autofluorescence after excitation with 442 nm laser light. Red and
green fluorescence were detected, displayed on a video monitor and,
using a computer interface, red/green (R/G) ratios were calculated for
any given area of the mucosa.
Red/green ratios for 22 distinct sites were measured and simultane
ously biopsied. A minimum of 30 histologic sections from each site were
examined and graded for dysplasia by a blinded observer. An R/G ratio
greater than 1.5 times the mean value of known normal mucosa was
considered significantly elevated. Using these criteria, dysplasia (n = 8),
carcinoma in situ (n — 3) and invasive carcinoma (n = 2) were
accurately localized (sensitivity 100%, specificity 87%). Lesions less than
2 mm in diameter could be detected. The R/G ratios were significantly
higher in carcinoma (5.64 ± 2.40) than in dysplasia (2.88 ± 1.39) (p <
0.025).
These data suggest that autofluorescence imaging can accurately
detect and localize premalignant and malignant squamous epithelium,
and may play a role as a noninvasive clinical diagnostic tool.
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INDICATIONS OF CHOLECYSTECTOMY WITH REGARD TO ITS
MORBIDITY AND MORTALITY. R.M. Girard, M. Morin. Department
of Surgery, Hopital Maisonneuve-Rosemont, Universite de Montreal,
Montreal, Que.

This retrospective study of 9455 cholecystectomies analyses the
incidence and causes of its morbidity and mortality.
Between 1971 and 1987, 9455 patients underwent a cholecystecto
my. Eighty-five percent of them had a chronic disease and 15% an acute
cholecystitis. One thousand twenty-one patients had an associated
choledochotomy.
There were 42 postoperative deaths (0.44%); 4 (0.07%) in patients
less than 50 years old; 23 (0.7%) in patients between 40 and 70 years
old and 15 (2.4%) in patients more than 70 years old. Overall mortality
of elective cholecystectomies was 0.28% and 0.46% in cholecystectomies
for acute disease. Among the 1021 patients who underwent an
associated choledochotomy, 16 died (1.6%). Cardiovascular complica
tions were the main cause of death. Acute pancreatitis and/or jaundice
was present at surgery in 21 of the deceased patients. Four hundred
thirty-three patients (5.1%) presented 474 complications, the most
frequent being wound complications (31%) and pulmonary complica
tions (24%). There were 76 biliary complications of which 27 were
operative bile-duct injuries.
Mortality increases with age (p < 0.001), with associated choledo
chotomy (p < 0.001) and with acute cholecystitis in patients more than
70 years old (p < 0.005). Acute pancreatitis and/or jaundice at the time
of surgery seems to increase the mortality risk. Morbidity increases with
age (p < 0.001) and with an associated choledochotomy (p < 0.001).
Because of its low mortality and morbidity, standard cholecystectomy
is still the gold standard in the treatment of symptomatic gallstones.

primary lesion was obtained from surgical specimens and frozen in
liquid nitrogen. Detergent extracted protein was separated by electro
phoresis through polyacrylamide gels. Western blots were performed
with monoclonal antibodies against c-fos and mutant p53. c-fos
expression was threefold greater in the carcinoma relative to mucosa at
1 cm from the carcinoma (p = 0.01), which in turn was fourfold greater
in comparison to mucosa at 5 cm from the primary lesion (p = 0.001).
There was no difference in c-fos expression at 5 and 10 cm. Similar
results were obtained for mutant p53 expression. The molecular
changes in c-fos and p53 were found within the carcinoma and the
histologically benign mucosa immediately adjacent to the carcinoma.
The presence of mutant p53 expression is thought to be associated with
loss of the wild-type protein function, a suppressor of neoplasia. It is
speculated that this loss results in an unopposed effect of c-fos
transcriptional activity. These results imply that there may be a field
defect in and beyond colorectal carcinoma and this offers a potential
explanation for local recurrence after resection.
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THE IN VITRO EFFECT OF SUBSTANCE P ON LYMPHOKINEACTIVATED KILLER (LAK) CELL CYTOTOXICITY AGAINST
CULTURED AND FRESH COLON CARCINOMA CELLS. H. Flageole, M. Senterman, J.L. Trudel. McGill University, Montreal, Que.

We postulated that LAK cell cytotoxicity of lymphocytes isolated from
the intestinal mucosa could be enhanced by substance P (SP). Intestinal
lamina mononuclear cells (LPMC) and colonic cancer cells were isolated
from operative specimens by successive mechanical and enzymatic
dissociation methods. Lymphokine-activated killer cells were induced by
culturing LPMC with recombinant interleukin 2 (IL-2). Substance P
(0.01 nM) was added to the culture medium. Targets consisted of fresh
colonic cancer cells and HT-29 (cultured colonic cancer line). After 4
days, cytotoxicity was measured by a 4-hour 51Cr release assay.
Lymphokine-activated killer cells alone showed moderate cytotoxicity
against HT-29 and none against fresh colonic cancer cells. Lymphokineactivated killer cells generated in the presence of SP showed moderate
cytotoxicity against HT-29 and strong cytotoxicity against fresh cancer
cells. The percent cytotoxicity at various effector to target (E:T) ratios
is:
E:T ratio
Effector

Target

No.

5:1

10:1

25:1

50:1

LAK
LAK/SP
LAK/SP
LAK

HT-29
HT-29
Fresh Ca
Fresh Ca

5
10
10
10

1.9
1.3
6.0
0*

11.9
4.6
13.9
0*

12.2
9.0
41.6*
0*

17.8
14.5
67.5'
0*

'denotes p < 0.05.

We conclude that SP significantly increases LAK cell cytotoxicity
against fresh colonic cancer cells but not against cultured cells. This
response may be due to differences in cell surface hormonal receptors.

309

311

EXPRESSION OF THE c-fos ONCOGENE AND THE p53 ANTI
ONCOGENE IN COLORECTAL CARCINOMA AND ITS ADJACENT
MUCOSA. M. Chung, B. Mitmaker, P.H. Gordon, E. Wang. Bloomfield
Centre for Research in Aging, Lady Davis Institute, The Sir Mortimer
B. Davis-Jewish General Hospital, Montreal, Que.

ELECTIVE (E) AND THERAPEUTIC (T) REGIONAL LYMPH-NODE
DISSECTION (LND) FOR CUTANEOUS MALIGNANT MELANOMA
(CMM): BRITISH COLUMBIA CANCER AGENCY (BCCA) EXPERI
ENCE 1972-1981. K.S. Wilson, V.E. Carmichael, R.E. Robins. BCCA
Victoria Clinic, School of Health Information Science, University of
Victoria, Victoria, BC and BCCA Vancouver Clinic, Vancouver, BC

The purpose of this study was to determine the oncogene protein
expression of c-fos, a proto-oncogene, and the mutant form of p53, an
anti-oncogene, in colorectal carcinoma and its adjacent mucosa. Tissue
from 10 colorectal carcinomas and mucosa at 1, 5 and 10 cm from the

Lymph-node dissection in cutaneous malignant melanoma (CMM) is
designated elective (E) or therapeutic (T). Records of 891 patients
registered at BCCA clinics between 1972 and 1981 with CMM have
CJS, VOL. 34. NO. 4, AUGUST 1991
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been reviewed with minimum follow-up of 8.5 years. Elective lymphnode dissection (ELND) was performed in 232 patients and was positive
pathologically in 36 (16%). Ranges and median depths of primary in
patients with positive and negative ELND were 0.85 to 8.00 mm and
3.0 mm and 0.45 to 7.0 mm and 1.6 mm respectively. Positive/negative
ELND ratios were 2 0 /8 6 and 16/102 in males and females; 3 /4 2
(upper limb primary); 16/76 (lower limb); 12/45 (trunk); and 5 /2 4
(head and neck): 0 /1 5 T1 primary, 5 /6 8 T2, 12/66 T3, 1 4 /2 0 T4.
Disease recurred in 23 (64%) ELND-positive and 47 (25%) ELND-negative patients with corresponding median survivals of 4.2 and 9.1 years.
Ten-year survivals were 67% for wide excision (WE) and WE plus
ELND. Therapeutic lymph-node dissection (TLND) was performed in 50
patients at primary diagnosis, and 36 (72%) were positive pathologically.
Range and median depth of primaries in patients with positive TLND
were 1.67 to 8.0 mm and 2.0 mm, respectively. Disease recurred in 24
(67%) positive TLND patients with median survival 2.7 years. Therapeu
tic lymph-node dissection was also performed in 103 patients with
regional lymph-node (LN) recurrence from previous primary CMM.
Range and median depth of responsible primaries were 1.0 to 7.0 mm
and 2.0 mm. Median time to LN recurrence was 1.6 years. Disease
recurred in 103 (100%) of these TLND patients and median survival
from TLND was 1.8 years.
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THE ROLE OF INTRAOPERATIVE ULTRASOUND (10US) IN
HEPATIC SURGERY: A PRELIMINARY REPORT. S.S. Hanna.
Division of General Surgery, Department of Surgery, Sunnybrook
Health Science Centre, University of Toronto, Toronto, Ont.
A prospective study of all patients undergoing IOUS during hepatic
surgery was initiated with the goal of determining the value, if any, of
IOUS during hepatic surgery.
Between October 1989 and January 1991 (15 months), 25 patients
underwent IOUS: 20 during the conduct of liver procedures, 4
underwent liver IOUS at laparotomy for other reasons and 1 underwent
splenic IOUS for recurrent congenital splenic cysts.
In 5 of the 20 patients (25%) undergoing IOUS during liver surgery,
there was a change in the operative plan because of the findings of
IOUS. In all five cases the planned liver procedure was abandoned. Two
of these five patients were cirrhotic; in one patient an additional
metastasis was seen and in the other patient tumour invasion of the
portal vein by a hepatoma precluded resection. Three of five were not
cirrhotic; in one, invasion of the left hepatic vein was seen and in the
remaining two patients, additional metastases were seen in the caudate
lobe (Couinaud segment 1). In one of four patients (25%) who
underwent liver IOUS during a laparotomy for another reason (three for
colon cancer and liver metastasis; and one for a Whipple procedure for a
carcinoma of the distal common bile duct), it was found to be useful
since it allowed ultrasound-guided biopsy of a small liver lesion.
In conclusion, IOUS was found to be useful in 25% of patients
undergoing this examination during hepatic surgery. In this subgroup
of patients, it prevented us from proceeding with liver resections that
would have been doomed to failure from an oncologic point of view.

No.

BN (control)
Lew (control)

8
8
10
7
7

39 ± 10
40 ± 4
38 ± 11
14 ± 10+
28 ±5*

BN-BN
BN-Lew

Nutrient absorption
from diet. %
Energy

Fat

83 ± 1
84 ± 1.3
83 ± 1
81 ± 1.7+
82 ± 1.2*

78 ± 1
79 ± 2
75 ±3*
76 ± 4.9t
74 ± 3.3*

Short circuit
current (Isc).
mA / citi2
94 ± 18
—

54 ± 16+
56 ± 16+

Permeability,
% oral 5'Cr
EDTA absorb
5.6 ± 1.9
2.1 ± 0.4
4.8 ± 1.9*
5.1 ± 2.6
12.7 ± 2.8*$

D-glucose§
nmol/100 mg
mucosa/min
841
679
651
869
724

± 66
± 59
± 38
± 67
±64

'p < 0.05 v. Lew controls; t p < 0.5 v. BN controls; tP < 0 05 v~ Lew-Lew transplants; § total uptake at 64 mM in bath.

These results suggest that transplanted bowel has increased permeabili
ty, reduced energy and fat absorption in vivo and reduced Isc response
to glucose in vitro. In fully allogeneic transplants, weight gain was
reduced. This suggests that careful functional studies in large animals
should be done prior to segmental SBT in man.
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THE ACCURACY OF OXIMETRY IN THE NONINVASIVE MEA
SUREMENT OF INTESTINAL BLOOD FLOW. P.H. MacDonald, P.K.
Dinda, I.T. Beck, C.D. Mercer. Gastrointestinal Diseases Research
Unit, Departments of Surgery and Medicine, Queen’s University,
Kingston, Ont.
Recent reports have suggested that oximetry may be useful in the
intraoperative determination of intestinal blood flow. The purpose of
this study was to examine the relationship between tissue oxygen
saturation (as measured with pulse oximetry), surface oxygen tension
(as measured with surface oximetry) and actual intestinal-tissue blood
flow (as measured with a radiolabelled microsphere technique). In five
dogs, tissue oxygen saturation of the proximal and distal small bowel,
surface oxygen tension of the mid small bowel and tissue blood flow of
these three sites were measured under basal conditions. A clamp around
the root of the superior mesenteric artery (SMA) was then tightened to
decrease its blood flow (as measured by an ultrasonic flow probe) by
50% and then by 75%. Tissue oxygen saturation, surface oxygen
tension and tissue blood flow measurements were repeated after each
reduction in the SMA blood flow.
Reduction of the SMA blood flow by 50% and 75% resulted in an
equivalent reduction in the intestinal-wall blood flow. These reductions
in tissue blood flow corresponded to a significant fall in both the
intestinal-tissue oxygen saturation and the surface oxygen tension.
Pulse-oximetry measured oxygen saturation (%) fell from a basal value
of 93 ± 1 to 83 ± 1 (p < 0.05) and then to 76 ± 1 (p < 0.05) with the
two progressive blood-flow reductions. The intestinal surface oxygen
tension fell more steeply, from a basal value of 97 ± 1 to 80 ± 6 (p <
0.05) and then to 64 ± 7 mm Hg (p < 0.05) with the same 50% and
75% reductions in tissue blood flow. Both techniques were capable of
estimating intestinal tissue blood flow, but pulse oximetry was quicker
and simpler to use. We conclude that the pulse oximeter has the
potential to be of value in the intraoperative assessment of intestinal
blood flow.
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THE PYLORIC-PRESERVING PANCREATODUODENECTOMY IN
CHRONIC PANCREATITIS. M. Gagner, D. McAnneny, R.L. Rossi,
J.W. Braasch. Department of Surgery, Lahey Clinic, Burlington, Mass.

313
FUNCTIONAL CAPACITY OF TRANSPLANTED BOWEL. D.L.
Sigalet, N.M. Kneteman, A.B.R. Thomson. Departments of Surgery
and Medicine, University of Alberta, Edmonton, Alta.
Recent clinical success with small-bowel transplantation portends
expanded applications, but studies of chronic bowel function are limited.
We examined this problem using a two-stage model of total orthotopic
small-bowel transplantation (SBT) in inbred (Brown Norway [BN] and
Lewis [Lew)) rats. Cyclosporine, 15 m g/kg q2d subcutaneously, was
given to all groups. Animals were followed for 60 days and the in-vitro
nutrient uptake and electrophysiological parameters were measured.
392
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Standard pancreatoduodenectomy has been used in the management of
selected patients with chronic pancreatitis. The pyloric-preserving
modification has been introduced to maintain gastric capacity and
gastric emptying, decrease postgastrectomy symptoms and, perhaps,
decrease malabsorption. Forty-five patients with a median age of 47
years, who underwent a pylorus-preserving pancreatoduodenectomy
(PPPD) for chronic pancreatitis (CP) since 1979 and have been followed
for a median of 60 months (18 to 122) were reviewed. All had
abdominal pain, 90% were taking narcotics, a history of ethanol abuse
was present in over half of the cases, and 35% of patients had a mass in
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the head of the pancreas. There was one operative death (2%) and 10
major complications (22%). The mean preoperative pain score (0 to 5) of
4.5 improved to 1.3 (p < 0.0001), the mean preoperative weight of 134
lbs improved to 137 lbs. The 40% incidence of clinical preoperative
exocrine insufficiency was not changed by PPPD. Ten patients (22%)
had preoperative endocrine insufficiency; postoperatively, 4 patients
(9%) had worsening of their endocrine insufficiency. Early gastric
complications (stasis) developed in 4% of patients, while late gastric
complications (gastric hemorrhages and/or ulcerations) were present in
13% of patients. Ninety percent of the patients felt their pain had
improved, with more than three-quarters of the patients not taking
narcotics or using a much lower dose than before operation. Pyloricpreserving pancreatoduodenectomy in selected patients with chronic
pancreatitis improves the pain in the majority of patients, can be safely
performed and is a good alternative to standard pancreatoduodenecto
my.

before ESWL. Sixty-one (49%) patients have at present no gallstone in
their gallbladder. Forty-four (35%) have fragments 5 mm or less and are
taking oral bile salts. Twenty-one patients (16%) are considered failure
to treatment. Failures were due to (a) unsatisfactory fragmentation in
16 cases (13%), (b) frequent biliary colic in 3 patients (2.4%), (c) acute
pancreatitis in 1 case (0.8%) and (d) severe diarrhea due to bile salts in 1
case (0.8%). The most frequent complications were biliary colic noted in
40 patients (26%). Twenty-four patients (16%) had mild diarrhea on
biliary salts, and severe diarrhea occurred only once. Four (2.6%)
patients presented with macroscopic hematuria, two (1.3%) suffered
acute pancreatitis and one (0.6%) vagal shock.
Extracorporeal shock-wave lithotripsy is a safe method of treatment
of symptomatic cholelithiasis. In selected cases, it could be a valuable
alternative to surgical treatment.
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THE ROLE OF THE TEACHING HOSPITAL IN THE DEVELOP
MENT OF A LAPAROSCOPIC CHOLECYSTECTOMY PROGRAM.
H.H. Sigman, G.M. Fried, E.J. Hinchey, J. Mamazza, M.J. Wexler, J.
Garzon, J.L. Meakins. McGill University, Montreal, Que.

THE EFFECTS OF LITHOTRIPSY AND OF A NEW NONTOXIC
SOLVENT ON GALLSTONES. R. Hraibeh, Y.M. Dion, M. Page, A.
Dauphin, J. Morin, R. Gregoire. Department of Surgery, Hopital
St-Francois D’Assise and Department of Biochemistry, Faculty of
Medicine, Universite Laval, Quebec, Que.

Recently, the classic treatment of symptomatic cholelithiasis has been
challenged by less invasive approaches. In the first part of our
experiment, we compared the efficacy of three types of lithotripters: a
piezoelectric lithotripter (ESWL), lithotripsy using a pulsed Nd:YAG
laser and lithotripsy with a standard mechanical device. In the second
part of the experiment, we analysed the in-vitro effects of a new solvent
on cholesterol and mixed gallstone fragments. Toxicity studies were
conducted on 18 dogs. Numerous hematologic, biochemical and
pathologic examinations were performed. Our results show that ESWL
provided significantly better gallstone fragmentation than laser or
mechanical lithotripsy (p < 0.01). Actually, 81% of the total stone mass
was reduced to fragments 1 mm or less in size when ESWL was used.
Laser lithotripsy reduced 41.7% of the total stone mass to fragments 1
mm or less while mechanical lithotripsy reduced to 1-ram fragments or
less only 17% of the total stone mass. In our experiment, no fragment
greater than 5 mm in size was observed when ESWL was used.
Dissolution rates provided by the solvent were significantly faster for
smaller (1 mm or less) than larger fragments (2 to 5 mm) (p < 0.01).
For a given fragment size, we noted no difference in the dissolution rate
in reference to the type of lithotripsy it had been subjected to. All
fragments 5 mm or less in size were dissolved in less than 4 hours. A
4-hour infusion of solvent in the gallbladder of dogs observed over a
period of 4 days showed no sign of local or systemic toxicity. The
efficacy of this solvent and its nontoxicity suggest that it could be used
after lithotripsy to dissolve the remaining fragments.
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A computerized database was developed to prospectively record data
from the time of introduction of laparoscopic cholecystectomy (LC). The
goal was to provide information suitable for quality assurance programs
and to evaluate the safety and results of this new procedure while
training attending and resident surgeons. A small core group developed
skills in LC then taught colleagues first with training boxes, animal
labs, and finally with progressive responsibility in the operating room.
Three hundred two of 318 patients, mean age 48 years (range 7 to
93), had successful LC. Twenty-six percent were obese, and 3%
morbidly obese. Sixteen (5%) were converted to open cholecystectomy
for anatomical or technical reasons: equipment failure, severe inflamma
tion or inexperience of the surgeon. Thirty-four percent had previous
abdominal surgery, 8% had acute cholecystitis. Intraoperative cholangi
ography was done selectively in 4.1% of patients. Endoscopic retrograde
cholangiopancreatography was done in eight patients preoperatively
(five normal, three papillotomy and extraction of stones) and in four
postoperatively (two normal, two papillotomy and extraction of stones).
Mean duration of operation was 92 minutes and of anesthesia 117
minutes. Two common-duct injuries occurred (0.6%), but there were no
other serious complications. Fifty-nine percent were discharged within
24 hours and 61% had returned to normal level of energy by 1 week
after surgery. Ten attending and six resident surgeons are now able to
perform LC independently.
In conclusion, LC can be introduced in a teaching environment safely
in a structured manner with excellent results and a low risk of
complications.
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EXTRACORPOREAL SHOCK-WAVE LITHOTRIPSY: CLINICAL
EXPERIENCE WITH 182 PATIENTS. Y.M. Dion, J. Morin. Depart
ment of Surgery, Hopital St-Franfois D’Assise, Universite Laval,
Quebec, Que.

From Jan. 19, 1989, to Nov. 23, 1990, 182 patients were offered
extracorporeal shock-wave lithotripsy (ESWL) for treatment of symp
tomatic cholelithiasis.
A piezoelectric lithotripter was used. Bile-acid treatment with ur
sodeoxycholic acid (10 m g/kg daily) was started 2 weeks prior to
ESWL and given for 3 months after complete dissolution of gallstone
fragments. The study protocol was accepted by the Canadian Health
Protection Branch.
Forty-four patients were excluded from the study: 28 (15%) because
of nonvisualization of gallstones by ultrasound, 13 (7%) because of
noncompliance and 3 (1.6%) because of a wrong ultrasound diagnosis

ULTRASOUND AND RADIOGRAPHIC EVALUATION OF PA
TIENTS FOLLOWING LAPAROSCOPIC CHOLECYSTECTOMY. R.
Smith, D. Kolyn, E. Sauerbrei, R. Pace. Queen’s University, Kingston
General Hospital, Kingston, Ont.

Laparoscopic cholecystectomy has rapidly become the procedure of
choice in many centres for the treatment of patients with cholelithiasis.
Because of its rapid introduction, there has been little chance to study
the normal postoperative changes due to this procedure. We prospec
tively studied the first 30 patients undergoing laparoscopic cholecystec
tomy at our institution by means of abdominal ultrasound and x-rays 24
hours after surgery. One patient required conversion to open cholecys
tectomy because of adhesions, and one patient developed postoperative
bile peritonitis due to a leak from the gallbladder bed. Mean operative
time was 72 minutes (35 to 150 minutes), with a mean postoperative
stay of 2.0 days. The postoperative ultrasound of the upper abdomen
was normal in 72% (21/29) with tiny loculations of fluid in the
gallbladder fossa in 6, an errant residual stone near the porta in 1 and a
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small amount of perihepatic free fluid in 1 patient. The plain abdominal
radiographs disclosed free intra-abdominal gas in 50% (14/28), but it
was a significant volume in only four of these patients. Abnormal
gaseous distension of the large bowel was present in 79% (22/28), with
a mean colonic diameter of 6.5 cm (range 5 to 12 cm). Scattered gas
throughout the small and large bowel, suggesting a partial ileus, was
present in 17% (5/28). The surprising lack of ultrasound abnormality
and the frequent findings of gaseous distension of the colon and small
bowel on radiologic evaluation of patients following laparoscopic
cholecystectomy must be borne in mind when assessing these patients
following surgery.
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THE POSTFUNDOPLICATION SYNDROME. G. Beauchamp, L.
Auger, C. Emond, D. Tasse. Hopital Maisonneuve-Rosemont, Univer
sity de Montreal, Montreal, Que.

320
ERCP MANAGEMENT OF BILIARY TRACT FISTULAS. K.A. Les
lie, R.B. Passi, R. Mimeault. Department of Surgery, University of
Western Ontario, London, Ont.

In 5586 ERCP procedures performed by one endoscopist over 10 years,
26 biliary tract fistulas were documented. Twenty-five were postopera
tive fistulas and 1 was a spontaneous fistula due to a perforated
gangrenous gallbladder. Two of the 26 had major ductal injuries and
were not considered for ERCP management. Both patients had preoper
ative diagnostic ERCP and percutaneous biliary drainage, then under
went a successful Roux-en-Y hepaticojejunostomy 6 and 20 weeks later.
Twenty-two of the remaining 24 patients (92%) had rapid resolution of
their fistulas after endoscopic management. The average healing time
was 4.3 ± 2.9 days. ERCP management consisted of endoscopic
sphincterotomy (18/24 patients) and nasobiliary catheter (10/24
patients). None had an endoprosthesis as part of their treatment. Fifteen
patients (62%) had retained CBD stones. T-tube management problems
caused fistula formation in 7 patients (27%). Failure of ERCP treatment
(8%) was linked to inadequate control of sepsis through percutaneous
drainage. Two patients (8%) had complications from ERCP and
sphincterotomy. There was one death in the study group.
Principles for successful ERCP management of biliary fistulas are (a)
relief of distal obstruction with sphincterotomy, (b) adequate percutane
ous drainage of subhepatic abscess/fluid collection and (c) nasobiliary
catheter insertion for biliary drainage and further contrast studies. We
had excellent success with ERCP management (92%) and feel that an
endoprosthesis is not required to treat minor biliary fistulas. Major
ductal injuries can be controlled by ERCP and percutaneous drainage,
then a definitive operative procedure can be performed.
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CHOLEDOCHAL CYSTS: A 20-YEAR SURGICAL EXPERIENCE
WITH 28 PATIENTS. D. Katyal, G.M. Lees. Division of General
Surgery, University of Alberta Hospital, Edmonton, Alta.

To determine the long-term consequences of a retained choledochal
cyst, 28 patients seen over a 20-year period were reviewed.
There were 23 females and 5 males. Twelve of 28 patients were
non-white with Native Indians (8) being the most common non-white
ethnic group. The mean age of presentation was 14.9 years (age range
6 weeks to 46 years). Pain an d /o r jaundice made up the majority of
presenting complaints (27), but the classic triad of pain, jaundice and
abdominal mass was seen in only three cases. Seven had secondary
biliary cirrhosis on initial presentation. Type I cysts were present in 24
patients. Primary excision was performed in 11 of 28 cases. Internal
drainage procedures were performed in 12 patients, external drainage in
2 and no direct operative procedure was done in 3 cases. Follow-up was
obtained in all 28 cases. Mean duration of follow-up was 10.3 years
(range was 1 to 20 years). Nine of 11 patients with primary excision
were asymptomatic. The remaining two had recurrent cholangitis and
required operative repair of bile-duct strictures. Of 17 patients with
retained cysts, 5 were asymptomatic. Nine patients had recurrent
cholangitis; five of these required at least one reoperation, but only two
had secondary excision of the cyst. There was one liver transplant
because of portal hypertension and one biliary-enteric bypass performed
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for cholangiocarcinoma. Overall, there were 12 patients with retained
cysts in this series (5 asymptomatic and 7 with symptoms).
This study supports the current recommendation of primary excision
of choledochal cysts as the procedure of choice. Symptomatic patients
with retained cysts should have secondary excision. Asymptomatic
patients should be followed with alkaline phosphatase levels and HIDA
scans.
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The definition of the post-Nissen syndrome (PFS) is not clear in the
literature. For us, the PFS is a complex series of new signs and
symptoms arriving in patients after an antireflux procedure with or
without relief of gastroesophageal (GE) reflux. To better define the PFS,
we have collected the symptoms of 92 patients, 1 to 10 years after a
primary transabdominal Nissen procedure. The great majority of the
patients were satisfied with the operation, but only 23% had no
symptoms after the surgery. Seventy-seven percent of the patients were
complaining of (a) supercontinence (gastric fullness, early satiety,
impossibility of burping and vomiting, meteorism, left upper quadrant
pain and rectal flatus with diarrhea), (b) gastroesophageal dysfunction
(changes in deglutition, dysphagia, esophageal spasm, precordialgia,
hiccup, epigastric pain with irradiation in the back) and (c) postvagoto
my symptoms such as dumping, severe diarrhea and gastric stasis. After
a Nissen fundoplication, more than 75% of the patients are complaining
of one or more symptoms of supercontinence of GE junction dysfunc
tion. These symptoms are often present without objective findings at
endoscopy, manometry or radiology.
For better communication, the term “gasbloat syndrome” should be
abandoned and the postfundoplication syndrome should include symp
toms related to supercontinence, GE junction dysfunction or post
vagotomy symptoms.
It should be easier with our definition for physicians to better identify
the symptoms related to fundoplication.
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FACTORS AFFECTING ANASTOMOTIC LEAK AND STRICTURE
FORMATION FOLLOWING ESOPHAGOGASTRECTOMY AND
GASTRIC INTERPOSITION. L. Dewar, G. Gelfand, B. Nelems, K.
Evans, R. Inculet, R. Finley. Departments of Surgery, University of
British Columbia, Vancouver, BC and University of Western Ontario,
London, Ont.

Anastomotic leak and stricture formation complicate esophageal recon
struction following esophagogastrectomy and gastric interposition in
approximately one-third of cases. Numerous preoperative parameters of
patient status and intraoperative technical factors have been felt to
influence the rates of these complications.
A retrospective study of 133 patients undergoing esophagectomy and
esophagogastric reconstruction for adenocarcinoma of the eso
phagogastric junction was performed in London, Ont. and Vancouver,
BC. A multivariate analysis of the data was completed.
Anastomotic leak was found to correlate significantly with a low
preoperative albumin (p - 0.005) and the course of the esophagogastric
reconstruction (anterior > posterior mediastinal route) (p = 0.049).
Anastomotic stricture formation was more frequent with the occurrence
of an anastomotic leak (p = 0.007), increasing stage of tumour (p =
0.031), anastomotic technique (running > interrupted) (p = 0.086) and
intraoperative blood loss (p = 0.09). Preoperative hyperalimentation and
radiotherapy were not significant factors.
Surgical factors resulting in a favourable outcome following eso
phagogastric anastomosis are normal serum albumin, low intraoperative
blood loss, placement of the gastric tube in the posterior mediastinum,
and interrupted sutured anastomosis.
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RESULTS OF SURGERY FOR SEPTAL VENTRICULAR TACHY
CARDIA IN CHRONIC MYOCARDIAL INFARCTION. P.L. Page, R.
Cardinal, M. Dubuc, R. Cossette. Department of Surgery, Hopital du
Sacre-Coeur, Universite de Montreal, Montreal, Que.

Using computerized epicardial (EPI) and endocardial (ENDO) mapping
to direct surgery of postinfarction ventricular tachycardias (VT), we
have identified a specific VT activation pattern associated with a higher
risk of surgical failure. This pattern (designated as “type 5” in a
previous study) consisted of an EPI breakthrough on the right ventricle
(RV) preceding the onset of left ventricular ENDO activation and
suggested deep septal involvement in the VT mechanism. To evaluate
the impact of this new information on the results of surgery, we divided
a cohort of 37 patients with at least one VT morphology originating in
the septum into two groups with similar clinical and anatomical
characteristics: group I consisted of 21 patients operated on before we
recognized the significance of the type 5 pattern during retrospective
analysis of mapping data and surgical results, and group II consisted of
16 patients operated on after it became possible to identify type 5
pattern intraoperatively and to modify the surgical techniques prospec
tively. Type 5 VT was identified in 11 group I patients (52%) and in 8
group II patients (50%). In group I, VT was ablated by regional
cryosurgery alone, whereas in group II, a septal endocardial resection
combined with cryosurgery at the same site, thereby allowing deeper
freezing injury, was used in eight patients.
Results: During mean follow-up of 24 ± 16 months, there were seven
arrhythmia events (two VT recurrence, one sudden death, four inducible
VT only) in group 1, all in patients with type 5 VT, whereas all patients
of group II remained arrhythmia-free without heart failure during 7 ± 4
months (p < 0.05). All arrhythmia events of group I occurred within the
first 3 months postoperatively.
Conclusions: (1) in patients with septal VT, computerized EPI/ENDO
mapping identifies a specific activation pattern which acts as a high risk
marker of subsequent surgical failure, (2) the associated deep septal
substratum can be treated successfully with aggressive transmural
ablation, without further worsening of LV function.
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PERFORATION OF THE ESOPHAGUS: A 10-YEAR EXPERIENCE.
A. Ayed, R. Inculet. Thoracic Surgery, University of Western Ontario,
Victoria Hospital, London, Ont.

A retrospective study was undertaken to examine the presentation,
treatment and outcome of all patients presenting with esophageal
perforation from 1980 to 1990 in London, Ont. There were 51 patients
(28 males, 23 females, mean age 62.9 years). Fifty-nine percent had
pre-existing esophageal disease (esophagitis [2], achalasia [7], stricture
[8], hiatus hernia [5], malignancy [8]). The sites of perforation were
cervical (n = 4), thoracic (n = 39) and intra-abdominal (n = 8). The
cause of perforation was traumatic in 36 patients (86% intraluminal
injury, 14% intraoperative extraluminal injury) with a 33% mortality.
Fifteen patients had a spontaneous perforation (26% had pre-existing
esophageal disease), which was associated with a higher mortality
(47%). Thirty-eight patients were managed surgically (Sx) (mortality
34%) and 13 patients were treated non-surgically (NSx) (mortality 46%).
The site of perforation did not affect mortality. Thoracic esophageal

perforation with intrapleural communication treated Sx had significantly
less mortality (36%) than those treated NSx (83%, p < 0.05). Four
patients with localized thoracic esophageal perforation were treated
NSx with no mortality. Pre-existing esophageal disease and postopera
tive complications significantly affected survival (p < 0.05). The
presence of sepsis (p < 0.01), presentation > 24 hours postperforation
(p < 0.04), pre-existing esophageal disease (p = 0.05) and cause of
perforation (p < 0.06) were all associated with increased length of
hospitalization (> 30 days). In the management of the perforated
esophagus, pre-existing esophageal disease, spontaneous perforation or
intrathoracic perforation warrants early, aggressive, surgical interven
tion to reduce mortality.
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THE ADVERSE EFFECT OF PROLONGED PRE-ARREST HYPO
THERMIC PERFUSION IN PEDIATRIC CARDIAC SURGERY. T.
Hosseinzadeh, R.C-J. Chiu, C.I. Tchervenkov. McGill University,
Montreal, Que.

We have previously shown in the newborn heart that rapid (R) cooling
provides better protection than does slow (S) cooling. Our objective was
to determine whether the detrimental effect of pre-arrest cooling was
due to the rate of cooling or duration of cold perfusion. Isolated
Langendorff hearts (n = 5 per group) from neonatal piglets (5 to 6 days
old) were perfused with oxygenated Krebs’ solution (38.5°C) for 30
minutes. A comparison of three modes of cooling was made: 5 minutes
R cooling to 15°C (group 1), 5 minutes R cooling + 15 minutes cold
perfusion at 15°C (group 2) or 20 minutes S cooling to 15°C (group 3).
Following cooling, global ischemia was induced and maintained for 2
hours at 15°C. All hearts then underwent 30 minutes of perfusion at
38.5°C. Postischemic recovery was expressed as a percentage of control
(% mean ± SEM). Right ventricular biopsies were taken for creatine
phosphate assay. Statistical analysis was performed using Anova and
Student’s f-test. Left ventricular (LV) developed pressure was signifi
cantly greater in group 1 v. groups 2 or 3 (80% ± 3% v. 64% ± 5% v.
61% ± 2%). Similarly, +dP/dT, —dP /dT were significantly greater in
group 1 v. groups 2 or 3 (77% ± 5% v. 60% ± 4% or 61% ± 1%); (84%
± 4% v. 63% ± 6% or 63% ± 2%). Rise in LV end-diastolic pressure was
significantly less in group 1 v. groups 2 or 3 (8% ± 5% v. 43% ± 14%
or 33% ± 7%). Creatine phosphate levels were compatible with
hemodynamic data. We conclude that R cooling followed by cold
perfusion offers less protection than R cooling alone, and the detrimen
tal effects of hypothermia are likely related to the duration of cold
perfusion rather than the rate of cooling. Our study suggests that
prolonged hypothermic perfusion prior to the onset of arrest is
detrimental to the newborn heart and should be avoided in pediatric
heart surgery.
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VERSATILITY OF THE GOTT SHUNT FOR REDO THORACIC
AORTIC SURGERY. A. Verdant, A. Page, R. Cossette, L. Dontigny,
R. Baillot, P. Page. Department of Cardiovascular and Thoracic
Surgery, Hopital du Sacre-Coeur, Universite de Montreal, Montreal,
Que.

Among 267 aneurysms of the descending thoracic aorta resected in the
last 16 years, 25 were complex reinterventions for two major indicaCJS, VOL. 34, NO. 4, AUGUST 1991
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tions: (a) failure of the original procedure (10 cases) required a
Dacron-graft reconstruction for the following conditions: four false
aneurysms, two recoarctations, two distal embolizations from under
sized Dacron grafts, two aneurysmal formations on the site of previous
PDA ligation; (b) proximal or distal progression of local arteriosclerotic
or dissecting residual disease (15 cases) required an aortic arch
replacement (1 case), a thoracoabdominal resection with reimplantation
of splanchnic vessels (2 cases) and a replacement of a segment of
descending aorta adjacent to a previous graft (12 cases). During aortic
cross-clamping (mean duration: 39 minutes), organ protection was
achieved with a 9-mm Gott shunt inserted proximally and distally to the
lesion. Shunt flows ranged from 1100 mL to 4900 mL/min (mean:
2526 mL/min). During aortic arch reconstruction, two Gott shunts
were utilized with two side branches for brain perfusion. For thoracoab
dominal resection, four side branches adapted on the Gott shunt allowed
perfusion of splanchnic vessels. No systemic heparinization was used.
An autotransfusion unit permits rapid reinfusion of blood if needed.
Overall hospital mortality is 16% (4/25). No paraplegia and no other
neurologic ischemic deficits occurred. One patient with profound
preoperative shock developed renal failure. The 9-mm Gott shunt is a
very reliable method of organ perfusion perfectly adaptable to more
complex aortic reconstructions.

73
BRONCHOALVEOLAR LYMPHOCYTE CYTOTOXICITY: AN INDI
CATOR OF THE ADEQUACY OF LUNG PRESERVATION. D.M.
Nguyen, C.M. Li, G. Schmidt, D.S. Mulder, H. Shennib. Department of
Surgery, McGill University, Montreal, Que.

We have previously detected high levels of bronchoalveolar lavage
lymphocyte cytotoxicity (BAL-LC) in non-protected ischemic lungs. We
hypothesize that measurement of BAL-LC can be useful to determine
the adequacy of lung preservation methods. Fourteen dogs underwent
left lung autoimplantation (group I [n = 4] immediate reimplantation
without preservation, group II [n = 4] modified Euro-Collins [mE-C]
flush followed by 2 hours cold ischemia, group III [n = 6] mE-C flush
and 4 hours cold ischemia). Aa02 gradient, pulmonary vascular
resistance (PVR), and extravascular lung water (EVLW) of the left lungs
were measured preoperatively (control) and at 60 hours after reperfu
sion to evaluate the degree of lung injury. BALs were performed at the
same intervals. BAL-LC was measured by the lectin-dependent cellmediated cytotoxicity (LDCMC) and natural killer (NK) assays. All lungs
had a period of warm ischemia of 45 ± 10 minutes during reimplanta
tion. Group III showed significant changes in all three parameters
measured. Moderate elevation of Aa02, EVLW and PVR (292 ± 20 v.
control 209 ± 54 mm Hg, 5.4 ± 0.1 v. 4.1 ± 0.3 g /g dry wt, 594 ± 36
v. 326 ± 60 dyne-s/cm5, p < 0.05) were accompanied by a dramatic
increase in BAL-LC (LDCMC: 310% ± 14% and NK: 304% ± 11% of
control, p < 0.001). Group I showed normal Aa02 but increased EVLW
and PVR. The latter two were associated with elevation in BAL-LC
(LDCMC: 190% ± 11% and NK: 170% ± 10% of control activity, p <
0.05). In group II, however, there was a minimal increase in PVR, and
BAL-LC was only marginally elevated. We conclude that (a) quantitation
of BAL-LC may be useful in assessing the severity of lung ischemia and
methods of lung preservation and (b) mE-C flush can provide adequate
lung protection within 2 hours of cold ischemia. However, by 4 hours,
progressive lung damage is likely to occur.
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ETUDE DES MECANISMES RESPONSABLES DE L'EFFET VASCULAIRE RENAL DE LA CYCLOSPORINE (CSA). F. Tronc, M.
Carrier, L.C. Pelletier. Departement de Chirurgie, Institut de Cardiologie de Montreal et Universite de Montreal, Montreal (Que.)

Le mecanisme des perturbations hemodynamiques renales induites par
la CSA est encore mal compris. L'injection de 10 mg de CSA pure en
poudre diluee dans 60 mL de sang autologue directement dans l’artere
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renale du chien perfuse par une pompe occlusive a debit constant a
permis d’objectiver un effet vasoconstricteur par une elevation de 81 ±
21 mm Hg de la pression de perfusion et une cyclosporinemie dans la
veine renale a 380 =t 82 nmol/L. Cet effet n’est pas modifie par une
sympathectomie chirurgicale (n = 6) (elevation de la pression de
perfusion de 78 ± 18 mm Hg avant et 106 ± 24 mm Hg apres) avec des
cyclosporinemies a 132 ± 27 et 301 ± 39 nmol/L, l’emploi de
phentolamine (/? = 6) (augmentation de 99 ± 7 avant et 101 ± 32 mm
Hg apres) et des cyclosporinemies de 279 ± 92 et 287 ± 78 nmol/L ou
l’utilisation d'un bloqueur des recepteurs vasculaires a l’angiotensine, la
saralazine (n = 6) (144 ± 7 avant et 167 ± 6 mm Hg apres) avec des
cyclosporinemies similaires a 428 ± 94 et 516 ± 64 nmol/L. Le
Pinane, inhibiteur competitif des recepteurs a la thromboxane A2 (TxA2)
a permis de reduire la vasoconstriction induite par la CSA de 101 ± 40
a 47 ± 15 mm Hg sur quatre chiens avec des cyclosporinemies a 223 =t
43 et 210 ± 44 nmol/L. En conclusion, la vasoconstriction arterielle
renale induite par la CSA est d'origine locale, non mediee par le systeme
renine-angiotensine, mais partiellement liee a une perturbation de la
synthese des prostaglandines.

75
CHIRURGIE DE LA STENOSE AORTIQUE CRITIQUE DU NOUVEAU-NE: CHOIX THERAPEUTIQUE VALABLE APRES 25 ANS
D’EXPERIENCE. S.J. Vobecky, H. Angate, C. Chartrand, P. Stanley.
Service de Chirurgie Cardio-Vasculaire, Hopital Sainte-Justine, Uni
versite de Montreal (Que.)

Vu l’importante mortality operatoire (20 % a 80 %) des stenoses
aortiques critiques du nouveau-ne, la valvuloplastie percutanee connait
un interet grandissant. Avant de modifier les modalites therapeutiques,
nous avons revu l’experience chirurgicale des 25 dernieres annees.
Depuis 1964 jusqu’en 1990, 37 nourrissons ont ete operes pour stenose
aortique critique. Leur age moyen au moment du diagnostic etait de
14,5 jours et a ete abaisse a 4,1 jours durant les 5 dernieres annees.
L’intervention chirurgicale a ete faite a une moyenne de 37,2 jours
avec 22 enfants ages de moins de 30 jours et 9 dans la premiere
semaine de vie. Cinq sont decedes suite a l’arythmie lors de 1’incision,
28 ont eu une valvulotomie trans-aortique classique, et 4 une valvulo
plastie trans-ventriculaire. La survie globale de 40,5 % a ete amelioree a
75 % dans les 5 derniers annees. Aucune des valvuloplasties trans-ventriculaires n’a survecu et l’unique patient avec valvuloplastie percutanee
est decede de defaillance cardiaque secondaire a l’insuffisance aortique.
Trente-huit pourcent des decedes avaient moins de 3 000 g a l’intervention contre 13 % des survivants (p < 0,05). Le temps de CEC a ete
egalement identifie comme facteur pronostic (p = 0,001). Un suivi
moyen de 66 mois a ete assure a 93,3 % et a l’exception d’un seul
patient, tous etaient dans la classe fonctionnelle I ou II NYHA. Notre
revue a permis d’identifier la valvulotomie transventriculaire, le poids a
la chirurgie et la duree de CEC comme des facteurs de mauvais
prognostic et a confirme que la chirurgie reste un bon choix therapeutique dans les stenoses aortiques critiques du nouveau-ne.
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REDUCED AIRWAY COMPLICATIONS POST-TRANSPLANTA
TION WITH NEW SURGICAL TECHNIQUES: TELESCOPING,
PGE1, EARLY CORTICOSTEROID. J.D. Miller, A. de Hoyos, J.
Ramirez, M. Scavuzzo, T. Winton, J. Maurer, G.A. Patterson.
University of Toronto, The Toronto Hospital, Toronto, Ont.

Between November 1986 and February 1991, 38 double-lung trans
plants (DLTX) were performed for cystic fibrosis (17) emphysema (13)
bronchiectasis (5), 1° pulmonary hypertension (2) and eosinophilic
granuloma (1). Actuarial survival rates were 72% and 64% at 1 and 3
years. Airway complications were a major cause of early morbidity (15)
and mortality (4). The first 18 patients underwent en-bloc DLTX: 13
tracheal anastomoses and 5 bilateral bronchial anastomoses. The last 20
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patients had sequential bilateral single lung transplants (SBSLTX), 12
end-to-end bronchial anastomoses and 8 telescoping bronchial anasto
moses. PGE1 was used in the last 24 harvests. Intraoperative and early
postoperative corticosteroid was used for the last 18 DLTX. There were
no differences in the graft ischemic times (GIT, min) among the groups
(p > 0.05). Earlier en-bloc DLTX suffered 10 airway complications
resulting in four deaths while the SBSLTX had only 5 airway
complications and no deaths.

PGE1
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Sequential SBSLTX
End-to-end anast.
Telescoping anast.

nombre total de pontages et le nombre de pontages mammaro-coronariens ont ete plus grands que dans le groupe echec. La mortalite
operatoire (8 v. 0, p < 0,05) et le taux d’infarctus perioperatoire (33 v.
4, p < 0,05) ont ete significativement plus eleves parmi le groupe echec,
particulierement chez les operes en urgence (deces : 6 /4 5 , 13 %;
infarctus : 2 5 /4 5 , 55 %). Le taux d’utilisation d’agents inotropes et de
ballons intra-aortiques a aussi ete plus eleve parmi les echecs. En
conclusion, l’ACP est une procedure dont I’utilite est bien etablie, mais
dont l’echec entraine une augmentation des taux de morbidity et de
mortalite de la chirurgie de revascularisation faite consecutivement en
urgence ou en semi-urgence.
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Better organ preservation, telescoping and early steroid use are
associated with reduced airway complications following DLTX.
77
HYPERKALEMIC CARDIOPLEGIA-INDUCED ENDOTHELIAL
FUNCTION DAMAGE IN THE ISOLATED RAT HEART. M. Pellerin,
R. Cartier, C. Hollman, J. Buluran. Department of Surgery, Montreal
Heart Institute, Montreal, Que.

Hyperkalemic cardioplegia is known to impair coronary endothelial
relaxation. This endothelial damage may be exacerbated by high
perfusion pressure. To verify this hypothesis we designed experiments
to study the influence of perfusion pressure as a modulating factor in
cardioplegia-induced endothelium impairment. Isolated heart of Sprague-Dawley rats (n = 6 per group) were studied in a Langerdorff
apparatus for coronary endothelial function. Different concentrations of
hyperkalemic cardioplegia (20, 40, 100 meq KC1/L) were perfused at
80 and 160 cm H20 of pressure at 37°C for 30 minutes. Endothelial
function and smooth-muscle function were respectively tested by
infusion of serotonin (10~6M) and sodium nitroprusside (10~6M), before
and after infusion of cardioplegia. At a perfusion pressure of 80 cm H20
no endothelial damage was induced by the three different concentrations
of hyperkalemic cardioplegia. However, at a perfusion pressure of 160
cm H20 endothelium-dependent vasorelaxation was abolished for the
three groups even though the endothelium-independent (smooth mus
cle) relaxation remained constant. This study demonstrates that perfu
sion pressure is a major determinant in hyperkalemic mediated endothe
lial damage.

THE RESULTS AND ROLE OF PNEUMONECTOMY FOR INFLAM
MATORY LUNG DISEASE. A.A. Conlan, M. Scoccianti, C. Hammond,
L. Battista. University Witwatersrand, Johannesburg, South Africa
and Queen’s University, Kingston, Ont.

The study was done to define the mortality and morbidity of pneumo
nectomy for inflammatory lung disease (ILD) in a modern-day thoracic
surgery unit. One hundred sixty-four patients with ILD underwent
pneumonectomy for recurrent or chronic infection, hemoptysis or
cancer. X-ray showed destroyed lungs (145), whole-lung atelectasis
(46), gross bronchiectasis (32), lung abscess (28) and empyema (25).
Contralateral lung disease was present in 55. Extrapleural pneumonec
tomy was done in 118 and standard pneumonectomy in 46. Surgery was
elective in 124 patients, but 40 had emergency resection (massive
hemoptysis 23, uncontrolled sepsis 17). Pulmonary separation was by
double-lumen tube (129), single tube (10), bronchus blocker (8) and
prone posture (9). Endobronchial spillage occurred in four. Operative
pleural spillage occurred in 56. Hospital mortality was 7.9% (13
patients) and due to sepsis and ARDS (6), air embolism (2) and
respiratory failure (1), gastrointestinal bleeding (1) and renal failure (1).
Morbidity included post-pneumonectomy empyema (30), postoperative
bleeding (11), pericardiotomy syndrome (3), hemiplegia (2) and pneumo
nia (2). Pneumonectomy was expeditious and effective therapy for the
serious complications of ILD and had an acceptably low mortality.
Post-pneumonectomy empyema was an important cause of early and
late morbidity.
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COMBINATION OF PHARMACOLOGICAL INTERVENTIONS FOR
PREVENTION OF SPINAL CORD ISCHEMIA-REPERFUSION IN
JURY INDUCED BY AORTIC CROSSCLAMPING. A.K. Qayumi, M.T.
Janusz, W.R.E. Jamieson, D.M. Lyster, A. Poostizadeh. Department of
Surgery, University of British Columbia, Vancouver, BC
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L’ECHEC DE L’ANGIOPLASTIE CORONARIENNE PERCUTANEE
(ACP) CHANGE-T-IL LE RISQUE DE LA CHIRURGIE DE REVAS
CULARISATION? F. Tronc, L.C. Pelletier, M. Carrier. Departement
de Chirurgie, Institut de Cardiologie de Montreal et Universite de
Montreal, Montreal (Que.)

Pour evaluer les resultats de la chirurgie coronarienne apres echec
d'ACP, nous avons etudie retrospectivement 95 patients (3,2 %) operes
apres echec d'ACP parmi les 2 933 procedures faites entre avril 1987 et
avril 1990. Les echecs se repartissent en trois groupes: chirurgie
urgente (moins de 6 heures, n = 45, 1,5 %), chirurgie semi-urgente (n =
23, 0,8 %), chirurgie elective apres echec sans complication (moins de 3
semaines, n = 26, 0,9 %). Une serie consecutive de 100 patients operes
pour revascularisation coronarienne au milieu de la periode d’etude a
servi de groupe temoin. Dans le groupe echec on note significativement
moins d’atteinte tritronculaire, de taux d'infarctus datant de plus d'un
mois, mais plus de patients diabetiques, dyslipidemiques ou ayant subi
une ACP anterieurement. Parmi les patients du groupe temoin. le

The efficacy of allopurinol, a xanthine oxidase inhibitor, and deferoxam
ine (Desferal), an iron chelating agent, in combination were tested in a
swine model of spinal cord injury simulating surgery on thoracic and
thoracoabdominal aortic aneurysm. Spinal cord ischemias was induced
by aortic crossclamping for 30 minutes followed by 24 hours of
observation. The study groups included: group A — control with no
interventional therapy, and group B — animals that were pretreated
with allopurinol (50 m g/kg daily orally) for 3 days and received
deferoxamine 50 m g/kg IV slow infusion completed 1 hour before
crossclamping. Animals were neurologically assessed (Tarlov criteria)
before surgery, 4 hours after the reperfusion and 24 hours after
reperfusion. Blood flow assessment was performed by microsphere
technique before the application of crossclamping, during crossclamp
time and following the removal of the crossclamp. Pathomorphological
and not ultrastructural specimens were taken at the end of the
experiments. Significant (p < 0.001) fall in spinal cord blood flow
confirmed the ischemia episode for both animals in all three groups.
Tarlov criteria demonstrated a highly significant (p < 0.01) improve
ment in neurologic status of experimental animals compared to the
CJS, VOL. 34, NO. 4, AUGUST 1991
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placebo. Animals in this group were standing and walking at 24 hours
after the reperfusion, while the placebo group animals were paraplegic.
Pathomorphologic and ultrastructural findings fully correlated with
neurologic findings. The additivity of this combination was as high as
82%. Both allopurinol and deferoxamine are clinically available agents.
We strongly recommend the use of this combination for patients
undergoing thoracoabdominal aneurysm resection.

81
CARDIAC SURGERY AFTER FAILED PERCUTANEOUS MITRAL
VALVULOPLASTY. L. Normandin, M. Carrier. Department of Sur
gery, Montreal Heart Institute and Universite de Montreal, Montreal,
Que.
Percutaneous mitral valvuloplasty (PMV) for selected patients with
symptomatic mitral stenosis (MS) has been proposed as a safe alterna
tive to open mitral commissurotomy (OMC) or mitral valvular replace
ment (MVR) in most instances. Among 146 consecutive patients
undergoing PMV from March 1987 to April 1990, 15 (10%) needed,
following the procedure, during the same hospital stay, urgent (7) or
delayed (average 6.5 days) (8), corrective surgery. There were 13 women
and 2 men with NYHA class II (2) or III (13) with intermediate risk for
PMV according to the echo score (mean = 8). The indications for
surgery were: massive mitral regurgitation caused by tearing of the
anterior leaflet (5), cardiac perforations: left atrium (2), left ventricle (3),
PMV technical failure (4), atrial shunting (1). Operative procedures
consisted of MVR (11), cardiac wound suturing only (3), OMC (1).
Operative mortality (within 30 days) was 27% (4/15) equally distributed
in the urgent or delayed group. Cause of death was hemorrhage (two),
severe cerebral ischemia (one) and unknown (one). Compared to
operative results with OMC (0/20) or MVR (2/54) as initial treatment
for MS, during the same period, failed or complicated PMV carries a
significant mortality (p = 0.004). Therefore, in order to reduce even
more the PMV procedural-related mortality and morbidity, optimal
patient selection and aggressive corrective surgery, when indicated,
should be carefully evaluated.

IMPROVED 24-HOUR CARDIAC PRESERVATION WITH CONTIN
UOUS PERFUSION USING THE UW SOLUTION. S. Jackson, A.
Guerraty, L.Q. Pu, J.F. Symes. Royal Victoria Hospital, McGill
University, Montreal, Que.
Recent studies using the UW solution for storage of isolated donor
hearts have not demonstrated significant prolongation of ischemia time
prior to transplantation. This study compares the UW solution with our
control solution (a modified Krebs-Henseleit) in a continuous hypo
thermic coronary perfusion model. Two groups of mongrel dogs were
used. Group I hearts were perfused with the control solution (n = 15)
while group II hearts were perfused with the Belzer UW cold storage
solution (n = 12). The canine hearts were rapidly excised after
hyperkalemic arrest, using our standard cardioplegia, and then mounted
in our perfusion apparatus for 24 hours. The hearts were then
transplanted in a cross-circulation model and parameters of function
measured, i.e., developed pressure (dP) and rate of pressure develop
ment (dP/dT).
Group I : dP = 56 ± 9 + d P /d T = 843 ± 1 5 4
Group II: dP = 80 ± 7 + d P /d T = 1433 ± 126
p < 0.05
p < 0.005

—dP/dT = 676 ± 106 (mean ± SEM)
-d P /d T - 958 ± 110
p < 0.05

The group II hearts also required less defibrillations (0.75 ± 0.45), with
3 of 12 hearts requiring no defibrillations and 9 requiring only one
defibrillation. Those in group I required 5.9 ± 7.9 defibrillations (p <
0.02). There were no significant differences in weight gain, coronary
resistance or creatine phosphokinase between the groups.
We conclude that the use of the UW solution as a continuous
coronary perfusate provides significantly better preservation of cardiac
function after 24 hours of perfusion. Further evaluation using orthotop
ic transplantation appears warranted.
84
ROLE OF INTRAOPERATIVE TRANSESOPHAGEAL COLOUR
DOPPLER ECHOCARDIOGRAPHY IN MITRAL VALVE REPAIR.
P. Bedard, K.L. Chan, R.A. Sochowski. University of Ottawa Heart
Institute, Ottawa Civic Hospital, Ottawa, Ont.
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NEUROGENIC TUMOUR OF THE THORACIC REGION. F.M. Shamji, B. Benoit, E. Vallieres, T.R. Todd, H.J. Sachs. University of
Ottawa, Ottawa Civic Hospital, Ottawa, Ont.
The evaluation and treatment of neurogenic tumours arising in the
thoracic region continues to present a challenge. Of special concern in
their management is the presence of spinal cord compression from
either intraspinal lesions or vertebral body destruction collapse. A
review of 13 such cases disclosed that there were two dumb-bell
tumours, four intrathoracic tumours, one neurofibromatosis with
multiple intraspinal neurogenic tumours, two malignant schwannomas
with vertebral body destruction with spinal cord compression and four
foraminal lesions with central intraspinal (extradural) extensions. There
were 3 men and 10 women, whose ages at the time of operation ranged
from 37 to 79 years. Three patients were asymptomatic (three of the
four intrathoracic tumours); the remaining 10 had symptoms ranging
from 3 weeks to 12 months (average, 9 months) before the diagnosis
could be made and surgery carried out. Back pain with intercostal
neuralgia was present in eight patients and neurologic signs were
present in six patients. Routine chest radiograph was abnormal in seven
patients. Thoracic spine x-rays were abnormal in four of the remaining
six patients. Surgical excision of the tumour was performed in all 13
cases. One postoperative wound infection developed in a patient
requiring laminectomy. Our experience suggests that (a) symptoms
demand thorough investigation since the chest radiograph may be
normal (6 out of 13 patients) and (b) dumb-bell neurogenic tumours and
those causing vertebral body destruction and collapse demand a
multidisciplinary one-stage surgical approach.
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Transesophageal colour doppler echocardiography (TEE) allows an
excellent assessment of the mitral valve and can be easily performed
intraoperatively during cardiac surgery. Since May 1, 1987, 70 patients
have undergone mitral valve repair for chronic mitral valve disease
performed by one of the authors at the University of Ottawa Heart
Institute. Of those, 53 were studied with intraoperative TEE following
their repair. Specific assessment of the mitral valve following repair is as
follows: mitral regurgitation (MR), leaflet prolapse (LP), systolic anterior
motion of the anterior leaflet (SAM), left ventricular outflow tract
obstruction (LVOTO) and mitral valve area (MVA).
Three of the seven patients who were found to have moderate to
severe MR were returned on cardiopulmonary bypass to receive an
annuloplasty (Carpentier ring) and their MR was reduced to none. A
patient with residual mitral stenosis (MVA 1.0 cm2) needed a mitral
valve replacement. Following the second repair the final results were as
follows: MR: none or trivial 30, mild 19, moderate 4; LP: none 51, mild
2; SAM: none 52, mild 1; LVOTO: none 52, mild 1; MVA: 2.5 cm2 (1.0
— 3.8) (± 0.76 SD) in 22 patients.
To validate the accuracy of diagnosing MR with colour flow, agitated
saline was injected in the left ventricle in 27 patients. There was an
excellent correlation in assessing the degree of MR using both methods,
with difference in one grade in five patients. Difference by more than
one grade was not found.
In conclusion, we strongly recommend the use of intraoperative TEE
to assess immediately the results of the mitral valve repair while the
chest is still open so that further repair or valve replacement may be
carried out if necessary.

A B STR A C TS
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ULTRASOUND STAGING OF ESOPHAGEAL CARCINOMA. T.W.
Rice, M.V. Sivak, T.J. Kirby. The Cleveland Clinic Foundation,
Cleveland, Ohio
Esophageal ultrasound (EUS) allows a unique visualization of the
esophageal wall and periesophageal tissue. Depth of tumour invasion
(T) and regional lymph-node metastases (N) can be assessed by EUS.
Prompted by this advance the UICC and AJCC introduced a new staging
system for esophageal carcinoma.
Preoperative staging was attempted in 52 patients with presumed
operable carcinoma of the esophagus or esophagogastric junction using
the Olympus UM-3 ultrasound endoscope and the new staging system.
Pathologic stage (PS) was independently determined by examination of
the resected specimens.

T

In c o m p le te E U S

infection (32.1 ± 23 days post-Tx) there were 3 with severe, 8 with mild
and 6 with no CAD. In four of six with severe CAD the donor died of a
cerebrovascular accident. Mean age of the six who died with severe CAD
was 26.6 ± 9.2 years. Donor age, ischemic times and inotropic
requirements were similar in the two groups. The left main coronary
was small (2 mm) in six patients, all in the PGF group (p < 0.01). Two
hearts with known CAD were used and survived long term. One received
a mammary graft for an isolated LAD lesion. The second had known
triple CAD and was used as a biologic bridge with re-Tx 1 week later.
The late incidence of CAD in this transplant population as documented
by annual coronary angiography was 3 /2 0 0 . We conclude that (a) there
is a significant incidence of unsuspected CAD in an apparently healthy
cardiac donor population, (b) late CAD may represent progression of
disease implanted with the graft, (c) a small incidence of primary graft
failure due to CAD in the donor is unavoidable and (d) early
angiography after surgery would be helpful in the management of some
patients with PGF and in distinguishing late initiation from progression
of CAD in the graft.

N
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There were eight incorrect determinations of T. All patients were
overstaged, three by two levels, five by one level. There were four
false-negative studies and two false-positive studies in the determination
of N. In the determination of N by EUS the sensitivity = 85%, specificity
= 82%, positive predictive value = 92% and the negative predictive
value = 69%.
EUS assessment of T and N is (a) accurate and (b) limited by
malignant strictures and nonvisualization of regional lymph nodes.
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PRIMARY GRAFT FAILURE AFTER CARDIAC TRANSPLANTA
TION. D. Sandler, F.N. McKenzie, A.H. Menkis, R.J. Novick, P.W.
Pflugfelder, W.J. Kostuk. University Hospital, London, Ont.
In a group of 240 adult cardiac transplant (Tx) recipients, 30 patients
died within 90 days and underwent autopsy. The severity of coronary
artery disease (CAD) (> 70% luminal obstruction), size of left main
coronary artery, age of donor, cause of death in donor and recipient and
ischemic times were noted. Of 13 patients who died of primary graft
failure (PGF) 5.5 ± 9 days postoperatively there were 3 with severe, 5
with mild and 5 with no CAD. Of 17 patients who died of rejection or

IMPACT OF RISK ON PERIOPERATIVE RESULT AND RE
SOURCE UTILIZATION. B.S. Goldman, S.E. Fremes, G.T. Christakis, R.D. MacLean, C. Tong. Sunnybrook Health Science Centre,
Toronto, Ont.
A new cardiac surgical unit opened Nov. 27, 1989, with limited physical
and human resources, despite adequate funding. Case mix (acuity and
complexity) was monitored and controlled to ensure (a) optimal
operating room and ICU utilization and (b) appropriate progression with
increasing operating room and ICU nurse experience. Certain high-risk
patients with multisystem disorders were referred elsewhere. By Dec.
31, 1990, 509 patients had undergone surgery: 72.9% CABG, 21%
valve and 6.1% other. Prospective data collection for 31 variables
provided 30-day perioperative data. Of 371 patients with CABG, 68%
were considered unstable but only 26% required urgent operation. The
incidence of LM stenosis was 15%, poor LV 10%; the mean age was 60
± 9 years, (15% > 70 years). Operative mortality (OM) was 0.8%,
perioperative MI 5%, postoperative IABP 2.7%, reoperative (bleeding)
2%, CVA 2% and sternal dehiscence 0%. Of the 107 valve patients, 61
underwent AVR (mean age 63 ± 13 years, 41% > 70), 23 with CABG;
OM was 3%, reoperative 7% and CVA 7%. For MVR, AVR/MVR and
MV repair, the mean age was lower (58 ± 15, 56 ± 12, 49 ± 15 years),
and only 10% > 70 years; the OM and significant morbidity was 0%.
Preoperative coagulation and perioperative hemostasis protocols result
ed in low blood utilization (1.4 units/patient). Average length of stay
for the ICU (both levels I and II) was 2.5 days and for hospital stay 8.6
days. The hospital realized a net profit from the CV program.
Conclusion: Attention to patient risk and case mix may positively
influence perioperative result and permit optimal resource utilization,
despite significant constraints, while providing service to the maximum
potential caseload.
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SARTORIUS MYOPLASTY IN THE TREATMENT OF EXPOSED
ARTERIAL GRAFTS. J.G. Sladen, R.P. Thompson, P.G. Kalman,
R.D. Martin. St. Paul’s Hospital, Vancouver, BC and Toronto General
Hospital, Toronto, Ont.

Classically, exposed grafts harbour infection and lead to acute hemorrh
age. During the last 10 years we have treated 16 exposed grafts with
surprisingly good results using sartorius flaps. Autogenous and pros
thetic grafts are equally worrisome and were treated in the same
manner. Each graft was either exposed on presentation or on explora
tion. The area was radically debrided and usually packed open for 5 to 7
days to allow granulation. Positive cultures were obtained in 14. The
sartorius can be used as a “twist,” “fan” or pedicle myoplasty. The
table presents our combined experience.

G ra m

G ra m

P r o b le m

Type

No.

p o s itiv e

n e g a tiv e

Exposed

A u to g e n o u s
P ro s th e tic

6
6

2

6
3

P ro s th e tic
P ro s th e tic

3
1

2
1

Each case went on to complete healing. Follow-up ranges from 6
months to 8 years. Late complications include an infected sinus, a false
aneurysm and one late graft occlusion. Specific technique, implication
of the infecting organism and a short review of the literature will be
presented. Sartorius myoplasty is an eloquent solution to the problem of
exposed vascular grafts.
743
SIBLING PREVALENCE OF ABDOMINAL AORTIC ANEURYSMS.
C.Wm. Cole, A.G. Bouchard, G.B. Hill, D. Moher. University of
Ottawa, Ottawa, Ont.

Purpose: Mortality from abdominal aortic aneurysm (AAA) ranks ninth
in the list of causes of death in elderly men. To reduce the incidence of
rupture from AAA, early detection by screening the male population 55
and over has been suggested. Estimates of the prevalence of AAA in this
population range around 4%; the strategy of screening would be even
more cost-effective if it could be focused on an even higher risk group.
Because AAA has been noted to occur more frequently amongst
first-order relatives, siblings of known AAA patients could represent
such a group. The hypothesis tested was that siblings of patients with
AAA have a higher prevalence of undetected AAA than the general
population.
Methods: A case control study was conducted. Ultrasound was used
to detect AAA in the abdominal aorta of siblings of known AAA patients
and in a control group. The sample size had sufficient statistical power
(80%) to detect a twofold increase in relative risk (RR) between the two
groups.
Results: The results are based on an interim analysis of 219 patients
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THE USE OF THE LATEX D-DIMER ASSAY TO EXCLUDE
CLINICALLY SIGNIFICANT VENOUS THROMBOSIS. D.L. Doyle,
C.J. Carter, S. Fowler, N. Dawson, D.V. Devine. University Hospital,
UBC Site, Vancouver, BC

C ulture

G ra ft

S in u s /u n s e a t e d
B le e d in g (F A )

(108 cases and 111 controls). Abdominal aortic aneurysm was observed
in 8% and 7% (RR = 1.2) of cases and controls, respectively.
Subsequent analysis revealed a strong gender effect; RR for females was
0.9; 1.8 for young men; 2.0 for old men. Thus far, AAA was observed in
21% of cases versus 15% in controls.
Conclusions: Abdominal aortic aneurysms are more prevalent in the
general male population than previously suggested, and therefore the
efficacy of a screening program for their early detection should be
tested. Siblings of known AAA patients appear to represent an even
higher risk group.
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Studies have shown that less than 25% of ambulant patients with
suspected deep venous thrombosis (DVT) actually have DVT. This has
led to the development of noninvasive techniques, which, though not as
accurate as venography, do permit safe management. Limitations of all
noninvasive tests for DVT include both temporal and geographic
availability. A rapid test that could safely exclude the presence of
significant DVT in the majority of the DVT-negative cases would greatly
aid management. An assay to exclude the presence of fibrin deposition
might serve such a role.
A series of 175 consecutive cases of suspected DVT were examined
with venous doppler, impedance plethysmography and D-Dimer assays.
One assay was a rapid latex bead assay that could detect 200 ng/m L of
D-Dimer. The other was an ELISA assay capable of detecting 20 ng/mL
of D-Dimer. Both assays were based on the DD3B6 (Agen) monoclonal
antibody. Of the 34 cases with DVT, 27 were detected by the latex assay
(sensitivity = 79%). Of the 141 normal cases the latex test gave 23
false-positive results (specificity = 83%). Using the ELISA assay on the
same samples and examining various cut-off levels to define positivity, a
level of < 150 ng/m L of D-Dimer gave a sensitivity of 90% for the
presence of DVT. Latex D-Dimer negativity in DVT was not restricted to
calf-vein thrombi. Proximal thrombi traditionally thought to require
anticoagulant treatment were also not detected. The natural history of
D-Dimer-negative thrombi is unknown. The only feature of the seven
“missed” cases was a delay between the onset of clinical symptoms and
D-Dimer testing of 7 or more days compared to a mean delay of 3.7
days for the cases that were correctly identified.
The above results suggest that for optimum clinical utility the
resolution of rapid D-Dimer tests needs to be increased to detect 150
ng/m L 'of D-Dimer. False-negative results will occur in patients with
symptoms of more than 1 week’s duration.
747
ACUTE THROMBOSIS OF THE ATHEROSCLEROTIC AORTA. G.
DeRose, K.A. Harris, L.W. Milne, S.J. Gutman, W.G. Jamieson.
Division of Vascular Surgery, Victoria Hospital, University of West
ern Ontario, London, Ont.

Between 1981 and 1990, patients with acute aortic occlusion were
retrospectively reviewed. Patients with embolic occlusion, previous
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aortoiliac repair and thrombosis of an abdominal aortic aneurysm were
excluded. This report deals with the remaining 14 patients treated for
acute aortic thrombosis.
The group had a mean age of 66 years with an equal sex distribution.
Ten patients had a history of claudication and 4 had pre-existing
hypertension. Nine of the 10 previously normotensive patients present
ed with associated hypertension. All patients presented with symptoms
of acute bilateral leg ischemia.
Preoperative angiography was obtained in only 9 patients, but all 14
patients were treated surgically. Nine patients had initial bilateral
retrograde femoral artery thrombectomy. This was unsuccessful in four
patients, three of whom went on to have axillobifemoral bypass (AxBF)
and one aortobifemoral bypass (ABF). The other five patients had
primary ABF bypass. All patients received postoperative anticoagula
tion.
The mortality rate was 21.4%. Of 11 patients who survived to
hospital discharge, 3 required amputation (27.3%), and 7 (63.6%) had a
lower-limb motor deficit. Life-table analysis yielded an overall 5-year
survival rate of 55%.
In conclusion, patients with acute aortic thrombosis have not only a
limb-threatening but also a life-threatening disease. Such patients
require prompt surgical management. Initial attempt at bilateral retro
grade femoral thrombectomy can be recommended and if this is
unsuccessful then AxBF is a suitable alternative to ABF bypass in such
high-risk patients.

disease. The author reports a 4-year experience with 92 carotid
endarterectomies undertaken without angiography. All had duplex
scans in the diagnostic vascular laboratory. Seventy-nine percent of
patients were symptomatic, 21% were asymptomatic with high-grade
advancing stenosis of 80% to 90%. All symptomatic patients had focal
signs and symptoms. Patients with nonfocal symptoms, abnormal
computed tomography scans or questionable duplex scans were submit
ted to angiography and were excluded from this study. There was no
mortality in this group and no morbidity in the asymptomatic group.
Perioperative (minor) stroke or transient ischemic attacks occurred in
3.7% of symptomatic patients. The author concludes that patients with
focal signs and symptoms and ipsilateral high-grade stenosis on duplex
scan and a negative CT scan can be safely offered carotid surgery
without undergoing angiography.
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Identification of patients at high risk for cardiac complications following
vascular surgery is possible with either Holter monitoring for silent
ischemia or dipyridamole myocardial perfusion imaging. We compared
the results Of Holter monitoring versus dipyridamole myocardial
perfusion imaging in 45 patients (67 years ± 8 years; 36 males, 9
females) scheduled for vascular surgery. Holter monitoring was carried
out for 48 hours using three-lead recorders. A Holter study was
considered positive for ischemia if one episode of 1-mm ST-segment
depression was recorded for 1 minute. Dipyridamole myocardial perfu
sion imaging was carried out at rest and after intravenous dipyridamole
(0.85 m g/kg over 10 minutes) using technetium-99m Cardiolite and
tomographic imaging. A positive dipyridamole myocardial perfusion
scan for ischemia was characterized as a perfusion abnormality
following dipyridamole stress with improvement on rest imaging. Holter
studies were positive in 18/45 (40%) patients and dipyridamole scans
were positive in 13/45 (29%) patients. Holter monitoring and dipyrida
mole myocardial perfusion scans were concordant (both positive or both
negative) in 2 6 /4 5 (57%) patients and discordant in 1 9 /4 5 (42%)
patients. Negative dipyridamole scans were found in 1 2 /1 8 (67%)
patients with positive Holter recordings. Similarly, negative Holter
recordings were observed in 7 /1 3 (54%) patients with positive dipyrida
mole scans. Thus, Holter monitoring and dipyridamole myocardial
perfusion imaging appeared to detect different patient groups and
cannot be used interchangeably. Combined testing with Holter monitor
ing and dipyridamole myocardial perfusion imaging may be helpful in
identifying patients at low risk (both tests negative), medium risk (only
one test positive) and high risk (both tests positive).

ENDARTERECTOMY REDUCES IPSILATERAL STROKE RATE IN
SYMPTOMATIC PATIENTS WITH APPROPRIATE CAROTID STE
NOSIS GREATER THAN 70%. P.M. Walker. Toronto General
Hospital, Toronto, Ont.
The effectiveness of carotid endarterectomy in addition to maximum
medical therapy was tested in symptomatic patients in a randomized
prospective multicentred trial (NASCET). Canadian vascular surgeons
played an important part in this study. As of February 1991, a total of
595 patients with linear stenosis greater than 70% were enrolled: 295
randomized to medical therapy and 300 to the surgical protocol. The
perirandomization morbidity and mortality was 3.4% in the medical
group and 5.3% in the surgical group. At 18 months’ follow-up the rate
of ipsilateral stroke was 24.4% in the medical group and 7.2% in the
surgical group (p < 0.00001). This sustained difference resulted in the
activation of the stopping rules set up in the original protocol with the
cessation of enrolment of those patients with greater than 70% stenosis
and the declaration that these patients should receive an endarterecto
my. There were 571 patients with stenosis less than 70% randomized,
and since this group did not reach differences that would invoke the
stopping rules they would continue to be enrolled. This study demon
strated both the usefulness of randomized studies to clearly indicate
surgical benefit as well as the role of carotid endarterectomy in reducing
ipsilateral stroke.
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HOLTER MONITORING AND DIPYRIDAMOLE MYOCARDIAL
PERFUSION IMAGING FOR PREOPERATIVE ASSESSMENT IN
PATIENTS UNDERGOING VASCULAR SURGERY. N.V. McPhail,
T.D. Ruddy, G.G. Barber, C.W. Cole, G.E. Hajjar, L. Marois, R.L.
Garnett, R.W. McIntyre, R.F. Davies, J.E. Calvin. University of Ottawa
Heart Institute and Division of Vascular Surgery, Ottawa Civic
Hospital, Ottawa, Ont.
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CAROTID ENDARTERECTOMY WITHOUT ANGIOGRAPHY — A
PERSONAL SERIES. P.D. Fry. Department of Surgery, University
Hospital, Vancouver, BC

INTRAOPERATIVE BALLOON ANGIOPLASTY — A SURGICAL
APPROACH. M. Al-Salman, P.D. Fry, D.L. Doyle, Y.N. Hsiang, M.
Fragoso. Department of Surgery, University of British Columbia,
Vancouver, BC

The standard method of investigating cerebral vascular insufficiency
includes cerebral angiography, which, however, can carry associated
stroke rates of 0.5% to 1% and mortality up to 0.5%. Rapid develop
ments in duplex-scanning techniques have resulted in reported sensitivi
ty of 99% and specificity of 84% for the diagnosis of carotid-artery

Percutaneous balloon angioplasty is a recognized treatment for periph
eral atherosclerosis involving the iliac and femoropopliteal segments.
We have recently been using intraoperative balloon angioplasty (IBA)
for tandem lesions requiring both balloon angioplasty and surgical
CAS, VOL. 34, NO. 4, AUGUST 1991
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intervention. The purpose of this study was to examine the efficacy of
this treatment in our hands.
From January 1988 to July 1990, 43 IBAs were performed in 38
patients (18 female, 20 male) who required inflow or outflow angioplas
ty in addition to surgical bypass. The indication for surgery was
incapacitating claudication in 32 (74%) and limb salvage in 11 (26%)
patients. Initial technical success was achieved in 15/18 (83%) iliac and
2 4 /2 5 (96%) femoropopliteal balloon dilatations. Four major complica
tions (9%) occurred, all of which required surgical intervention. These
were dissection with thrombosis (one), false passage (one) and failure to
improve pressure gradient (two).
Follow-up from 2 to 15 months (mean 8.2 months) was available in
all patients. Fourteen of the remaining 15 iliac segments and 22 of the
remaining 24 femoropopliteal segments remained patent. Two failures
in the femoropopliteal segment required late amputation.
In our hands, IBA has proved to be a worthwhile adjunct for tandem
lesions in the iliac and femoropopliteal segments. Although initial
technical success for iliac lesions was lower than expected, we feel that
IBA offers a suitable alternative to percutaneous balloon angioplasty
followed by surgery.
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ATHERECTOMY, EARLY USE OF THREE DIFFERENT METHODS.
Y.N. Hsiang, J.D.S. Reid, J.G. Sladen, P.D. Fry, L. Machan, P.
Chipperfield, I. Marsh, P. Harrison, D.L. Doyle. Division of Vascular
Surgery and Department of Radiology, University of British Columbia,
Vancouver, BC
Recanalization of peripheral arteries by atherectomy is a new frontier in
vascular surgery. We have been using three methods, Kensey, Simpson
and TEC, and report our early experience with these techniques. From
December 1989 until February 1991, 36 procedures have been
performed. Of these, 16 used the Kensey method, 12 the Simpson
method and 8 the TEC method. The choice for specific atherectomy
catheters was dependent on lesion type: Kensey for occlusions and
Simpson or TEC for stenoses. The indications were limb salvage in 9
and limiting claudication in 11. Access was gained via a percutaneous
route in 33. The procedure was successfully completed in 28 of 36.
There were eight complications of the procedure including three arterial
perforations and one groin hemorrhage requiring operative intervention.
There were no distal embolizations. Of the 16 patients who are 6
months or more after the procedure, 13 are patent (81%). While there
are varying indications for utilizing the different methods of atherecto
my, the early results appear acceptable.
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VASCULAR ACCESS SURGERY FOR CHRONIC HEMODIALYSIS.
D. Johnson, J. Rothschild, M. Schnieder, J. Williams, F. Sutherland.
University of Calgary, Department of Surgery, Foothills Hospital,
Calgary, Alta.
All vascular access procedures performed at the Foothills Hospital over
a 2-year period were reviewed. One hundred sixty-one vascular accesses
were created in 134 patients, aged 13 to 83 (mean 52.5 years).
Seventeen were either never used (13) or lost to follow-up (4). The
remaining patients were analysed with respect to patency rate and
complications. One hundred eight patients received a Brescia-Cimino
arteriovenous fistula (AVF) and 36 patients received a synthetic (PTFE)
graft. The majority of AVFs (72%) were the initial access procedure,
while the majority of PTFE recipients (81%) had at least one prior
access. Sixteen AVFs underwent 22 salvage procedures and 21 PTFE
grafts underwent 67 salvage procedures (thrombectomy, angioplasty or
402
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patch graft). Arteriovenous fistulas had a patency rate of 68% and 61%
at 1 and 2 years, respectively, and PTFE grafts had a 1- and 2-year
patency rate of 59% and 40%, respectively. Arteriovenous fistulas done
as the first access procedure had a 1-year patency of 72%. The 1-year
patency rate was only 31% when the AVF was done as a subsequent
access (p < 0.05, log rank test). In diabetics (n = 22), an AVF 1-year
patency of 58% was not significantly lower than nondiabetics. In elderly
patients (> 65 years) AVFs had a 79% 1-year patency and PTFEs 61%.
PTFE graft infections occurred in nine patients (24%) at a mean 13
months postoperatively. No infections were recorded in 108 AVFs. A
low patency rate and infection remain significant problems when using
PTFE grafts. Arteriovenous fistulas continue to be the initial procedure
of choice for vascular access in chronic hemodialysis patients, including
diabetics and the elderly.
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SALMONELLA ARTERITIS WITH ANEURYSM FORMATION:
TWO CASES. F. Flamand, K.A. Harris, G. DeRose, B. Karam, W.
Jamieson. Victoria Hospital, London, Ont.
Although Salmonella infections of arteries are rare they remain one of
the most common causes of primary mycotic aneurysms. The experi
ence in our centre includes two cases of aneurysms infected with
Salmonella, one of the aorta and the other of the common femoral
artery. The presentation is one of sepsis, positive cultures for Salmonel
la with rapid expansion or rupture of the aneurysm. The diagnosis of
mycotic aneurysm must be considered in any patient with an aneurysm
and positive cultures for Salmonella. Both reported cases were treated
with excision of the aneurysm, extra-anatomic reconstruction in an area
remote from the infected field, and appropriate antibiotics over the long
term. One patient remains alive 32 months following resection. Review
of the English and French literature reveals 42 cases of abdominal
aortic aneurysms infected with Salmonella with a survival rate of 40%.
The appropriate antibiotic therapy will be discussed and the issue of
in-situ vascular reconstruction versus extra-anatomic bypass will be
addressed.
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LATE VASCULAR INJURIES FOLLOWING TOTAL HIP REPLACE
MENT (THR). M. Al-Salman, D. Taylor. Department of Surgery,
University of British Columbia, Vancouver, BC
Seven patients (eight THR) with severe medial displacement of the
acetabular component were reviewed. All patients were women with a
mean age of 65 years. Vascular injury from medial displacement of the
acetabular prosthesis was identified preoperatively by: pelvic mass
(3/8), pelvic bruit (2/8), pelvic pain (8/8), cement in pelvis on x-ray
(3/8), acetabular prosthesis in pelvis on x-ray (8/8), computed
tomography scan showing cement in pelvis and proximity of migrated
acetabulum to iliac vessels (4 /4 CT scans). Arteriography showed
displacement or compression of vessels (7 /7 angiograms).
Operative management in all cases involved medial exposure and
mobilization of the iliac vessels away from the acetabular prosthesis via
an extraperitoneal (7/8) or intraperitoneal approach (1/8). Mobilization
of vessels away from the acetabular prosthesis only was performed in
six cases, primary repair of the iliac artery in one case and vein
interposition graft in one case.
Postoperative complications included deep vein thrombosis (DVT)
(3/8), in spite of DVT prophylaxis, and occlusion of vein graft (1/8)
requiring femoral crossover graft replacement. There were no deaths.
There was no limb loss and no hemorrhagic complications.
In patients with medial displacement of total hip arthroplasty we
advocate preoperative identification of potential iliac-vessel involvement
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by angiography and CT scan. The operative approach to these patients
should involve medial exposure, mobilization and repair of the iliac
vessels prior to removal of the displaced acetabular prosthesis to
prevent major hemorrhagic complications.
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PRIMARY AORTODUODENAL FISTULA (ADF) REVISITED. P.
Cloutier, A.H. Spanier, N. Miller, N.M. Sheiner. Department of
Surgery, The Sir Mortimer B. Davis-Jewish General Hospital, McGill
University, Montreal, Que.

DIAGNOSIS AND MANAGEMENT OF CHRONIC VENOUS DIS
EASE OF THE LOWER EXTREMITY — ROLE OF DESCENDING
VENOGRAPHY. W. Jamieson, G. DeRose, K.A. Harris, B. Karam.
Victoria Hospital, London, Ont.

Primary ADF is a rare entity with less than 200 reported cases. We have
encountered three cases of ADF within the last 24 months. The patients
were elderly males with a mean age of 78.6 years. All presented with a
“herald" bleed followed by exsanguinating hemorrhage. Gastroscopy in
each case excluded bleeding in the esophagus, stomach or proximal
Symptoms resulting from chronic venous disease create a major duodenum. In one case the diagnosis was suspected, but the patient
morbidity for the patient. Varicose-vein stripping with subfascial ligation exsanguinated prior to surgery. In the second, an aortic aneurysm was
of any incompetent perforators and compression therapy often are discovered on a tagged red cell scan and the diagnosis of primary ADF
inadequate in the management of this problem. We have investigated was entertained. The patient was taken to the operating room where the
patients with refractory chronic venous stasis due to primary valvular aneurysm was resected, the duodenum closed and the graft covered
incompetence, outflow obstruction and congenital abnormalities. Meth with omentum. In the third case, surgery was performed for massive
ods of investigation included history and physical examination, hand hemorrhage. Following an extended gastroduodenostomy, which failed
held doppler interrogation, ascending and descending venography, to determine the site of bleeding, an ADF was found and the same
impedance and air plethysmography and duplex scanning. Specifically, procedure performed. Both these patients survived.
descending venography and duplex scanning (eight patients) indicated
In conclusion, primary ADF must be suspected in all patients who
chronic valvular insufficiency leading to appropriate direction of man present with massive gastrointestinal hemorrhage and in whom endos
agement. In these patients, early results of valvuloplasty, vein transposi copy fails to identify the source. Ultrasound or computed tomography
tion, valve transplant, plus venous bypass have been gratifying. Based scan should be performed if time permits. In unexplained massive
on this experience, conclusions are drawn as to the methods of hemorrhage, the aorta must be evaluated at laparotomy. A high index
investigation and indications for the different surgical therapies avail of suspicion followed by appropriate emergency surgery will yield the
able in the management of refractory venous stasis disease.
best results.
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TRANSPLANT SURGEON: ON - The MultiOrgan Transplantation Programme at the Uni
versity o f Toronto and the Toronto Hospital is
seeking a general surgeon with training and
experience in all aspects of Gl transplantation,
including hepatic and pancreatic transplanta
tion. The individual should have an MD and
FRCSC or its equivalent and be eligible to
practise medicine in Ontario. He/she will be
required to initiate and manage all aspects of
a clinical program in pancreatic transplanta
tion and to initiate and manage a research
program in a related area. This program will
function as an integral part of the Multi-Organ
Transplantation Programme at the University
of Toronto and at the Toronto Hospital. Re
sponsibilities will include undergraduate and
postgraduate education, advanced training in
transplantation and collaborative work with
clinicians and basic scientists involved in the
overall program. In accordance with Canadian
immigration regulations, this advertisement is
directed to Canadian citizens and permanent
residents of Canada. The University of Toron
to encourages both men and women to apply
for this position. Interested candidates should
forward their curriculum vitae to: Dr. B.R.
Taylor, Head of the Division of General Sur
gery, University of Toronto, Toronto General
Hospital, Eaton North 9-232, Toronto, ON
M5G 2C4. Deadline for receipt of applications
is Sept. 30, 1991.
-S91-60

GENERAL SURGEON: PE - A general sur
geon is required for a 30-member clinic in
Charlottetown, Prince Edward Island. The
clinic is staffed with several family physicians
and specialists. One of the tw o general sur
geons is appoaching retirement. The area is
served by a new, modern 350-bed hospital.
The recreational facilities in the area are excel
lent w ith numerous golf courses as well as
boating facilities. Subspecialties are well cov
ered. Apply to: Mr. Ken Heckbert, Manager,
Polyclinic, 199 Grafton St., Charlottetown, PE
C IA 1L2.
-S91-49
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GENERAL SURGEON AVAILABLE: - Expe
rienced surgeon looking for position in central
and northern Canada. Interested in gastroen
terology, trauma, vascular surgery. FRCS
(Glasgow), FCS (South Africa). CV on request.
Contact: P. Willemse, PO Box 1208, Pietersburg, 0700, South Africa. Telefax 01521
72720.
-S91-67

THORACIC VASCULAR AND CARDIAC
SURGEON AVAILABLE: - FRCSC, U S. and
Canada trained, with 10 years of clinical
practice. Extensive experience in cancer of
the esophagus and portal hypertension. Direc
tor of vascular laboratory for past 7 years.
Extensive scientific publications. Wishes to
relocate. Thoracic and vascular or cardiovas
cular positions will be considered. CV avail
able upon request. Reply: Box 177, CJS.
-S91-65

CARDIAC SURGICAL FELLOWSHIP: ON Available beginning July 1, 1991 at university
medical centre doing a large volume and
diversity of adult cardiac surgical procedures;
program affiliated with the University of To
ronto, Canada. Medical licence in Ontario
necessary. Ideal for FRCS or ABTS board
eligible/certified general surgeon awaiting
thoracic residency, or board eligible/certified
individual in thoracic surgery seeking addition
al experience. Salary commensurate with ex
perience, board status and potential for billing
(Canadians only). Please respond with CV to:
Bernard S. Goldman, MD, Head, Division of
Cardiovascular Surgery, Sunnybrook Health
Science Centre, 2075 Bayview Ave., Ste.
H410, Toronto, ON Canada M4N 3M5. Tel:
(416)480-6070.
-S91-48

RESIDENCY IN
CARDIOVASCULAR AND
THORACIC SURGERY
Opening available in July 1992 for 3-year
training program in busy adult (600) and
pediatric (150) cardiac surgery program in
cluding arrhythmia surgery, heart and heart/
lung transplantation, and vascular and tho
racic surgery. Outstanding facilities and fully
accredited program at a major Canadian
university. ABS certification or eligibility re
quired.
Please reply to:
Patricia A. Penkoske, MD
Department of Surgery
Room 2D 2.09 Walter MacKenzie Center
University of Alberta
Edmonton, AB T6G 2R7
Tel: (403) 4 9 2 -8 0 5 7
_S91_66

CLINICAL BURN FELLOWSHIP: ON - The
regional adult burn centre for Toronto, Cana
da - located at the Wellesley Hospital in
downtown Toronto - has a position available
for a 1-year clinical burn fellowship beginning
Jan. 1, 1992. This modern, self-contained,
well-staffed and well-funded unit has 10
acute beds and 100 annual admissions. The
fellow is responsible for the surgical and
critical care management of all patients. Ex
tensive well-funded research programs are in
progress in burn immunology and metabolism
and nutrition. Clinical investigations are en
couraged. Candidate should have completed a
residency in plastic surgery or general sur
gery. Foreign graduates from outside the U.S.
or Canada must have successfully completed
the Medical Council of Canada Evaluating
exam before applying. The position is fully
funded. Please reply to: Dr. Walter Peters,
The Wellesley Hospital, 160 Wellesley St. E.,
2nd Floor, Ste. 224, Turner Wing, Toronto,
ON, Canada M4Y 1J3. Tel: (416) 926-7790.
Fax:(416)926-4997.
-S91-58

GENERAL
SURGEON

Centenary Health Centre, a 645-bed
community general hospital in
Scarborough, Ontario, with a regional
referral base, requires a replacement
General Surgeon due to retirement.
Candidates must have FRCS(c) and be
licenced to practice in Ontario. A subspecialty is a definite advantage. Final
appointment is subject to impact analysis
and Board approval.
Inquiries and curriculum vitae should
be forwarded to:
Dr. B.J. Woolford
Chief, Department of Surgery
Centenary Health Centre
2867 Ellesmere Road
Scarborough, Ontario
M1E 4B9
— S91-73

GENERAL SURGEON
Excellent opportunity exists in Sarnia/Lambton
County to develop a lucrative private practice
covering the full scope of general surgery. There
are two hospitals in Sarnia providing a full range of
inpatient and outpatient care normally found in
com m unity h o sp ita ls and som e services of
regional calibre. Support services are excellent
and include exceptional diagnostic and ambulatory
care departments.
The city of Sarnia and county of Lambton catchment
area has a total population of 120 000. Superior
recreation facilities for persons who enjoy sailing
and other water sports, golf and curling, etc., are
available.
For further information call or write to:
K. W. Dickie, MD, FRCSC
Chief of Surgery, Sarnia General Hospital
220 North Mitton Street
Sarnia, Ontario
N7T 6H6
Tel: (519) 332-0210 (office)
P. N. Mehta, MD, FRCSC
Chief of Surgery, St. Joseph’s Hospital
290 North Russell Street
Sarnia, Ontario
N7T 6S3
Tel: (519) 336-7860 (office)
sm-ei
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CARDIAC
SURGEONS
The Division of Cardiovascular and Thoracic Surgery at
the University of Alberta Hospitals invites applications
from cardiac surgeons for a position in the Division.
C andidates should be experienced in adult
cardiovascular surgery. Expertise in cardiac and
cardiopulm onary
tra n sp la n ta tio n
w ould
be
advantageous. Certification by The Royal College of
Physicians and Surgeons of Canada in Cardiovascular
and Thoracic Surgery or equivalent is required. The
Division currently perform s over 700 open heart
procedures per year, including surgery of congenital
heart disease, adult cardiac surgery, surgery of
electrophysiologic disturbances, and heart and lung
transplantation.
A strong com m itm ent to academ ic endeavors is
required of all prospective candidates.
Please address applications and inquiries to Dr. Bryce
K.A. Weir, Professor and Chairman, Department of
Surgery, University of Alberta Hospitals 2D2.24
W M C, 8 4 4 0 - 112 S tre e t, E d m o n to n , A lb e rta
T6G 2B7
—S91-71

CARDIAC SURGEONS
The Sir Mortimer B. Davis — Jewish General Hospital requires
two full-time cardiac surgeons immediately to re-establish their
adult cardiac surgery program. The hospital is a tertiary care
McGill University hospital with a very active cath lab. It is
expected that the program will support 300 open heart
procedures in its first year and will increase to 400 cases by
the third or fourth year. In addition the hospital has excellent
opportunities for clinical and basic research. Salary and
university appointment will be commensurate with experience
and qualification.
Please send CV to:
Or. Nathan Sheiner
Surgeon-In-Chief
Sir Mortimer B. Davis — Jewish General Hospital
3755 Cote des Neiges, Suite A-500
Montreal, Quebec
H3T 1E2
— S 9 1 -6 9

CLASSIFIED ADVERTISING
Unlike a tabloid or newspaper that is read today and discarded
tomorrow, an advertisement in the Classified Advertising section
of CJS is read today and reread tomorrow.
CJS is the only Canadian publication exclusively for surgeons.
No other Canadian surgical publication reaches over 9000
subscribers every 2 months, giving wide coverage for your
advertising dollar.
Average issue readership of CJS (81 %) is among the highest of
any medical journal in Canada, and the latest readership
studies confirm the best and most cost efficient way to reach
Canadian surgeons is through the pages of CJS.
LET CJS CLASSIFIED ADS WORK FOR YOU

CJS, VOL. 34, NO. 4, AUGUST 1991
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The Department of Surgery
University of Toronto

-V

A

announces the continuation of
Post Graduate Courses
in Laparoscopic Cholecystectomy
for General Surgeons
Course Director: Dr. Steven M. Strasberg

■

A V1

The courses are scheduled between September and December 1991
and will be two days in duration. They will involve theoretical and practical
sessions in the surgical laboratory and in the operating room.
-V

For further information write or call:
Kelly Daly, Course Co-ordinator
Mount Sinai Hospital
Room 1225
600 University Avenue
Toronto, Ontario
M5G 1X5
Fax: (416) 586-8392
Tel: (416) 586-8420
_________________
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Professor and Chair
Department of Surgery
Faculty of Medicine
University of Toronto
The Faculty of Medicine at the University of
Toronto is seeking a Professor and Chair for
the Department of Surgery. This position will
be available July f, 1992.
The department is made up of nine divisions
and carries out its programs in 10 Toronto
general and sp ecialty hospitals. The
department has major undergraduate and
postgraduate teaching responsibilities. The
postgraduate program in the Department of
Surgery has 180 trainees involved in clinical
or research activities. There is a major clinical
fellows program and a strong research
program.
The faculty is seeking a highly qualified
surgeon with a demonstrated academic
reputation in te a ch in g /e d u ca tio n and
research; with experience in administration,
leadership, and interpersonal relationships.
Applications should be sent to:
Dr. John H. Dirks, Dean
Faculty of Medicine
Room 2109 Medical Sciences Building
University of Toronto
Toronto, ON
M5S 1A8.
A p p lica n ts should e n clo se a current
curriculum vitae and the names of three
referees. Applications should be received
before Sept. 30, 1991.
The University of Toronto encourages both
men and women to apply for positions.
In accordance with Canadian immigration
requirements, this advertisement is directed to
Canadian citizens and permanent residents.
—S91-68
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The University of Calgary
CHIEF, ORTHOPAEDIC
SURGERY
T h e U n iv e rs ity o f C alg ary D e p a r tm e n t
o f S u rg ery in v ite s a p p lic a tio n s fo r a
p a r t- tim e a c a d e m ic a p p o in tm e n t as
C h ie f o f th e D iv is io n o f O r th o p a e d ic
Surgery.
T h e in c u m b e n t w ill b e r e s p o n s ib le fo r
th e d e v e lo p m e n t a n d p r o m o tio n o f
re s e a rc h in itia tiv e s w ith in th e D iv isio n .
O th e r r e s p o n s ib ilitie s in c lu d e a d m in istra tiv e d u tie s re la te d to th e fu n c tio n s
o f a n a c a d e m ic d iv is io n a n d th e
p r o m o tio n o f e x c e lle n c e in e d u c a tio n .
A cad em ic r a n k a n d sa la ry c o m m e n su ra te w ith e x p e r ie n c e a n d q u a lific a 
tio n s. T h e s ta r tin g d a te is Ju ly 1, 1992.
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P lea se s u b m it a c u r r ic u lu m v ita e a n d
th e n a m e s o f th r e e re fe re n c e s by
S e p te m b e r 1, 1991, to:

Dr. R.Y. M cM urtry
P r o fe s s o r an d H ead
D e p a r tm e n t o f S u rg ery
T h e U n iv e r sity o f C algary
1403 - 2 9 S tr e e t N.W.
C algary, A lb erta
T 2N 2T 9
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THE SURGEON'S CHOICE
STERILE SINGLE USE SURGICAL BLADES & SCALPELS
SCALPELS WITH BLADES - SINGLE USE

SURGICAL BLADES

>
\ K

s '/ / ,

Superb sharpness, foil wrapped individually in quickdispenser boxes. Made from the highest quality materials,
for assured uniformity.
' Available in all sizes:
# ’s 1G, II, 12, 14, 15A, 15, 20,21,22,23, 24 and 25.
Any size, 100 per box.
VERY SPECIAL:

$14.99

bx

REGULAR $19.99

Each scalpel is packed in a polyester and aluminum foil to
protect blade edges. Unique dispenser box of 20 scalpels.
Each scalpel in individually inspected.
Available in all sizes:
10, 11, 12, 14, 15A, 15, 20, 21, 22, 23, 24 and 25.
Any size, 20 per box.
SUPER SPECIAL:

$9.99

Box of 20

REGULAR $13.99

STAINLESS STEEL HANDLES
M ade from Rust-Free stainless steel. Arrow shaped design for assured grip. Sim ply T h e Finest. G uaranteed

VERY SPECIAL:

$6.95

MICROBLADES AND MICROKNIVES
These Microblades have been developed in conjunction with leading surgeons and have achieved the aim of
developing a well balanced instrument to ensure precision and consistency in microsurgery.

v

•
•
•

Sterile and disposable.
Microblade cutting edges are available in four standard angles.
Blade after blade, cutting edges are precision-ground for sharpness
and consistent cutting angles.

•

Microblades are color-coded to determine different blade angles.
For greater cutting edge protection, microblades are individually
encased in plastic and wrapped in a pre-sterilized "peel-off" pouch.
CODEHiMND-lSO (Blue)

M icroblades
SPECIAL 10/Box:

$39.50/bx

Microknives
REGULAR $59.95

MICROBLADE HANDLE ONLY

SPECIAL ONLY:

$49.95 10/b x

SPECIAL: $ 19.95 each

REGULAR $69.95/ 10/bx

DAVIS+GECK
Cyanamid Canada Inc.
88 McNabb Street
Markham, Ontario
L3R 6E6

